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A B S T R A C T
Background
About 10% of reproductive-aged women suffer from endometriosis, a costly chronic disease causing pelvic pain and subfertility.
Laparoscopy is the gold standard diagnostic test for endometriosis, but is expensive and carries surgical risks. Currently, there are no
non-invasive or minimally invasive tests available in clinical practice to accurately diagnose endometriosis. Although other reviews have
assessed the ability of blood tests to diagnose endometriosis, this is the first review to use Cochrane methods, providing an update on
the rapidly expanding literature in this field.
Objectives
To evaluate blood biomarkers as replacement tests for diagnostic surgery and as triage tests to inform decisions on surgery for en-
dometriosis. Specific objectives include:
1. To provide summary estimates of the diagnostic accuracy of blood biomarkers for the diagnosis of peritoneal, ovarian and deep
infiltrating pelvic endometriosis, compared to surgical diagnosis as a reference standard.
2. To assess the diagnostic utility of biomarkers that could differentiate ovarian endometrioma from other ovarian masses.
Search methods
We did not restrict the searches to particular study designs, language or publication dates. We searched CENTRAL to July 2015,
MEDLINE and EMBASE to May 2015, as well as these databases to 20 April 2015: CINAHL, PsycINFO, Web of Science, LILACS,
OAIster, TRIP, ClinicalTrials.gov, DARE and PubMed.
Selection criteria
We considered published, peer-reviewed, randomised controlled or cross-sectional studies of any size, including prospectively collected
samples from any population of reproductive-aged women suspected of having one or more of the following target conditions: ovarian,
peritoneal or deep infiltrating endometriosis (DIE). We included studies comparing the diagnostic test accuracy of one or more blood
biomarkers with the findings of surgical visualisation of endometriotic lesions.
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Data collection and analysis
Two authors independently collected and performed a quality assessment of data from each study. For each diagnostic test, we classified
the data as positive or negative for the surgical detection of endometriosis, and we calculated sensitivity and specificity estimates.
We used the bivariate model to obtain pooled estimates of sensitivity and specificity whenever sufficient datasets were available. The
predetermined criteria for a clinically useful blood test to replace diagnostic surgery were a sensitivity of 0.94 and a specificity of 0.79
to detect endometriosis. We set the criteria for triage tests at a sensitivity of ≥ 0.95 and a specificity of ≥ 0.50, which ’rules out’ the
diagnosis with high accuracy if there is a negative test result (SnOUT test), or a sensitivity of ≥ 0.50 and a specificity of ≥ 0.95, which
’rules in’ the diagnosis with high accuracy if there is a positive result (SpIN test).
Main results
We included 141 studies that involved 15,141 participants and evaluated 122 blood biomarkers. All the studies were of poor method-
ological quality. Studies evaluated the blood biomarkers either in a specific phase of the menstrual cycle or irrespective of the cycle
phase, and they tested for them in serum, plasma or whole blood. Included women were a selected population with a high frequency
of endometriosis (10% to 85%), in which surgery was indicated for endometriosis, infertility work-up or ovarian mass. Seventy studies
evaluated the diagnostic performance of 47 blood biomarkers for endometriosis (44 single-marker tests and 30 combined tests of
two to six blood biomarkers). These were angiogenesis/growth factors, apoptosis markers, cell adhesion molecules, high-throughput
markers, hormonal markers, immune system/inflammatory markers, oxidative stress markers, microRNAs, tumour markers and other
proteins. Most of these biomarkers were assessed in small individual studies, often using different cut-off thresholds, and we could only
perform meta-analyses on the data sets for anti-endometrial antibodies, interleukin-6 (IL-6), cancer antigen-19.9 (CA-19.9) and CA-
125. Diagnostic estimates varied significantly between studies for each of these biomarkers, and CA-125 was the only marker with
sufficient data to reliably assess sources of heterogeneity.
The mean sensitivities and specificities of anti-endometrial antibodies (4 studies, 759 women) were 0.81 (95% confidence interval
(CI) 0.76 to 0.87) and 0.75 (95% CI 0.46 to 1.00). For IL-6, with a cut-off value of > 1.90 to 2.00 pg/ml (3 studies, 309 women),
sensitivity was 0.63 (95% CI 0.52 to 0.75) and specificity was 0.69 (95% CI 0.57 to 0.82). For CA-19.9, with a cut-off value of > 37.0
IU/ml (3 studies, 330 women), sensitivity was 0.36 (95% CI 0.26 to 0.45) and specificity was 0.87 (95% CI 0.75 to 0.99).
Studies assessed CA-125 at different thresholds, demonstrating the following mean sensitivities and specificities: for cut-off > 10.0 to
14.7 U/ml: 0.70 (95% CI 0.63 to 0.77) and 0.64 (95% CI 0.47 to 0.82); for cut-off > 16.0 to 17.6 U/ml: 0.56 (95% CI 0.24, 0.88)
and 0.91 (95% CI 0.75, 1.00); for cut-off > 20.0 U/ml: 0.67 (95% CI 0.50 to 0.85) and 0.69 (95% CI 0.58 to 0.80); for cut-off >
25.0 to 26.0 U/ml: 0.73 (95% CI 0.67 to 0.79) and 0.70 (95% CI 0.63 to 0.77); for cut-off > 30.0 to 33.0 U/ml: 0.62 (95% CI 0.45
to 0.79) and 0.76 (95% CI 0.53 to 1.00); and for cut-off > 35.0 to 36.0 U/ml: 0.40 (95% CI 0.32 to 0.49) and 0.91 (95% CI 0.88
to 0.94).
We could not statistically evaluate other biomarkersmeaningfully, including biomarkers that were assessed for their ability to differentiate
endometrioma from other benign ovarian cysts.
Eighty-two studies evaluated 97 biomarkers that did not differentiate women with endometriosis from disease-free controls. Of these,
22 biomarkers demonstrated conflicting results, with some studies showing differential expression and others no evidence of a difference
between the endometriosis and control groups.
Authors’ conclusions
Of the biomarkers that were subjected to meta-analysis, none consistently met the criteria for a replacement or triage diagnostic test.
A subset of blood biomarkers could prove useful either for detecting pelvic endometriosis or for differentiating ovarian endometrioma
from other benign ovarian masses, but there was insufficient evidence to draw meaningful conclusions. Overall, none of the biomarkers
displayed enough accuracy to be used clinically outside a research setting. We also identified blood biomarkers that demonstrated no
diagnostic value in endometriosis and recommend focusing research resources on evaluating other more clinically useful biomarkers.
P L A I N L A N G U A G E S U M M A R Y
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How accurate are blood tests in detecting endometriosis? Can any blood test be accurate enough to replace or reduce the need for
surgery in the diagnosis of endometriosis?
Background
Women with endometriosis have endometrial tissue (the tissue that lines the womb and is shed during menstruation) growing outside
the womb within the pelvic cavity. This tissue responds to reproductive hormones, causing painful periods, chronic lower abdominal
pain and difficulty conceiving. Currently, the only reliable way of diagnosing endometriosis is to perform keyhole surgery and visualise
the endometrial deposits inside the abdomen. Because surgery is risky and expensive, we evaluated whether the results of blood tests
(blood biomarkers) can help to detect endometriosis non-invasively. An accurate blood test could lead to the diagnosis of endometriosis
without the need for surgery, or it could reduce the need for diagnostic surgery to a group of women who were most likely to have
endometriosis. Separate Cochrane reviews from this series evaluate other non-invasive ways of diagnosing endometriosis using urine,
imaging, endometrial and combination tests.
Study characteristics
The evidence included in this review is current to July 2015. We included 141 studies involving 15,141 participants. All studies
evaluated reproductive-aged women who were undertaking diagnostic surgery because they were suspected of having one or more of
the following target conditions: ovarian, peritoneal or deep infiltrating endometriosis (DIE). Cancer antigen-125 (CA-125) was the
most common blood biomarker studied. Seventy studies evaluated 47 blood biomarkers that were expressed differently in women with
and without endometriosis, and 82 studies identified 97 biomarkers that did not distinguish between the two groups. Twenty-two
biomarkers were in both categories.
Key results
Only four of the assessed biomarkers (anti-endometrial Abs (anti-endometrial autoantibodies), interleukin-6 (IL-6), CA-19.9 and CA-
125) were evaluated by enough studies to provide a meaningful assessment of test accuracy. None of these tests was accurate enough to
replace diagnostic surgery. Several studies identified biomarkers that might be of value in diagnosing endometriosis, but there are too
few reports to be sure of their diagnostic benefit. Overall, there is not enough evidence to recommend testing for any blood biomarker
in clinical practice to diagnose endometriosis.
Quality of the evidence
Generally, the reports were of low methodological quality, and most blood tests were only assessed by a single or a small number of
studies. When the same biomarker was studied, there were significant differences in how studies were conducted, the group of women
studied and the cut-offs used to determine a positive result.
Future research
More high quality research trials are necessary to accurately assess the diagnostic potential of certain blood biomarkers, whose diagnostic
value for endometriosis was suggested by a limited number of studies.
B A C K G R O U N D
Target condition being diagnosed
Endometriosis
Endometriosis is defined as an inflammatory condition char-
acterised by endometrial-like tissue at sites outside the uterus
(Johnson 2013). Endometriotic lesions can occur at different loca-
tions, including the pelvic peritoneum and the ovary, or they can
penetrate pelvic structures below the surface of the peritoneum
(defined as deeply infiltrating endometriosis, or DIE). Current
knowledge suggests that each of these types of endometriosis is a
separate clinical entity, but they can coexist in the same woman.
Rarely, endometriotic implants can be found at more distant sites,
including the lung, liver, pancreas and operative scars, with con-
sequent variations in presenting symptoms.
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Endometriosis afflicts 10% of reproductive-aged women, caus-
ing dysmenorrhoea (painful periods), dyspareunia (painful inter-
course), chronic pelvic pain and infertility (Vigano 2004). The
clinical presentation can vary from asymptomatic and unexplained
infertility to severe dysmenorrhoea and chronic pain. These symp-
toms can occur with bowel or urinary symptoms, an abnormal
pelvic examination or the presence of a pelvic mass; however, no
symptom is specific to endometriosis. The estimated prevalence
of endometriosis in the symptomatic population is 35% to 50%
(Giudice 2004).
Women with endometriosis are also at increased risk of devel-
oping several cancers and autoimmune disorders (Sinaii 2002;
Somigliana 2006). The presence of disease is associated with
changes in the immune response, vascularisation, neural func-
tion, the peritoneal environment and the eutopic endometrium
(tissue lining the uterine cavity), suggesting that endometriosis is
a systemic rather than localised condition (Giudice 2004). En-
dometriosis has a profound effect on psychological and social
well-being and imposes a substantial economic burden on society.
Women with endometriosis may incur significant direct medical
expenses from diagnostic and therapeutic surgeries, hospital ad-
missions and fertility treatments, while indirect costs, including
absenteeism and loss of productivity, compound the economic im-
pact (Gao 2006; Simoens 2012). In the United States, the finan-
cial burden of endometriosis is about USD 12,419 per woman
(Simoens 2012).
Although research has not been able to fully elucidate the patho-
genesis of endometriosis, specialists commonly believe that it oc-
curs when endometrial tissue contained within themenstrual fluid
implants at an ectopic site within the pelvic cavity through ret-
rograde flow (Sampson 1927). However, this theory does not ex-
plain the fact that only 10% of women develop endometriosis,
while retrograde menstruation occurs in up to 90% of women
(Halme 1984). There is evidence that a variety of environmen-
tal, immunological and hormonal factors are associated with en-
dometriosis and genetic loci that confer a risk of endometriosis,
but the relative contribution of these and other causal factors is
still unclear (Nyholt 2012; Vigano 2004).
Although it is impossible to time the onset of disease, on average,
women have a 6- to 12-year history of symptoms before obtain-
ing a surgical diagnosis, indicative of considerable diagnostic delay
(Matsuzaki 2006). Untreated endometriosis is associated with re-
duced quality of life and contributes to outcomes such as depres-
sion, inability to work, sexual dysfunction andmissed opportunity
for motherhood (Gao 2006). Since endometriosis is a progressive
disease in up to 50% of women, early diagnosis has the potential to
offer early treatment and prevent progression (D’Hooghe 2002).
Treatment of endometriosis
There is no cure for endometriosis. Treatment options include
expectant management, pharmacological (hormonal) therapy and
surgery (Johnson 2013). Treatment is individualised, taking into
consideration a therapeutic goal (pain relief or conception) and the
location of the disease. Current pharmacological therapies such as
the combined oral contraceptive pill, progestogens, weak andro-
gens and GnRH agonists and antagonists act to reduce the effect
of oestrogen on endometrial tissues and suppress menstruation.
These drugs can ameliorate the symptoms of dysmenorrhoea and
chronic pelvic pain but are associatedwith side effects such as breast
discomfort, irritability, androgenic symptoms and bone loss. Sur-
gical excision of endometriotic lesions can reduce pain symptoms,
but it is associated with high recurrence rates of 40% to 50% at five
years postsurgery (Guo 2009). Early treatment of endometriosis
improves pain levels as well as physical and psychological function-
ing. Furthermore, improvements in menstrual management (the
use of the intrauterine system (hormonal coil) and the continuous
use of the combined contraceptive pill) and fertility preservation
(oocyte vitrification) raise the possibility of suppressing the pro-
gression of endometriosis and prospectively managing subfertility
in endometriosis sufferers. The potential success of these preven-
tive strategies depends on an accurate and early diagnosis. A ma-
jor impediment to earlier and more efficacious treatment of this
disease is diagnostic delay, due to the invasive nature of standard
diagnostic tests (Dmowski 1997).
Diagnosis of endometriosis
Clinical history and pelvic examination can raise the possibility
of a diagnosis of endometriosis, but the heterogeneity in clinical
presentation, the high prevalence of asymptomatic endometriosis
(2% to 50%) and the poor association between presenting symp-
toms and severity of the disease contribute to the difficulty in ob-
taining a reliable diagnosis based solely on presenting symptoms
(Ballard 2008; Fauconnier 2005; Spaczynski 2003). Although an
abnormal pelvic examination correlates with the presence of en-
dometriosis on laparoscopy in 70% to 90% of cases (Ling 1999),
there is a wide differential diagnosis for most positive physical
findings. Furthermore, a normal clinical examination does not ex-
clude endometriosis, as laparoscopically proven disease has been
diagnosed in more than 50% of women with a clinically normal
pelvic examination (Eskenazi 2001). A variety of tests utilising
pelvic imaging, blood markers, eutopic endometrium character-
istics, urinary markers or peritoneal fluid components have been
suggested as diagnosticmeasures for endometriosis. Although large
numbers of the reported markers distinguish women with and
without endometriosis in small pilot studies, many do not show
convincing potential as a diagnostic test when they are evaluated
in larger studies by different research groups. The diagnostic value
of these tests has not previously been fully systematically evaluated
and summarised using Cochrane methods. Currently, there is no
simple non-invasive test for the diagnosis of endometriosis that is
routinely implemented in clinical practice.
Surgical diagnostic procedures for endometriosis include la-
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paroscopy (minimal access, or keyhole surgery) or laparotomy
(open surgery via an abdominal incision). In the last several
decades, laparoscopy has become an increasingly common proce-
dure and has largely replaced traditional open surgery in patients
suspected of having endometriosis (Yeung 2009). Laparoscopy has
significant advantages over laparotomy, including fewer complica-
tions and shorter recovery times. Furthermore, a magnified view
at laparoscopy allows better visualisation of the peritoneal cavity.
Despite continuing controversy in the literature with regard to the
superiority of one surgical modality over another in treating pelvic
pathology, laparoscopy is the preferred technique to evaluate the
pelvis and abdomen and to treat benign conditions such as ovar-
ian endometriomas (Medeiros 2009). Surgery is currently also the
only acceptable method of determining the extent and severity
of endometriosis. There are several different classification systems
for endometriosis (Adamson 2008; Batt 2003; Chapron 2003a;
Martin 2006), but most researchers and clinicians use the revised
American Society for Reproductive Medicine (rASRM) classifica-
tion, which is internationally accepted as a respected tool for the
objective assessment of the disease (ASRM 1997). The rASRM
classification system considers the appearance, size and depth of
peritoneal or ovarian implants and adhesions that are visualised
during laparoscopy and allows uniform documentation of the ex-
tent of disease (Table 1). Unfortunately, this classification system
has little value in clinical practice due to the lack of correlation
between laparoscopic staging, the severity of symptoms and re-
sponse to treatment (Chapron 2003b; Guzick 1997; Vercellini
1996). TheWorld Endometriosis Society has recently undertaken
an endeavour to attain consensus around the optimal classification
for endometriosis (Johnson 2015).
The European Society of Human Reproduction and Embryol-
ogy (ESHRE) Special Interest Group for Endometriosis stated in
their diagnostic and treatment guidelines that for most forms of
endometriosis, women presenting with symptoms cannot obtain
a definitive diagnosis without visual inspection of the pelvis at
laparoscopy as the gold standard investigation (Kennedy 2005).
Currently the visual or histological identification of endometri-
otic tissue in the pelvic cavity during surgery is not just the best
available but the only diagnostic test for endometriosis in clinical
practice.
The disadvantages of laparoscopic surgery include (but are not
limited to) the high cost, the need for general anaesthesia and
the potential for adhesion formation postprocedure. Laparoscopy
has been associated with a 2% risk of injury to pelvic organs, a
0.001% risk of damaging a major blood vessel and a mortality
rate of 0.0001% (Chapron 2003c). Even though the major com-
plications of laparoscopy are rare, it is difficult to determine the
exact incidence of complications, and delayed recognition adds
to surgical morbidity and mortality. Only a third of women who
undertake a laparoscopic procedure will receive a diagnosis of en-
dometriosis; therefore many disease-free women are unnecessarily
exposed to surgical risk (Frishman 2006).
The validity of laparoscopy as a reference test for endometriosis
has is highly dependent on the skills of the surgeon. The diag-
nostic accuracy of laparoscopic visualisation has been compared
with histological confirmation in a sole systematic review, and it
was estimated as having a sensitivity of 0.94 and specificity of
0.79 (Wykes 2004). Subsequent studies suggested that incorpo-
rating histological verification in the diagnosis of endometriosis
may improve diagnostic accuracy (Almeida Filho 2008; Marchino
2005; Stegmann 2008), but these papers have not been system-
atically reviewed. The clinical significance of histological verifica-
tion remains debatable, and a diagnosis based on visual findings
is generally reliable as long as properly trained and experienced
surgeons perform an appropriate inspection of the abdominal cav-
ity (Redwine 2003). Furthermore, excised potential endometriotic
tissues are rarely serially sectioned in clinical practice, and patholo-
gists can miss small lesions in mild disease. Thus, sampling incon-
sistencies are also likely to influence the accuracy of histological
reporting.
Summary
A diagnostic test without the need for surgery would reduce the
associated surgical risks, increase accessibility to a diagnostic test
and improve treatment outcomes. The need for an accurate non-
invasive diagnostic test for endometriosis continues to encourage
extensive research in the field and was endorsed at the interna-
tional consensus workshop at the 10th World Congress of En-
dometriosis in 2008 (Rogers 2009). Although multiple markers
and imaging techniques have been explored as diagnostic tests for
endometriosis, none of them have been implemented routinely in
clinical practice, and many have not been subject to a systematic
review.
Index test(s)
This review assesses blood-based biomarkers that have been pro-
posed as non-invasive tests for the diagnosis of endometriosis as
part of the review series on non-invasive diagnostic tests for en-
dometriosis (Table 2). The other reviews from this series include
’Imaging modalities for the non-invasive diagnosis of endometrio-
sis’, ’Endometrial biomarkers for the non-invasive diagnosis of en-
dometriosis’, ’Urinary biomarkers for the non-invasive diagnosis
of endometriosis’, and ’Combination of the non-invasive tests for
the diagnosis of endometriosis’, which also summarises all the re-
views from the series.
The definition of ’non-invasive’ varies between medical dictionar-
ies but refers to a procedure that does not involve penetration of
skin or physical entrance to the body (McGraw-Hill Dictionary
of Medicine 2006; The Gale Encyclopedia of Medicine 2011).
Although venipuncture for blood collection is invasive by this def-
inition, blood tests are generally considered to be non-invasive or
minimally invasive when compared to diagnostic surgery. For the
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purpose of these reviews, we will define all tests that do not involve
anaesthesia and surgery as non-invasive.
The advantages of using a blood test for the diagnosis of en-
dometriosis are that it is minimally invasive, readily available, ac-
ceptable to women, provides a rapid result and is more cost-effec-
tive when compared to surgery. However, blood testing is depen-
dent on the reliability of laboratory techniques and quality con-
trol protocols. Blood biomarker levels may also be susceptible to
variation during the menstrual cycle.
Research has identified cellular and molecular processes that char-
acterise ectopic endometrium and peritoneal fluid in human and
animal models (D’Hooghe 2001; Hull 2008; Kao 2003). Dif-
ferent studies have evaluated markers of these pathophysiological
processes in blood samples as a single test or a combination of sev-
eral biomarkers. Categories of blood markers include: angiogenic
and growth factors; markers of apoptosis; cell adhesion molecules
and other matrix-related proteins; cytoskeleton molecules; DNA-
repair/telomere maintenance molecules; hormonal markers; high-
throughput molecular markers; hormonal markers; immune sys-
tem and inflammatory markers; nerve growth markers; oxidative
stress markers; post-transcriptional regulators of gene expression
(circulating nuclear DNAs, microRNAs); tumour markers; and
other peptides/proteins shown to influence key events implicated
in endometriosis. Most blood-based tests have only been evaluated
in a limited number of small studies with varying methods, labo-
ratory techniques and types of assay.The most extensively studied
biomarker for endometriosis is cancer antigen-125 (CA-125), a
glycoprotein expressed on coelomic epithelial tissues such as the
peritoneum. An older meta-analysis concluded that CA-125 had
a limited ability to diagnose endometriosis (Mol 1998). However,
the review did not describe the selection process to include stud-
ies. Since then, further studies evaluating CA-125 have been pub-
lished, and the methodologies of diagnostic test reviews have im-
proved, so an updated review of CA-125 is warranted (Brosens
2003; Bedaiwy 2004; Matalliotakis 2008; Yang 2004).
A large systematic review of all proposed biomarkers for en-
dometriosis in serum, plasma and urine identified over 100 pu-
tative biomarkers, but the authors were unable to identify any
biomarker (single or in a panel) that they could recommend for
use in clinical practice (May 2010). A more recent narrative re-
view concurred with this conclusion (Fassbender 2015). There is
a current need to re-evaluate the diagnotic test accuracy of blood
tests for endometriosis using Cochrane methods.
Clinical pathway
Women presenting with symptoms of endometriosis (dysmenor-
rhoea, dyspareunia, chronic pelvic pain or difficulty conceiving)
are generally investigated with a pelvic ultrasound scan to exclude
other pathologies, which is in line with international guidelines
(ACOG 2010; Dunselman 2014; SOGC 2010). There are no
other standard investigative tests, and although evidence suggests
that MRI is superior to ultrasound, it is used conservatively be-
cause of its cost. If patients seek pain management rather than
conception, physicians generally initiate empirical treatment with
progestogens or the combined oral contraceptive pill. Diagnostic
laparoscopy is considered if empirical treatment fails or if women
decline or do not tolerate empirical treatment. In women who
have difficulty conceiving, laparoscopy can be undertaken before
fertility treatment (particularly if severe pelvic pain or endometri-
oma are present) or after failed assisted reproductive technology
(ART) treatments. Physicians may also diagnosis endometriosis
during fertility investigations in women who have minimal or no
pain symptomatology.
On average there is a delay of 6 to 12 years fromonset of symptoms
to definitive diagnosis at surgery. Early referral to a gynaecologist
with the capability to performdiagnostic surgery is associated with
a shorter time to diagnosis. Collectively, young women, women
in remote and rural locations and women of lower socioeconomic
status have reduced access to surgery and are less likely to obtain
a prompt diagnosis of endometriosis.
Prior test(s)
Mostwomenpresentingwith symptoms suggestive of endometrio-
sis have a full history and examination and a routine gynaecological
ultrasound before physicians recommend they undergo diagnostic
surgery. However, there is no consensus on whether any other test
should be routinely used as part of a standardised approach.
Role of index test(s)
A new diagnostic test can fulfil one of three roles.
1. Replacement: replacing an existing test due to better
accuracy or a similar accuracy with other advantages.
2. Triage: used as an initial step in a diagnostic pathway to
identify the group of patients who need further testing with an
existing test. Although ideally a triage test has a high sensitivity
and specificity, it may have a lower sensitivity but higher
specificity than the current test or vice versa. The triage test does
not aim to improve the diagnostic accuracy of the existing test
but rather to reduce the number of individuals having an
unnecessary diagnostic test.
3. Add-on: used in addition to existing testing to improve
diagnostic performance (Bossuyt 2008).
Ideally a diagnostic test is expected to correctly identify all patients
with a disease and to exclude all patients without that disease; in
other words, it should have a sensitivity and specificity of 1.00. A
high sensitivity indicates that there are a low number of patients
who have a negative test and do have the disease (i.e. a low num-
ber of false negative results). High specificity corresponds to a low
number of patients who have a positive test but do not have the
disease (i.e. low false positive results). In practice, however, it is
extremely rare to find a test with equally high sensitivity and speci-
ficity. An acceptable replacement test would need to have a similar
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or higher sensitivity and specificity than the current gold standard.
In the case of laparoscopy for diagnosis of endometriosis, the only
systematic review reported a sensitivity of 0.94 and a specificity
of 0.79, and we have taken this as a cut-off for a replacement test
(Wykes 2004).
The purpose of triage tests can vary depending on the clinical con-
text and patients’ priorities. One reasonable approach is to exclude
the diagnosis to avoid further unnecessary and expensive diagnos-
tic investigations. High sensitivity tests have few false negative re-
sults and act to rule conditions out (SnOUT). A negative result
from a test with high sensitivity will exclude the disease with high
certainty independent of the specificity. As women without dis-
ease would be assured of having a negative test, unnecessary inva-
sive interventions can be avoided. However, a positive result has
less diagnostic value, particularly when the specificity is low. We
predetermined that a clinically useful SnOUT triage test should
have a sensitivity of 0.95 or more and a specificity of 0.50 and
above.We set the sensitivity cut-off for a SnOUT triage test at 0.95
and above, assuming that a 0.05 false negative rate is statistically
and clinically acceptable. We set the specificity cut-off at 0.50 and
above, to avoid diagnostic uncertainty in more than 50% of the
population with a positive result.
An alternative approach would be to avoid a missed diagnosis.
High specificity tests have few false positive results and act to rule
conditions ’in’ (SpIN). A positive result for a highly specific triage
test indicates a high likelihood of having endometriosis. This in-
formation could be used to prioritise these patients for surgical
treatment. A positive SpIN test could also provide a clinical ra-
tionale to start targeted disease-specific medical management in
a patient without a surgical diagnosis, under the assumption that
disease is present. Surgical management could then be reserved for
cases when conservative treatment fails. This is particularly rele-
vant in some populations where the therapeutic benefits of surgery
for endometriosis have to be carefully balanced with the disad-
vantages (e.g. young women, women with medical conditions or
pain-free patients with a history of infertility). In this scenario we
considered a sensitivity of 0.50 and above and a specificity of 0.95
and higher as suitable cut-offs for a SpIN triage test.
We evaluated blood tests for their potential to replace surgery (re-
placement test) or to improve the selection of women for surgery
(triage test to rule out (SnOUT) or rule in (SpIN) the disease).
Both types of triage tests are clinically useful, minimising the num-
ber of unnecessary interventions. Sequential implementation of
SnOUT and SpIN tests can also optimise a diagnostic algorithm
(Figure 1). We did not assess any test as an add-on test, as we
sought tests that reduce the need for surgery and not tests that
improve the accuracy of the currently available surgical diagnosis.
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Figure 1. Sequential approach to non-invasive testing of endometriosis.
Alternative test(s)
There are no routine alternative tests for the diagnosis of en-
dometriosis in clinical practice.
Rationale
Many women with endometriosis suffer longstanding pelvic pain
and infertility prior to a diagnosis. Surgery is the only current
method of diagnosing endometriosis, but it is associated with high
costs and surgical risks. A simple and reliable non-invasive test
for endometriosis, with the potential to either replace laparoscopy
or to triage women in order to reduce surgery, would minimise
surgical risk and reduce diagnostic delay. Physicians could then
detect endometriosis at less advanced stages and institute earlier
interventions. Early diagnosis would provide the opportunity for a
preventive approach for this debilitating disease, potentially reduc-
ing healthcare-related costs and favouring more cost-effective and
efficient treatments. Furthermore, identifying blood biomarkers
that do not pertain to endometriotic disease would help clinicians
and researchers focus on clinically relevant biomarker detection.
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O B J E C T I V E S
Primary objectives
To evaluate blood biomarkers as replacement tests for diagnostic
surgery and as triage tests to inform decisions to undertake surgery
for endometriosis. Specific objectives include the following.
1. To provide summary estimates of the diagnostic accuracy of
blood biomarkers for the diagnosis of peritoneal, ovarian and
deep infiltrating pelvic endometriosis, compared to surgical
diagnosis as a reference standard.
2. To assess the diagnostic utility of biomarkers that could
differentiate ovarian endometrioma from other ovarian masses.
Secondary objectives
1. To investigate the influence of heterogeneity on the
diagnostic accuracy of blood biomarkers for endometriosis.
Potential sources of heterogeneity include:
i) participant characteristics: age (adolescents versus later
reproductive years), clinical presentation (subfertility, pelvic
pain, ovarian mass, asymptomatic women), stage of disease
(rASRM classification system), geographic location of study;
ii) histological confirmation in conjunction with
laparoscopic visualisation compared to laparoscopic visualisation
alone;
iii) changes in technology over time: year of publication,
modifications applied to conventional laboratory techniques;
iv) methodological quality: differences in the revised
Quality Assessment of Diagnostic Accuracy Studies (QUADAS-
2) evaluation (Table 3), including low versus unclear or high risk;
consecutive versus non-consecutive enrolment; and blinding of
surgeons to the results of index tests;
v) study design (single-gate design versus two-gate design
studies).
2. To assess biomarkers that were not affected by
endometriosis and hence were unlikely to discriminate between
women with and without the disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Published peer-reviewed studies that compared the results of one
or several types of blood biomarker tests with the results obtained
from a surgical diagnosis of endometriosis.
We included the following types of studies.
1. Randomised controlled trials (RCTs).
2. Observational studies with the following designs.
i) Single-gate design (studies with a single set of
inclusion criteria defined by clinical presentation). All
participants had clinically suspected endometriosis.
ii) Two-gate design (studies where participants are
sampled from distinct populations with respect to clinical
presentation). The same study includes participants with a
clinical suspicion of having the target condition (e.g. women
with pelvic pain) and also participants in whom the target
condition is not suspected (e.g. women admitted for tubal
ligation). Two-gate studies were eligible only where all cases and
controls belonged to the same population with respect to the
reference standard (i.e. all the participants were scheduled for
laparoscopy) (Rutjes 2005).
3. Studies performed on prospectively collected samples,
irrespective of the actual time of the test assay. The timing of
sample collection relative to surgery is important because the
surgical excision of endometriotic lesions could influence blood
biomarker expression and hence bias the results. Therefore, we
only included studies that drew blood before the surgical
procedure, i.e. ’prospectively collected’. We considered to be
eligible the studies performed on tissue bank samples collected
from prospectively recruited, well-defined populations, which
prevented the omission of valuable data from adequately
designed studies. The time interval between sample collection
and laboratory testing may influence test outcomes, which could
be dependent on sample storage conditions and the stability of
each individual biomarker during storage and freeze-thawing.
This information was not readily available for most molecules,
and we did not address it in this review, but we will consider it in
future updates if more evidence emerges.
We did not impose limits on eligibility related to the healthcare
settings where the study took place, the language of publication,
the number of participants in the included studies or the number
of studies that evaluated each index test.
We excluded the following types of studies.
1. Narrative or systematic reviews.
2. Studies of retrospective design where investigators collected
samples after execution of the reference test.
3. Studies of retrospective design where investigators selected
participants from retrospective review of the case notes/archived
samples and where information on recruitment methods or
study population was not available.
4. Case reports or case series.
5. Studies reported only in abstract form or in conference
proceedings where the full text was not available. We applied this
limitation after facing substantial difficulty in obtaining the
information from the abstracts, which precluded a reliable
assessment of eligibility and methodological quality.
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Participants
Study participants included reproductive-agedwomen (puberty to
menopause) with suspected endometriosis based on clinical symp-
toms, pelvic examination or both, who undertook the index test
as well as the reference standard.
Participants came from populations of women undergoing ab-
dominal surgery for the following indications.
• Clinically suspected endometriosis (pelvic pain, infertility,
abnormal pelvic examination, or a combination of the above).
• Ovarian mass, regardless of symptoms.
• A mixed group consisting of women with suspected
endometriosis/ovarian mass or women with other benign
gynaecological conditions (e.g. surgical sterilisation, fibroid
uterus, etc).
• Asymptomatic women who have an incidental finding of
endometriosis at surgery performed for another indication.
Studies that included participants of postmenopausal age were el-
igible when the data for the reproductive age group was available
in isolation. We excluded studies with participants that clearly
would not undergo the index test in the relevant clinical situation
or would not benefit from the test (e.g. women with ectopic preg-
nancies or acute pelvic inflammatory disease). We also excluded
publications that only analysed participants with a positive index
test or reference standard and did not provide data for the whole
cohort.
Index tests
We assessed any type of blood-based biomarker for endometriosis
either separately or in combination with other blood tests. We
included index tests performed on whole blood, plasma or serum.
We present the assessed index tests in Table 2 (classified by biolog-
ical subgroups) and in Appendix 1 (alphabetical order with anno-
tation for biological subgroups). We included the tests performed
in one or several phases of menstrual cycle.
The combined evaluations of blood biomarkers with other meth-
ods for diagnosing endometriosis (e.g. pelvic examination, imag-
ing, urine or endometrial tests) are beyond the scope of this review
and are presented separately in another review, ’Combined tests for
the non-invasive diagnosis of endometriosis’. We excluded studies
that solely assessed specific technical aspects, presented qualitative
descriptions of lesion appearance or reported interobserver vari-
ability of the index tests, without reporting the data on diagnostic
performance. When the evaluated biomarker(s) showed differen-
tial expression between the groups of women with and without
endometriosis, we only considered the study if it reported data
with sufficient detail for the construction of 2 x 2 contingency
tables. However, when the contingency tables were not available
because the expression level of index test did not significantly dif-
fer between the groups and the inclusion criteria were otherwise
met, wemade a critical appraisal and presented the study in the de-
scriptive part of the review. Thus, we evaluated the adequately de-
signed studies that identified biomarkers without diagnostic value,
as they provide information that is likely to focus future research
on other more clinically useful biomarkers.This methodology also
identified biomarkers that were associated with endometriosis in
some but not other studies. We did not include evaluations of
screening or predictive accuracy tests in this review.
We considered the diagnostic performance of an index test to
be high when the test reached the criteria for a replacement test
(sensitivity of equal or greater than 0.94 with specificity of equal or
greater than 0.79) or triage test (sensitivity of equal or greater than
0.95 with specificity of equal or greater than 0.50 or vice versa) or
approached these criteria (diagnostic estimates within 0.05 of the
set thresholds). We considered all other diagnostic estimates to be
low.
Target conditions
Pelvic endometriosis, defined as endometrial tissue located in the
pelvic cavity: involving any of the following: pelvic organs, peri-
toneum and pouch of Douglas.
We assessed three types of pelvic endometriosis.
1. Peritoneal endometriosis, defined as endometrial deposits
detected on peritoneum covering pelvic organs, pelvic side walls
or pouch of Douglas.
2. Ovarian endometriosis (endometrioma), defined as an
ovarian cyst lined by endometrial tissue, appearing as an ovarian
mass of varying size.
3. Deep infiltrating endometriosis (DIE), defined as
subperitoneal infiltration of endometrial implants, i.e. when the
endometriotic implants penetrate the retroperitoneal space at a
distance of 5 mm or more (Koninckx 1991). DIE may be present
in multiple locations, involving either the anterior or posterior
pelvic compartments, or both.
We did not include certain rare types of endometriosis such as ex-
trapelvic, bladder and ureteric endometriosis because the majority
were reported in case reports or case series, and laparoscopy or la-
parotomy are not reliable reference standards for these conditions.
We excluded the studies where diagnosis of endometriosis was not
the primary outcome (e.g. malignant versus benign masses or nor-
mal versus abnormal pelvis) and separate data for endometriosis
was not available.
We also excluded the studies where the findings of the index test
formed the basis of selection for the reference standard, because
this was likely to distort an assessment of the diagnostic value of
the index test.
We did include studies that recruited selected populations of
womenwith endometriosis (i.e. thosewith specific rASRMstages),
because there is a poor correlation between the rASRM classifica-
tion and infertility or pain symptoms. Exclusion of these studies
could result in the loss of potentially important diagnostic infor-
mation from otherwise eligible publications. Where possible, we
addressed the impact of these studies in the assessment of hetero-
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geneity. When a study analysed a large population with a wide
spectrum of endometriosis and additionally reported a subgroup
analysis of the different stages of disease severity, we only consid-
ered estimates for the entire population. This is because a subgroup
analysis would not directly address the review question regarding
the clinical utility of the biomarker in disease detection.
Reference standards
The reference standard was visualisation of endometriosis at
surgery (laparoscopy or laparotomy) with or without histological
confirmation, as this is currently the best available test for en-
dometriosis. If reported, we reviewed information regarding the
inter- and intraobserver correlation of the reference standard.
Weonly included studies inwhich the reference testwas performed
within 12 months of the blood sample collection, on the assump-
tion that disease status could change within a period of one year
or longer, either naturally or as a result of treatment. We excluded
studies in which the participants did not undergo the reference
standard or where the findings of the index test formed the basis of
selection for undertaking the reference standard, as this was likely
to distort an assessment of the diagnostic value of the index test.
Summary of inclusion and exclusion criteria
Inclusion criteria
1. Types of studies
i) Published and peer-reviewed
ii) RCTs
iii) Observational designs, including:
a) single-gate design (single set of inclusion criteria
defined by clinical presentation): all the participants had
clinically suspected endometriosis;
b) two-gate design (two sets of inclusion criteria
with respect to clinical presentation and one set of inclusion
criteria with respect to reference standard): the participants with
or without a clinical suspicion of endometriosis scheduled for
abdominal surgery.
iv) Published in any language
v) Performed in any healthcare setting
vi) Any sample size
2. Participants
i) Reproductive-aged women
ii) Clinically suspected endometriosis, including:
a) women who underwent abdominal surgery for
other benign gynaecological conditions and had a surgical
assessment for presence/absence of endometriosis;
b) asymptomatic women who have an incidental
finding of endometriosis at surgery performed for another
indication.
iii) Undertook both the index test and reference standard
3. Index tests
i) One or several types of blood biomarkers
ii) Data reported in sufficient detail for the construction
of 2 x 2 tables for the tests that showed differential expression
between the groups
iii) Biomarkers where a 2 x 2 tables could not be
constructed because the results did not differ between women







d) Combinations of the above
5. Reference standard
i) Surgical visualisation of lesions for the diagnosis of
endometriosis (laparoscopy or laparotomy) with or without
histological verification
ii) Performed within 12 months of the endometrial
sample collection
Exclusion criteria
1. Types of studies
i) Narrative or systematic reviews
ii) Retrospective design where the execution of reference
test preceded the collection of the blood sample
iii) Prospectively collected samples that were selected from
the archived material, but where information on the study
population or the selection process was unclear
iv) Case reports or case series
v) Conference proceedings
2. Participants
i) Included cohort was not representative of the target
population that would benefit from the test (e.g. women with
known genital tract malignancy, ectopic pregnancies or acute
pelvic inflammatory disease)
ii) Study included participants of postmenopausal age,
and the data for the reproductive age group were not available in
isolation
iii) Analysis only included participants with positive index
test or positive reference standard
3. Index tests
i) Blood biomarkers presented in combination with
other diagnostic tests for endometriosis, and separate
information for blood biomarkers was not available
ii) Study presented only specific technical aspects of an
index test or focused on the biological events, rather than
diagnostic performance of the test
iii) Study assessed screening or predictive test accuracy
4. Target condition
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i) Endometriosis was not the primary outcome of the
trial (e.g. malignant versus benign masses or normal versus
abnormal pelvis)
ii) Atypical, rare sites of endometriosis
5. Reference standard
i) Reference standard performed only in a subset of
study/control group
ii) Findings of the index test formed the basis of selection
for the reference standard
iii) Other than specified in inclusion criteria
Search methods for identification of studies
We developed the search strategy in collaboration with the Tri-
als Search Coordinator of the Gynaecology and Fertility Review
Group, following recommendations of the Cochrane Handbook
for Systematic Reviews of Diagnostic Test Accuracy (De Vet 2008).
We did not limit the searches to particular types of study design
or impose language or publication date restrictions. The search
strategy incorporated words in the title, abstract, text words across
the record and the medical subject headings (MeSH). We initially
created the search for one broad review looking at all diagnostic
markers for endometriosis, but due to complexity, the review team
split the originally planned review into five separate reviews. We
designed two separate search strategies: one for all the biomarkers-
based tests, and another for the imaging tests; we used the for-
mer in this review. We performed all searches from database in-
ception to April - July 2015. We present the search strategies for
each database and the number of hits per search in Appendix 2;
Appendix 3; Appendix 4; Appendix 5; Appendix 6. The summary
of the results is presented in Results of the search.
Electronic searches
We searched the following databases to identify the published
studies that assessed the diagnostic value of blood biomarkers for
endometriosis.
◦ CENTRAL (2015, July).
◦ MEDLINE (inception to May 2015).
◦ EMBASE (inception to May 2015).
◦ CINAHL (inception to April 2015).
◦ PsycINFO (inception to April 2015).
◦ Web of Science (inception to April 2015).
◦ LILACS (inception to April 2015).
◦ OAIster (inception to April 2015).
◦ TRIP (inception to April 2015).
◦ Databases of the trial registers.
⋄ ClinicalTrials.gov (inception to April 2015).
⋄ World Health Organization (WHO)
International Clinical Trials Registry Platform (ICTRP)
(inception to April 2015).
◦ Databases to identify reviews and guidelines as sources
of references to potentially relevant studies.
⋄ MEDION (inception to January 2014, the last
available date).
⋄ DARE (inception to April 2015).
⋄ PubMed, a ’Systematic Review’ search under the
’Clinical Queries’ link (inception to April 2015).
◦ Searches for papers recently published and not yet
indexed in the major databases:
⋄ PubMed (simple search for the 6 months to April
2015).
Searching other resources
We handsearched the reference list of all relevant publications
(retrieved full texts of the key articles and identified reviews).
We abandoned an initial attempt to locate the grey literature (un-
published studies and conference proceedings), as we faced sub-
stantial difficulty in obtaining full text publications or further de-
tails of studies reported in an abstract form.
Data collection and analysis
Selection of studies
Three authors of this review (RS, DA, VN) and three authors
from the other reviews in this series (Emily Liu, Devashana Gupta
and Lucy Prentice) scanned the titles of studies identified by our
search to remove any clearly irrelevant articles. We reviewed the
titles and abstracts of the remaining studies to select potentially
relevant publications, and we divided the relevant articles into
four categories of endometriosis biomarkers: blood, endometrial,
urinary and combined tests. Two out of four review authors (of
VN, LH, RS and DA) independently reviewed each of the full text
versions of the articles that we had selected by title and abstract,
assessing them for eligibility based on the criteria listed in ’Criteria
for considering studies for this review’. A single failed eligibility
criterion was sufficient for a study to be excluded from the review.
The review authors who assessed the relevance of the studies and
eligibility for inclusion were not blind to the information about
each article, including the publishing journal, the names of au-
thors, the institution and the results. We resolved any disagree-
ments by discussion and, if necessary, in consultation with a third
review author (VJ) who is an expert in methodological aspects of
Cochrane systematic reviews.
When papers updated previous publications and were performed
on the same study population at different recruitment points, we
used the most complete data set that superseded previous pub-
lications to avoid double counting participants or studies. We
retrieved missing data directly by contacting authors to clarify
study eligibility. When we found potentially relevant studies in
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languages other than English, we had them translated. For ex-
cluded studies, we documented the reasons for exclusion and de-
tails of which criteria were not met. We present the characteristics
of included studies, excluded studies and studies awaiting classifi-
cation in ’Characteristics of included studies’, ’Characteristics of
excluded studies’ and ’Characteristics of studies awaiting classifi-
cation’, respectively.
Data extraction and management
Two out of five review authors (of VN, LH, RS, DA and CS) ex-
tracted data from each eligible study, resolving any disagreements
by adjudication from the third review author (VJ). If required, we
contacted study investigators to resolve any questions regarding
the data.
To collect details from included studies, we used a purpose-de-
signed data extraction form, designed specifically for this review
and pilot tested on three studies of diagnostic accuracy tests for
endometriosis. The following information was recorded for each
study.
• General information and study design: first author, year of
publication, country, language, setting, objectives, inclusion/
exclusion criteria, type of enrolment.
• Characteristics of the study participants: age, symptoms/
history/previous tests, type of target condition and its prevalence
in the study population, number of participants enrolled and
available for analysis, reasons for withdrawal.
• Features of the index test and reference standard: type,
diagnostic criteria, number and experience of the operators,
blinding of the operators to other tests or clinical data,
interobserver variability, time interval between index test and
reference standard.
• The reported number of true positives (TP), false negatives
(FN), true negatives (TN) and false positives (FP), which we
used to construct a 2 x 2 table for each index test. If studies did
not report these values, we attempted to reconstruct the 2 x 2
tables from the summary estimates presented in the study.
We extracted data into Review Manager 5 software (RevMan
2014), whichwe used to graphically display the quality assessment,
the diagnostic estimates data and the descriptive analyses.
Assessment of methodological quality
To assess the quality of each included study, we used QUADAS-
2, a modified version of the QUADAS tool for systematic reviews
of diagnostic accuracy studies (Whiting 2011).
We present the review-specific QUADAS-2 tool and explanatory
document in Table 3.We judged each study to be at ’low’, ’high’ or
’unclear’ risk for each of four domains, and we assessed concerns
about applicability in three domains. We considered studies as
having low methodological quality when they were at high or
unclear risk of bias or when we had a high concern regarding
applicability at least in one domain. Two out of the four reviewers
(of RS,DA,VN andLH) independently performed the assessment
of each included study, settling disagreements with a third author
(VJ) or by consensus. Two review authors (VN,RS) independently
piloted the topic-specific tool to rate four of the included studies
with a high level of agreement. We made modifications specific
to the blood biomarkers review to the signalling questions of the
original QUADAS-2 tool as follows.
Domain 1: We rephrased an original signalling question, ’Was a
case-control design avoided?’ as ’Was a two-gate design avoided?
’. The diagnostic studies are cross-sectional in nature, aiming to
compare the result of an index test with the result of the refer-
ence standard in the same group of participants. Study investiga-
tors measure the parameters at a single point in time and classify
the groups by the outcome of the reference standard, albeit they
perform the analysis retrospectively. Therefore, unlike epidemio-
logical studies, the terminology ’cohort’ and ’case-control’ is less
informative for diagnostic test trials, so we substituted them for
’single-gate’ and ’two-gate’ designs. We included this question be-
cause a two-gate design has more potential to introduce selection
bias.
Domain 2: We introduced an additional signalling question, ’Was
the phase of the menstrual cycle considered in interpreting the
index test?’ to assess bias in the interpretation of the test results.
Some biochemical markers are sensitive to fluctuation in steroid
sex hormone levels across a menstrual cycle, which could result in
the differential expression of endometriosis biomarkers at different
cycle phases.
We undertook the assessment of methodological quality for each
domain, but we did not calculate a summary score to estimate the
overall quality of studies (Whiting 2005).
Statistical analysis and data synthesis
We generated the estimates of sensitivity and specificity in for-
est plots and plotted them in the receiver operating characteristic
(ROC) space for each index test using Review Manager 5 soft-
ware (RevMan 2014).We investigated the diagnostic performance
of each test and visually explored interstudy variation in the per-
formance of each index test in relation to patient characteristics,
study design and study quality considerations. When there were
two or more tests evaluated in the same cohort, we included them
as separate data sets, since the unit of analysis was the test result,
not the patient.
For studies that reported subgroup analyses per phase of the men-
strual cycle, we presented the data in a clinically relevant way. For
instance, we presented pooled estimates when there was no statis-
tically significant difference in biomarker expression between cycle
phases. Alternatively, where putative biomarkers demonstrated cy-
cle-dependent expression or were noted to be modulated by ovar-
ian hormones, we reported the test performance either at several
time points across the menstrual cycle or in the phase that demon-
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strated the most distinct difference between groups.
We estimated the expected operating point (mean sensitivity and
specificity) and corresponding 95% confidence region using the
bivariate logit normal random-effects model for all meta-analyses
with four studies or more. When the number of studies was fewer
than four, we did not attempt to estimate the covariance and re-
ported a zero. To estimate the performance of the other tests in
small meta-analyses (two or three data sets), we performed fixed-
effect meta-analysis of sensitivity and specificity, in the absence of
substantial heterogeneity. We performed the meta-analyses using
SAS NLMIXED software (Cary, NC: SAS Institute Inc). We en-
tered results from SAS into Review Manager 5 to provide plots of
the mean or summary point(s) and confidence region(s), superim-
posed on the study specific estimates of sensitivity and specificity
(RevMan 2014).
We assessed the comparative accuracy of index tests in two ways.
In direct, fully paired comparisons where all the study participants
receivedmore than one index test as well as the reference standard,
we plotted the estimates in Review Manager 5 (RevMan 2014).
If meta-analysis was possible, we used test-level covariates in the
bivariate logit normal model to identify statistically significant
differences. Otherwise we reported the available comparative data
in a narrative way and illustrated it using forest and ROC plots.
When judging test performance against the predetermined diag-
nostic criteria, we considered the point estimates of sensitivity
and specificity as the most informative presentation of test perfor-
mance. We acknowledge that tests with point estimates that did
not reach the predetermined criteria, but with confidence intervals
(CIs) that contained values above the threshold, could have diag-
nostic value. Furthermore, tests with point estimates that reached
the criteria but with CIs containing values below the threshold
could have an overestimated diagnostic value. If we use the range
of the CIs rather than the point estimates of the data, the pre-
determined cut-off becomes meaningless. Therefore we did not
consider CIs in qualifying the test performance but used this in-
formation in interpreting the reliability of the obtained data.
Dealing with missing data
We defined missing data as any information on the study popula-
tion, index tests or reference standard that were not available from
the publication and that were required to determine the eligibility
of the study for inclusion, assess the methodological quality, or
construct the results table. If we identified missing data, we con-
tacted the authors in an attempt to obtain them. If missing data
prevented a clear judgment regarding applicability for inclusion or
the construction of accurate 2 x 2 tables and the data were unavail-
able from the primary investigators (for example we were unable
to locate the contact details of the authors, there was no reply from
the authors or the authors replied that the requested information
was unavailable), we excluded the study from the review.
Investigations of heterogeneity
We initially assessed heterogeneity by visually examining the forest
plots of sensitivities and specificities and the ROC plots for each
index test. We describe the potential sources of heterogeneity in
the Secondary objectives. For diagnostic tests where there were
more than 10 eligible studies, we initially planned to formally
explore heterogeneity by using study level covariates, and to assess
the sensitivity of results to the inclusion and exclusion of outlier
studies in all analyses. However, we refrained from taking these
steps because of the small numbers of studies in most analyses. It
is important to use caution when interpreting small meta-analyses
(few studies) with a limited total sample size.
Sensitivity analyses
We planned to conduct sensitivity analyses to assess the impact of
the methodological quality of included studies on the results of
any meta-analyses if sufficient data were available. We defined low
quality studies as those for which we identified a high risk of bias
for one or more QUADAS-2 domains. We also planned to use
the ’leave-one-out’ procedure (Higgins 2008) to assess the impact
of each study on the meta-analysis results (leading study effect).
However, we could not undertake this action due to the paucity
of studies evaluating each biomarker, except CA-125.
Assessment of reporting bias
A comprehensive search of multiple sources for eligible studies, a
search of trial registers and no language restrictions minimised the
risk of reporting bias. However, publication bias generally arises
when studies have a higher chance of being published if their re-
sults are positive. Therefore we initially searched and evaluated
unpublished and published study databases and conference pro-
ceedings. During the process of qualifying the studies for inclu-
sion in this review, we faced substantial difficulty in obtaining
full text publications or further details of studies published in an
abstract form. This precluded a reliable assessment of eligibility
and methodological quality, and we decided not to include these
publication sources in this review.
R E S U L T S
Results of the search
The literature search identified 33,438 references in the follow-
ing databases: CENTRAL (N = 226), MEDLINE (N = 10,328),
EMBASE (N = 10,313), CINAHL (N = 1131), PsycINFO (N =
174), Web of Science (N = 7425), LILACS (N = 420), OAIster
(N = 446), Trip (N = 1648), trial registers for ongoing and reg-
istered trials (N = 523), MEDION (N = 2), DARE (N = 99),
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PubMed, a ’systematic review’ search (N = 418) and simple search
(N = 267). We present the flow of the selection process in Figure
2. We screened titles to exclude duplicates (N = 9312) and clearly
irrelevant studies (N = 21,534). We eliminated a further 2212 ref-
erences after reviewing the abstracts because they either did not
address the research question or clearly did not meet the inclusion
criteria. We retrieved the full texts of the remaining 376 records
and assessed them for eligibility. Data from 86 studies required
additional clarification from the authors, and we had 42 non-En-
glish publications translated. Ultimately, 141 studies were eligible
and provided data for the review, while we excluded 235 studies.
We identified four ongoing trials through clinical trials registries
(Characteristics of ongoing studies), but as trial outcomes were
not available, we will address the progress of these studies in future
updates.
Figure 2. Flow of the studies identified in literature search for systematic review on imaging modalities for a
non-invasive diagnosis of endometriosis.
Basic features of the included studies
We present a list of the details of the included studies in
’Characteristics of included studies’. The 141 eligible studies in-
cluded 15,141 participants, with a median of 88 women per study
(range 17 to 834). Of these studies, 70 estimated the diagnostic ac-
curacy of blood biomarkers, 82 reported negative findings and 11
were in both groups. Seventy studies included enough data to esti-
mate the diagnostic performance of an investigated test (N = 8716
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participants, median 97, range 35 to 775 women). Each study
evaluated one or several biomarkers, and some authors reported
several estimates for the same biomarker at different menstrual
cycle phases, different cut-off thresholds or both. When this oc-
curred, we considered every estimation to be a separate test; how-
ever, we did not combine the diagnostic data sets for the biomarker
of interest in one meta-analysis if obtained from the same or an
overlapping cohort. Most studies reported diagnostic estimates
for biomarkers that demonstrated differential expression between
women with and without endometriosis, although in eight stud-
ies this assessment was undertaken for biomarkers that demon-
strated no differential expression (Ferreira 1994; Gurgan 1990;
Molo 1994; Muscatello 1992; Somigliana 2004; Tokmak 2011;
Vigil 1999; Yang 1994). Eighty-two studies did not show any dif-
ference in the expression between the women with and without
endometriosis, and they did not evaluate the diagnostic test accu-
racy of the blood biomarker (N = 7482 participants, median 73,
range 17 to 834 women). This set of studies were methodologi-
cally eligible, but the biomarkers identified are unlikely to be of
diagnostic utility and hence may not be worthy of further inves-
tigation.
Seventy of the included studies took place in Europe, 31 inAsia, 17
inNorth America, 14 in South America, 5 in theMiddle East, 2 in
Australia and 2 in unspecified locations. Ninety-five per cent (130/
137) of the studies took place in university hospitals, of which at
least 14 were referral centres for endometriosis. The earliest study
was published in 1986, 107 studies were published after 2000, and
44 studies were published after 2010. All the included studies as-
sessed women of reproductive age, and two focused exclusively on
adolescent girls after menarche. All the studies were observational,
mainly of cross-sectional design. Seventy-eight studies had a sin-
gle-gate design, where both cases and controls were from the same
patient population. Of these, 57 studies included women with
suspected endometriosis based on clinical presentation (women
presenting with pelvic pain, infertility, ovarian mass or a combi-
nation of these), 10 studies included only women undergoing an
infertility work-up, eight studies included only a population with
a persistent ovarian mass, two studies reported pelvic pain as a
sole presenting symptom and one study evaluated asymptomatic
women. Sixty-one studies had a two-gate design and included a
wider group of participants who were undergoing surgery for var-
ious indications. Two studies presented insufficient information
to determine whether they used a single- or two-gate design. La-
paroscopy was the predominant surgical modality in the included
studies; surgeons used either laparoscopy or laparotomy in29 stud-
ies, and three studies did not report information on the type of
surgery. Seventy-five of the included studies used histopathology
to confirm the surgical diagnosis.
Most of the studies (N = 123) evaluated pelvic endometriosis, 13
studies addressed only ovarian endometriosis, two studies focused
on a combination of ovarian endometriosis and DIE, two studies
looked only at peritoneal endometriosis, and one study considered
only ultrasound-negative endometriosis.The reported prevalence
of endometriosis varied from16%to84%.Eleven studies included
only participants with minimal-mild endometriosis (rASRM stage
I-II), 15 studies included only participants with moderate-severe
endometriosis (rASRM stage III to IV), and eight studies did not
report information regarding the severity of the disease. Fifty-one
studies received financial support, of which 8 reported funding
by biotech or pharmaceutical companies. In six of the eight com-
mercially supported studies, there was no statement regarding a
conflict of interest. For the remaining two studies, one group of
authors reported that most of the authors worked in the biotech-
nology industry, and one group had nothing to declare. Overall,
the authors of 33 studies declared no conflict of interest, with five
reporting that there was no financial support from any external
source. Three groups reported conflicts of interest (employee of
a biotech company, lecturing honorarium from pharmaceutical
companies and not specified), and no information was available
from the remaining studies.
Basic features of the excluded studies
We present the list and descriptions of the excluded studies in
’Characteristics of excluded studies’. Based on a full text assess-
ment, we excluded 235 studies, of which 23 were retrospective
with the blood samples being collected after the surgical proce-
dure. A further 88 studies reported biomarker levels that were
statistically significant when the study and control groups were
compared, but they did not provide enough information for the
construction of 2 x 2 contingency tables. Forty-six of the excluded
studies used a reference standard other than abdominal surgery
and did not provide information regarding the surgical diagnosis.
We excluded an additional 20 studies because they did not provide
enough detail on the research methods, the study population or
both to assess eligibility, and this information was not available
from the authors. In 24 studies, the index test was outside the
inclusion criteria, including comparisons between different types
or stages of endometriosis without including a disease-free group
(N = 13); reports on biological events or technical aspects of the
test without direct comparison of biomarker levels between the
groups (N = 6); evaluations of a screening or predictive rather than
a diagnostic test (N = 3); or use of male or umbilical cord samples
as control group (N = 2). In nine studies, the population was out-
side the inclusion criteria because they enrolled postmenopausal
women, pregnant women or women with genital tract malignan-
cies, and an independent assessment of reproductive-aged women
without these conditions was not possible. We excluded a further
nine studies as their population cohort overlapped with another
updated, included study. In five of the excluded studies, the target
condition was outside the inclusion criteria, comparing a benign
versus malignant mass or normal versus abnormal pelvis without
any independent data for endometriosis. We excluded three stud-
ies because they were review articles, and we were unable to locate
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the full text for another three studies.
Methodological quality of included studies
We illustrate the quality of the included studies in the QUADAS-
2 results summary (Figure 3; Figure 4). Overall, the studies were
of poor methodological quality, and all studies had an unclear or
high risk of bias in at least one domain.
Figure 3. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies
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Figure 4. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study
18Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Thirteen studies presented a low risk of patient selection bias (
Chen 1998; Fairbanks 2009; Guerriero 1996a; Guerriero 1996b;
Koninckx 1996; Molo 1994; Podgaec 2007; Ramos 2012; Rosa E
Silva 2007; Somigliana 2002; Somigliana 2004; Vercellini 1993;
Vigano 2002), 53 studies demonstrated an unclear risk, and 75
studies were assessed at high risk for this domain. Non-consecutive
or non-random patient selection, utilisation of a two-gate design
for patient selection, the absence of a clear definition of inclusion/
exclusion criteria and use of a highly selected group of women
were the main reasons for a high risk assessment of bias.
One study demonstrated a low risk of index test interpretation
bias (Pittaway 1989), 14 studies demonstrated an unclear risk and
126 studies carried a high risk. A lack of clear pre-specified criteria
for a positive diagnosis and index test operators not being blind
to the results of reference standard were the main reasons for a
high risk assessment. We also assigned a high risk of bias for this
domain to studies where the phase of menstrual cycle was not
considered when interpreting the index test. This was considered
an important criterion, since varying ovarian hormones across the
cycle could influence biomarker expression and undermine the
reliability of the results. Studies rarely reported the skill level of a
test operator or the interobserver variability, both of which directly
relate to test performance. As the positive index test criteria were
variable between the studies and the index test protocols were not
standardised, quality judgements for the index test were complex.
Eighty-six studies were at low risk of bias in the reference stan-
dard domain (Agic 2008; Barbosa 2009; Barcz 2002; Bilibio
2014; Borkowski 2008; Calienno 2008; Chen 1998; Cho 2007;
Dayangan Sayan 2013; De Placido 1998; Drosdzol-Cop 2012a;
Drosdzol-Cop 2012b; Elgafor el Sharkwy 2013; Fairbanks 2009;
Fassbender 2009; Fassbender 2012; Fedele 1989; Ferreira 1994;
Ferrero 2005a; Florio 2007; Florio 2009; Gagne 2003a; Gagne
2003b; Gazvani 1998; Glitz 2009; Gogacz 2014; Guerriero
1996a; Guerriero 1996b; Gurgan 1999; Hallamaa 2012; Hassa
2009; Jee 2008; Jia 2013; Kalu 2007; Khan 2006; Khan 2012;
Khan 2013; Khanaki 2012; Kim 2008; Kitawaki 2005; Kocbek
2013; Kocbek 2014a; Kocbek 2014b; Kubatova 2013; Kuessel
2014; Kurdoglu 2009; Lambrinoudaki 2009; Li 2005; Lin 2005;
Mabrouk 2012; Mihalyi 2010; Mohamed 2013; Odukoya 1996;
Ohata 2008; Olkowska-Truchanowicz 2013; Othman 2008;
Paiva 2014; Patton 1986; Philippoussis 2004; Pittaway 1989;
Podgaec 2007; Ramos 2012; Rosa E Silva 2014; Salehpour 2009;
Somigliana 2002; Somigliana 2004; Szczepanska 2001b; Szubert
2012; Thubert 2014; Tokmak 2011; Tuten 2014a; Vigano 2002;
Vodolazkaia 2011; Vodolazkaia 2012; Vouk 2012; Wang 2013a;
Webster 2013; Wei 2005; Wild 1991a; Wolfler 2009; Yagmur
2013; Yavuzcan 2013; Zhang 2005a; Zhang 2005b; Zhang 2006a;
Zhang 2006b), while the rest (N = 55) were at unclear risk. No
studies demonstrated a high risk. We assigned an unclear risk of
bias if there was not enough information to assess how likely the
reference standard was to have correctly classified the target condi-
tion. This could occur when authors did not adequately describe
surgical procedures, state the positive reference standard criteria,
clarify whether they used histology to confirm the surgical diagno-
sis or provide information regarding the expertise of the surgeons
and pathologists involved.
One hundred and ten studies presented a low risk of bias in
the flow and timing domain (Acien 1989; Agic 2008; Akoum
1996; Andreoli 2011; Barbati 1994; Barbosa 2009; Bilibio 2014;
Borkowski 2008; Braun 1996; Calienno 2008; Chen 1998;
Cho 2007; Colacurci 1996a; De Placido 1998; Drosdzol-Cop
2012a; Drosdzol-Cop 2012b; Fairbanks 2009; Fassbender 2009;
Fassbender 2012; Ferreira 1994; Ferrero 2005a; Florio 2007;
Florio 2009; Foda 2012; Gagne 2003a; Gagne 2003b; Glitz
2009; Gogacz 2014; Goluda 1998; Gorai 1993; Guerriero 1996a;
Guerriero 1996b; Gurgan 1990; Gurgan 1999; Hallamaa 2012;
Harada 2002; Hornstein 1995; Iwasaki 1993; Jee 2008; Jia 2013;
Khanaki 2012; Kianpour 2012; Kianpour 2013; Kitawaki 2005;
Kocbek 2013; Kubatova 2013; Kuessel 2014; Lambrinoudaki
2009; Li 2005; Lima 2006; Lin 2005; Liu 2009; Mabrouk
2012; Maeda 2002a; Maeda 2002b; Maiorana 2007; Markham
1997a; Martinez 2007; Matalliotakis 2003a; Matalliotakis 2004;
Matveeva 1990; Mier-Cabrera 2011; Mihalyi 2010; Mohamed
2013;Molo 1994;Morin 2005;Muscatello 1992;Odukoya 1996;
Oku 2004;Olkowska-Truchanowicz 2013;Othman2008;Ozhan
2014; Paiva 2014; Patton 1986; Philippoussis 2004; Pittaway
1989; Podgaec 2007; Ramos 2012; Riley 2007; Rosa E Silva 2007;
Salehpour 2009; Somigliana 2002; Somigliana 2004; Steff 2004a;
Suen 2014; Szczepanska 2001a; Szczepanska 2001b; Szubert
2012; Tokmak 2011; Tuten 2014a; Vercellini 1993; Verit 2008;
Vigano 2002; Vodolazkaia 2011; Vodolazkaia 2012; Vouk 2012;
Wang 2013a;Webster 2013;Wild 1991a;Wolfler 2009;Wu1998;
Yagmur 2013; Yang 1994; Yavuzcan 2013; Zeng 2005; Zhang
2005a; Zhang 2005b; Zhang 2006a; Zhang 2006b), nine stud-
ies demonstrated an unclear risk and 22 studies carried a high
risk. All participants received the same reference standard. The
time interval between the index test and the reference standard
was 12 months or less, and the most commonly reported time
interval was immediately before surgery. We assigned an unclear
risk if authors did not clearly state the time interval, but if their
descriptions suggested that the interval was reasonably short. We
assigned a high risk of bias if there were unexplained withdrawals
that exceeded 5% of the enrolled population or if the reason for
withdrawal could introduce selection bias regarding the samples
analysed.
Sixty-one studies presented a low concern for patient selection ap-
plicability (Barbati 1994; Borkowski 2008; Chen 1998; Colacurci
1996a; Drosdzol-Cop 2012a; Drosdzol-Cop 2012b; Fairbanks
2009; Fassbender 2009; Fassbender 2012; Fedele 1989; Ferreira
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1994; Foda 2012; Franchi 1993; Gogacz 2014; Gurgan 1999;
Harada 2002;Hassa 2009;Hornstein 1995; Inagaki 2003; Iwasaki
1993; Khan 2006; Khan 2012; Kim 2008; Lamp 2012; Lanzone
1991; Lin 2005; Liu 2009; Mabrouk 2012; Matalliotakis 2003a;
Matalliotakis 2004; Mihalyi 2010; Muscatello 1992; Odukoya
1996; Oku 2004; Othman 2008; Ozhan 2014; Paiva 2014;
Philippoussis 2004; Pittaway 1989; Podgaec 2007; Ramos 2012;
Rosa E Silva 2007; Salehpour 2009; Somigliana 2002; Somigliana
2004; Szczepanska 2001b; Szubert 2012; Szubert 2014; Tuten
2014a; Vercellini 1993; Vigano 2002; Vigil 1999; Vodolazkaia
2011; Vodolazkaia 2012; Wang 2013a; Webster 2013; Wild
1991a; Wu 1998; Yagmur 2013; Yang 1994; Zeng 2005), eight
demonstrated an unclear concern and 72 were of high concern.
We assigned high concern in patient selection applicability if the
study utilised two-gate selection for cases and controls or if it only
evaluated a limited spectrum of disease. In our view, any sampling
deviation from a representative group of the entire clinically rele-
vant population could skew the estimates of diagnostic accuracy in
either direction. We reported unclear concern if this information
was unclear, for example if the severity of endometriosis was not
reported.
In 136 studies there was a low concern in index test applicability,
whereas in five studies the concern was unclear (Calienno 2008;
Kurdoglu 2009; Rosa E Silva 2007; Vigil 1999; Zeng 2005), and
none of the studies presented a high concern. We assigned an
unclear concern when the study did not present sufficient infor-
mation regarding the conduct of the tests, such as the laboratory
methods, reagents used or the level of expertise of the test opera-
tors.
All 141 studies were of low concern for applicability with regard
to the reference standard, and none had a high or unclear concern.
All the included studies implemented pelvic surgery (laparoscopy
or laparotomy) as a reference standard, which could be relied upon
to match the review question.
Findings
We evaluated a total of 122 blood biomarkers in 141 included
studies; 47 biomarkers had a diagnostic evaluation in 70 studies.
Studies assessed 44 biomarkers as a single blood test, along with 29
combinations of two to six biomarkers (Summary of findings). The
presence of endometriosis did not alter 97 biomarkers evaluated
in 79 studies (Appendix 7). Twenty-two biomarkers demonstrated
altered levels in endometriosis in some studies and showed no dif-
ference in expression in other studies. We report the findings for
two separate groups: blood biomarkers that were evaluated for the
diagnosis of pelvic endometriosis, when any type of endometriosis
was assessed against disease-free controls; and blood biomarkers
that could differentiate ovarian endometrioma from other benign
ovarian cysts in women of reproductive age, when assessing ovar-
ian endometriosis against other types of ovarian masses. We have
biologically subcategorised biomarkers and presented them under
these categories in alphabetical order. To assist readers in the search
for a specific biomarker, we present an index of the biomarkers
with biological annotation in Appendix 1 .
Blood biomarkers evaluated for the diagnosis of
pelvic endometriosis (peritoneal, ovarian and deep
infiltrating)
1. Angiogenesis/growth factors and their receptors
1.1. Glycodelin-A (PP14 or PAEP) (or placental protein 14
or progestogen-associated endometrial protein)
Two studies, including three data sets with a total of 198 par-
ticipants, assessed the value of glycodelin in detecting pelvic en-
dometriosis (Figure 5). Investigators assigned three different cut-
off thresholds in each data set.
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Figure 5. Summary ROC plot of Glycodelin for detection of endometriosis. Each point represents the pair
of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and
the shape designates the tests with different cut-off values. The bars correspond to 95% CIs of each individual
evaluation. Two evaluations (> 9 ng/ml and > 18 ng/ml) were performed on overlapping populations. The data
were not assessed by meta-analysis.
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1. > 2.07 ng/ml (1 study, 99 participants, follicular or luteal
cycle phase, rASRM I to IV), showing a sensitivity of 0.82 (95%
CI 0.70 to 0.91) and a specificity of 0.79 (95% CI 0.63 to 0.90);
Kocbek 2013.
2. > 18 ng/ml (1 study, 99 participants, all cycle phases,
rASRM I to IV), showing a sensitivity of 0.62 (95% CI 0.48 to
0.74) and a specificity of 0.44 (95% CI 0.28 to 0.60); Kocbek
2013.
3. > 9.0 ng/ml (1 study, 45 participants, follicular cycle phase,
rASRM I to IV), showing a sensitivity of 0.71 (95% CI 0.51 to
0.87) and a specificity of 0.35 (95% CI 0.14 to 0.62);
Vodolazkaia 2012.
The same study (Kocbek 2013) performed two tests on an overlap-
ping population of women, and other studies used varying thresh-
olds, so it was not possible to combine studies in a meta-anal-
ysis. In three contrasting studies (206 participants, rASRM I to
IV), glycodelin concentrations did not change in women with en-
dometriosis in the follicular phase (Drosdzol-Cop 2012a), follic-
ular or luteal phase (Joshi 1986), or when the cycle phase was not
specified (Paiva 2014). It appears that there is little clinical value
in using glycodelin-A to diagnose endometriosis.
1.2. IGFBP-3 (insulin-like growth factor-binding protein-3)
One study evaluated the accuracy of IGFBP-3 in detecting pelvic
endometriosis in 99 women with ultrasound negative, rASRM I
to IV endometriosis (Vodolazkaia 2012). This study included two
evaluations: all the participants in all phases of menstrual cycle
(cut-off threshold > 210 ng/ml), demonstrating a sensitivity of
0.55 (95% CI 0.42 to 0.68) and a specificity of 0.44 (95% CI
0.28 to 0.60); and only in participants in the follicular cycle phase
(45 women, cut-off threshold > 200 ng/ml), with a sensitivity of
0.71 (95% CI 0.51 to 0.87) and a specificity of 0.29 (95% CI
0.10 to 0.56). There were no significant differences in for IGFBP-
3 levels between women with and without endometriosis in two
additional studies (116 participants, follicular and luteal or only
luteal cycle phase, rASRM I to IV) (Gurgan 1999; Philippoussis
2004). These data suggest that IGFBP-3 is not sensitive or specific
enough to be clinically useful in diagnosing endometriosis.
1.3. Leptin
The diagnostic performance of leptin was assessed as a component
of a combination of blood biomarkers (see below under ’Com-
bined tests’). Four other studies (311 participants, rASRM I to IV)
demonstrated that leptin levels alone did not differ between the
groups of women with and without endometriosis when tested in
all phases of menstrual cycle or when the cycle phase was not spec-
ified (Ozhan 2014; Paiva 2014; Vigano 2002;Wei 2005). Overall,
leptin did not appear to be reliable as a marker for endometriosis.
1.4. VEGF (vascular endothelial growth factor)
Three studies with a total of 254 participants evaluated VEGF
for the diagnosis of pelvic endometriosis (Vodolazkaia 2012; Foda
2012;Mohamed 2013)(Figure 6). Each study differed with regard
to the population studied, the cycle phase and cut-off thresholds.
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Figure 6. Summary ROC plot of VEGF for detection of endometriosis. Each point represents the pair of
sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the
shape designates the tests with different cut-off values. The bars correspond to 95% CIs of each individual
evaluation. The data were not assessed by meta-analysis.
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• VEGF with a cut-off of > 1.5 ng/ml (1 study, 99
participants in all phases of menstrual cycle, ultrasound negative
endometriosis, rASRM I to IV) had a sensitivity of 0.50 (95%
CI 0.37 to 0.63) and a specificity of 0.61 (95% CI 0.45 to 0.76);
Vodolazkaia 2012.
• VEGF with a cut-off of > 236.00 pg/ml (1 study, 95
participants in follicular cycle phase, rASRM I to IV) showed a
sensitivity of 0.92 (95% CI 0.83 to 0.97) and a specificity of
0.77 (95% CI 0.58 to 0.90); Foda 2012.
• VEGF with a cut-off of > 680.00 pg/ml (1 study, 60
participants in follicular cycle phase, rASRM III to IV)
demonstrated a sensitivity of 0.93 (95% CI 0.78 to 0.99) and a
specificity of 0.97 (95% CI 0.83 to 1.00); Mohamed 2013.
The last test had the highest diagnostic accuracy, but investigators
only evaluated it for moderate-severe disease. Substantial varia-
tions in the methodology and the populations studied precluded
combining this data in ameta-analysis. Another seven studies (842
women, rASRM I to IV) demonstrated that VEGF levels were
not influenced by endometriosis in the follicular phase (Da Silva
2014; Mabrouk 2012), luteal phase (Gagne 2003b), follicular or
luteal phase (Cho 2007; Kianpour 2013; Othman 2008), or when
the cycle phase was not specified (Paiva 2014). There is consider-
able inconsistency in the VEGF-A data, although follicular phase
VEGF-A testing appears to have some potential in diagnosing en-
dometriosis. Further work to confirm or refute this observation
and determine the value of VEGF-A blood testing to diagnose
endometriosis is warranted.
1.5. Urocortin
Two studies reported on urocortin, both of which assessed the ac-
curacy of this biomarker in discriminating ovarian endometrio-
sis from other benign ovarian masses. These studies are presented
separately under ’Blood biomarkers that could differentiate ovar-
ian endometrioma from other benign ovarian cysts in women of
reproductive age’.
1.6. Angiogenesis/growth factors that exhibited no
differential expression in endometriosis
We present a detailed summary of other angiogenesis and growth
factors that did not display significant differences in expression
levels in women with endometriosis in Appendix 7. The list in-
cludes:
1. angiogenic activity of serum (Barcz 2002; 84 participants);
2. CAC (Webster 2013; 64 participants);
3. EGF (Philippoussis 2004; 72 participants);
4. sEGF-R (Matalliotakis 2003a; 48 participants);
5. sFlt-1 (sVEGFR-1) (Cho 2007; 70 participants);
6. HGF (Khan 2006; 58 participants);
7. IGF-1 (Matalliotakis 2003a; Steff 2004a; 196 participants);
8. IGF-2 (Gurgan 1999; 44 participants);
9. PDGF (Kalu 2007; 40 participants).
Collectively, the results were discouraging, but not sufficient to




Investigators evaluated the diagnostic performance of annexin-V
in conjunction with other blood biomarkers as a part of combined
test, and we report the findings below under ’Combined tests’.
One additional study (101 participants, cycle phase not reported,
rASRM I to IV) demonstrated that annexin-V was not differen-
tially expressed in women with and without endometriosis (Paiva
2014). Further work in a well-characterised population is needed
to support this observation.
2.2. Survivin
One study (60 participants, follicular cycle phase) evaluated sur-
vivin for the diagnosis of DIE and ovarian endometriosis and
found a very low sensitivity of 0.07 (95% CI 0.02 to 0.20) and
a specificity of 0.90 (95% CI 0.68 to 0.99). The authors did not
report a cut-off threshold. There were no other eligible studies that
assessed this biomarker.
2.3. Apoptosis markers that exhibited no differential
expression in endometriosis
We present additional markers of apoptosis that were not altered
in endometriosis in Appendix 7, including: anti-survivin antibody
(Lamp 2012; 145 participants); apoptotic cells (Mier-Cabrera
2011; 62 participants); and sFas (Kalu 2007; 40 participants).
Overall, there was insufficient data to make recommendations
regarding these biomarkers.
3. Cell adhesion molecules and other matrix-related
proteins
3.1. sICAM-1 (soluble form of intercellular-adhesion
molecule-1)
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Two studies evaluated the accuracy of sICAM-1 in detecting pelvic
endometriosis. One study included women with ultrasound nega-
tive pelvic endometriosis, rASRM I to IV, and presented two over-
lapping data sets, which we therefore did not combine in a meta-
analysis (Vodolazkaia 2012).One data set from this study included
99 participants at all phases of menstrual cycle and demonstrated a
sensitivity of 0.55 (95% CI 0.42 to 0.68) and a specificity of 0.50
(95% CI 0.34 to 0.66) for a cut-off threshold of < 243 ng/ml. The
second data set comprised 28 participants in the menstrual cycle
phase and showed a sensitivity of 0.73 (95% CI 0.39 to 0.94) and
a specificity of 0.29 (95% CI 0.10 to 0.56) for a cut-off of < 254.6
ng/ml. Another study (60 participants, rASRM I to IV, cycle phase
not reported) demonstrated an opposite direction of differential
expression of sICAM-1 in endometriosis (higher sICAM-1 levels
in endometriosis as opposed to the former study where expression
in endometriosis was lower than in controls (Zhang 2006b). Util-
ising a cut-off threshold of > 241.46 µg/ml, the sensitivity was
0.6 (95% CI 0.41 to 0.77) and the specificity was 0.87 (95% CI
0.69 to 0.96). Four studies reported negative findings for the same
test (271 participants, various phases of menstrual cycle); three
of those studies assessed a wide spectrum of pelvic endometriosis,
rASRM I to IV (De Placido 1998; Paiva 2014; Somigliana 2002),
and one study assessed only minimal-mild disease, rASRM I-II
(Goluda 1998). This evidence suggests that sICAM-1 molecule is
not reliable as a diagnostic test for endometriosis.
3.2. LN-1 (laminin-1)
One study evaluated the value of LN-1 in detecting pelvic en-
dometriosis (73 participants, cycle phase not specified, rASRM II
to IV), demonstrating a sensitivity of 0.72 (95% CI 0.58 to 0.83)
and a specificity of 0.70 (95% CI 0.46 to 0.88). There is insuffi-
cient evidence to comment on the diagnostic performance of this
biomarker.
3.3. Cell adhesion molecules that exhibited no differential
expression in endometriosis
Three studies reported negative findings for three additional
biomarkers from this group (Appendix 7): biglycan (Kocbek
2014b; 96 participants); MMP-9 (Mabrouk 2012; 60 partici-
pants); and sE-selectin (Goluda 1998; 20 participants). In view
of the paucity of data, the diagnostic role of these biomarkers in
endometriosis requires further investigation.
4. Cytoskeleton molecules
4.1. CK19 (Cytokeratin-19) exhibited no differential
expression in endometriosis
One study (79 participants, follicular or luteal cycle phase, severity
not reported) evaluated expression of CK19 in pelvic endometrio-
sis and demonstrated no significant differences in CK19 expres-
sion between the groups (Kuessel 2014). This observation pro-
vides too few data to draw conclusions regarding the diagnostic
role of this blood biomarker in endometriosis.
5. DNA-repair/telomere maintenance molecules
5.1. Telomere length exhibited no differential expression in
endometriosis
One study evaluated telomere length of peripheral bloodmononu-
clear cells (50 participants, luteal cycle phase, rASRM I to IV)
and demonstrated no significant difference between the women
diagnosed with pelvic endometriosis and the disease-free group
(Hapangama 2008). Further studies are required before the di-
agnostic role of telomere length in peripheral blood cells in the
diagnosis of endometriosis can be determined.
6. High-throughput molecular markers
6.1. Metabolome
One study assessed the accuracy of the metabolome in detect-
ing endometriosis (92 participants, all phases of menstrual cy-
cle, ovarian endometriosis, rASRM III to IV) using electrospray
ionisation mass spectrometry (ESI-MS/MS). A diagnostic model
including hydroxy sphingomyelin SMOH C16:1 and the ratio
of phosphatidylcholine PCaa C36:2 to ether-phospholipid PCae
C34:2 was selected using stepwise regression. When adjusted for
age and BMI, it showed a sensitivity of 0.90 (95%CI 0.76 to 0.97)
and a specificity of 0.85 (95% CI 0.72 to 0.93). These estimates
approach the criteria for a SnOUT triage test; however, the trial
assessed a limited spectrum of disease and did not provide the cut-
off thresholds. Although promising, these findings require further
confirmation in a broader group of women with endometriosis.
6.2. Proteome
Four studies included six data sets with a total of 425 partici-
pants, assessing the accuracy of the proteome in detecting en-
dometriosis. All the included studies evaluated rASRM I to IV
pelvic endometriosis and performed matrix-assisted Surface-En-
hanced Laser Desorption Ionization Time-of-Flight Mass Spec-
trometry (SELDI-TOF-MS) (Figure 7). The different groups took
varying approaches to the data analysis and the construction of
a diagnostic model. They described distinct sets of proteins as
discriminating between women with and without endometrio-
sis, precluding a meta-analysis. One study (31 participants, cycle
phase not reported) identified three protein peaks with molecular
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weights of 3,956.00 Da, 11,710.00 Da and 6,986.00 Da, and it
reported a sensitivity of 0.88 (95% CI 0.62 to 0.98) and a speci-
ficity of 0.80 (95% CI 0.52 to 0.96) (Liu 2009). Another group
(139 participants, all phases of menstrual cycle) showed six pro-
tein peaks with molecular weights of 1629.00 Da, 3047.00 Da,
3526.00 Da, 3774.00 Da, 5046.00 Da and 5068.00 Da. This
test demonstrated a sensitivity of 0.66 (95% CI 0.52 to 0.77)
and a specificity of 0.99 (95% CI 0.93 to 1.00) (Seeber 2010)
which meets the criteria for a SpIN triage test. A further study
(90 participants, follicular or luteal cycle phase), demonstrated
that five protein peaks with molecular weights of 4159.00 Da,
5264.00 Da, 5603.00 Da, 9861.00 Da and 10,533.00 Da had a
sensitivity of 0.78 (95% CI 0.65 to 0.89) and a specificity of 0.59
(95% CI 0.42 to 0.74) in detecting endometriosis (Wolfler 2009).
The most recent study reported three separate evaluations for each
menstrual cycle phase with varying sets of proteins for each cycle
phase (Fassbender 2012). Specifically, testing 67participants in the
menstrual cycle phase revealed five peaks with molecular weights
of 9,926.31 Da, 10,072.20 Da, 6753.04 Da, 4302.67 Da and
9328.49 Da, with a sensitivity of 0.40 (95%CI 0.26 to 0.56) and a
specificity of 0.82 (95%CI 0.60 to 0.95). Evaluation of 98 women
in the follicular cycle phase showed that five peaks with molecular
weight of 2831.02 Da, 7554.66 Da, 4241.29 Da, 2953.25 Da and
9927.73 Da had a sensitivity of 0.38 (95% CI 0.27 to 0.51) and a
specificity of 0.85 (95% CI 0.68 to 0.95). In the same study, five
protein peaks in 88 women in the luteal cycle phase hadmolecular
weights of 11,366.30, 5712.69, 10,070.70, 3017.68, 3824.44 Da
had a sensitivity of 0.53 (95% CI 0.39 to 0.66) and a specificity of
0.82 (95% CI 0.65 to 0.93) to detect endometriosis. None of the
studies reported diagnostic cut-off thresholds. Further evaluations
of this diagnostic approach through using standardised analytical
processes with similar sets of markers and defined cut-off thresh-
olds is required for a comprehensive assessment of this diagnostic
tool.
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Figure 7. Summary ROC plot of proteome by SELDI-TOF-MS for detection of endometriosis. Each point
represents the pair of sensitivity and specificity for each evaluation. The size of each point is proportional to
the sample size and the shape designates the tests with different sets of proteins determined by molecular
weight (MW) in daltons (Da). The bars correspond to 95% CIs of each individual evaluation. The data were not
assessed by meta-analysis.
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7. Hormonal markers
7.1. Prolactin
One study that included two data sets with a total of 97 partic-
ipants in the luteal cycle phase explored the diagnostic accuracy
of prolactin for pelvic endometriosis, rASRM I to IV. The study
evaluated two different cut-off thresholds: > 14.8 ng/ml, which
demonstrated a sensitivity of 0.44 (95% CI 0.32 to 0.58) and a
specificity of 0.94 (95% CI 0.80 to 0.99) and > 20 ng/ml, with a
sensitivity of 0.21 (95% CI 0.11 to 0.33) and a specificity of 1.00
(95% CI 0.90 to 1.00). Despite the high specificity, the sensitivity
for the both thresholds remains unacceptably low even for a triage
test. These data are not sufficient to drawmeaningful conclusions.
7.2. Hormonal biomarkers that exhibited no differential
expression in endometriosis
Blood levels of the following hormonal markers showed no sta-
tistically significant difference in women with and without en-
dometriosis (Appendix 7): E2 and progesterone (Hapangama
2008; 50participants); FSHandLH(Lima 2006; 49participants).
Even though we only identified one study for each of these mark-
ers, the findings are consistent with other studies in the litera-
ture addressing hormonal alterations in endometriosis. We do not
therefore recommend further research on the diagnostic accuracy
of these biomarkers for endometriosis.
8. Immune system and inflammatory markers
8.1. Autoantibodies
8.1.a. Anti-endometrial autoantibodies (anti-endometrial
Abs)
Five studies comprising 795 participants assessed the value of
anti-endometrial Abs in detecting pelvic endometriosis. Of these,
four studies (759 participants, varying phases of menstrual cycle,
rASRM I to IV (3 studies) or unclear severity (1 study)) evalu-
ated IgG anti-endometrial Abs using various immunofluorescence
methods and different definitions of a positive test.The estimates
for sensitivity ranged from 0.56 to 0.87 and for specificity from
0.57 to 0.93. The mean sensitivity and specificity of all these eval-
uations were 0.81 (95% CI 0.76 to 0.87) and 0.75 (95% CI 0.46
to 1.00), which did not meet the criteria for either a replacement
or triage test. Forest plots (Figure 8) and the ROC plot (Figure 9)
showed a high degree of heterogeneity for estimates of both sen-
sitivity and specificity. An additional study (36 participants, cycle
phase not reported, rASRM I to IV) demonstrated that anti-en-
dometrial Abs of a specific molecular weight (MW) were differen-
tially expressed in endometriosis, and the expression of at least one
of the antibodies with MWs of 26 kDa, 34 kDa or 42 kDa had a
sensitivity of 1.00 (95% CI 0.81 to 1.00) and a specificity of 0.39
(95% CI 0.17 to 0.64) (Gorai 1993) (Figure 9; Figure 8). This
study could not be added to the meta-analysis as the definition of
the index test was different, and we considered it separately. The
same study assessed an alternate set of antibodies with MWs of 28
kDa, 38 kDa and 64 kDa, the expression of which was not altered
in presence of endometriosis. A further study (80 participants, cy-
cle phase not reported, rASRM I to IV) also demonstrated that the
serum levels of anti-endometrial Abs were comparable between
control and endometriosis groups (Ozhan 2014).
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Figure 8. Forest plot of anti-endometrial Abs for detection of endometriosis. Plot shows study-specific
estimates of sensitivity and specificity (squares) with 95% CI (black line), country in which the study was
conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each
study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP:
false positive; TN: true negative; TP: true positive.
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Figure 9. Summary ROC plot of anti-endometrial Abs, IgG for detection of endometriosis. Each point
represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to
the sample size and the shape designates the tests with different sets of antibodies tested. The bars
correspond to 95% CIs of each individual evaluation. The solid black circle represents the mean sensitivity and
specificity, which is surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed
line). Meta-analysis was performed for 4 studies (the data for Anti-endometrial Abs (MW 26/34/42 kd) were
not included, considering it as a separate test).
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8.1.b. Anti-laminin autoantibodies (anti-laminin-1 Abs)
One study (68 participants, cycle phase not reported, rASRM I to
IV) evaluated an accuracy of anti-laminin-1Abs in detecting pelvic
endometriosis. Using a cut-off threshold of > 1 U/ml, the test had
a sensitivity of 0.40 (95%CI 0.26 to 0.57) and a specificity of 0.88
(95% CI 0.70 to 0.98). Although there is insufficient evidence to
have certainty regarding the role of anti-laminin-1 Abs as a marker
for endometriosis, these data suggest it is of limited value.
8.1.c. Autoantibodies that exhibited no differential expression
in endometriosis
Two additional types of autoantibodies, anti-sperm and anti-
zona pellucida Abs, were evaluated in association with minimal
endometriosis in one study (98 participants, luteal cycle phase,
rASRM I) (Szczepanska 2001a). The levels of these antibodies did
not significantly differ in women with and without endometriosis;
however, further data from additional studies for broader spec-
trum of disease is required to draw meaningful conclusions.
8.2. Chemokines
8.2.a. CCR1 (C-C motif receptor 1)
None of the eligible studies assessed the performance of CCR1 as a
single test for detecting endometriosis. This biomarker was a part
of a panel that constitutes a combinedblood test for endometriosis,
as presented below under ’Combined tests’.
8.2.b. MCP-1 (monocyte chemotactic protein-1)
One study assessed the diagnostic accuracy of MCP-1 in pelvic
endometriosis (101 participants, menstrual cycle phase, rASRM
I to IV) and demonstrated a sensitivity of 0.65 (95% CI 0.51
to 0.77) and a specificity of 0.61 (95% CI 0.45 to 0.76). Four
other studies (361 participants, various phases of menstrual cycle)
revealed that MCP-1 levels were not altered by a wide spectrum of
pelvic endometriosis, rASRM I to IV (Drosdzol-Cop 2012b; Kim
2008; Paiva 2014) or by only minimal-mild disease, rASRM I-II
(Kalu 2007). Based on the available evidence, MCP-1 in blood
appears to have little value as a diagnostic test for endometriosis.
8.3. Other Cytokines
8.3.a. IFN-γ (interferon-gamma)
One study (45 participants, follicular cycle phase, rASRM I to IV)
evaluated IFN-γ and demonstrated a sensitivity of 0.68 (95% CI
0.48 to 0.84) and a specificity of 0.65 (95% CI 0.38 to 0.86) for
the diagnosis of pelvic ultrasound negative endometriosis using
a cut-off value of < 76.00 pg/ml. Another five studies (455 par-
ticipants, rASRM I to IV) demonstrated no difference in IFN-
γ levels in women with and without pelvic endometriosis in the
follicular phase (Hassa 2009), follicular or luteal phase (Podgaec
2007; Seeber 2008), or when the cycle phase was not specified
(Matalliotakis 2003a; Wu 1998). In view of the data available,
IFN-γ appears to be unreliable as a test for pelvic endometriosis.
8.3.b. MIF (macrophage migration inhibitory factor)
One study evaluated the value of MIF in detecting pelvic en-
dometriosis (93 participants, follicular or luteal cycle phase,
rASRM I to IV), and showed a sensitivity of 0.65 (95% CI 0.51
to 0.78) and a specificity of 0.66 (95% CI 0.49 to 0.80) at a cut-
off threshold of > 0.57 ng/ml. Three studies (322 participants,
menstrual cycle phase not reported, rASRM I to IV) reported that
MF levels were not altered in pelvic endometriosis in follicular or
luteal cycle phase (Seeber 2008) or when the cycle phase was not
specified (Ozhan 2014; Paiva 2014), suggesting thatMIF has little
value in diagnosing endometriosis.
8.3.c. TNF-α (tumour necrosis factor alpha)
Three studies evaluated the accuracy of TNF-α in detecting pelvic
endometriosis (256 participants, rASRM I to IV), (Figure 10).
Two studies evaluated diagnostic test performance in the follicu-
lar phase, using contradictory cut-off values of above 12.45 pg/
ml (Foda 2012) and below 45.60 pg/ml (Vodolazkaia 2012), and
another study assessed the test in luteal cycle phase with no re-
ported cut-off value (Mihalyi 2010). The estimates of sensitivity
ranged from 0.68 to 0.89 and the estimates of specificity ranged
from 0.35 to 0.87 (Summary of findings). We did not perform
a meta-analysis because of the diverse definitions of a positive
test. Alternatively, eight studies (633 participants, various phases
of menstrual cycle) showed unchanged levels of TNF-α in blood
in a wide spectrum of pelvic endometriosis, rASRM I to IV (Da
Silva 2014; Drosdzol-Cop 2012a; Othman 2008; Podgaec 2007;
Seeber 2008; Vercellini 1993; Yagmur 2013) or in only minimal-
mild disease, rASRM I-II (Kalu 2007). These conflicting results
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indicate that TNF-α for the detection of endometriosis is unlikely
to be clinically useful.
Figure 10. Summary ROC plot of TNF-α for detection of endometriosis. Each point represents the pair of
sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the
shape designates the tests with different cut-off values. The bars correspond to 95% CIs of each individual
evaluation. The data were not assessed by meta-analysis.
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8.3.d. Other cytokines that exhibited no differential
expression in endometriosis
Additional cytokines evaluated in the included studies (Appendix
7) were Epo (Yagmur 2013; 55 participants) and sGM-CSF
(Matalliotakis 2003a; Othman 2008; Paiva 2014; 287 partici-
pants). While the data is scarce for Epo, it is sufficient to suggest
that GM-CSF is an inadequate marker for the diagnosis of pelvic
endometriosis.
8.4. Immune cells
8.4.a. Neutrophils, NLR (neutrophil-to-lymphocyte ratio),
WBC (white blood cells)
One study (100 participants, menstrual phase, rASRM I to IV)
evaluated the accuracy of immune cells in diagnosing pelvic en-
dometriosis and reported unsatisfactory estimates for neutrophils
at a cut-off of > 4058 cells/ml (sensitivity 0.68, 95% CI 0.53 to
0.80, specificity 0.60, 95% CI 0.45 to 0.74); for NLR (neutrophil
lymphocyte ratio), at a cut-off of > 2.19 (sensitivity 0.76, 95%
CI 0.62 to 0.87, specificity 0.82, 95% CI 0.69 to 0.91) and for
WBC at a cut-off of > 6400 cells/ml (sensitivity 0.64, 95% CI
0.49 to 0.77, specificity 0.54, 95% CI 0.39 to 0.68). Other stud-
ies reported negative findings for these biomarkers, specifically
for neutrophils and NLR (Yavuzcan 2013); 94 participants, cycle
phase not reported, rASRM III to IV) and for WBC (3 studies,
222 participants, follicular or undetermined cycle phase, rASRM
I to IV in Gogacz 2014 and Tuten 2014a), or rASRM III to IV
in Yavuzcan 2013). These data indicate that WBC levels are not
reliable as a diagnostic test for endometriosis, whilst the data for
neutrophils and NLR are discouraging but scant.
8.4.b. Immune cells that exhibited no differential expression
in endometriosis
We investigated additional peripheral immune cells and found
them to be similar in women with and without endometriosis, as
presented in Appendix 7. The tested markers from this subgroup
included:
1. lymphocytes (Gogacz 2014; Hassa 2009; Matveeva 1990;
Yavuzcan 2013; 352 participants);
2. B-lymphocytes (Iwasaki 1993; Maeda 2002a; Zhang
2006a; 223 participants);
3. monocytes/macrophages (Maeda 2002a; 54 participants);
4. NK cells (Hassa 2009; Iwasaki 1993; Maeda 2002a; Zhang
2006a; 320 participants);
5. NKR CD158b+ (KIR2DL2+NK) and NKR CD94+
(Maeda 2002b; Zhang 2006a; 206 participants);
6. T-lymphocytes and specific T-cell populations:
i) T-cells (Iwasaki 1993; Maeda 2002a; Matveeva 1990;
Zhang 2006a; 6 data sets, 342 participants);
ii) T-inducers (Iwasaki 1993; 45 participants);
iii) T-helpers (Hassa 2009; Iwasaki 1993; Maeda 2002a;
Matveeva 1990; Mier-Cabrera 2011; Zhang 2006a; 501
participants);
iv) T-suppressors (Hassa 2009; Maeda 2002a; Matveeva
1990; Mier-Cabrera 2011; Zhang 2006a; 6 data sets, 456
participants);
7. Treg cells (regulatory T cells) (Gogacz 2014;
Olkowska-Truchanowicz 2013; 3 data sets, 74 participants);
8. haemoglobin (Yavuzcan 2013; 94 participants);
9. MPV (Yavuzcan 2013; 94 participants);
10. platelet count (Yavuzcan 2013; 94 participants);
11. PLR (Yavuzcan 2013; 94 participants).
This evidence clearly indicates that most of the evaluated periph-
eral blood mononuclear cells have no role as a diagnostic marker
for endometriosis. The finding is consistent with the general theme
of literature addressing other components of full blood count (hae-
moglobin, platelets, MPV). Therefore, except for the unexplored
phenotypes of Treg cells, we do not recommend further research
on the diagnostic accuracy of these biomarkers for endometriosis.
8.5. Interleukins
8.5.a. IL-1β (interleukin-1β)
One study (45 participants, follicular cycle phase, rASRM I to
IV) evaluated the diagnostic role of IL-1β in ultrasound negative
pelvic endometriosis, showing a sensitivity of 0.82 (95% CI 0.63
to 0.94) and a specificity of 0.35 (95% CI 0.14 to 0.62) for the
cut-off value of < 0.90 pg/ml. Four additional studies (248 par-
ticipants, various cycle phases) showed that IL-1β remained un-
changed in a wide spectrum of pelvic endometriosis, rASRM I to
IV (Bedaiwy 2002; Oku 2004; Szubert 2014), or in only mini-
mal-mild disease, rASRM I-II (Kalu 2007). Taken together, these
results demonstrate that IL-1β has a limited value in detecting
pelvic endometriosis.
8.5.b. IL-4 (interleukin - 4)
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One study reported the diagnostic accuracy of IL-4 (50 women,
follicular cycle phase, rASRM I to IV), showing inadequate es-
timates for both sensitivity and specificity for a cut-off value ≥
3.00 pg/ml (0.64, 95% CI 0.45 to 0.80 and 0.65, 95% CI 0.38 to
0.86, respectively). Two other studies reported negative data for
this biomarker (195 participants, rASRM I to IV) in either the
follicular cycle phase or follicular and luteal cycle phase (Hassa
2009; Podgaec 2007), indicating that IL-4 is unlikely to be an
accurate diagnostic test for endometriosis.
8.5.c. IL-6 (interleukin-6)
Eight studies including 12 data sets with a total of 726 participants
assessed the diagnostic accuracy of IL-6 for endometriosis. All the
studies evaluated pelvic endometriosis (rASRM I to IV in 6 stud-
ies and rASRM I-II in 2 studies), but were performed at various
phases of the menstrual cycle and utilised different cut-off values
(Figure 11). The cut-offs varied from > 1.03 pg/ml to > 25.75 pg/
ml, whilst one study used a cut-off of < 10.00 pg/ml. We only
included three studies (309 participants, of varying cycle phase,
rASRM I to IV) in a meta-analysis, which revealed the summary
sensitivity and specificity of 0.63 (95% CI 0.52 to 0.75) and 0.69
(95% CI 0.57 to 0.82) for the cut-off threshold > 1.90 to 2.00 pg/
ml. The test did not satisfy the criteria for either a replacement or
triage test. Forest plots (Figure 12) and the ROC plot (Figure 13)
showed a high degree of heterogeneity for diagnostic estimates,
ranging from 0.20 to 0.89 for sensitivity and from 0.66 to 0.80 for
specificity. Individual studies evaluated other cut-off thresholds,
as presented in Summary of findings. Studies reported the highest
diagnostic estimates for cut-off value > 12.20 pg/ml (95 partici-
pants, follicular cycle phase, rASRM I to IV) with a sensitivity of
0.95 (95%CI 0.87 to 0.99) and a specificity of 0.83 (95%CI 0.65
to 0.94), which met the criteria for a replacement test; however,
wide confidence intervals, especially for specificity, advises caution
in interpreting these results (Foda 2012). Two studies compared
different cut-off values, specifically > 1.03 pg/ml versus > 1.90 pg/
ml versus > 2.60 pg/ml (Othman 2008) and > 2.00 pg/ml versus >
4.00 pg/ml versus > 7.50 pg/ml (Bedaiwy 2002); however, all had
wide overlapping confidence intervals and presented inconclusive
results (Figure 14). In contrast, six other studies (473 participants,
various phases of menstrual cycle) demonstrated that IL-6 levels
were not affected by the presence of endometriosis when consid-
ering different spectra of disease: rASRM I to IV (Drosdzol-Cop
2012a; Seeber 2008; Somigliana 2004), rASRM I-II (Kalu 2007)
or rASRM III to IV (Jee 2008; Suen 2014). Although the reports
are conflicting, further testing of IL-6 in the follicular cycle phase
at a cutoff value of > 12.20 pg/ml could reveal some diagnostic
benefit.
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Figure 11. Forest plot of IL-6 (all the included evaluations) for detection of endometriosis. Plot shows
estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in
which the study was conducted, menstrual cycle phase at which the test was performed and severity of the
disease assessed by each study, reported as rASRM stage. The studies are ordered according to the study
names. FN: false negative; FP: false positive; TN: true negative; TP: true positive.
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Figure 12. Forest plot of IL-6 with cut-off values above 1.9-2 pg/ml for detection of endometriosis. Plot
shows estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation,
country in which the study was conducted, menstrual cycle phase at which the test was performed and
severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to
the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive.
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Figure 13. Summary ROC plot of IL-6 with cut-off values ranging > 1.9-2 pg/ml for detection of
endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of
each point is proportional to the sample size the shape designates the tests with different sets of antibodies
tested. The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the
summary sensitivity and specificity.
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Figure 14. Forest plot of direct comparisons of IL-6 for detection of endometriosis performed between
different cut-off values in 2 separate studies. Plot shows the estimates of sensitivity and specificity (squares)
with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual
cycle phase at which the test was performed and severity of the disease assessed by each study, reported as
rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN:
true negative; TP: true positive.
8.5.d. IL-8 (interleukin-8)
Two studies explored the accuracy of IL-8 in diagnosing pelvic
endometriosis (217 participants, various cycle phases, rASRM I to
IV), of which one utilised a cut-off value of > 24.00 pg/ml and one
did not report a diagnostic threshold. Due to the heterogeneity
of the methodology, we could not perform a meaningful meta-
analysis. The estimates of sensitivity ranged between 0.49 and 0.62
and of specificity between 0.71 and 0.73 (Summary of findings;
Figure 15). An additional study (91 participants, cut-off value >
25.00 pg/ml) specifically addressed ovarian endometriosis versus
other benign ovarian cysts; we present its findings below under
’Blood biomarkers that could differentiate ovarian endometrioma
from other benign ovarian cysts in women of reproductive age’.
Five other studies (389 participants,various cycle phases) reported
negative data for IL-8 in pelvic endometriosis rASRM I to IV
(Barcz 2002;Gazvani 1998;Othman2008;Ozhan2014), rASRM
I-II (Kalu 2007), or rASRM III to IV (Calienno 2008). These
conflicting results suggest that IL-8 has questionable value as a
diagnostic test for endometriosis.
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Figure 15. Summary ROC plot of IL-8 for detection of endometriosis. Each point represents the pair of
sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size and
the shape designates the tests with different cut-off values. The bars correspond to 95% CIs of each individual
evaluation. The data were not assessed by meta-analysis.
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8.5.e. Interleukins that exhibited no differential expression in
endometriosis
The included studies reported negative findings for endometriosis
with additional types of interleukins, as presented in Appendix 7.
1. IL-2 Drosdzol-Cop 2012b; Hassa 2009; Li 2005; Othman
2008; Podgaec 2007; 433 participants).
2. IL-10 (Andreoli 2011; Braun 1996; Hassa 2009; Podgaec
2007; 305 participants).
3. IL-12 (Andreoli 2011; Bedaiwy 2002; Fairbanks 2009;
Kubatova 2013; Suen 2014; Szczepanska 2001b; 433
participants).
4. IL-13 (Bedaiwy 2002; 53 participants).
5. IL-15 (Othman 2008; 138 participants, biomarker below
detection limit in both groups).
6. IL-16 (Lin 2005; Zhang 2005a; 88 participants).
7. IL-17 (Andreoli 2011; Paiva 2014; 181 participants).
8. IL-18 (Fairbanks 2009; Glitz 2009; Oku 2004; Zhang
2005b; 301 participants).
9. IL-23 (Andreoli 2011: 80 participants).
Many of these interleukins were evaluated by more than one study
and are unlikely to be worthy of further investigation as diagnostic
biomarkers for endometriosis.
8.6. Other immune/inflammatory markers
8.6.a. sCD23 (soluble CD23)
One study evaluated the diagnostic performance of sCD23 for
pelvic endometriosis (97 participants, follicular or luteal cycle
phase, rASRM I to IV), demonstrating a sensitivity of 0.25 (95%
CI 0.14 to 0.38) and a specificity of 0.93 (95% CI 0.80 to 0.98).
Another study (102 participants, menstrual or follicular cycle
phase, rASRM I to IV) demonstrated no significant difference in
sCD23 levels in women with and without endometriosis, indi-
cating that sCD23 is likely to have limited diagnostic value, al-
beit further studies are needed to support this statement (Ramos
2012).
8.6.b. Copeptin, vasopressin surrogate
One study evaluated the accuracy of copeptin in detecting pelvic
endometriosis (87 participants, cycle phase not reported, rASRM
I to IV), showing a sensitivity of 0.65 (95% CI 0.50 to 0.78) and
a specificity of 0.58 (95% CI 0.41 to 0.74). There is insufficient
data to draw meaningful conclusions on the findings from this
single study.
8.6.c. hs-CRP (high sensitive C-reactive protein)
Three studies including six data sets (506 participants, various
menstrual cycle phases, rASRM I to IV) explored the diagnostic
accuracy of hs-CRP for pelvic endometriosis, using various cut-
off thresholds, ranging from 0.60 mg/l to 438 mg/l. Five data sets
included overlapping populations. We did not perform a meta-
analysis because of the methodological heterogeneity. Diagnostic
estimates from the included studies varied, with sensitivities rang-
ing from 0.41 to 0.83 and specificities ranging from 0.47 to 0.87
(Summary of findings; Figure 16; Figure 17). Studies reported
the highest estimates for hs-CRP with a cut-off of > 438 mg/l
(1 study, 95 participants in follicular cycle phase) with a sensi-
tivity of 0.83 (95% CI 0.72 to 0.91) and a specificity of 0.87
(95% CI 0.69 to 0.96) (Foda 2012). One group compared hs-
CRP diagnostic estimates in the menstrual, follicular, luteal or
combination of all phases of the cycle in a total of 295 partici-
pants (Vodolazkaia 2011). The authors established the best cut-
off values in a ROC analysis, which varied depending on the cycle
phase. The diagnostic estimates were low for all evaluations, rang-
ing from 0.54 to 0.68 for sensitivity and from 0.47 to 0.64 for
specificity (Figure 16). Six additional studies (1333 participants,
various cycle phases) demonstrated no difference in expression lev-
els of CRP or hs-CRP in a wide spectrum of pelvic endometriosis,
rASRM I to IV (Dayangan Sayan 2013; Riley 2007; Szubert 2014;
Thubert 2014; Tuten 2014a) or when the severity of the disease
was not reported (Kianpour 2012). The methods included the hs-
CRP assay in Thubert 2014 (834 participants) and the CRP as-
say in the other studies (499 participants). A comparison between
the two assay methods concluded that hs-CRP assay had higher
diagnostic accuracy than the traditional CRP assay (Vodolazkaia
2011). Collectively, the available evidence suggests that CRP eval-
uated by either method is not a reliable biomarker for detecting
endometriosis.
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Figure 16. Forest plot of hs-CRP for detection of endometriosis. Plot shows the estimates of sensitivity and
specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was
conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each
study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP:
false positive; TN: true negative; TP: true positive.
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Figure 17. Summary ROC plot of hs-CRP for detection of endometriosis. Each point represents the pair of
sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and the
shape designates the tests with different cut-off values. The bars correspond to 95% CIs of each individual
evaluation. Five evaluations (excluding 1 with a cut-off > 438 µg/ml) were performed on overlapping
populations. The data were not assessed by meta-analysis.
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8.6.d. Other immune system and inflammatory markers that
exhibited no differential expression in endometriosis
The other immune system and inflammatory biomarkers for
which only negative data were reported included (Appendix 7):
1. C3a (Fassbender 2009; 160 participants);
2. sHLA-I (De Placido 1998; 30 participants);
3. immunoglobulins: IgA, IgG (Matveeva 1990; 119
participants);
4. MPO (Da Silva 2014; 17 participants);
5. NAG (Da Silva 2014; 17 participants);
6. PGE2 (Khan 2012; 86 participants);
7. phospholipid fatty acids (Khanaki 2012; 138 participants,
16 fatty acids);
8. PLA2G2A (Kocbek 2014a; 91 participants);
9. RANTES (Kalu 2007; Markham 1997a; 72 participants).
Except for RANTES, all other biomarkers from this group were
assessed in a single study, and their association with endometriosis
remains unclear.
9. Nerve growth markers
9.1. Nerve growth markers that exhibited no differential
expression in endometriosis
One study (101 participants, cycle phase not reported, rASRM
I to IV) evaluated four nerve growth markers (CNTF, GDNF,
NGF,NT4), showing no association between any of these tests and
endometriosis (Paiva 2014), as presented in Appendix 7. Future
research needs to confirm the expression of these biomarkers in
endometriosis and their value in the diagnosis of the disease.
10. Other peptides/proteins shown to influence key events
implicated in endometriosis
10.1. Follistatin
Follistatin was only evaluated in the context of ovarian endometri-
oma and is presented below under ’Blood biomarkers that could
differentiate ovarian endometrioma from other benign ovarian
cysts in women of reproductive age’.
10.2. STX-5 (syntaxin-5)
One study reported on the diagnostic performance of STX-5 in
endometriosis (80 participants, cycle phase not reported, rASRM
I to IV), using a cut-off of > 55 ng/ml, with a sensitivity of 0.78
(95% CI 0.66 to 0.88) and a specificity of 0.70 (95% CI 0.46
to 0.88); Ozhan 2014. The diagnostic estimates did not meet the
criteria for an adequate diagnostic test (replacement or triage), but
additional studies need to support this observation.
10.3. Other peptides/proteins that exhibited no differential
expression in endometriosis
Three additional proteins (DBP (Borkowski 2008; Ferrero 2005a;
171 participants), enolase and PDPK1 (Ozhan 2014; 80 partic-
ipants) were evaluated for their association with endometriosis.
Their serum levels did not distinguish women with endometriosis
from controls (Appendix 7).
11. Oxidative stress markers
11.1. Carbonyls
One study (Rosa E Silva 2014) assessed the diagnostic role of car-
bonyls in endometriosis (108 participants, cycle phase and spec-
trum of the disease not reported), demonstrating a sensitivity of
0.94 (95% CI 0.85 to 0.98) and a specificity of 0.51 (95% CI
0.35 to 0.67) at a cut-off value of < 14.9 µm. This approaches
the criteria for a SnOUT triage test, but large high quality studies
need to confirm this finding.
11.2. PON-1 (paraoxonase-1)
One study (Verit 2008) reported on the ability of PON-1 to diag-
nose pelvic endometriosis (87 participants, follicular cycle phase,
rASRM I to IV). The diagnostic estimates were high enough to
fulfil the criteria for a replacement test (sensitivity 0.98, 95% CI
0.89 to 1.00 and specificity 0.80, 95% CI 0.64 to 0.91), using a
cut-off threshold of < 141.5 U/ml. Further studies are required to
confirm this finding.
11.3. Thiols
One study (Rosa E Silva 2014) tested the accuracy of thiols in
detecting pelvic endometriosis (108 participants, cycle phase and
spectrum of the disease not reported), showing a sensitivity of 0.73
(95% CI 0.61 to 0.83) and a specificity of 0.80 (95% CI 0.65 to
0.91) at a cut-off value of < 396.44 µm. Further data is required
before a comment can be made on its diagnostic role.
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11.4. Oxidative stress markers that exhibited no differential
expression in endometriosis
Additional oxidative stressmarkers that appeared to have compara-
ble levels in women with and without endometriosis (Appendix 7)
included ascorbic acid andmalondialdehyde (Mier-Cabrera 2011;
62 participants); GSH, nitrotyrosine, SOD3 and vitamin E (Paiva
2014; 101 participants); HSP70 (Khan 2013; Lambrinoudaki
2009; 116 participants); and IMA and TRX (Lambrinoudaki
2009; 66 participants).
Although the diagnostic studies for these biomarkers are encour-
aging (Figure 18), there is insufficient evidence to draw meaning-
ful conclusions regarding any biomarker from this group, and fur-
ther research is recommended to confirm the positive and negative
findings presented above.
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Figure 18. Summary ROC plot of oxidative stress biomarkers for detection of endometriosis. Each point
represents the pair of sensitivity and specificity from each evaluation. The size of each point is proportional to
the sample size and the shape designates different biomarkers from this group, each assessed in a single study.
The bars correspond to 95% CIs of each individual evaluation. The data were not assessed by meta-analysis.
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12. Post-transcriptional regulators of gene expression
(microRNAs)
There were two eligible studies that evaluated the role of microR-
NAs (miRs) in detecting endometriosis (Figure 19). One study
(85 participants, follicular or luteal cycle phase) assessed diagnos-
tic accuracy of six microRNAs in pelvic endometriosis, rASRM I
to IV (Wang 2013a).
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Figure 19. Summary ROC plot of microRNAs for detection of endometriosis. Each point represents the
pair of sensitivity and specificity from each evaluation. The size of each point is proportional to the sample size
and the shape designates different biomarkers from this group, each assessed in a single study. The bars
correspond to 95% CIs of each individual evaluation. The data were not assessed by meta-analysis.
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1. miR-9* (sensitivity 0.68, 95% CI 0.55 to 0.80 and
specificity 0.96, 95% CI 0.80 to 1.00).
2. miR-122 (sensitivity 0.80, 95% CI 0.68 to 0.89 and
specificity 0.76, 95% CI 0.55 to 0.91).
3. miR-141* (sensitivity 0.72, 95% CI 0.59 to 0.83 and
specificity 0.96, 95% CI 0.80 to 1.00).
4. miR-145* (sensitivity 0.70, 95% CI 0.57 to 0.81 and
specificity 0.96, 95% CI 0.80 to 1.00).
5. miR-199a (sensitivity 0.78, 95% CI 0.66 to 0.88 and
specificity 0.76, 95% CI 0.55 to 0.91).
6. miR-532-3p (sensitivity 0.80, 95% CI 0.68 to 0.89 and
specificity 0.92, 95% CI 0.74 to 0.99).
The authors did not report the cut-off values for any of the tested
biomarkers.
Another group published data on diagnostic performance of three
microRNAs (40 participants, follicular or luteal cycle phase) in
moderate-severe pelvic endometriosis, rASRMIII to IV (Jia 2013):
miR-17-5 (sensitivity 0.70, 95% CI 0.46 to 0.88 and specificity
0.70, 95% CI 0.46 to 0.88 for the cut-off of < 0.9057); miR-20a
(sensitivity 0.60, 95%CI0.36 to 0.81 and specificity 0.90, 95%CI
0.68 to 0.99, for the cut-off of < 0.6879) and miR-22 (sensitivity
0.90, 95% CI 0.68 to 0.99 and specificity 0.80, 95% CI 0.56 to
0.94 for the cut-off of < 0.5647). Both Jia 2013 and Wang 2013a
varied in laboratory methodology and approach to quantifying
and analysing the data. MiR-9*, miR-141* and miR-145* met
the criteria of a SpIN triage test, and miR-532-30, miR-20a and
miR-22 approached these criteria.While several microRNAs show
some promise as diagnostic markers for endometriosis, the two
published studies identified completely independent microRNA
biomarkers. These results require further validation in a large,
well-defined population with a wide spectrum of disease, using a
standardised reproducible methodology.
13. Tumour markers
13.1. CA-15.3 (cancer antigen-15.3)
Two studies (Tuten 2014a; Muscatello 1992) (207 participants,
various phases of menstrual cycle, rASRM I to IV) assessed the
diagnostic performance of CA-15.3 in endometriosis with sub-
stantially heterogeneous estimates. Each study used different cut-
off thresholds, so we did not include them in a meta-analysis. In
both studies the levels of CA-15.3 were not significantly different
in women with and without endometriosis, although the diagnos-
tic test estimates were calculated. None of the included studies
exhibited high diagnostic accuracy, with sensitivities ranging from
0.65 to 0.04 and specificities from ranging 0.62 to 0.92.
13.2. CA-19.9 (cancer antigen-19.9)
Seven studies (8 data sets, 793 participants, various phases of men-
strual cycle, rASRM I to IV) explored the role of CA-19.9 in pelvic
endometriosis. Three evaluations were performed in an overlap-
ping population (Harada 2002; Kurdoglu 2009; Mabrouk 2012;
Mihalyi 2010; Somigliana 2004;Tuten 2014a;Vodolazkaia 2012).
Studies used very diverse cut-off thresholds, ranging from > 7.5
U/ml to > 37.0 U/ml, while two studies did not report the cut-off.
In view of inconsistencies in the methods, a meta-analysis was le-
gitimate only for three studies with a total of 309 participants that
assessed CA-19.9 for a cut-off value > 37.0 U/ml. The summary
sensitivity was 0.36 (95%CI 0.26 to 0.45) and the summary speci-
ficity was 0.87 (95% CI 0.75 to 0.99) (Harada 2002; Kurdoglu
2009; Somigliana 2004) (Figure 20). One study from this sub-
group (80 participants, all cycle phases, rASRM I to IV) demon-
strated that the serum levels of CA-19.9 were comparable between
the control and endometriosis groups (Somigliana 2004). Other
evaluations of this biomarker were reported separately, and none
presented clinically meaningful diagnostic estimates, with a sensi-
tivity ranging from0.36 to 0.73 and a specificity from0.56 to 0.90
(see Summary of findings; Figure 21). An additional study (118
participants, follicular cycle phase; Guerriero 1996a) addressed
only ovarian endometriosis versus other benign ovarian cysts and is
reported separately (see ’Blood biomarkers that could differentiate
ovarian endometrioma from other benign ovarian cysts in women
of reproductive age’).
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Figure 20. Summary ROC plot of CA-19.9 with a cut-off value > 37 U/ml for detection of endometriosis.
Each point represents the pair of sensitivity and specificity from each evaluation. The size of each point is
proportional to the sample size and the shape designates the tests with different sets of antibodies tested. The
bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the summary
sensitivity and specificity.
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Figure 21. Forest plot of CA-19.9 (all the evaluations) for detection of endometriosis. Plot shows estimates
of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the
study was conducted, menstrual cycle phase at which the test was performed and severity of the disease
assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN:
false negative; FP: false positive; TN: true negative; TP: true positive.
13.3. CA-72 (TAG-72) (cancer antigen-72 or tumour
associated glycoprotein-72)
Two studies (Molo 1994; Muscatello 1992) evaluated the role of
CA-72 in detecting pelvic endometriosis in varying phases of men-
strual cycle, using different cut-off values. One study (35 partic-
ipants in the follicular cycle phase, rASRM stage not reported)
reported a sensitivity 0.05 (95% CI 0.00 to 0.26) and a speci-
ficity 0.75 (95% CI 0.48 to 0.93) for the cut-off > 4.0 U/ml;
Molo 1994. A second study (119 participants in luteal cycle phase,
rASRM I to IV) demonstrated a sensitivity of 0.09 (95% CI 0.04
to 0.17) and a specificity of 0.89 (95% CI 0.75 to 0.97) for the
cut-off value > 6.0 U/ml; Muscatello 1992. A meta-analysis was
not performed as the methodology was heterogeneous, but both
presented unacceptably low sensitivities indicating no clinically
applicable alteration of blood CA-72 levels in the presence of en-
dometriosis, which shows that this biomarker is not suitable for
detecting disease.
13.4. CA-125 (cancer antigen-125)
Forty-five studies including 60 data sets with a total of 5534 par-
ticipants explored the accuracy of CA-125 in the diagnosis of en-
dometriosis. The included evaluations were performed in varying
phases of the menstrual cycle for different spectra of the disease
and using a broad range of cut-off thresholds, from > 10.0 U/ml to
> 42.0 U/ml (Summary of findings; Figure 22). Since a sufficient
number of studies assessed CA-125 for most of the diagnostic cut-
offs, the studies for overall pelvic and ovarian endometriosis were
included in the analysis for each cut-off threshold, with a subse-
quent sensitivity analyses after excluding the data for ovarian en-
dometriosis. We grouped the tests by clinically relevant target cut-
off ranges as follows.
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Figure 22. Forest plot of CA-125 (all the included evaluations) for detection of endometriosis. Plot shows
the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation,
country in which the study was conducted, menstrual cycle phase at which the test was performed and
severity of the disease assessed by each study, reported as rASRM stage. The studies are ordered according to
the study names. FN: false negative; FP: false positive; TN: true negative; TP: true positive.
51Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1. CA-125 with the cut-off values of > 10.0 to 14.7 U/ml (5
studies 769 participants, cycle phase varied, rASRM stage varied)
had a mean sensitivity of 0.70 (95% CI 0.63 to 0.77) and mean
sensitivity of 0.64 (95% CI 0.47 to 0.82), excluding two
overlapping evaluations (Figure 23).
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Figure 23. Summary ROC plot of CA-125 with cut-off values ranging > 10-14.7 U/ml for detection of
endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of
each point is proportional to the sample size and the shape designates the tests with different cut-off values.
The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence
region (dotted line) and by 95% prediction region (dashed line). Meta-analysis was performed for 5 studies (the
data for 2 evaluations (CA-125 > 11.5 U/ml and CA-125 > 13.5 U/ml were not included as overlapping
populations with already included study).
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1. CA-125 with a cut-off threshold of > 16.0 to 17.6 U/ml (5
studies, 430 participants, cycle phase varied, rASRM stage
varied) had a mean sensitivity of 0.56 (95% CI 0.24 to 0.88) and
mean specificity of 0.91 (95% CI 0.75 to 1.00) (Figure 24).
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Figure 24. Summary ROC plot of CA-125 with cut-off values ranging > 16-17.6 U/ml for detection of
endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of
each point is proportional to the sample size and the shape designates the tests with different cut-off values.
The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence
region (dotted line) ad by 95% prediction region (dashed line).
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1. CA-125 with a cut-off threshold of > 20.0 U/ml (6 studies,
1304 participants, cycle phase varied, rASRM stage varied) had a
mean sensitivity of 0.67 (95% CI 0.50 to 0.85) and mean
specificity of 0.69 (95% CI 0.58 to 0.80) (Figure 25). This group
included two studies that specifically aimed to differentiate
ovarian endometriosis from the other benign ovarian masses.
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Figure 25. Summary ROC plot of CA-125 with cut-off values > 20 U/ml for detection of endometriosis. Each
point represents the pair of sensitivity and specificity from each evaluation. The size of each point is
proportional to the sample size. The solid black circle represents the mean sensitivity and specificity, which is
surrounded by a 95% confidence region (dotted line) and by 95% prediction region (dashed line).
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1. CA-125 with a cut-off of > 25.0 to 26.0 U/ml (3 studies,
963 participants, cycle phase varied, rASRM stage varied) had a
summary sensitivity of 0.73 (95% CI 0.67 to 0.79) and
specificity of 0.70 (95% CI 0.63 to 0.77) (Figure 26). In this
group, two studies assessed overall pelvic endometriosis, whilst
one study looked at ovarian endometriosis versus other ovarian
cysts.
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Figure 26. Summary ROC plot of CA-125 with cut-off values ranging > 25-26 U/ml for detection of
endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of
each point is proportional to the sample size and the shape designates the tests with different cut-off values.
The bars correspond to 95% CIs of each individual evaluation. The solid black circle represents the summary
sensitivity and specificity.
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1. CA-125 with a cut-off of > 30.0 to 33.0 U/ml (6 studies,
1206 participants, cycle phase varied, rASRM stage varied) had a
mean sensitivity of 0.62 (95% CI 0.45 to 0.79) and specificity of
0.76 (95% CI 0.53 to 1.00) (Figure 27). Two studies included in
the analysis focused on differentiation of ovarian endometriosis
from the other ovarian cysts.
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Figure 27. Summary ROC plot of CA-125 with cut-off values ranging > 30-33 U/ml for detection of
endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of
each point is proportional to the sample size and the shape designates the tests with different cut-off values.
The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence
region (dotted line) and by 95% prediction region (dashed line).
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1. CA-125 with a cut-off threshold of > 35.0 to 36.0 U/ml
(27 studies, 3276 participants, cycle phase varied, rASRM stage
varied) had a mean sensitivity of 0.40 (95% CI 0.32 to 0.49) and
specificity of 0.91 (95% CI 0.88 to 0.94) (Figure 28). Meta-
analysis included two studies differentiating ovarian
endometrioma from other ovarian cysts.
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Figure 28. Summary ROC plot of CA-125 with cut-off values ranging > 35-36 U/ml for detection of
endometriosis. Each point represents the pair of sensitivity and specificity from each evaluation. The size of
each point is proportional to the sample size and the shape designates the tests with different cut-off values.
The solid black circle represents the mean sensitivity and specificity, which is surrounded by a 95% confidence
region (dotted line) and by 95% prediction region (dashed line).
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1. Only two studies reported CA-125 with a cut-off of > 42.0
to 43.0 U/ml, of which one (104 participants, cut-off value >
42.0 U/ml) assessed the performance of CA-125 in
differentiating ovarian endometrioma from other benign ovarian
cysts (presented separately). The second study (62 participants,
cycle phase not reported, rASRM III to IV, cut-off value > 43.0
U/ml) was not confined to ovarian disease and included any type
of endometriosis, demonstrating a sensitivity of 1.00 (95% CI
0.92 to 1.00) and a specificity of 0.80 (95% CI 56 to 0.94). The
studies were not combined in a meta-analysis due to the
heterogeneity of the included populations and paucity of the
data.
2. The cut-off thresholds were not reported in four evaluations
of CA-125, three of which had overlapping populations and
were presented separately (Summary of findings).
Overall, none of the cut-off thresholds for CA-125 subjected to
a meta-analysis met the criteria for either a replacement or triage
test. Only CA-125, with a cut-off value > 16.0 to 17.6 U/ml ap-
proached the criteria for a SpIN triage test, but results showed a
substantial degree of heterogeneity and wide confidence intervals.
Even though the reported diagnostic estimates for CA-125 with a
cut-off of > 43.0 U/ml met the criteria for a replacement test, this
cut-off value came from an individual study and only for moder-
ate-severe forms of endometriosis. This is consistent with the com-
monly reported observation that CA-125 levels were significantly
increased in advanced stages of endometriosis and minimally al-
tered in minimal-mild disease. Further large, well-designed diag-
nostic studies are required to evaluate the role of CA-125 with
a cut-off > 43.0 U/ml in a population with a wide spectrum of
endometriosis.
Two further studies (112 participants, follicular or follicular and
luteal cycle phase) showed no association between CA-125 and
endometriosis when assessing the full spectrum of the disease
(rASRM I to IV) (Riley 2007) or only minimal-mild endometrio-
sis (Barbosa 2009), as presented in Appendix 7.
A meta-analysis was undertaken for each specific cut-off value
of CA-125 and included the studies that assessed its ability to
detect pelvic endometriosis as well as the studies that aimed to
determine if an ovarian mass was an endometrioma. The estimates
from the studies that specifically evaluated ovarian endometrioma
are also reported separately under ’Blood biomarkers that could
differentiate ovarian endometrioma from other benign ovarian
cysts in women of reproductive age’ with the aim of evaluating
the role of the test in differential diagnosis of ovarian masses in
reproductive-aged women.
Direct comparisons for CA-125
Eight studies presented direct head-to-head comparisons between
different cut-off thresholds for CA-125.
1. > 20.0 U/ml versus > 35.0 U/ml (Bilibio 2014).
2. > 16.0 U/ml versus >35.0 U/ml (Ferreira 1994).
3. > 30.0 U/ml versus > 36.0 U/ml (Florio 2007).
4. > 12.8 U/ml versus > 35.0 U/ml (Gagne 2003a).
5. > 20.0 U/ml versus > 25.0 U/ml versus > 35.0 U/ml
(Guerriero 1996b).
6. > 20.0 U/ml versus > 26.0 U/ml versus > 30.0 U/ml versus
> 35.0 U/ml (Kitawaki 2005).
7. > 10.0 U/ml versus > 20.0 U/ml (Rosa E Silva 2007).
8. > 20.0 U/ml versus >35.0 U/ml (Yang 1994).
Neither threshold appeared to be superior in most studies, and
even when the diagnostic performance was improved when a dif-
ferent threshold was utilised, none of the threshold levels met the
criteria for an adequate replacement or triage diagnostic test for
endometriosis (Figure 29). Two studies performed head-to-head
comparisons between different phases of menstrual cycle: > 11.5
U/ml follicular versus > 13.5 U/ml luteal versus > 12.5 U/ml all
cycle phases (Vodolazkaia 2012); and menstrual versus follicular
versus luteal, no cut-off reported (Mihalyi 2010). The test per-
formance appeared to be improved in the follicular phase in one
study (Vodolazkaia 2012) and in themenstrual or follicular phases
in another study (Mihalyi 2010); however, the estimates were still
lower than the criteria for an adequate replacement or triage test
(Figure 30). Twenty-one studies directly compared the diagnos-
tic performance of CA-125 with other blood biomarkers (Bilibio
2014; Dayangan Sayan 2013; Florio 2007; Florio 2009; Foda
2012; Harada 2002; Kurdoglu 2009; Mabrouk 2012; Martinez
2007; Mihalyi 2010; Mohamed 2013; Molo 1994; Muscatello
1992;Ohata 2008;Ozhan 2014; Somigliana 2004; Tokmak 2011;
Tuten 2014a; Vodolazkaia 2012;Wild 1991a; Yang 1994). In view
of the unsatisfactory diagnostic performance of CA-125 as a diag-
nostic or triage test, we do not discuss these comparisons in detail.
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Figure 29. Forest plot of direct comparisons of CA-125 for detection of endometriosis performed between
different cut-off values in 8 separate studies. Plot shows the estimates of sensitivity and specificity (squares)
with 95% CI (black line) specific for each evaluation, country in which the study was conducted, menstrual
cycle phase at which the test was performed and severity of the disease assessed by each study, reported as
rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false positive; TN:
true negative; TP: true positive.
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Figure 30. Forest plot of direct comparisons of CA-125 for detection of endometriosis performed between
different phases of menstrual cycle in 2 separate studies. Plot shows the estimates of sensitivity and specificity
(squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted,
menstrual cycle phase at which the test was performed and severity of the disease assessed by each study,
reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false
positive; TN: true negative; TP: true positive.
13.5. Tumour markers that exhibited no differential
expression in endometriosis
There was no significant difference in the serum levels for sev-
eral other tumour markers in women with and without en-
dometriosis (Appendix 7), including AFP, c-erbB-2 (HER-2/neu)
(Philippoussis 2004; 72 participants) and HE4 (Hallamaa 2012;
175 participants). Additional studies need to confirm these data.
14. Combined blood tests
There were 28 combined tests, comprised of two to six blood
biomarkers that were evaluated as diagnostic tests for endometrio-
sis and two other tests that attempted to discriminate ovarian en-
dometriosis from other benign masses. We present the data for all
the evaluated combined biomarkers, including the cut-off values
and the analytical methods, in Summary of findings and Figure 31.
Twenty-three tests combined CA-125 with other blood biomark-
ers (Figure 32). Each set of biomarkerswas tested in individual clin-
ical trials that varied with respect to the selection of the biomark-
ers constituting the test and the population studied. The most
promising results were reported for eight combined tests (Figure
33).
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Figure 31. Forest plot of the combined tests (all the included evaluations) for detection of endometriosis,
which consist of the combinations of 2-6 blood biomarkers. Plot shows the estimates of sensitivity and
specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the study was
conducted, menstrual cycle phase at which the test was performed and severity of the disease assessed by each
study, reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP:
false positive; TN: true negative; TP: true positive.
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Figure 32. Forest plot of the combined tests for detection of endometriosis, which consist of the
combinations of CA-125 with other blood biomarkers. Plot shows the estimates of sensitivity and specificity
(squares) with 95% CI (black line) specific for each evaluation, country in which the study was conducted,
menstrual cycle phase at which the test was performed and severity of the disease assessed by each study,
reported as rASRM stage. The studies are ordered according to the study names. FN: false negative; FP: false
positive; TN: true negative; TP: true positive.
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Figure 33. Forest plot of the most promising combined tests of blood biomarkers for detection of
endometriosis. Plot shows the estimates of sensitivity and specificity (squares) with 95% CI (black line) specific
for each evaluation, country in which the study was conducted, menstrual cycle phase at which the test was
performed and severity of the disease assessed by each study, reported as rASRM stage. FN: false negative; FP:
false positive; TN: true negative; TP: true positive.
1. miR-199a + miR-542-3p (85 participants, follicular or
luteal cycle phase, rASRM I to IV) with a sensitivity of 0.97
(95% CI 0.88 to 1.00) and a specificity of 0.88 (95% CI 0.69 to
0.97), demonstrating estimates that reached the criteria for either
replacement or SnOUT triage test (Wang 2013a).
2. CA-125 +/CCR1 +/MCP-1 (151 participants, follicular
cycle phase; rASRM I to IV) with a sensitivity of 0.92 (95% CI
0.85 to 0.97) and a specificity of 0.82 (95% CI 0.68 to 0.91),
demonstrating diagnostic estimates that approached that of a
replacement or SnOUT triage test (Agic 2008).
3. miR-199a + miR-122 + miR-145* + miR-542-3p (85
participants, follicular or luteal cycle phase; rASRM I to IV) with
a sensitivity of 0.93 (95% CI 0.84 to 0.98) and a specificity of
0.96 (95% CI 0.80 to 1.00), demonstrating diagnostic estimates
that approached that of a replacement or SnOUT triage test
(Wang 2013a).
4. CA-125 + STX-5 + LN-1, cut-off not reported (80
participants, cycle phase not reported, rASRM I to IV) with a
sensitivity of 0.95 (95% CI 0.86 to 0.99) and a specificity of
0.70 (95% CI 0.46 to 0.88), meeting the criteria for SnOUT
triage test (Ozhan 2014).
5. IL-6 > 12.20 pg/ml + TNF-α >12.45 pg/ml (96
participants, follicular cycle phase, rASRM I to IV) with a
sensitivity of 0.70 (95% CI 0.57 to 0.80) and a specificity of
1.00 (95% CI 0.88 to 1.00), meeting the criteria for SpIN triage
test (Foda 2012).
6. IL-6 > 12.20 pg/ml + CRP > 438 µg/ml (95 participants,
follicular cycle phase, rASRM I to IV) with a sensitivity of 0.75
(95% CI 0.63 to 0.85) and a specificity of 1.00 (95% CI 0.88 to
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1.00), meeting the criteria for SpIN triage test (Foda 2012).
7. TNF-α > 12.45 pg/ml + CRP > 438 µg/ml (95
participants, follicular cycle phase, rASRM I to IV) with a
sensitivity of 0.74 (95% CI 0.61 to 0.84) and a specificity of
1.00 (95% CI 0.88 to 1.00), meeting the criteria for SpIN triage
test (Foda 2012).
8. IL-6 > 12.20 pg/ml + TNF-α > 12.45 pg/ml + CRP > 438
µg/ml (95 participants, follicular cycle phase, rASRM I to IV)
with a sensitivity of 0.63 (95% CI 0.50 to 0.75) and a specificity
of 1.00 (95% CI 0.88 to 1.00), meeting the criteria for SpIN
triage test (Foda 2012).
With a few exceptions, the panels of multiple biomarkers did not
appear to be superior to some single biomarker tests. These find-
ings need to be confirmed in large, well-designed diagnostic stud-
ies and independent test populations.
Blood biomarkers that could differentiate ovarian
endometrioma from other benign ovarian cysts in
women of reproductive age
Seven studies evaluated blood biomarkers for their potential to dis-
tinguish ovarian endometrioma fromother benign ovarianmasses,
with six formally evaluating diagnostic test performance and one
study presenting negative findings. We summarise the evaluated
biomarkers in a forest plot (Figure 34) and describe them here.
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Figure 34. Forest plot of the tests for detection of ovarian endometriosis performed through comparisons
in women with endometriosis versus other benign ovarian cysts in 6 studies. Plot shows the estimates of
sensitivity and specificity (squares) with 95% CI (black line) specific for each evaluation, country in which the
study was conducted, menstrual cycle phase at which the test was performed and severity of the disease
assessed by each study, reported as rASRM stage. The studies are ordered according to the study names. FN:
false negative; FP: false positive; TN: true negative; TP: true positive.
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1. Angiogenesis/growth factors and their receptors
1.1. Urocortin
Two studies, including three data sets with a total of 168 partici-
pants, assessed the accuracy of urocortin in detecting ovarian en-
dometriosis (Figure 35). One study evaluated two different cut-
offs in the same population (80 participants, cycle phase not re-
ported, rASRM III to IV; Florio 2007): urocortin with a cut-off of
> 29.00 pg/ml had a sensitivity of 0.97 (95% CI 0.87 to 1.00) and
a specificity of 0.85 (95%CI 0.70 to 0.94), meeting the criteria for
a replacement test; and urocortin with a cut-off of > 33.00 pg/ml
had a sensitivity of 0.88 (95% CI 0.73 to 0.96) and a specificity of
0.90 (95% CI 0.76 to 0.97), approaching the criteria for a SpIN
triage test. Another study (88 participants, follicular cycle phase,
rASRM III to IV; Tokmak 2011) demonstrated urocortin levels
that were not statistically different in women with and without
endometriosis. The test was still performed at a cut-off of > 41.60
pg/ml, demonstrating a sensitivity of 0.76 (95% CI 0.61 to 0.88)
and a specificity of 0.46 (95% CI 0.31 to 0.61). We did not per-
form a meta-analysis in view of the heterogeneity of the cut-off
thresholds between studies. Further evaluation of urocortin across
the spectrum of endometriosis may help to clarify its diagnostic
role in endometriosis.
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Figure 35. Summary ROC plot of urocortin for detection of endometriosis. Each point represents the pair
of sensitivity and specificity for each evaluation. The size of each point is proportional to the sample size and
the shape designates the tests with different cut-off values. The bars correspond to 95% CIs of each individual
evaluation. Two evaluations (> 29 pg/ml and > 33 pg/ml) were performed in the same population. The data
were not assessed by meta-analysis.
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2. Immune system and inflammatory markers
2.1. IL-8 (interleukin-8)
One study assessed the performance of IL-8 in detecting ovar-
ian endometriosis (91 participants, follicular or luteal cycle phase,
cut-off value >25.00 pg/ml; Ohata 2008), demonstrating a sen-
sitivity of 0.71 (95% CI 0.59 to 0.82) and a specificity of 0.81
(95% CI 0.58 to 0.95) (Summary of findings; Figure 15). The
diagnostic estimates were higher compared to those reported for
overall pelvic endometriosis but remained far below the criteria for
either replacement or triage test, and there were insufficient data
for meaningful comparisons.
2.2. Immune system and inflammatory markers that
exhibited no differential expression in endometriosis
One study (95 participants, cycle phase not reported) demon-
strated no significant difference in peripheral levels of IL-6 and
sCD163 when women with ovarian endometrioma were com-
pared to a group with other benign ovarian cysts (Jee 2008). This
supports the negative findings reported for IL-6 in overall pelvic
endometriosis (see above). The data for sCD163 is insufficient to
comment on its diagnostic role.
3. Other peptides/proteins shown to influence key events
implicated in endometriosis
3.1. Follistatin
One study evaluated follistatin (104 participants, follicular cycle
phase, ovarian endometriosis, rASRM III to IV; Florio 2009) and
showed a high sensitivity of 0.92 (95% CI 0.81 to 0.98) and high
specificity of 0.92 (95%CI 0.81 to 0.98), using a cut-off value of >
1433.00 pg/ml. The diagnostic estimates approached the criteria
for either a replacement or both SnOUT and SpIN triage test, but
further validation in larger studies that evaluate a wider spectrum
of disease is required.
4. Tumour markers
4.1. CA-19.9 (cancer antigen-19.9)
One study (118 participants, follicular cycle phase; Guerriero
1996a) evaluated the performance of CA-19.9 at a cut-off value
> 12 U/ml in differentiating ovarian endometriosis from other
benign ovarian cysts. The reported diagnostic estimates (sensitivity
0.62, 95% CI 0.45 to 0.77 and specificity 0.70, 95% CI 0.58 to
0.79) were below the diagnostic thresholds for either replacement
or triage test, and this was similar to the findings reported for CA-
19.9 in overall pelvic endometriosis (Figure 21).
4.2. CA-125 (cancer antigen-125)
Seven studies assessed CA-125 in differentiating ovarian en-
dometriosis from other ovarian cysts, using several cut-off values.
1. CA-125 with a cut-off value of > 20 U/ml (Guerriero
1996b; Tokmak 2011; 189 women, follicular cycle phase) had
sensitivities of 0.79 and 0.88 (95% CI 0.60 to 0.92 and 0.74 to
0.96) and specificities of 0.56 and 0.63 (95% CI 0.43 to 0.67
and 0.48 to 0.77).
2. CA-125 with a cut-off value of ≥ 25 U/ml (Guerriero
1996b; 101 women, follicular cycle phase) demonstrated a
sensitivity of 0.76 (95% CI 0.56 to 0.90) and a specificity of
0.67 (95% CI 0.55 to 0.77).
3. CA-125 with a cut-off value of > 30 U/ml (Florio 2007;
Ohata 2008; 171 women, various cycle phases) exhibited
sensitivities of 0.75 and 0.57 (95% CI 0.59 to 0.87 and 0.44 to
0.69) and specificities of 0.85 and 0.94 (95% CI 0.70 to 0.94
and 0.73 to 1.00).
4. CA-125 with a cut-off value of > 35 U/ml (Guerriero
1996b; 101 women, follicular cycle phase) had a sensitivity of
0.59 (95% CI 0.39 to 0.76) and a specificity of 0.79 (95% CI
0.68 to 0.88).
5. CA-125 with a cut-off value of > 36 U/ml (Florio 2009; 80
women, follicular cycle phase) had a sensitivity of 0.65 (95% CI
0.98 to 0.79) and a specificity of 0.90 (95% CI 0.76 to 0.97).
6. CA-125 with a cut-off value of > 42 U/ml (Florio 2009,
104 women, follicular cycle phase) had a sensitivity of 0.44
(95% CI 0.30 to 0.59) and a specificity of 0.90 (95% CI 0.79 to
0.97). None of the tests met the criteria for a replacement or
triage test and CA-125 with a cut-off value > 36 U/ml only
approached the criteria of a SpIN triage test; however, there were
insufficient data to perform meaningful analyses specific for
ovarian endometrioma for any of the cut-offs.
5. Combined blood tests
Twocombinations of biomarkerswere specifically assessed for their
ability to distinguish ovarian endometrioma from other ovarian
cysts.
1. CA-125 + CA-19.9 with the cut-off values ≥ 25 U/ml and
≥ 12 U/ml, respectively (Guerriero 1996a; 118 women,
follicular cycle phase) demonstrated a sensitivity of 0.90 (95%
CI 0.76 to 0.97) with a specificity of 0.41 (95% CI 0.3 to 0.52)
when either positive biomarker was considered and a sensitivity
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of 0.54 (95% CI 0.37 to 0.70) with a specificity of 0.90 (95%
CI 0.81 to 0.96) when both positive biomarkers were included.
2. CA-125 + IL-8 with the cut-off values > 30 U/ml and ≥ 25
U/ml, respectively (Ohata 2008; 91 women, follicular or luteal
cycle phase) had a sensitivity of 0.86 (95% CI 0.75 to 0.93) and
a specificity of 0.72 (95% CI 0.47 to 0.90).
Small numbers of studies assessed each test evaluated for their abil-
ity to distinguish ovarian endometriosis from other benign masses,
and we could not draw a firm conclusion. The available evidence
is scant; however, several biomarkers showed some diagnostic po-
tential as summarised in ’Summary of main results’ under ’Tests
to be validated for their diagnostic potential’. Further evaluations
of these biomarkers are necessary to improve the certainty with
regard to their diagnostic value in ovarian endometriosis.
Investigation of heterogeneity and sensitivity analyses
The potential sources of heterogeneity are outlined in Secondary
objectives. Although we attempted to assess these sources, there
were not enough studies evaluating each test to make this a mean-
ingful analysis, except for the meta-analysis comprised of 27 stud-
ies for CA-125 with a cut-off value > 35 to 36 U/ml.
1. Two studies were published between 1986 and 1989; 13
studies, between 1990 and 1999; 9 studies, between 2000 and
2009; and 3 studies, between 2010 and 2014.
2. Fourteen studies took place in Europe, five studies in Asia,
four studies in North America, three studies in South America,
and one study in the Middle East.
3. Nineteen studies used a single-gate design, and eight studies
had a two-gate design.
4. One study assessed only minimal-mild endometriosis
(rASRM I to II); 3 studies, only moderate-severe disease (rASRM
III to IV); one study did not provide information on the severity,
and 22 studies evaluated a wide spectrum of endometriosis
(rASRM I to IV). Of these 22 studies, 11 presented separate
diagnostic estimates for different rASRM stages in addition to
the data for the entire group, but we did not include this
information in the review and did not consider it in the
assessment of heterogeneity.
5. Thirteen studies used histopathology in adjunct to
laparoscopy as a reference standard, while 14 studies relied on
visual inspection of pelvic cavity.
6. Two studies were specific for the diagnosis of ovarian
endometrioma, one study assessed only peritoneal endometriosis,
and the remaining 24 studies evaluated overall pelvic
endometriosis.
7. Nine studies evaluated the diagnostic performance of CA-
125 in the follicular cycle phase; six studies, in the luteal phase;
two studies, in the follicular or luteal phase; and three studies, in
all cycle phases. Seven studies did not report the cycle phase.
8. Nineteen studies included various clinical presentations
(pain ± infertility ± ovarian mass), of which one study reported
separate estimates for populations with infertility and with pelvic
pain, one study included only participants with pelvic pain, three
studies were confined to women presenting with infertility, three
studies evaluated only women with ovarian mass, and one study
did not specify clinical presentation.
There was no significant difference in sensitivity or specificity be-
tween the studieswith regard to the study design (single-gate versus
two-gate studies), the rASRM stages of endometriosis, the refer-
ence standard (histological confirmation versus laparoscopic visu-
alisation alone), the target condition (ovarian versus overall pelvic
endometriosis), the menstrual cycle phase of testing or the clinical
presentations (pain, infertility, ovarian mass versus infertility only
or pain only).
With regards to the geographical areas of the studies, studies based
in North America reported higher sensitivity compared to the
other continents (P = 0.0003), but we were unable to identify the
reason for this difference. The other significant factor was year of
publication. Studies published after 2010 reported lower estimates
of sensitivity compared to the studies published before 2000 (P =
0.026), which is likely to be an indicator that other things have
changed in the laboratory methodology including sample process-
ing and types of assays.
We were unable to explore the effect of the following potential
sources of heterogeneity.
• Age (adolescents versus later reproductive years): only one
study presented separate data for different age groups (younger
than 25 years old and 25 to 41 years) in addition to the estimates
for the entire included population, and all the remaining studies
reported data for the whole reproductive age group.
• Methodological quality: low versus unclear or high risk: all
the studies were of low methodological quality with high or
unclear risk of bias.
We couldnot formally assess observer variability bias or bias related
to interpretation of results in this review.
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Summary of findings
Review question What is the diagnost ic accuracy of the blood biomarkers in detect ing pelvic endometriosis (peritoneal endometriosis, endometrioma, deep inf ilt rat ing
endometriosis)?
Importance A simple and reliable non-invasive test for endometriosis with the potent ial to either replace laparoscopy or to triage pat ients in order to reduce surgery,
would minim ise surgical risk and reduce diagnost ic delay
Patients Reproduct ive aged women with suspected endometriosis or persistent ovarian mass, or women undergoing infert ility work-up or gynaecological
laparoscopy
Settings Hospitals (public or private of any level), outpat ient clinics (general gynaecology, reproduct ive medicine, pelvic pain) or research laboratories
Reference standard Visualisat ion of endometriosis at surgery (laparoscopy or laparotomy) with or without histological conf irmation
Study design Cross-sect ional of a single-gate design (N = 25) or a two-gate design (N = 44); unable to determ ine if single- or two-gate design for 1 study; prospect ive
enrolment; a single study could assess more than one test
Risk of bias Overall judgement Poor quality of most of the studies (no study had a ’low risk’ assessment in all 4 domains)
Pat ient select ion bias High risk: 31 studies; unclear risk: 32 studies; low risk: 7 studies
Index test interpretat ion bias High risk: 56 studies; unclear risk: 12 studies; low risk: 2 studies
Reference standard interpretat ion bias High risk: 0 studies; unclear risk: 30 studies; low risk: 40 studies
Flow and tim ing select ion bias High risk: 11 studies; unclear risk: 3 studies; low risk: 56 studies
Applicability con-
cerns
Concerns regarding pat ient select ion High concern: 32 studies; unclear concern: 5 studies; low concern: 33 studies
Concerns regarding index test High concern: 0 studies; unclear concern: 4 studies; low concern: 66 studies





































































































Diagnostic criteria Replacement test: sensit ivity ≥ 94 and specif icity ≥ 79
SnOUT triage test: sensit ivity ≥ 95 and specif icity ≥ 50

















1. Angiogenesis and growth factors and their receptors
Glycodelin-A





99 (1) 47 9 33 10 Sens = 0.82 (0.70 to
0.91);
spec = 0.79 (0.63 to
0.90)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
Glycodelina#
cut-of f threshold > 9.




45 (1) 20 11 6 8 Sens = 0.71 (0.51 to
0.87);
spec = 0.35 (0.14 to
0.62)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
Glycodelina#




99 (1) 36 23 18 22 Sens = 0.62 (0.48 to
0.74);
spec = 0.44 (0.28 to
0.60)
Insuf f icient evi-





cut-of f threshold >
45 (1) 20 12 5 8 Sens = 0.71 (0.51 to
0.87);
spec = 0.29 (0.10 to
0.56)
Insuf f icient evi-

















































































































99 (1) 32 23 18 26 Sens = 0.55 (0.42 to
0.68);
spec = 0.44 (0.28 to
0.60)
Insuf f icient evi-





cut-of f threshold > 1.
5 pg/ m l
any cycle phase
rASRM I-IVb
99 (1) 29 16 25 29 Sens = 0.50 (0.37 to
0.63);
spec = 0.61 (0.45 to
0.76)
Insuf f icient evi-










95 (1) 60 7 23 5 Sens = 0.92 (0.83 to
0.97);
spec = 0.77 (0.58 to
0.90)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
approaches the cri-
teria for a replace-
ment and SnOUT
triage test; further






cut-of f threshold >
680 pg/ ml
follicular cycle
60 (1) 28 1 29 2 Sens = 0.93 (0.78 to
0.99);
spec = 0.97 (0.83 to
1.00)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
meets criteria for







































































































teria for a replace-
ment test; further di-









80 (1) 39 6 34 1 Sens = 0.97 (0.87 to
1.00);
spec = 0.85 (0.70 to
0.94)
In-
suf f icient evidence
to draw meaningful
conclusions; meets
criteria for a replace-
ment and SnOUT
triage test; further









80 (1) 35 4 36 5 Sens = 0.88 (0.73 to
0.96);
spec = 0.90 (0.76 to
0.97)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
approaches criteria
for a SpIN triage
test; further diag-




cut-of f threshold >




88 (1) 32 25 21 10 Sens = 0.76 (0.61 to
0.88);
spec = 0.46 (0.31 to
0.61)
Insuf f icient evi-












































































































rASRM stage not re-
portede
60 (1) 3 2 18 37 Sens = 0.07 (0.02 to
0.20);
spec = 0.90 (0.68 to
0.99)
Insuf f icient evi-
dence to draw mean-
ingful conclusions









99 (1) 32 21 21 26 Sens = 0.55 (0.42 to
0.68);
spec = 0.50 (0.34 to
0.66)
Insuf f icient evi-






cut-of f threshold <




28 (1) 8 12 5 3 Sens = 0.73 (0.39 to
0.94);
spec = 0.29 (0.10 to
0.56)
Insuf f icient evi-










60 (1) 18 4 26 12 Sens = 0.60 (0.41 to
0.77);
spec = 0.87 (0.69 to
0.96)
Insuf f icient evi-
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73 (1) 38 6 14 15 Sens = 0.72 (0.58 to
0.83);
spec = 0.70 (0.46 to
0.88)
Insuf f icient evi-
dence to draw mean-
ingful conclusions








age/ body mass in-
dex-adjusted
92 (1) 36 8 44 4 Sens = 0.90 (0.76 to
0.97);
spec = 0.85 (0.72 to
0.93)
Insuf f icient evi-


















31 (1) 14 3 12 2 Sens = 0.88 (0.62 to
0.98);
spec = 0.80 (0.52 to
0.96)
Insuf f icient evi-













90 (1) 40 16 23 11 Sens = 0.78 (0.65 to
0.89);
spec = 0.59 (0.42 to
0.74)
Insuf f icient evi-






















































































































67 (1) 18 4 18 27 Sens = 0.40 (0.26 to
0.56);
spec = 0.82 (0.60 to
0.95)
Insuf f icient evi-
















98 (1) 25 5 28 40 Sens = 0.38 (0.27 to
0.51);
spec = 0.85 (0.68 to
0.95)
Insuf f icient evi-















88 (1) 29 6 27 26 Sens = 0.53 (0.39to
0.66);
spec = 0.82 (0.65 to
0.93)
Insuf f icient evi-









(6 peaks with MW
1629, 3047, 3526,
3774, 5046 and
139 (1) 40 1 77 21 Sens = 0.66 (0.52 to
0.77);
spec = 0.99 (0.93 to
1.00)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
meets criteria for














































































































cut-of f threshold >
14.8 ng/ m l
luteal cycle phase
rASRM I-IVc
97 (1) 28 2 32 35 Sens = 0.44 (0.32 to
0.58);
spec = 0.94 (0.80 to
0.99)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
Prolact in1aˆ




97 (1) 13 0 34 50 Sens = 0.21 (0.11 to
0.33);
spec = 1.00 (0.90 to
1.00)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
6. Immune system and inflammatory markers
Anti-endometrial
Abs
cut-of f threshold -
def init ions for posi-
t ive result varied
cycle phase varied
(not specif ied in 2
studies)
rASRM I-IV in 3 stud-
ies; not reported in 1
study
759 (4) 359 48 276 76 Sens = 0.81 (0.76 to
0.87);
spec = 0.75 (0.46 to
1.00)
Summary est imates
did not meet the pre-
determ ined criteria






Abs (MW of 26/ 34/
42 kd)
cut-of f threshold:
36 (1) 18 11 7 0 Sens = 1.00 (0.81 to
1.00);
spec = 0.39 (0.17 to
0.64)
Insuf f icient evi-






































































































dark band in the blot











68 (1) 17 3 23 25 Sens = 0.40 (0.26 to
0.57);
spec = 0.88 (0.70 to
0.98)
Insuf f icient evi-












97 (1) 14 3 37 43 Sens = 0.25 (0.14 to
0.38);
spec = 0.93 (0.80 to
0.98)
Insuf f icient evi-










101 (1) 37 17 27 20 Sens = 0.65 (0.51 to
0.77);
spec = 0.61 (0.45 to
0.76)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
Copeptin
cut-of f threshold >
251.2 pg/ m l
cycle phase not
87 (1) 33 15 21 18 Sens = 0.65 (0.50 to
0.78);
spec = 0.58 (0.41 to
0.74)
Insuf f icient evi-









































































































t ive C-react ive pro-
tein)a$




295 (1) 126 40 51 78 Sens = 0.62 (0.55 to
0.68);
spec = 0.56 (0.45 to
0.66)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
hs-CRP (high sensi-
t ive C-react ive pro-
tein)a$





60 (1) 28 10 9 13 Sens = 0.68 (0.52 to
0.82);
spec = 0.47 (0.24 to
0.71)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
hs-CRP (high sensi-
t ive C-react ive pro-
tein)a$





119 (1) 45 18 18 38 Sens = 0.54 (0.43 to
0.65);
spec = 0.50 (0.33 to
0.67)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
hs-CRP (high sensi-







95 (1) 54 4 26 11 Sens = 0.83 (0.72 to
0.91);
spec = 0.87 (0.69 to
0.96)
Insuf f icient evi-







































































































t ive C-react ive pro-
tein)a$




116 (1) 47 13 23 33 Sens = 0.59 (0.47 to
0.70);
spec = 0.64 (0.46 to
0.79)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
hs-CRP (high sensi-
t ive C-react ive pro-
tein)a$




116 (1) 32 11 27 46 Sens = 0.41 (0.30 to
0.53);
spec = 0.71 (0.54 to
0.85)
Insuf f icient evi-









45 (1) 19 6 11 9 Sens = 0.68 (0.48 to
0.84);
spec = 0.65 (0.38 to
0.86)
Insuf f icient evi-










93 (1) 36 13 25 19 Sens = 0.65 (0.51 to
0.78);
spec = 0.66 (0.49 to
0.80)
Insuf f icient evi-







95 (1) 58 4 26 7 Sens = 0.89 (0.79 to
0.96);
spec = 0.87 (0.69 to
0.96)
Insuf f icient evi-












































































































cut-of f threshold <




45 (1) 19 11 6 9 Sens = 0.68 (0.48 to
0.84);
spec = 0.35 (0.14 to
0.62)
Insuf f icient evi-









116 (1) 62 10 28 16 Sens = 0.79 (0.69 to
0.88);
spec = 0.74 (0.57 to
0.87)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
Neutrophils
cut-of f threshold >




100 (1) 34 20 30 16 Sens = 0.68 (0.53 to
0.80);
spec = 0.60 (0.45 to
0.74)
Insuf f icient evi-









100 (1) 38 9 41 12 Sens = 0.76 (0.62 to
0.87);
spec = 0.82 (0.69 to
0.91)
Insuf f icient evi-








































































































cut-of f threshold >




100 (1) 32 23 27 18 Sens = 0.64 (0.49 to
0.77);
spec = 0.54 (0.39 to
0.68)
Insuf f icient evi-




cut-of f threshold < 0.




45 (1) 23 11 6 5 Sens = 0.82 (0.63 to
0.94);
spec = 0.35 (0.14 to
0.62)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
IL-4 (interleukin - 4)





50 (1) 21 6 11 12 Sens = 0.64 (0.45 to
0.80);
spec = 0.65 (0.38 to
0.86)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
IL-6 (interleukin - 6)
a$





138 (1) 55 34 36 13 Sens = 0.81 (0.70 to
0.89);
spec = 0.51 (0.39 to
0.64)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
IL-6 (interleukin - 6)
a$,aˆ
cut-of f threshold > 1.
9-2.0 pg/ m l
cycle phase varied
rASRM I-IV
309 (3) 107 43 97 62 Sens = 0.63 (0.52 to
0.75);
spec = 0.69 (0.57 to
0.82)
Summary est imates
did not meet the
predeterm ined cri-








































































































IL-6 (interleukin - 6)
a$
cut-of f threshold > 2.




138 (1) 41 21 49 27 Sens = 0.60 (0.48 to
0.72);
spec = 0.70 (0.58 to
0.80)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
IL-6 (interleukin - 6)
aˆ





91 (1) 48 7 28 8 Sens = 0.86 (0.74 to
0.94);
spec = 0.80 (0.63 to
0.92)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
IL-6 (interleukin - 6)
aˆ
cut-of f threshold > 7.




91 (1) 45 5 30 11 Sens = 0.80 (0.68 to
0.90);
spec = 0.86 (0.70 to
0.95)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
IL-6 (interleukin - 6)





45 (1) 20 14 3 8 Sens = 0.71 (0.51 to
0.87);
spec = 0.18 (0.04 to
0.43)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
IL-6 (interleukin - 6)
cut-of f threshold >




95 (1) 62 5 25 3 Sens = 0.95 (0.87 to
0.99);
spec = 0.83 (0.65 to
0.94)
In-
suf f icient evidence
to draw meaningful
conclusions; meets






































































































t riage test; further
diagnost ic test ac-
curacy studies rec-
ommended
IL-6 (interleukin - 6)
cut-of f threshold >




78 (1) 34 7 33 4 Sens = 0.89 (0.75 to
0.97);
spec = 0.82 (0.67 to
0.93)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
IL-6 (interleukin - 6)





84 (1) 8 12 60 3 Sens = 0.73 (0.39 to
0.94);
spec = 0.83 (0.73 to
0.91)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
IL-6 (interleukin - 6)




116 (1) 46 9 29 32 Sens = 0.59 (0.47 to
0.70);
spec = 0.76 (0.60 to
0.89)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
IL-8 (interleukin - 8)





101 (1) 31 14 37 19 Sens = 0.76 (0.60 to
0.89);
spec = 0.73 (0.58 to
0.84)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
IL-8 (interleukin - 8)





91 (1) 50 4 17 20 Sens = 0.71 (0.59 to
0.82);
spec = 0.81 (0.58 to
0.95)
Insuf f icient evi-






































































































IL-8 (interleukin - 8)




116 (1) 38 11 27 40 Sens = 0.49 (0.37 to
0.60);
spec = 0.71 (0.54 to
0.85)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
7. Other peptides and proteins shown to influence key events implicated in endometriosis
Follistat in





104 (1) 48 4 48 4 Sens = 0.92 (0.81 to
0.98);
spec = 0.92 (0.81 to
0.98)
Insuf f icient evi-




and SnOUT or SpIN
triage test; further
diagnost ic test ac-
curacy studies rec-
ommended
STX-5 (syntaxin - 5)





80 (1) 47 6 14 13 Sens = 0.78 (0.66 to
0.88);
spec = 0.70 (0.46 to
0.88)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
8. Oxidative stress markers
Carbonyls




rASRM stage not re-
ported
108 (1) 63 20 21 4 Sens = 0.94 (0.85 to
0.98);
spec = 0.51 (0.35 to
0.67)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
approaches criteria
for a SnOUT triage
test; further diag-














































































































87 (1) 46 8 32 1 Sens = 0.98 (0.89 to
1.00);
spec = 0.80 (0.64 to
0.91)
In-
suf f icient evidence
to draw meaningful
conclusions; meets
criteria for a re-
placement or SnOUT
triage test; further




of f threshold < 396.
44 µM cycle phase
not specif ied
rASRM stage not re-
ported
108 (1) 49 8 33 18 Sens = 0.73 (0.61 to
0.83);
spec = 0.80 (0.65 to
0.91)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
9. Post- transcriptional regulators of gene expression (microRNAs)
miR-9*





85 (1) 41 1 24 19 Sens = 0.68 (0.55 to
0.80);
spec = 0.96 (0.80 to
1.00)
In-
suf f icient evidence
to draw meaningful
conclusions; meets
criteria for a SpIN
triage test; further









40 (1) 14 6 14 6 Sens = 0.70 (0.46 to
0.88);
spec = 0.70 (0.46 to
0.88)
Insuf f icient evi-












































































































40 (1) 12 2 18 8 Sens = 0.60 (0.36 to
0.81);
spec = 0.90 (0.68 to
0.99)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
approaches criteria
for a SpIN triage
test; further diag-









40 (1) 18 4 16 2 Sens = 0.90 (0.68 to
0.99);






criteria for a re-
placement or SnOUT
triage test; further









85 (1) 48 6 19 12 Sens = 0.80 (0.68 to
0.89);
spec = 0.76 (0.55 to
0.91)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
miR-141*





85 (1) 43 1 24 17 Sens = 0.72 (0.59 to
0.83);
spec = 0.96 (0.80 to
1.00)
In-
suf f icient evidence
to draw meaningful
conclusions; meets
criteria for a SpIN
triage test; further












































































































rASRM stage not re-
ported
85 (1) 42 1 24 18 Sens = 0.70 (0.57 to
0.81);
spec = 0.96 (0.80 to
1.00)
In-
suf f icient evidence
to draw meaningful
conclusions; meets
criteria for a SpIN
triage test; further









85 (1) 47 6 19 13 Sens = 0.78 (0.66 to
0.88);
spec = 0.76 (0.55 to
0.91)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
miR-532-3p





85 (1) 48 2 23 12 Sens = 0.80 (0.68 to
0.89);
spec = 0.92 (0.74 to
0.99)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
approaches criteria
for a SpIN triage
test; further diag-











88 (1) 33 14 23 18 Sens = 0.65 (0.50 to
0.78);
spec = 0.62 (0.45 to
0.78)
Insuf f icient evi-












































































































119 (1) 3 3 35 78 Sens = 0.04 (0.01 to
0.10);
spec = 0.92 (0.79 to
0.98)
Insuf f icient evi-








76 (1) 32 14 18 12 Sens = 0.73 (0.57 to
0.85);
spec = 0.56 (0.38 to
0.74)
Insuf f icient evi-








198 (1) 64 34 47 53 Sens = 0.55 (0.45 to
0.64);
spec = 0.58 (0.47 to
0.69)
Insuf f icient evi-









88 (1) 33 14 23 18 Sens = 0.65 (0.50 to
0.78);
spec = 0.62 (0.45 to
0.78)
Insuf f icient evi-









119 (1) 24 24 55 15 Sens = 0.62 (0.45 to
0.77);
spec = 0.70 (0.58 to
0.79)
Insuf f icient evi-








































































































cut-of f threshold >
37 IU/ ml
cycle phase varied
(not specif ied in 2
studies)
rASRM I-IV
330 (3) 88 11 72 159 Summary
est imates:
Sens = 0.36 (0.26 to
0.45);
spec = 0.87 (0.75 to
0.99)
Summary est imates
did not meet the
predeterm ined cri-































Sens = 0.53 (0.36 to
0.68);
spec = 0.90 (0.68 to
0.99)
---------------------
Sens = 0.36 (0.25 to
0.48);
spec = 0.71 (0.54 to
0.85)
In-















rASRM stage not re-
ported
35 (1) 1 4 12 18 Sens = 0.05 (0.00 to
0.26);
spec = 0.75 (0.48 to
0.93)
Insuf f icient evi-















































































































119 (1) 7 4 34 74 Sens = 0.09 (0.04 to
0.17);
spec = 0.89 (0.75 to
0.97)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
CA-125 (cancer ant i-
gen-125)a!,a%,a∗




2 evaluat ions ex-
cluded as over-
lapping populat ions
(CA-125 cut-of f >
11.5 U/ ml and cut-
of f > 13.5 U/ ml,
Vodolazkaia 2012)
733 (5) 329 174 155 129 Summary
est imates:
Sens = 0.70 (0.63 to
0.77);
spec = 0.64 (0.47 to
0.82)
Summary est imates
do not meet the pre-
determ ined criteria
for a triage or re-
placement test
CA-125 (cancer ant i-
gen-125)a!





cluded f rom the
above group as over-
lapping evaluat ion)
45 (1) 24 6 11 4 Sens = 0.86 (0.67 to
0.96);
spec = 0.65 (0.38 to
0.86)
Insuf f icient evi-






































































































CA-125 (cancer ant i-
gen-125) a!




cluded f rom the
above group as over-
lapping evaluat ion)
35 (1) 15 11 5 4 Sens = 0.79 (0.54 to
0.94);
spec = 0.31 (0.11 to
0.59)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
CA-125 (cancer ant i-
gen-125)a#
cut-of f value > 16-
17.6 U/ ml
cycle phase varied
(not specif ied in 2
studies)
rASRM stage varied
(I in 1 study, I-IV in 4
studies)
430 (5) 146 17 154 113 Summary
est imates:
Sens = 0.56 (0.24 to
0.88);




ria for a SpIN triage
test; varying popu-
lat ions across the
studies
CA-
125 (cancer ant igen-
125)a@,aˆ,a&,a∗,a!!




(1 studyc, 2 studies
d )
1304 (6) 504 200 361 239 Summary
est imates:
Sens = 0.67 (0.50 to
0.85);
spec = 0.69 (0.58 to
0.80)
Summary est imates
do not meet the
predeterm ined cri-




CA-125 (cancer ant i-
gen-125)aˆ,a&
cut-of f value > 25-26
U/ ml
cycle phase varied;
not specif ied in 1
963 (3) 373 137 314 139 Summary
est imates:
Sens = 0.73 (0.67 to
0.79);
spec = 0.70 (0.63 to
0.77)
Summary est imates
do not meet the
predeterm ined cri-











































































































CA-125 (cancer ant i-
gen-125)a$,a&
cut-of f value > 30-33
U/ ml (1 study > 33
U/ ml)
cycle phase varied




1206 (6) 417 103 411 275 Summary
est imates:
Sens = 0.62 (0.45 to
0.79);
spec = 0.76 (0.53 to
1.00)
Summary est imates
do not meet the
predeterm ined cri-





125 (cancer ant igen-
125)a@,a#,a$,a%,a&,a!!
cut-of f value > 35-36
U/ ml (1 study > 36
U/ ml)
cycle phase varied;
not specif ied in 7
studies
rASRM stage varied;
not reported in 2
studies (1 studyc, 2
studiesd , 1 studye)
3447 (27) 895 169 1281 1102 Summary
est imates:
Sens = 0.40 (0.32 to
0.49);
spec = 0.91 (0.88 to
0.94)
Summary est imates
do not meet the
predeterm ined cri-




CA-125 (cancer ant i-
gen-125);a$





104 (1) 23 5 47 29 Sens = 0.44 (0.30 to
0.59);
spec = 0.90 (0.79 to
0.97)
Insuf f icient evi-






































































































CA-125 (cancer ant i-
gen-125)
cut-of f value > 43 U/
ml
cycle phase not re-
ported
rASRM III-IV
63 (1) 42 4 16 0 Sens = 1.00 (0.92 to
1.00);
spec = 0.80 (0.56 to
0.94)
In-
suf f icient evidence
to draw meaningful
conclusions; meets
criteria for a replace-
ment and SnOUT
triage test; further
diagnost ic test ac-
curacy studies rec-
ommended
CA-125 (cancer ant i-
gen-125)























































Sens = 0.72 (0.56 to
0.85);
spec = 0.79 (0.54 to
0.94)
----------------------
Sens = 0.65 (0.54 to
0.75);
spec = 0.72 (0.55 to
0.86)
----------------------
Sens = 0.82 (0.67 to
0.93);
spec = 0.90 (0.68 to
0.99)
----------------------
Sens = 0.68 (0.56 to
0.78);
spec = 0.71 (0.54 to
0.85)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
1 study approaches
criteria for a SpIN
triage test; further
diagnost ic test ac-
curacy studies rec-
ommended with de-
f ined cut-of f value;
varying populat ions
and undef ined cut-
of f values; not com-
bined in meta-analy-
sis






































































































CA-125 +/ or CA-19.
9 U/ mla#
cut-of threshold CA-
125 ≥ 25 U/ ml; CA-






118 (1) 35 47 32 4 Sens = 0.90 (0.76 to
0.97);
spec = 0.41 (0.30 to
0.52)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
CA-125 + CA-19.9 U/
mla#
cut-of threshold CA-
125 ≥ 25 U/ ml; CA-






118 (1) 21 8 71 18 Sens = 0.54 (0.37 to
0.70);
spec = 0.90 (0.81 to
0.96)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
approaches criteria
for a SpIN triage
test; further diag-
nost ic test accu-
racy studies recom-
mended
CA-125 + Prolact ina$
cut-of f
threshold CA-125 >
19.8 U/ l; Prolact in >





97 (1) 49 4 30 14 Sens = 0.78 (0.66 to
0.87);
spec = 0.88 (0.73 to
0.97)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
CA-125 + Prolact ina$
cut-of f thresh-
old CA-125 > 35 U/ l;
Prolact in > 20 ng/ ml
luteal cycle phase
97 (1) 28 1 33 35 Sens = 0.44 (0.32 to
0.58);
spec = 0.44 (0.32 to
0.58)
Insuf f icient evi-












































































































CA-125 > 17.6 U/ ml;






95 (1) 50 2 28 15 Sens = 0.77 (0.65 to
0.86);
spec = 0.93 (0.78 to
0.99)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
approaches criteria
for a SpIN triage
test; further diag-






CA-125 > 20 U/ l; ant i-




select ion or classi-
f icat ion method not
reported
42 (1) 17 3 11 11 Sens= 0.61 (0.41 to
0.78);
spec = 0.79 (0.49 to
0.95)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
CA-125 x NLR







100 (1) 40 7 43 10 Sens = 0.80 (0.66 to
0.90);
spec = 0.86 (0.73 to
0.94)
Insuf f icient evi-







































































































CA-125 +/ or IL-8
cut-of f thresh-
old CA-125 > 30 U/






83 (1) 56 5 13 9 Sens = 0.86 (0.75 to
0.93);
spec = 0.72 (0.47 to
0.90)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
CA-125 + IL-8








and by ROC analysis
294 (1) 143 27 58 66 Sens = 0.71 (0.64 to
0.77);
spec= 0.71 (0.61 to
0.80)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
IL-6 + TNF-α
cut-of f threshold IL-
6 > 12.2 pg/ m l; TNF-






96 (1) 46 0 30 20 Sens = 0.70 (0.57 to
0.80);
spec = 1.00 (0.88 to
1.00)
In-
suf f icient evidence
to draw meaningful
conclusions; meets
criteria for a SpIN
triage test; further




cut-of f threshold IL-
6 >12.2 pg/ m l; CRP
> 438 µg/ ml
follicular cycle
phase
95 (1) 49 0 30 16 Sens = 0.75 (0.63 to
0.85);
spec = 1.00 (0.88 to
1.00)
In-
suf f icient evidence
to draw meaningful
conclusions; meets














































































































cut-of f threshold NF-
α > 12.45 pg/ ml;






95 (1) 48 0 30 17 Sens = 0.74 (0.61 to
0.84);
spec = 1.00 (0.88 to
1.00)
In-
suf f icient evidence
to draw meaningful
conclusions; meets
criteria for a SpIN
triage test; further











test by discrim inant
and ROC analysis
85 (1) 58 3 22 2 Sens = 0.97 (0.88 to
1.00);
spec = 0.88 (0.69 to
0.97)
In-
suf f icient evidence
to draw meaningful
conclusions; meets
criteria for a replace-
ment and SnOUT
triage test; further










test by discrim inant
and ROC analysis
85 (1) 48 5 20 12 Sens = 0.80 (0.68 to
0.89);
spec = 0.80 (0.59 to
0.93)
Insuf f icient evi-
dence to draw mean-
ingful conclusions






































































































CA-125 + CA-19-9 +
survivin









60 (1) 35 2 18 5 Sens = 0.88 (0.73 to
0.96);
spec = 0.90 (0.68 to
0.99)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
approaches criteria
for a SpIN triage
test; further diag-
nost ic test accu-
racy studies recom-
mended
CA-125 + STX-5 +
LN-1






mult ivariate logist ic
regression and ROC
analysis
80 (1) 57 6 14 3 Sens = 0.95 (0.86 to
0.99);
spec = 0.70 (0.46 to
0.88)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
meets criteria for a
SnOUT triage test
and approaches cri-
teria for a replace-
ment test; further di-
agnost ic test accu-
racy studies recom-
mended
CA-125 +/ or CA-19.
9 +/ or IL-6
cut-of f thresh-
old CA-125 > 35 U/
ml; CA-19.9 > 37 U/





80 (1) 19 10 25 26 Sens = 0.42 (0.28 to
0.58);
spec = 0.71 (0.54 to
0.85)
Insuf f icient evi-







































































































CA-125 +/ or CCR1
+/ or MCP-1
CA-125 > 50 U/ ml;
CCR1 > 1.16; MCP-1




select ion or classi-
f icat ion method not
reported
151 (1) 94 9 40 8 Sens = 0.92 (0.85 to
0.97);
spec = 0.82 (0.68 to
0.91)
Insuf f icient evi-






nost ic test accu-
racy studies recom-
mended
CA-125 + MCP-1 +
Lept in
cut-of f thresh-
old CA-125 > 20 U/
ml; MCP-1 > 152.7




combined test by a
two-t iered algorithm
using classif icat ion
and regression tree
(CART)
141 (1) 31 5 73 32 Sens = 0.49 (0.36 to
0.62);
spec = 0.94 (0.86 to
0.98)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
approaches criteria
for a SpIN triage
test; further diag-
nost ic test accu-
racy studies recom-
mended
CA-125 + IL-8 + TNF-
α








116 (1) 70 11 27 8 Sens = 0.90 (0.81 to
0.95);
spec = 0.71 (0.54 to
0.85)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
approaches criteria
for a SnOUT triage
test; further diag-









































































































IL-6 + TNF-α + CRP
cut-of f threshold IL-
6 > 12.2 pg/ m l; TNF-
α > 12.45 pg/ ml;






95 (1) 41 0 30 24 Sens = 0.63 (0.50 to
0.75);
spec = 1.00 (0.88 to
1.00)
In-
suf f icient evidence
to draw meaningful
conclusions; meets
criteria for a SpIN
triage test; further
diagnost ic test ac-
curacy studies rec-
ommended
13. Combined test - 4 blood biomarkers
CA-125 + VEGF + an-
nexin V + glycodelin
a#






mult ivariate logist ic
regression and ROC
analysis
19 (1) 9 2 6 2 Sens = 0.82 (0.48 to
0.98);
spec = 0.75 (0.35 to
0.97)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
CA-125 + VEGF + an-
nexin V + glycodelin
a#







19 (1) 9 3 5 2 Sens = 0.82 (0.48 to
0.98);
spec = 0.63 (0.24 to
0.91)
Insuf f icient evi-









































































































SVM) and ROC anal-
ysis
CA-125 + VEGF + an-
nexin V + sICAM-1








or a least squares
support vector ma-
chines model (LS-
SVM) and ROC anal-
ysis
19 (1) 9 2 6 2 Sens = 0.82 (0.48 to
0.98);
spec = 0.75 (0.35 to
0.97)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
CA-125 + MCP-1 +
Lept in + MIF
cut-of f threshold
CA-125 > 20 U/ ml;
MCP-1 > 53.5 pg/ m l;
Lept in > 29.1 ng/ m l;
MIF > 14.7 ng/ m l
any cycle phase
rASRM II-IV
combined test by a
two-t iered algorithm
using classif icat ion
and regression tree
(CART)
141 (1) 63 51 27 0 Sens = 1.00 (0.94 to
1.00);
spec = 0.35 (0.24 to
0.46)
Insuf f icient evi-








































































































+ miR-145* + miR-
542-3p






test by discrim inant
and ROC analysis
85 (1) 56 1 24 4 Sens = 0.93 (0.84 to
0.98);
spec = 0.96 (0.80 to
1.00)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
meets criteria for
a SpIN triage test
and approaches cri-
teria for a replace-
ment test; further di-
agnost ic test accu-
racy studies recom-
mended
14. Combined test - 6 blood biomarkers
CA-125 + CA-19.9 +
IL-6 + IL-8 + TNF-α +
hs-CRPa$









295 (1) 181 44 49 20 Sens = 0.90 (0.85 to
0.94);
spec = 0.53 (0.42 to
0.63)
Insuf f icient evi-
dence to draw mean-
ingful conclusions;
approaches criteria
for a SnOUT triage
test; further diag-
nost ic test accu-
racy studies recom-
mended
CA-125 + CA-19.9 +
IL-6 + IL-8 + TNF-α +
hs-CRP a$







59 (1) 36 5 14 4 Sens = 0.90 (0.76 to
0.97);
spec = 0.74 (0.49 to
0.91)
Insuf f icient evi-

















































































































CA-125 + CA-19.9 +
IL-6 + IL-8 + TNF-α +
hs-CRPa$










119 (1) 48 10 26 35 Sens = 0.58 (0.46 to
0.69);
spec = 0.72 (0.55 to
0.86)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
CA-125 + CA-19.9 +
IL-6 + IL-8 + TNF-α +
hs-CRPa$









116 (1) 67 11 27 11 Sens = 0.86 (0.76 to
0.93);
spec = 0.71 (0.54 to
0.85)
Insuf f icient evi-
dence to draw mean-
ingful conclusions
a Same biomarker was tested in the same/ overlapping cohort ; sim ilar symbol designates studies/ groups of studies with overlapping cohorts, hence can not be combined in
meta-analysis
b Only for US-negat ive endometriosis
c Only peritoneal endometriosis
d Only ovarian endometriosis versus other benign ovarian cysts





































































































M W: molecular weight; rASRM : revised American Society for Reproduct ive Medicine; ROC: receiver operat ing characterist ic







































































































D I S C U S S I O N
Summary of main results
We evaluated the diagnostic performance for 47 of the 122 blood
biomarkers included in this review. Only four biomarkers were
assessed in a sufficient number of studies for a meta-analysis: CA-
125 for different cut-offs, CA-19.9 for a cut-off value of > 37 U/
ml, IL-6 for a cut-off value of > 1.90 to 2.00 pg/ml and anti-
endometrial antibodies. None of the meta-analyses revealed a test
with the diagnostic accuracy for a suitable replacement test (sen-
sitivity ≥ 0.94 and specificity ≥ 0.79) or triage test (either a sen-
sitivity ≥ 0.95 with specificity ≥ 0.50, SnOUT, or a sensitivity ≥
0.50 with a specificity ≥ 0.95, SpIN).
CA-125 was the most studied biomarker, and studies analysed
multiple cut-off values within the following groups: > 10.0 to 14.7
U/ml, >16.0 to 17.6 U/ml, > 20.0 U/ml, > 25.0 to 26.0 U/ml, >
30.0 to 33.0 U/ml, > 35.0 to 36.0 U/ml, > 42.0 to 43.0 U/ml.
None of these tests were sensitive or specific enough to be consid-
ered as a replacement or triage test. The summary estimates of the
mean sensitivity and the mean specificity of CA-125 did not all
show the expected pattern (higher sensitivity and lower specificity
with lower thresholds), but this was likely related to the indirect
nature of the comparisons and heterogeneous study groups from
different populations. The cut-off > 16.0 to 17.6 U/ml was the
best performing of all the CA-125 thresholds subjected to meta-
analysis, but it only approached the criteria for a SpIN triage test
and showed substantial heterogeneity. CA-125 with a cut-off of >
43.0 U/ml reached the criteria for a replacement test for detecting
advanced endometriosis, but only one study demonstrated this,
and the data for a wide spectrum of disease was lacking.
The sensitivity of CA-19.9 in detecting endometriosis was too low
to meet the criteria for a replacement or triage test. Although only
the cut-off value of > 37.0 U/ml was adequately assessed for this
biomarker, other thresholds reported in individual studies did not
show promising results.
In this review anti-endometrial antibodies and IL-6 with a cut-off
value of > 1.90 to 2.00 pg/ml displayed unsatisfactory diagnostic
estimates to qualify for either a replacement or triage test. There
were too few studies to perform a meaningful evaluation for other
cut-off values of IL-6. Although, IL-6 with a cut-off of > 12.20 pg/
ml, had a sufficiently high sensitivity and specificity to satisfy the
criteria for a replacement test, it was explored in only one study
and warrants further validation.
Readers should interpret the findings of the meta-analyses pre-
sented in this review with caution. Considering both the level of
heterogeneity and the high/unclear risk of bias of the included
studies, the results do not seem to be reliable enough to inform
clinical practice.
The remaining biomarkers were classified as follows.
• Tests to be validated for their diagnostic potential. This
group included:
◦ those with an adequate diagnostic performance, but
insufficient data to confidently comment on their diagnostic role
(less than three studies with the diagnostic estimates meeting the
criteria for either a replacement or triage test); and
◦ tests where the diagnostic estimates approached the
criteria for replacement or triage tests in a small number of
studies and where it is possible that they would reach this criteria
in further studies (less than three studies with the diagnostic
estimates within 5% of the criteria for either replacement or
triage tests). These tests are presented in Table 4.
• Tests of limited diagnostic value (at least three studies
demonstrating low diagnostic estimates that do not meet or
approach the criteria for either replacement or triage test, or
report negative findings). We advise against further evaluation of
these biomarkers in the diagnosis of endometriosis. We present
these tests in Appendix 8.
• Tests that appear to have limited diagnostic value, but
where there is insufficient data to confidently comment on their
diagnostic role (less than three studies with low diagnostic
estimates or negative findings). We present the full list of tests
from this group in Appendix 9. We advise considering further
investigation with a focus of specific phases of menstrual cycle,
specific types of endometriosis, different cut-off values or
different laboratory methods.
Strengths and weaknesses of the review
This review is part of a comprehensive review series on minimally
invasive biomarkers for the diagnosis of endometriosis.
The strengths of this review are the following.
1. A very large number of studies, including data for 15,141
women from 141 studies, which allowed meta-analyses for some
blood biomarker tests.
2. A very thorough search of the current literature, including
studies written in languages other than English.
3. Data extraction by two independent reviewers and use of a
modified QUADAS-2 tool to perform quality assessments.
4. Stringent selection criteria, ensuring that eligible studies
used prospectively collected samples and only included women
of reproductive age, which minimised the risk of bias in
interpreting the reference standard and index test.
5. Attempts to contact study authors to obtain any missing
information required to assess eligibility and critically appraise
the studies.
6. The inclusion of studies that reported negative findings (i.e.
demonstrated that biomarker levels did not significantly differ in
endometriosis), which provided a more comprehensive
evaluation of diagnostic role of the biomarkers and identified the
tests of no value in diagnosing the disease.
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Themain limitation of this review is that there were a low number
of small, heterogeneous studies for the majority of the evaluated
index tests. This may undermine the reliability of the summary
estimates from the meta-analyses and is likely to have contributed
to themarked variability in sensitivity and specificity seen formost
index tests. For the vast majority of minimally invasive diagnostic
tests (or combinations of tests), nometa-analysis was possible. The
studies varied with respect to the included populations, severity of
endometriosis, menstrual cycle phase at testing, laboratory meth-
ods and the cut-off thresholds for index tests. We could not for-
mally explore sources of heterogeneity for themajority of tests due
to the low number of studies in most evaluations. Also,most of the
included studies evaluated the diagnostic cut-off thresholds using
a ROC analysis without any subsequent validation in an indepen-
dent cohort. Lack of validation of the diagnostic data in conjunc-
tion with the low number of studies for the majority of the pre-
sented tests contributed to the low quality of evidence presented
in this review. We now have an available standardised methodol-
ogy for fluid biospecimen collection, processing and storage, and
we recommend adhering to these standards in future diagnostic
studies (Rahimoglu 2014).
Additional weaknesses of this review series are the following.
1. The variation in the selection of the case and control groups
with inclusion of participants that may not reflect a clinically
representative population. The reported prevalence of
endometriosis in this and the other reviews was generally higher
(16% to 84%) than previously reported (6% to 10% in the
general female population and 35% to 50% in symptomatic
women) (Giudice 2004). This may reflect a high level of surgical
diagnostic expertise but could be due to pre-selection of more
challenging cases in tertiary referral centres, and there is a high
risk of patient selection bias in most of the studies. Selection bias
appeared to be reduced but not eliminated by consecutively
enrolling participants; however, the information on the method
of enrolment was missing in most of the included studies. More
than a third of the included studies (61/141, 43%) had a two-
gate design and included a wide group of participants who
underwent surgery for various indications. Inclusion of healthy
asymptomatic individuals or participants with other pathological
conditions represents a potential selection bias with regard to the
control group, which could have biased the test outcomes.
Thirty-four studies included either women with a limited
spectrum of endometriosis (N = 26) or they did not provide
information on the severity of target condition (N = 8). we
included these studies to avoid omission of potentially valuable
diagnostic information, but each of the above factors could skew
the diagnostic estimates in either direction and subsequently
interfere with the interpretation of the index test results. It was
not possible to evaluate population and disease spectrum effects
on the data because there were too few reports for most of the
blood biomarkers.
2. We could not rule out inappropriate assignment to the
endometriosis and control groups in many studies. Surgical
misdiagnosis is a potential cause of bias as most of the included
studies did not adequately describe the number and experience
of the surgical team, the surgical diagnostic criteria and the
surgical methods. We now have a standardised technique for
performing laparoscopy, and we recommend that any future
studies use this method (Becker 2014). Additionally, we did not
confine the studies included in this review to those that reported
histological confirmation of endometriotic lesions. Although a
recent ESHRE guideline stated that evidence is lacking to
support laparoscopy without histology to confirm endometriosis
(Dunselman 2014), the clinical significance of histological
verification remains debatable. Diagnosis by surgical visualisation
only remains a common clinical practice and can be considered
reliable when an accurate inspection of the abdominal cavity is
performed by experienced surgeons. We chose to include the 66
studies that only reported surgical visualisation as the reference
standard, and we did not wish to lose this potentially valuable
information. However, this could impact the accuracy of
assignment to the case and control groups.
3. The methodology of systematic reviews of diagnostic test
accuracy is still emerging, and there are no well-established
criteria for replacement or triage diagnostic tests, therefore we
chose criteria that were both realistic and clinically applicable to
assist in the interpretation of the complex results. For a
replacement test, we considered the threshold reported by the
one and the only systematic review on accuracy of the reference
standard (laparoscopy) in detecting endometriosis to be the most
objective (Wykes 2004). The meta-analysis was published in
2004 and included four eligible studies comprising 433 women.
We acknowledge the limitations associated with emphasising a
single review, particularly if it does not present the latest and
possibly more accurate data that reflect advances in surgical
expertise and technology. Several studies on accuracy of
laparoscopy in detecting endometriosis have been published in
the last decade; however, their results were not addressed in a
systematic way. A further systematic analysis to evaluate the
accuracy of laparoscopy was beyond the scope of this review. The
criteria for triage tests utilised the common concepts of SnOUT
and SpIN in medical statistics, and the cut-offs were set at levels
we considered to be clinically relevant (see Role of index test(s)).
We encourage the readers to apply independent interpretations
of the presented diagnostic estimates by using thresholds that
may be more applicable to specific populations and clinical
circumstances.
Applicability of findings to the review question
Based on our use of theQUADAS-2, we assigned a low rank (high
concern) to clinical applicability with respect to patient selection
in 51% of the studies (72/141). This occurred when the set of
participants in the study was broader that seen in clinical practice
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or when the spectrum of the target condition was limited and
the findings may not be applicable to the review question and
to clinical practice. We judged the applicability of the index test
and reference standard to be satisfactory using the QUADAS-2
tool for all studies. However, the majority of included studies took
place in academic institutions with a high level of expertise in
laboratory techniques, and the index test outcome measures may
not be able to be reproduced in all institutions or extrapolated to
general practice.
We excluded some potentially relevant well-designed studies, as
they did not directly address the review question. For example,
we excluded studies that reported on biomarkers with differential
expression in endometriosis, but that did not provide enough in-
formation to assess the diagnostic performance of the biomarker.
Additionally, we excluded most of the studies that compared en-
dometrioma with other ovarianmasses, as they either did not meet
our inclusion criteria for reproductive age or assessed the num-
bers of cysts rather than the number of participants. Therefore we
could not fully address the review question on non-invasive diag-
nosis of ovarian endometriosis. We also excluded some forms of
endometriosis, such as bladder, ureteric or endometriosis involv-
ing the extrapelvic sites (e.g. umbilicus, hernia sacs, abdominal
wall, lung, kidney, etc.), as they are informed predominantly by
case reports or small case series, and diagnostic laparoscopy is not
an applicable reference test for these conditions. Although these
target conditions are rare, from a clinical perspective the diagnos-
tic options for these forms of endometriosis remain unclear.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
CA-125 was the most studied technique, but showed only mod-
erate sensitivity and moderate specificity for pelvic endometriosis,
which did not meet the criteria for a replacement or triage test.
This is consistent with international guidelines, which do not rec-
ommend CA-125 testing in women with suspected endometriosis
(ACOG 2010; Dunselman 2014; SOGC 2010).
CA-19.9 (cut-off > 37.0U/ml), IL-6 (cut-off > 1.90 to 2.00 pg/ml)
and anti-endometrial antibodies demonstrated an unsatisfactory
diagnostic performance in detecting endometriosis and hence have
no role in clinical practice.
We suggest cautious interpretation of the presented results. Al-
though studies demonstrated diagnostic potential for a number
of tests, the level of heterogeneity, wide confidence intervals and
high/unclear risk of bias in most studies included from this review
series undermine reliability of the presented results, and hence
these data are insufficient to confidently inform clinical practice.
Additional biomarkers, reported in individual studies, displayed
diagnostic estimates that qualified for either replacement or triage
tests; however, there were not enough data for a meaningful rec-
ommendation on the use of any of these tests.
As there is an absence of well-established criteria for an adequate
diagnostic test, the diagnostic criteria for replacement and triage
tests were determined by the authors of this review in a way that
we believe will aid the interpretation for clinically active readers.
However, we encourage readers to apply different criteria accord-
ing to each clinical population and situation.
There is wide recognition that an accurate non-invasive test for
endometriosis is likely to confer several advantages over a surgi-
cal diagnosis for women with symptoms of endometriosis. These
potential advantages include a reduction in cost (both in direct
medical costs and in time off work), reduced discomfort, shorter
recovery times and a reduction in the rare but serious complica-
tions of anaesthesia and surgery. Another benefit of an accurate,
non-invasive diagnostic test for endometriosis is the prospect of
early diagnosis and timely therapeutic interventions to minimise
progression of disease, which can occur in up to 50% of women
(D’Hooghe 2002).
An accurate ’negative’ non-invasive test is expected to reduce the
need for diagnostic surgery in 50 - 70% of women with chronic
pelvic pain or infertility (Giudice 2004), although it is likely that
some women with a negative test would still require surgery to ex-
plore other pathologies. An accurate ’positive’ non-invasive test for
endometriosis is likely to increase the need for surgery in women
withmild symptoms or subfertility (D’Hooghe 2006). Thus, until
an accurate non-invasive diagnostic test is developed and tested in
large clinical populations, it is impossible to accurately predict its
impact on surgical uptake and the number of women that would
benefit from performing the test.
Implications for research
Currently, randomised controlled treatment trials require women
with and without endometriosis to have had diagnostic surgery for
accurate group allocation. For ethical reasons, therapeutic surgery
is usually performed at the same time, potentially biasing treat-
ment trial outcomes. Thus our current inability to diagnose and
assess the progression of endometriosis in a non-invasive way is
a significant limitation to the advancement of clinical research in
endometriosis.
Several blood biomarkers reported in this review showed promis-
ingly high diagnostic estimates for detecting endometriosis, but
there were too few evaluations to determine their value as replace-
ment or triage tests for a laparoscopic diagnosis. Further well-de-
signed diagnostic studies are necessary to establish the diagnostic
test accuracy and clinical utility of these blood tests.
In this review we identified a list of biomarkers that have no value
in detecting endometriosis and hence are not recommended for
evaluation in future diagnostic studies. This is important for ap-
propriate allocation of research resources and to guide clinically
114Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
relevant experimental work in the field. These biomarkers com-
prise: glycodelin, IGFBP-3, leptin, sICAM-1, MCP-1, hs-CRP,
IFN-γ , MIF, TNF-α, WBC, IL-1β, IL-2, IL-4, IL-8, IL-10, IL-
12, IL-18, sGM-CSF and the above-mentioned tests evaluated in
the meta-analyses.
The QUADAS-2 quality assessment of the included studies iden-
tified several weakness in study design that can impede an objec-
tive evaluation of the findings. We recommend that future authors
consider:
1. including large cohorts after pre-defining the sample size via
a power calculation (Liu 2005);
2. focusing on a single-gate design that only includes a
clinically relevant population (Rutjes 2005);
3. utilising a diagnostic accuracy study design that adheres to
the recommendations of the Standards for Reporting of
Diagnostic Accuracy (STARD) initiative (Bossuyt 2003);
4. incorporating the QUADAS checklist into the study design
(Whiting 2011);
5. formally assessing inter- and intraobserver variability of the
laboratory methods;
6. establishing universally acceptable laboratory methodologies
and a diagnostic criteria for a positive test (Rahimoglu 2014);
7. utilising universally acceptable methods of performing
laparoscopy as the reference standard test (Becker 2014);
8. implementing validation techniques to assess how the
results of a statistical analysis will generalise to an independent
data set;
9. undertaking direct comparisons of promising tests in
conjunction with a cost-effectiveness analysis;
10. applying testing to different clinical phenotypes rather than
to women classified according to rASRM staging (Vitonis 2014);
and
11. assessing the long term outcomes and lifetime healthcare
costs of women that have participated in diagnostic test accuracy
trials of specific diagnostic tests.
Specific opportunities for further research identified by this review
include:
1. assessing the diagnostic potential of anti-endometrial
antibodies and the tests identified as promising replacement or
triage tests in detecting pelvic endometriosis in larger, high
quality studies;
2. exploring the value of sequential testing, implementing
SnOUT and SpIN triage tests in diagnosing endometriosis in
conjunction with a cost-effectiveness evaluation of such testing;
3. directly comparing promising biomarkers in well-designed
diagnostic accuracy studies;
4. evaluation of the whole spectrum of disease across all phases
of menstrual cycle, aiming to identify the most appropriate
target population and the best time of testing;
5. attempting testing in the populations that differ by clinical
phenotype rather than by rASRM staging in view of the poor
correlation of this classification with clinical presentations and
treatment outcomes;
6. adding separate evaluations of blood biomarkers,
particularly urocortin and follistatin, CA-125 with the cut-off
values above 30 to 42 U/ml and a combination of CA-125 and
CA-19.9 to determine if ovarian endometrioma can be
distinguished from other ovarian masses in reproductive-aged
women; and
7. assessing the long-term outcomes and lifetime healthcare
costs of women in diagnostic test accuracy trials that have
evaluated specific diagnostic blood tests.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Acien 1989
Study characteristics
Patient sampling Primary objective: to measure the levels of CA-125 in the serum of normal women and in patients
with endometriosis before, during and after treatment with danazol or a luteinising hormone-
releasing hormone agonist, to evaluate the influence of these treatments on the levels of CA-125
and the possible relation with reactivation of endometriosis after treatment
Participants: women with endometriosis confirmed by laparoscopy and a group of regularly men-
struating women with a normal pelvis at laparoscopy
Selection criteria: not specified
Study design: longitudinal, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: endometriosis group - infertility in 70.4%, not specified otherwise
Age: range 22-43 years
Number of participants enrolled: 68 women (11 postmenopausal women were enrolled and analysed
separately - not considered in this review)
Number of participants available for analysis: 68 women (all in luteal cycle phase)
Setting: not stated; authors’ affiliations: the Royal Free (University) Hospital, London; and School
of Medicine, University of Alicante, Spain
Place of study: not specified, Europe
Period of study: not stated
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serumCA-125 was measured with an immunoradiometric
assay (AbbotCA-125RIA); working assay rangewas 6-500U/ml. sample processing and experiments
not described
Threshold for positive result: > 30 U/ml, not pre-specified
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: interassay and intra-assay CV 3.5%-6.4%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 54/68 (79%): stage I-II 40, stage III-IV 14; controls
n = 14
Reference standard: laparoscopy N = 68 (100%)
Description of positive case definition by reference standard as reported: visual inspection, staging ac-
cording to the rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: samples were taken at laparoscopy
Withdrawals: none
Comparative
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Acien 1989 (Continued)
Key conclusions by the authors Increases in CA-125 values above 30U/ml weremore likely to indicate reactivation of endometriosis
than when CA-125 did not increase
Conflict of interest Not reported
Notes The reported CA-125 values during and after treatment with Danazol or GnRH analogues are not
included in this review
Additional control group of postmenopausal women (N = 11) was not considered in calculation of
diagnostic estimates
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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Acien 1989 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the combination of CCR1 mRNA, MCP-1, and CA-125 protein
measurements in peripheral blood as a diagnostic test for endometriosis and to study the possible
use of these markers in the peripheral blood of patients with adenomyosis
Participants: patients who underwent laparoscopy for various indications
Selection criteria: Inclusion criteria: no endocrine therapy for at least 3 months; exclusion criteria:
suspected or ascertained diagnosis ofmalignancy, pregnancy,menopausal age or refusal to participate
in the study
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: endometriosis group - dysmenorrhoea, dyspareunia, chronic pelvic pain and
infertility; 12 women with known history of endometriosis; controls - undergoing surgery for
subserosal leiomyomata or tubal ligation
Age: reproductive age
Number of participants enrolled: 151 women (11 women with adenomyosis were enrolled and anal-
ysed separately - not considered in this review)
Number of participants available for analysis: 151 women (all in follicular cycle phase)
Setting: Department of O&G, University of Schleswig-Holstein
Place of study: Luebeck, Germany
Period of study: not stated
Language: English
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Agic 2008 (Continued)
Index tests Index test: CA-125, CCR1, MCP-1
Details of the index test procedure as stated: CCR1 expression detected by RT-PCR (SuperScriptTM
II RT, SYBR Green MM, normalised to HPRT housekeeping gene); MCP-1 levels detected by
using a commercially available ELISA kit (R&D Systems, GmbH, Germany) with assay sensitivity
of 5 pg/ml; CA-125 level detected by using a commercially available electro-chemiluminescent
immunometric assay (ECLIA, Roche Diagnostics GmbH, Germany) with assay sensitivity of 0.6
IU/ml; all the experiments were repeated x 3 times; the test was considered positive for endometriosis
if at least
one of the markers was above the threshold; sample processing and experiments described
Threshold for positive result: CCR1/HPRT > 1.16, MCP-1 > 140 pg/ml, CA-125 > 50 IU/ml- all
pre-specified
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: for MCP-1 the intra- and interassay CV was 2.5% and 4.5%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 102/151 (68%): stage I-II 37, stage III-IV 65; controls
n = 49
Reference standard: laparoscopy N = 151 (100%) + histology
Description of positive case definition by reference standard as reported: visual inspection, histological
diagnosis; staging according to the rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were obtained 24 hours prior
to anaesthesia and laparoscopy
Withdrawals: none
Comparative
Key conclusions by the authors The results imply the potential use of CCR1 mRNA, MCP-1, and CA-125 protein measurements
for the diagnosis or exclusion of endometriosis
Conflict of interest Not reported
Notes The reported estimates for diagnosis of adenomyosis are not presented in this review
The reported diagnostic estimated per severity of endometriosis are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes
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Agic 2008 (Continued)




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Akoum 1996
Study characteristics
Patient sampling Primary objective: to evaluate MCP-1 in the peripheral blood of women with and without en-
dometriosis
Participants: women who underwent laparoscopy for infertility and pelvic pain (endometriosis
group) and fertile women who underwent tubal ligation or reanastomosis with normal pelvis (con-
trols)
Selection criteria: inclusion criteria: no other pelvic disorders; no treatment with any antiinflamma-
tory or hormonal medications at least 3 months before laparoscopy
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: endometriosis group - infertility - 26 (46%) and pelvic pain; healthy fertile
controls
Age: mean age 31.2 ± 7.2 years (endometriosis group), 33.7 ± 5.6 years (controls)
Number of participants enrolled: 101 women
Number of participants available for analysis: 101 women (in follicular or luteal phase of menstrual
cycle)
Setting: university hospital, Saint-Francois d’Assise hospital Universite Laval
Place of study: Quebec, Canada
Period of study: not stated
Language: English
Index tests Index test: MCP-1
Details of the index test procedure as stated: MCP-1 concentrations were measured, with ELISA (R
& D Systems, Minneapolis); the biologic activity of MCP-1 (monocyte chemotaxis induction) was
evaluated by using a Boyden chamber and a human cell line (U937); assay sensitivity limit 50 pg/
ml; sample processing and experiments described in detail
Threshold for positive result: > 100 pg/ml - not pre-specified
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: Intra- and interassay CV < 6%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 57/101 (56%): stage I-II 47, stage III-IV - 10; controls
n = 44
Reference standard: laparoscopy N = 101 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rAFS system
Examiners: no information provided




Key conclusions by the authors Endometriosis is associated with increased level and activity of MCP-1 in the peripheral blood. The
elevation and activation of this cytokine could play a relevant role in the immuno-inflammatory
process associated with the disease
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Akoum 1996 (Continued)
Conflict of interest Not reported; supported by a grant No. MT-12541 from the Medical Research Council, Ottawa,
Canada
Notes The reported data on monocyte chemotactic activity are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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Akoum 1996 (Continued)
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the role of IL-10, -12, -17, and -23 in infertile patients withminimal-
mild endometriosis
Participants: women who underwent laparoscopy for investigation of infertility or for tubal ligation
Selection criteria: exclusion criteria: presence of autoimmune disease, absence of peritoneal liquid
during laparoscopy, coexistence of other causes of infertility, and hormonal medication in the 3
months before surgery
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: endometriosis group - infertility 100% and pelvic pain (40%), other causes
of infertility were excluded by hysterosalpingography, spermiogram, and measurements of serum
FSH, PRL, and TSH levels; control group - women requesting tubal ligation
Age: mean age 32.48 ± 4.99 years (endometriosis group), 33.63 ± 6.51 years (controls)
Number of participants enrolled: 80 women
Number of participants available for analysis: 80 women (all in follicular phase of menstrual cycle)
Setting: university hospital, Hospital de Cl nicas de Porto Alegre, Universidade Federal do Rio
Grande do Sul
Place of study: Porto Alegre, Brazil
Period of study: March 2007 - December 2008
Language: English
Index tests Index test: IL-10, IL-12, IL-17, and IL-23
Details of the index test procedure as stated: IL-10, IL-12 (p70), IL-17a, and IL-23 (p19/p40) con-
centrations were measured, with ELISA Human Ready-SET-Go! commercial kits (eBioscience, San
Diego, CA); the sensitivity was 2 pg/ml, 4 pg/ml, 4 pg/ml, and 15 pg/ml, respectively
Threshold for positive result: not reported
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not reported
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Andreoli 2011 (Continued)
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 40/80 (50%): all stage I-II; controls n = 40
Reference standard: laparoscopy N = 80 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rAFS system
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were drawn at laparoscopy
Withdrawals: none
Comparative
Key conclusions by the authors Higher IL-23 levels were encountered in the peritoneal fluid of women with endometriosis, sug-
gesting a possible role of this cytokine in these women’s infertility
Conflict of interest The authors reported no conflict of interests
Notes The data for markers measured in peritoneal fluid are not presented in this review
For all the biomarkers there was no statistically significant difference between the groups - no data
available for meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
146Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Andreoli 2011 (Continued)
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate CA-125 in peritoneal fluid as an indicator of endometriosis
Participants: women undergoing laparotomy or diagnostic laparoscopy for infertility or pelvic pain
Selection criteria: inclusion criteria: no hormonal medications at least 3 months before surgery, mid-
follicular cycle phase
Study design: cross-sectional, single-gate design, prospective enrolment and collection of samples
Patient characteristics and set-
ting
Clinical presentation: Inertility or pelvic pain
Age: range 23-41 years (endometriosis group), 16-55 years (controls)
Number of participants enrolled: 45 women
Number of participants available for analysis: 45 women (all in mid-follicular cycle phase, day 8-12)
Setting: Institute of O&G, University of Rome ’La Sapienza’
147Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Barbati 1994 (Continued)
Place of study: Rome, Italy
Period of study: not stated
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serum levels of CA-125 were measured by immunoradio-
metric ’one step’ sandwich assay (IRMA CA-125 II K, Sorin Biomedica, Italy); minimal detectable
concentration 1.4 U/ml; sample processing and experiments are described in details
Threshold for positive result: > 35 U/ml, not pre-specified
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: Intra- and interassay CV was 7.5% and 8.7%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 18/45 (40%): stage I-II 12, stage III-IV 6; controls
n = 27: normal pelvis - 7, other benign pathologies - 20
Reference standard: laparoscopy/laparotomy N = 45 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rAFS system
Examiners: no information provided




Key conclusions by the authors The sensitivity ofCA-125 test for endometriosis in peritoneal fluid is greater than in serum.Therefore
its measurement could be useful in the detection of early stage of endometriosis, which tends to be
overlooked by the CA-125 serum test
Conflict of interest Not reported; supported by a grant 92.02130.39 ACRO from the National Research Council,
Rome, Italy
Notes The reported data on CA-125 in peritoneal fluid is not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes
Was a ’two-gate’ design
avoided?
Yes
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Barbati 1994 (Continued)
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Barbosa 2009
Study characteristics
Patient sampling Primary objective: to determine the frequency of endometriosis and the correlation between serum
CA-125 levels and the presence of endometriotic lesions in the peritoneum of asymptomatic fertile
patients
Participants: women who underwent laparoscopy for tubal ligation
Selection criteria: inclusion criteria: reproductive age, no symptoms of endometriosis
Study design: cross-sectional, single-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: asymptomatic fertile women requesting tubal ligation
Age: mean age 33.68 ± 4.63 years, range 21-44 years
Number of participants enrolled: 80 women
Number of participants available for analysis: 80 women (all in follicular phase of menstrual cycle)
Setting: university hospital, family planning outpatient clinic of Faculdade de Medicina do ABC
(FMABC)
Place of study: Santo André, Brazil
Period of study: not specified
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: Serum CA-125 levels were measured in accordance with
the manufacturer’s instructions (BYK-Sangtec Diagnostica GmbH, Germany). When the CA-125
values were higher than 35 U/ml, a second measurement was performed to confirm the result;
sample handling described
Threshold for positive result: > 35 U/ml, pre-specified
Examiners: not specified, unclear if blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 13/80 (16.2%); all stage I-II; controls n = 67
Reference standard: laparoscopy N = 80 (100%) + histopathology
Description of positive case definition by reference standard test as reported: the criterion for histological
classification of endometriosis was identification of stromal endometrioid or epithelial elements of
Müllerian type, with or without stroma, associated with signs of haemorrhage and fibrosis (peri-
toneal biopsy from four different sites: left and right ovarian fossae, and left and right sacrouterine
ligaments; 320 slides stained with hematoxylin-eosin were studied); themorphological criteria were:
stromal disease - only endometrial stroma was found; well-differentiated disease - glands similar
to topical endometrium were found; undifferentiated disease - the appearance of the glands was
different from topical endometrium; and mixed disease - the appearance of the glands was atypical
or undifferentiated; staging according to the rAFS system
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were drawn on the first 3 days
of cycle prior to surgery
Withdrawals: none
Comparative
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Barbosa 2009 (Continued)
Key conclusions by the authors The presence of endometriotic lesions in the peritoneum of fertile patients supports the hypothesis
that incidental findings ofminimal ormild endometriosismay not be of clinical significance, and that
the progression of the disease probably occurs as a result of immunological and genetic abnormalities.
Serum CA-125 levels did not show any diagnostic significance with regard to detecting the disease
Conflict of interest The authors reported no conflict of interests; there was no funding for the study
Notes For CA-125 there was no statistically significant difference between the groups - no data available
for meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Barbosa 2009 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to determine the angiogenic activity and concentrations of IL-8 in peritoneal fluid
and sera of patients suffering from endometriosis
Participants: women who underwent laparoscopy for various indications
Selection criteria: exclusion criteria for control group: pelvic inflammatory disease, ovarian cysts and
peritoneal adhesions; not specified otherwise
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: reproductive age
Number of participants enrolled: 84 women
Number of participants available for analysis: 84 women (all in follicular phase of menstrual cycle)
Setting: university hospital, Department of O&G, the Medical University of Warsaw
Place of study: Warsaw, Poland
Period of study: not specified
Language: English
Index tests Index test: IL-8; angiogenic activity
Details of the index test procedure as stated: angiogenic activity was determined as the number of
newly formed blood vessels, induced by intradermal injection of peritoneal fluid and sera obtained
from the patients into at least 3 mice according to the Sidky and Auerbach experimental model; all
the newly formed blood vessels were identified and counted using the criteria suggested by Sidky
and Auerbach; referenced to the primary source; IL-8 concentrations were determined using ELISA
method (R&D SYSTEM); laboratory technique and sample handling described
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Threshold for positive result: not reported
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 52/84 (62%): stage I-II 22, stage III-IV 30; controls
n = 32
Reference standard: laparoscopy N = 84 (100%) + histopathology
Description of positive case definition by reference standard test as reported: endometriosis was diagnosed
on the basis of visualised changes and histopathological examination; staging according to the rAFS
system
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were drawn at laparoscopy
Withdrawals: for IL-8 no data available for 10 women from the control and for 5 women from
endometriosis group, withdrawals not explained
Comparative
Key conclusions by the authors Angiogenesis plays an important role in pathogenesis of endometriosis. Although IL-8 takes part in
neovascularisation,
there are other factors modulating angiogenesis in endometriosis
Conflict of interest Not reported
Notes The data for the biomarkers measured in peritoneal fluid are not presented in this review
For serum angiogenic activity and IL-8, there was no statistically significant difference between the
groups - no data available for meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the ability of a group of serum/peritoneal fluid markers to non-
surgically predict endometriosis
Participants: patients undergoing laparoscopy for pain, infertility, tubal ligation or sterilisation re-
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versal
Selection criteria: exclusion criteria: blood contaminated peritoneal fluid
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: median age 32.5 years, range 18-44 years
Number of participants enrolled: 130 women
Number of participants available for analysis: 91 women (in follicular or luteal phase the cycle,
numbers not reported)
Setting: tertiary care referral centre, the Cleveland Clinic Foundation
Place of study: Cleveland, Ohio, USA
Period of study: 1998-2000
Language: English
Index tests Index test: IL-6, IL-ß, IL-12, IL-13,TNF-α
Details of the index test procedure as stated: serum levels of IL-ß IL-6, IL-12, IL-13 and TNF-α
were measured in parallel for each patient by using commercially available, cytokine-specific, ELISA
(R&D Systems Inc, Minneapolis, USA); assay sensitivities 1.0, 0.7, 5.0, 32.0 and 4.4 pg/ml, with
standard curve ranges of 3.9-250, 3.12-300, 7.8-500, 62.5-4000 and 15.6-1000 pg/ml, respectively;
sample preparation described
Threshold for positive result: IL-6 > 2 pg/ml; > 4 pg/ml; > 7.5 pg/ml - selected during analysis, not
pre-specified
Examiners: no information provided; not blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 56/91 (62%): stage I-II 34, stage III-IV 22; controls
n = 35
Reference standard: laparoscopy N = 91 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rASRM system
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: “Blood samples were collected from each
patient pre-operatively”, from the context - just prior to surgery
Withdrawals: 39 patients were excluded because of blood-contaminated peritoneal fluid (did not
meet inclusion criteria)
Comparative
Key conclusions by the authors In summary, serum IL-6 and peritoneal fluid TNF-α may be good markers for endometriosis and
permit non-surgical diagnosis; such findings must be verified in larger group of patients and controls
before being applied within the clinical situation
Conflict of interest Not reported; the study was supported by a research grant from MISC of the Cleveland Clinic
Foundation (RPC#2156)
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Notes For IL-ß, IL-12, IL-13 there was no statistically significant difference between the groups - no data
available for meta-analysis
The levels of TNF-α were statistically significantly higher in endometriosis, but there was no data
to construct 2 x 2 tables - not included in this review
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
No
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate serum prolactin and CA-125 levels as biomarkers for the diagnosis of
peritoneal endometriosis
Participants: women who underwent laparoscopy for infertility, pelvic pain or tubal ligation
Selection criteria: inclusion criteria for endometriosis group: superficial peritoneal implants con-
firmed by biopsy, regular menstrual cycles, negative transvaginal ultrasonography for endometri-
oma and deep endometriosis; exclusion criteria: endocrine disorders, drugs that could affect the
parameters of the tests employed, irregular menstrual cycles, infertility or pain were not caused by
endometriosis, any hormonal medications in 3/12 months before surgery
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: endometriosis group - infertility, pelvic pain or both; other causes of infertility
were excluded by hysterosalpingography, semen analysis, and measurements of serum FSH and
TSH levels on the 3rd day of the menstrual
cycle
Age: mean age 33.34 ± 4.66 and 33.67 ± 7.16 years (endometriosis group); 33.03 ± 4.42 years
(control group)
Number of participants enrolled: 97 women
Number of participants available for analysis: 97 women (all in luteal phase of menstrual cycle)
Setting: Department of O&G, Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de
Porto Alegre
Place of study: Porto Alegre, Brazil
Period of study: not specified
Language: English
Index tests Index test: CA-125, prolactin
Details of the index test procedure as stated: Prolactin was analysed with Roche Diagnostics GmbH,
Mannheim, Germany and CA-125 with Roche Diagnostics; sample handling described
Threshold for positive result: for prolactin > 14.80 ng/ml and > 20 ng/ml, for CA-125 > 19.80 U/I
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and > 35 U/l; not pre-specified
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: for prolactin the intra- and interassay CV was 2.0% and 1.7%, for CA-125
1.8% and 1.6%
Target condition and reference
standard(s)
Target condition: peritoneal endometriosis
Prevalence of target condition in the sample: n = 63/97 (65%): stage I-II 40, stage III-IV 23; controls
n = 34
Reference standard: laparoscopy n = 97 (100%) + histopathology
Description of positive case definition by reference standard test as reported: visual inspection, confirmed
by histopathology; staging according to the rASRM classification
Examiners: the same surgical staff performed all endoscopic procedures; the surgeons were blinded
to the result of index test




Key conclusions by the authors Serum CA-125 and prolactin levels assessed together, and considering the cut-off for CA-125 (19.
9 U/I) and prolactin (14.8 ng/ml), allow the diagnosis of peritoneal endometriosis with acceptable
sensitivity and specificity (77 and 88%) and a high negative predictive value (97%)
Conflict of interest Not reported
Notes The separate data for different clinical presentations od endometriosis (pain only or infertility only)
are not presented in this review
The reported diagnostic estimates for the subgroups by severity of endometriosis are not included
in the review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
158Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bilibio 2014 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate total serumandperitoneal concentrations of vitaminD-bindingprotein
in women with endometriosis, known as an inflammation-associated disease
Participants: women undergoing surgical visualisation because of pain, infertility or both
Selection criteria: inclusion criteria: pre-menopausal age, regular cycle (25-32 days)
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Study design: cross-sectional, single-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, infertility or both
Age: range 21-50 years
Number of participants enrolled: 43 women
Number of participants available for analysis: 43 women (all in follicular phase of the menstrual cycle)
Setting: Department ofO&G,Wroc awMedical University; Laboratory of Reproductive Immunol-
ogy, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
Place of study: Wroc aw, Poland
Period of study: not stated
Language: English
Index tests Index test: vitamin D-binding protein
Details of the index test procedure as stated: serum vitamin D-binding protein was measured by using
ELISA (using goat polyclonal antibody against human Gc globulin; absorbance at 490 nm was
read by using a Bio-Tek 340 EL spectrophotometer; data analysed with KC3 software (Bio-Tek
Instruments; Winooski, USA); concentration were calculated by interpolation from a six-point
logarithmic standard curve); sample processing and experiments described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: intra- and interassay CV < 10% and < 15%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 26/43 (61%): stage I-II 11, stage III-IV 15; controls
n = 17
Reference standard: laparoscopy N = 43 (100%) + histology
Description of positive case definition by reference standard as reported: visual inspection, confirmed by
histopathology; staging according to the rASRM classification
Examiners: no information provided




Key conclusions by the authors Serum and peritoneal DBP concentrations are not affected in women with endometriosis; however,
based on the latest published data, it is possible that both the serum and peritoneal concentrations
of vitamin D-binding protein may be dependent on Gc genotype, which results in differential
modulation of monocyte/macrophage activity
Conflict of interest Not reported; supported by grantNo. 3P05E 077 24 from the PolishMinistry for Scientific Research
and Information Technology
Notes For vitamin D-binding protein there was no statistically significant difference between the groups
- no data available for meta-analysis
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the capacity of peripheral blood monocytes (PBM) from women
with endometriosis to secrete tumour necrosis factor-alpha (TNF-α), interleukin (IL) IL-6, IL-8,
and IL-10
Participants: women who underwent laparoscopy for suspected endometriosis or tubal ligation
Selection criteria: not reported
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: reproductive age
Number of participants enrolled: 30 women
Number of participants available for analysis: 30 women (all in luteal phase of menstrual cycle)
Setting: Institute for the Study and Treatment of Endometriosis, Department of Medicine, Rush
Medical College
Place of study: Chicago, IL, US
Period of study: not specified
Language: English
Index tests Index test: TNF-α, IL-6, IL-8, and IL-10
Details of the index test procedure as stated: concentrations of cytokines in peripheral blood monocytes
we measured by using commercially available ELISA kits (Biosourse International, CA) according
to the manufacturer instructions; sensitivity of assays ranged from < 1 pg/ml (TGF-a) to 11 pg/ml
(IL-8; sample handling and laboratory methods described
Threshold for positive result: not reported
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 20/30 (67%): stages not reported; controls n = 10
Reference standard: laparoscopy N = 30 (100%)
Description of positive case definition by reference standard test as reported: laparoscopic examination
and staging
Examiners: the same surgical staff performed all endoscopic procedures; the surgeons were blinded
to the result of index test
Flow and timing Time interval between index test and reference standard: blood samples were drawn at surgery
Withdrawals: none reported
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Comparative
Key conclusions by the authors Endometriosis is associated with increased basal and stimulated synthesis and secretion of several
different cytokines by PBM. Each of the cytokines found to be affected has the capacity to play a
role in the symptomatology or pathogenesis of the disease
Conflict of interest Not reported; the work was supported in part by Public Health Service grants CA58922, Bethesda
Maryland and a grant from Sterling International, New York
Notes The data for induced monocyte cytokine biosynthesis are not included in the review
For TNF-α, IL-6 and IL-8 there was statistically significant difference between the groups, but there
were insufficient data to construct 2 x 2 tables - not included in this review
For IL-10 there was no statistically significant difference between the groups - no data available for
meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate whether endometriotic cells themselves are able to secrete cytokines
that may contribute in creating a favourable microenvironment for their implantation and survival
in the peritoneal cavity; and to consider levels of inflammatory and chemotactic mediators that can
justify a possible immune system involvement
Participants: women who underwent surgery for suspected endometriosis or benign ovarian cyst
Selection criteria: not specified
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: mean age 34.76 ± 2.14 years, range 20-50 years
Number of participants enrolled: 30 women
Number of participants available for analysis: 30 women (14 in follicular and 16 in luteal phase of
menstrual cycle)
Setting: Department O&G, Hospital San Gerardo di Monza, University of Milan - Bicocca
Place of study: Milano-Bicocca, Italy
Period of study: not specified
Language: Italian
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Index tests Index test: MCP-1, IL-8
Details of the index test procedure as stated: the concentrations of both markers were measured by
using ELISA method; not specified otherwise
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 20/30 (67%): stage I-II 2, stage III-IV 18; controls
n = 10
Reference standard: laparoscopy/laparotomy N = 30 (100%) + histopathology
Description of positive case definition by reference standard test as reported: visual inspection, confirmed
by histopathology; staging according to the rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none reported
Comparative
Key conclusions by the authors Increased tissue levels of IL-8 and MCP-1 in patients affected by endometriosis may play an impor-
tant role in the pathogenesis and development of this disease. Moreover, higher serum concentra-
tion of MCP-1 in patients affected by endometriosis may indicate a higher activation of circulating
monocytes
Conflict of interest Not reported
Notes For MCP-1 there was statistically significant difference between the groups, but there were insuffi-
cient data to construct 2 x 2 tables - not included in this review
For IL-8 there was no statistically significant difference between the groups - no data available for
meta-analysis
The data for markers measured in endometriotic tissue are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Was a ’two-gate’ design
avoided?
No
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High High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to review the CA-125 concentration in women with dysmenorrhoea in order to
delineate the predicting value for the diagnosis of endometriosis and its severity; to evaluate the
significance of CA-125 in monitoring therapy and follow-up
Participants: patients undergoing laparoscopy for dysmenorrhoea
Selection criteria: inclusion criterion: luteal cycle phase, not specified otherwise
Study design: longitudinal prospective single-gate design, consecutive enrolment
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: mean age 30.8 ± 7.3 years, range 15-45
Number of participants enrolled: 157 women
Number of participants available for analysis: 155 women (all in luteal phase of menstrual cycle)
Setting: tertiary teaching hospital Keelung Chang Gung Memorial Hospital
Place of study: Taiwan
Period of study: January 1993 - January 1995
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serum CA-125 was determined by immunoradiometric
assay ELISA-CA 125 II kit (GIF-SUR-YVETTE CEDEX, France); no other details provided
Threshold for positive result: > 35 U/ml, pre-specified
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: not stated
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 131/157 (83%); stage I-II 56, stage III-IV 75; controls
n = 26
Reference standard: laparoscopy N = 157 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection, histological
confirmation; staging according to the rAFS system
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were taken at admission for
laparoscopy
Withdrawals: 2 patients (1%) excluded from analysis because of fibroid uterus
Comparative
Key conclusions by the authors For endometriosis, CA-125 is a valuable adjuvant in the follow-up of recurrence in patients with
advanced endometriosis and initially elevated CA-125 levels. It is not an effective screening tool
for patients with dysmenorrhoea, or for monitoring therapy. There was no significant correlation
between the development of endometriosis and reproductive factors
Conflict of interest Not reported
Notes The reported diagnostic estimates for different stages of endometriosis are not included in this
review
The reported CA-125 levels at different time points during and after Danazol treatment and rela-
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tionship CA-125 are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate serum and urinary levels of vascular endothelial growth factors TNF-
α and sFlt-1 in patients with endometriosis
Participants: women who underwent laparoscopy or laparotomy for different indications including
pelvic masses, pelvic pain, suspicious endometriosis, infertility and diagnostic evaluation
Selection criteria: inclusion criteria: pre-menopausal age
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, infertility, pelvic mass, other not specified
Age: mean age 32.65 ± 6.82 years (endometriosis group), 30.96 ± 6.36 years (controls)
Number of participants enrolled: 43 women
Number of participants available for analysis: 43 women (in follicular or luteal cycle phase, numbers
not specified)
Setting: Department of O&G, Yongdong SeveranceHospital, Yonsei University College ofMedicine
Place of study: Seoul, Korea
Period of study: not stated
Language: English
Index tests Index test: VEGF, sFlt-1, TNF-α, CA-125
Details of the index test procedure as stated: serum concentrations of VEGF, sFlt-1, and TNF-α,
were measured using specific commercial sandwich ELISA kit according to manufacturer protocols
(Quantikine; R&D systems Inc, MN, USA); sample processing described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 46/70 (66%): stage I-II 15, stage III-IV 31; controls
n = 24
Reference standard: laparoscopy/laparotomy N = 70 (100%) + histology
Description of positive case definition by reference standard as reported: visual inspection, confirmed by
histopathology in all patients; staging according to the rASRM classification
Examiners: no information provided
169Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cho 2007 (Continued)




Key conclusions by the authors The pathogenesis of minimal-mild endometriosis and moderate-severe endometriosis seems to be
different. Increased sFlt-1 levels in serum and urine of minimal-mild disease indicate that sFlt-1
may have an important role in inhibiting angiogenic process of the disease
Conflict of interest Not reported
Notes For VEGF and sFlt-1 there was no statistically significant difference between the groups - no data
available for meta-analysis
For TNF-α and CA-125 there was a statistically significant difference between the groups, but there
were insufficient data to construct 2 x 2 tables - not included in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate the clinical utility of CA-125 in the diagnosis of endometriosis and to
compare the sensitivity of the serum and peritoneal test as indicators of disease
Participants: women undergoing laparoscopy for infertility
Selection criteria: inclusion criteria: mid-follicular cycle phase
Study design: cross-sectional, single-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility
Age: mean age 31.2 ± 4.5 years (endometriosis group), 32.6 ± 6.1 years and 27.0 ± 5.8 years (controls)
Number of participants enrolled: 45 women
Number of participants available for analysis: 40 women, all in mid-follicular cycle phase (day 7-10)
Setting: Institute of O&G, School of Medicine, 2nd University of Naples
Place of study: Naples, Italy
Period of study: not stated
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serum CA-125 levels were measured by immunoradio-
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metric ’two-step method’ (IRMA-mat, Byk-Stangtee Diagnostic GmbH&Co Kgy, Dietzenbach);
sample processing and experiments are described in details
Threshold for positive result: > 35 U/ml, pre-specified
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: Intra- and interassay CV was 4.3% and 7.7%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 18/40 (45%): stage I-II 10, stage III-IV 8; controls
n = 22: normal pelvic - 12, other benign pathologies - 10
Reference standard: laparoscopy N = 40 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rAFS system
Examiners: no information provided




Key conclusions by the authors Further investigations are needed to verify the sensitivity of serum and peritoneal CA-125 as diag-
nostic test for endometriosis using cut-off levels lower for serum and higher for peritoneal fluid, or
different assays with high dilution of the samples
Conflict of interest Not reported
Notes The reported data on CA-125 in peritoneal fluid is not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate the presence of myeloperoxidase (MPO), N-acetyl-b-Dglu-
cosaminidase (NAG), tumour necrosis factor alpha (TNF-α) and vascular endothelial growth factor
(VEGF) in peripheral and menstrual blood in women with and without endometriosis
Participants: women undergoing laparoscopy for infertility, pelvic pain or both, or for tubal ligation
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Selection criteria: inclusion criteria: regular menstrual cycles, no use of hormonal nor anti-inflam-
matory agents in the previous three months and surgical confirmation or exclusion of endometriosis
in agreement with the ESHRE guidelines
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: endometriosis group: infertility, pelvic pain or both; control group - infertility
or request for tubal ligation; none of the women had a significant past medical history
Age: median age 36 years, range 31-48 years
Number of participants enrolled: 17 women
Number of participants available for analysis: 17 women, all in follicular cycle phase (day 1-4)
Setting: University Hospital: Hospital das Clinicas at Universidade Federal de Minas Gerais
Place of study: Belo Horizonte, Minas Gerais, Brazil
Period of study: February 2011 - December 2012
Language: English
Index tests Index test: NAG, MPO, TNF-α, VEGF
Details of the index test procedure as stated: Serum NAG and MPO activity were quantified by
measuring the levels of the lysosomal enzyme NAG and by assaying MPO activity as previously
reported (described and referenced to primary source; values expressed as change in absorbance
(OD) at 400 nm and 450 nm, respectively); TNF-α andVEGF levelsmeasured by using commercial
specific ELISA kits (Human VEGF (Duoset R&D Systems DY293B range: 31,2-2000 pg/ml)
and Human TNF-α (Duoset R&D Systems DY210, MN -USA, range: 15,6-1000 pg/ml); sample
handling described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 10/17 (59%): stage II 5, stage IV 2, undetermined
stage 3; controls n = 7
Reference standard: laparoscopy n = 17 (100%)
Description of positive case definition by reference standard test as reported: diagnosis according to
ESHRE guidelines; staging according to rASRM
Examiners: no information provided




Key conclusions by the authors These findings point to the existence of an increased local inflammatory activity in women with
endometriosis
Conflict of interest Not reported; the work was supported by a grant from the Brazilian Research Council (CNPq)
grant number 474132/2010-2
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Notes For NAG, MPO, TNF-α and VEGF there was no statistically significant difference between the
groups - no data available for meta-analysis
The data for markers measured in menstrual blood are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the usefulness of serum IL-8 and the NLR, either by themselves or
as adjuncts to CA-125, in the diagnosis of various stages of endometriosis
Participants: women of reproductive age who were scheduled to undergo laparoscopy or laparotomy
because of clinical indications of tubal ligation, benign ovarian cysts, infertility, or pelvic pain
Selection criteria: inclusion criterion: follicular phase of menstrual cycle; exclusion criteria: hormonal
medications for 6 months before surgery, ovarian neoplasia, PID, pregnancy, acute/chronic inflam-
mation, autoimmune disease, refusal to participate, patients with suspected or confirmed leiomy-
oma or adenomyosis
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: mean age 26.8 ± 6.2 years (endometriosis), 27.4 ± 7.2 years (controls)
Number of participants enrolled: 110 women
Number of participants available for analysis: 100 women (all in follicular cycle phase)
Setting: tertiary referral centre, Zekai Tahir BurakWomen’sHealth Education and ResearchHospital
Place of study: Ankara, Turkey
Period of study: March 2009 - April 2009
Language: English
Index tests Index test: CRP, CA-125, IL-8, Neutrophils, NLR
Details of the index test procedure as stated: CRP levels were measured using immuno-turbidimetric
assay (Hitachi 917/Tina Quant,Roche Diagnostics, Germany), CA-125 levels - using CA-125 II
assay (ADVIA Centaur, Siemens, Los Angeles, USA), IL-8 - using IMMULITE 1000 (Siemens);
assay sensitivity for CRP 0.003 mg/l, for CA-125 2 U/ml, for IL-8 0.7 pg/ml
Threshold for positive result: WCC > 6400/ml, CA-125 > 29.9 IU/ml, IL-8 > 24 pg/ml, neutrophils
> 4058/ml, NLR > 2.19, Combined marker > 43.1, not pre-specified
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: Intra- and interassay CVs for CRP 0.2% and 2.5%; for CA-125 4.03%;
IL-8 2.5% and 4.5%
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Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 50/87 (58%): stage I-II 18, stage III-IV 32; controls
n = 50
Reference standard: laparoscopy N = 87 (87%)/laparotomy N = 13 (13%) + histology
Description of positive case definition by reference standard test as reported: visualisation at surgery with
subsequent histological confirmation; staging according to the rAFS classification
Examiners: trained surgeons who were skilled at detecting and identifying all forms of endometriotic
lesions
Flow and timing Time interval between index test and reference standard: blood samples were taken “prior to surgery”,
implies short time before surgery
Withdrawals: 10 patients excluded from the study (did not meet inclusion criteria)
Comparative
Key conclusions by the authors Neutrophilia accompanied by a relative lymphocytopenia yielded an increased NLR in patients
with endometriosis, and the data generated in our study show that a combination of putative
inflammatorymarkers andCA-125 could serve as amultiple-marker screening test for endometriosis
Conflict of interest Not reported
Notes The reported diagnostic estimates for different stages of endometriosis are not included in this
review
For CRP there was no difference between the groups - no data available for meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to verify whether sHLA-I and sICAM-1 serum concentrations are related to the
various stages of pelvic endometriosis, which is an immune-related disorder associated with impaired
in-vitro NK cell activity
Participants: women undergoing laparoscopy for various indications
Selection criteria: not reported
Study design: cross-sectional, two-gate design, prospective collection of samples
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Patient characteristics and set-
ting
Clinical presentation: indications for surgery: endometriosis group - infertility, pelvic pain, adnexal
mass; controls - infertility, tubal ligation, mullerian malformation; none of the subjects was affected
by any systemic or pelvic disease other than endometriosis
Age:mean age 25.6 years, range 22-33 years (endometriosis group), 25.4 years, range 20-31 (controls)
Number of participants enrolled: 30 women
Number of participants available for analysis: 30 women (16 in follicular, 14 in luteal cycle phase)
Setting: University Hospital: Department O&G, Universita degli studi di Napoli
Place of study: Naples, Italy
Period of study: not stated
Language: English
Index tests Index test: sICAM-1, sHLA-I
Details of the index test procedure as stated: serum levels of sICAM-1 and sHLA-I were measured by
using commercial ELISA kits (CD-54 ICAM-1: EIA PAC, Ancell Corp, Bayport, USA and sHLA-
STAT Class I: SangStat Medical Corp, Menlo Park, USA); assay sensitivity for sICAM-1 5 ng/l, for
sHLA-I CA-125 3 ng/ml
Threshold for positive result: not reported
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: Intra- and interassay CVs < 12% for both assays
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 15/30 (50%): stage I-II 5, stage III-IV 10; controls
n = 15
Reference standard: laparoscopy N = 30 (100%) + histology
Description of positive case definition by reference standard test as reported: visualisation at surgery with
subsequent histological confirmation; staging according to the rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none reported
Comparative
Key conclusions by the authors Studies on sHLA-I and sICAM-1 may help to clarify the pathogenic mechanisms of endometriosis,
and their serum concentrations may serve as additional markers for the early detection of recurrence
of the disease during the monitoring of treatment outcome
Conflict of interest Not reported
Notes For sHLA-I and sICAM-1 there was no difference between the groups - no data available for meta-
analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Patient sampling Primary objective: to determine the role of serum and peritoneal interleukin (IL)-6, tumour necrosis
factor (TNF)-α and glycodelin A levels as diagnostic markers of endometriosis in adolescent girls
Participants: adolescent girls after menarche undergoing laparoscopy for chronic pelvic pain
Selection criteria: inclusion criteria: chronic pelvic pain, defined as non-cyclic lower abdominal
pain, not connected with the menstrual cycle, lasting at least 3 months or cyclic pain ongoing for
6 months, severe enough to cause functional disability or require medical or surgical treatment;
exclusion criteria: general, chronic, autoimmune or endocrinological diseases, history of pregnancy
or hormonal medications for at least 6 months prior to the study
Study design: cross-sectional, single-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: Chronic pelvic pain; age of menarche (12.2 ± 1.4 and 12.8 ± 1.3 years) and
percentage of ovulatory menstrual cycles (n = 15, 45.5% and n = 8, 47.1%) were comparable in
both groups
Age: mean age 17.4 ± 1.1 years (endometriosis group) and 16.4 ± 2.0 years (controls)
Number of participants enrolled: 50 participants
Number of participants available for analysis: 50 participants (all in follicular cycle phase, day 3-7)
Setting: University Hospital: Woman’s Health Institute, the Medical University of Silesia
Place of study: Katowice, Poland
Period of study: not stated
Language: English
Index tests Index test: IL-6, TNF-α and glycodelin A
Details of the index test procedure as stated: Serum levels of IL-6, TNF-α and glycodelin A were
measured by using commercial ELISAkits according to themanufacturers instructions; the detection
limit of IL-6 was 2 pg/ml, of TNF-α was 0.7 pg/ml and of glycodelin A was 6 ng/ml; sample
handling described
Threshold for positive result: not reported
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: Intra- and interassay CVs were: for IL-6 4.3% and 4.9%, for TNF-α 6.5%
and 3.9%, for glycodelin A 8.3% and 4.6%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 33/50 (66%): stage I-II 19, stage III-IV 14; controls
n = 17
Reference standard: laparoscopy N = 50 (100%) + histology
Description of positive case definition by reference standard test as reported: visualisation at surgery with
subsequent histological confirmation; staging according to the rAFS classification
Examiners: no information provided
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Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none reported
Comparative Studies on sHLA-I and sICAM-1 may help to clarify the pathogenic mechanisms of endometriosis,
and their serum concentrations may serve as additional markers for the early detection of recurrence
of the disease during the monitoring of treatment outcome
Key conclusions by the authors At the cut-off value of 3.00 pg/ml, peritoneal TNF-α can be a reliable screening marker for the
prediction of endometriosis in adolescents, giving a 14.6-fold higher probability of endometriosis
detection in girls with chronic pelvic pain
Conflict of interest The authors declared no conflict of interests
Notes For IL-6, TNF-α and glycodelin A there was no difference between the groups - no data available
for meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to determine serum and peritoneal IL-2, IL-4, andmonocyte chemotactic protein-
1 levels as diagnostic markers of endometriosis in adolescent girls
Participants: adolescent girls after menarche undergoing laparoscopy for chronic pelvic pain
Selection criteria: inclusion criteria: chronic pelvic pain, defined as non-cyclic lower-abdominal
pain, not connected with the menstrual cycle, lasting at least 3 months or cyclic pain ongoing for
6 months, severe enough to cause functional disability or require medical or surgical treatment;
exclusion criteria: general, chronic, autoimmune or endocrinological diseases, history of pregnancy
or hormonal medications for at least 6 months prior to the study
Study design: cross-sectional, single-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: chronic pelvic pain; age of menarche (12.2 ± 1.4 and 12.8 ± 1.3 years) and
percentage of ovulatory menstrual cycles (n = 15, 45.5% and n = 8, 47.1%) were comparable in
both groups
Age: mean age 17.4 ± 1.1 years (endometriosis group) and 16.4 ± 2.0 years (controls)
Number of participants enrolled: 50 participants
Number of participants available for analysis: 50 participants (allin follicular cycle phase, day 3-7)
Setting: university Hospital: Woman’s Health Institute, the Medical University of Silesia
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Place of study: Katowice, Poland
Period of study: not stated
Language: English
Index tests Index test: IL-2, IL-4, and MCP-1
Details of the index test procedure as stated: serum levels of IL-2, IL-4 and MCP-1 were measured by
using commercial ELISA kits according to the manufacturers instructions; the detection limit of
IL-2 was 9.9 pg/ml, IL-4 was 1.2 pg/ml and MCP-1 was 2.3 pg/ml; sample handling described
Threshold for positive result: IL-4 ≥ 3.00 pg/ml, not pre-specified
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: Intra- and interassay CVs were: for IL-2 - 5.2% and 8%, for IL-4 - 3.75%
and 5.05%, for MCP-1 - 4.7% and 8.7%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 33/50 (66%): stage I-II 19, stage III-IV 14; controls
n = 17
Reference standard: laparoscopy N = 50 (100%) + histology
Description of positive case definition by reference standard test as reported: visualisation at surgery with
subsequent histological confirmation; staging according to the rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none reported
Comparative
Key conclusions by the authors The serum IL-4, peritoneal IL-2 and IL-4 provided a good method of discrimination between
subjects with endometriosis and controls
Conflict of interest The authors declared no conflict of interests
Notes For IL-2 and MCP-1 there was no difference between the groups - no data available for meta-
analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes
Was a ’two-gate’ design
avoided?
Yes
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Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to evaluate the diagnostic value of serum measurement of IL-6 combined with
the presence of nerve fibres in the functional layer of endometrium for diagnosis of minimal-mild
endometriosis
Participants: women undergoing laparoscopy for evaluation of infertility, pelvic pain or both at the
authors’ institution
Selection criteria: inclusion criteria: reproductive age (18-36 years), follicular cycle phase, regular
menstrual cycle; exclusion criteria: any current infection (genital or systemic), anymedication within
1/12 months prior to laparoscopy, previous surgery for endometriosis, smoking or drinking alcohol
Study design: cross-sectional, single-gate design, prospective recruitment and collection of samples
Patient characteristics and set-
ting
Clinical presentation (n/N): dysmenorrhoea - 64/114; dyspareunia - 17/114; dyschezia - 6/114;
pelvic pin - 35/114; infertility - 91/114
Age: mean age 31 ± 1.1 years (endometriosis group), 29 ± 0.6 years (controls)
Number of participants enrolled: 114 women
Number of participants available for analysis: 78 women (only minimal-mild endometriosis included;
all in follicular cycle phase)
Setting: Department of O&G, Zagazig University Hospital
Place of study: Zagazig, Egypt
Period of study: December 2010 - April 2012
Language: English
Index tests Index test: IL-6
Details of the index test procedure as stated: serum IL-6 level using a commercially available ELISA
(DRG, Germany); sample processing described
Threshold for positive result: > 15.4 pg/ml, not pre-specified
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 74/114 (65%): stage I-II 38, stage III-IV 36; controls
n = 40
Reference standard: laparoscopy n = 114 (100%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to the rASRM classification
Examiners: Three experienced gynaecologists in endometriosis
Flow and timing Time interval between index test and reference standard: blood samples were obtained ’in themorning,
the day before laparoscopy’
Withdrawals: 36 participants with moderate-severe disease were not included in final analysis
Comparative
Key conclusions by the authors Combination of both serum IL-6 and presence of nerve fibres in the endometrium is more reliable
method for diagnosis of minimal-mild endometriosis than in single test
Conflict of interest The authors declared no conflict of interest
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Notes The reported data on endometrial biomarkers and combined endometrial-blood test are not pre-
sented in this review
Only minimal-mild disease evaluated
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate IL-12 and IL-18 levels in the serum and peritoneal fluid of women
with and without endometriosis
Participants: women who underwent laparoscopy for clinically suspected endometriosis
Selection criteria: inclusion criteria: eumenorrhoea, age 18-40 years; exclusion criteria: any autoim-
mune disease, absence of peritoneal liquid at laparoscopy, the coexistence of any other causes of
infertility, and any hormonal medications in the 3 months before surgery
Study design: cross-sectional, single-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: severe dysmenorrhoea, deep dyspareunia, chronic pelvic pain, infertility, uri-
nary symptoms (pain, bleeding or both) or cyclic bowel abnormalities (pain, bleeding or both)
Age: range 18-40 years
Number of participants enrolled: 105 women
Number of participants available for analysis: 105 (85 in follicular, 20 in luteal cycle phase)
Setting: endometriosis referral centre, School of Medicine, University of Sao Paulo
Place of study: Sao Paulo, Brazil
Period of study: February 2004 - December 2005
Language: English
Index tests Index test: IL-12, IL-18
Details of the index test procedure as stated: serum IL-12 and IL-18 levels were measured using Human
IL-12 (p70) kits (Human IL-12 p70 Kit, BD Biosciences, San Diego, CA), and ELISA (IL-18
ELISA, IBL, Hamburg, Germany); the measurement of IL-12 and IL-18 levels was performed after
all data had been collected; the detection limits for IL-2 kit 4 pg/ml and for IL-18 kit 9.2 pg/ml;
sample processing described
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: not provided
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Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 72/105 (69%): stage I-II 28, stage III-IV 44; controls
n = 33
Reference standard: laparoscopy N = 105 (100%) + histology
Description of positive case definition by reference standard test as reported: visualisation at surgery
with subsequent histological confirmation; staging according to the rAFS classification; surgical
diagnostic criteria described in details for peritoneal, ovarian and DIE
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood was collected before anaesthesia
Withdrawals: none
Comparative
Key conclusions by the authors Patients with severe endometriosis have higher IL-12 levels irrespective of IL-18 levels, suggesting
that in this disease an alternative pathway is involved in induction of the Th1 immune response
Conflict of interest Not reported
Notes For IL-12 and IL-18 there was no difference between the groups - no data available for meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
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Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to test the hypothesis that the plasma concentration of complement factor C3a
(anaphylatoxin) can be used as a non-invasive test in the diagnosis of endometriosis
Participants: women who had undergone laparoscopic surgery for subfertility, pelvic pain or both
Selection criteria: not specified
Study design: cross-sectional prospective single-gate design, non-consecutive enrolment
Patient characteristics and set-
ting
Clinical presentation: infertility - 160, dysmenorrhoea - 26, hx of hormonal treatment, chronic PID
or STI - nil; ethnicity: Caucasian - 136, other - 24
Age: median (range) 30 (18-46) years (endometriosis), 33 (20-46) years (controls)
Number of participants enrolled: 160 women
Number of participants available for analysis: 160 women (49 in menstrual, 55 in follicular, 56 in
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luteal cycle phase)
Setting: Leuven University Fertility Centre
Place of study: Leuven, Belgium
Period of study: not stated
Language: English
Index tests Index test: C3a (anaphylatoxin)
Details of the index test procedure as stated: plasma concentration of C3a-des-Arg was determined
with a commercially available immunoassay (Quidel Inc, San Diego, USA); quantification with
a standard curve; sensitivity of this experiment was 34 ng/ml; sample handling and laboratory
technique described in details
Threshold for positive result: not reported
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: Intra-and interassay CV ranged 1.5%-2.8% and 11%-23%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 109/160 (68%); severity: stage I-II 54, stage III-IV
55; controls n = 51
Reference standard: laparoscopy N = 160 (100%) + histology
Description of positive case definition by reference standard test as reported: visualisation at surgery with
subsequent histological confirmation; staging according to the rAFS classification
Examiners: no information provided




Key conclusions by the authors Our data do not confirm our hypothesis that C3a-des-Arg concentration in plasma can be used as
a biomarker for the non-invasive diagnosis of endometriosis, but does not rule out the possibility
that that measurement of complement activation at the level of the cervix or endometrium may be
useful for this purpose
Conflict of interest Not reported; supported by the Flemish fund for scientific research (FWO) & Leuven University
Council (Dienst Onderzoekscoordinatie KU Leuven, Leuven, Belgium)
Notes For C3a there was no difference between the groups - no data available for meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
191Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fassbender 2009 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Patient sampling Primary objective: to test the hypothesis that differential surface-enhanced laser desorption/ionisation
time-of-flight mass spectrometry protein or peptide expression in plasma can be used in infertile
women with or without pelvic pain to predict the presence of laparoscopically and histologically
confirmed endometriosis
Participants: samples from women who had undergone laparoscopic surgery for subfertility, pelvic
pain or both, stored in biobank
Selection criteria: exclusion criteria: hormonal medications, surgery performed within 6 months
before the time of sample collection
Study design: cross-sectional, single-gate design, prospective sample collection retrospective recruit-
ment
Patient characteristics and set-
ting
Clinical presentation: infertility - 240, dysmenorrhoea - 177, dyspareunia - 67, CPP - 30, dyschezia
- 17, myoma - 16, irregular cycle - 40
Age: median age 31 years, range 23-44 years
Number of participants enrolled: 254 women
Number of participants available for analysis: 254 women (68 in menstrual, 98 in follicular, 88 in
luteal cycle phase)
Setting: Leuven University Fertility Centre
Place of study: Leuven, Belgium
Period of study: 2001-2009
Language: English
Index tests Index test: proteome by SELDI-TOF-MS (five peptide and protein peaks, different for each cycle
phase)
Details of the index test procedure as stated: surface-enhanced laser desorption/ionisation coupled to
time-of-flight mass spectrometry (plasma depletion by using Proteominer depletion kit, Bio-Rad)
; sensitivity of this experiment was 34 ng/ml; sample handling and procedure described in details;
“training data set” (70%) was used to identify a pattern that discriminates between the presence
and absence of disease and to construct the final least squares support vector machine model; “test
data set” (30%) evaluated potential biomarkers - the final performance of model was averaged over
100 random splits
Threshold for positive result: presence of specific protein peaks intensities, not pre-specified
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: intra- and interassay CV ranged from 1.5% to 2.8% and 11% to 23%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 165/254 (65%): stage I-II 89, stage III-IV 76; controls
- 89
Reference standard: laparoscopy N = 254 (100%) + histology
Description of positive case definition by reference standard test as reported: visualisation at surgery with
subsequent histological confirmation; staging according to the rAFS classification
Examiners: no information provided
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Key conclusions by the authors A non-invasive test using proteomic analysis of plasma samples obtained during themenstrual phase
enabled the diagnosis of endometriosis undetectable by ultrasonography with high sensitivity and
specificity
Conflict of interest The authors reported no conflicts of interest; supported by a number of grants
Notes The diagnostic estimates were calculated separately for each menstrual cycle phase
The diagnostic estimates for the validation test set are reported in this review
The reported diagnostic estimates for different stages of endometriosis are not included in this
review
The reported diagnostic estimates for subgroup of ultrasound-negative endometriosis are not in-
cluded in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in
interpretation of the result of
index test?
Yes
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High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to assess the reliability of serum CA-125 in the detection of endometriosis in a
large series of patients with different stages of the disease
Participants: women undergoing laparoscopy for infertility, pelvic pain or both
Selection criteria: not stated
Study design: cross-sectional single-gate design, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: mean 30.9 years (endometriosis), 31.2 years (controls)
Number of participants enrolled: 264 women
Number of participants available for analysis: 154 women (menstrual cycle phase not specified)
Setting: Tteaching hospital, Luigi Mangiagalli, University of Milan
Place of study: Milan, Italy
Period of study: October 1985 - July 1987
Language: English
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Index tests Index test: CA-125
Details of the index test procedure as stated: serum CA-125 was measured by immunoradiometric
assay (Sorin Biomedica, Saluggia VC, Italy)
Threshold for positive result: > 35 U/ml, pre-specified
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 102/264 (39%): stage I-II 55, stage III-IV 47; controls
n = 52
Reference standard: laparoscopy N = 264 (100%) + histology
Description of positive case definition by reference standard test as reported: diagnosis based on endoscopic
findings, histologic findings or both; staging according to the rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were drawn immediately before
surgery
Withdrawals: 110 women did not have index test: “CA-125 was measured only in patients in whom
endometriosis was found at laparoscopy and in patients with apparently normal pelvis”
Comparative
Key conclusions by the authors The usefulness of serum CA-125 measurements as an initial diagnostic tests is scanty. Because of
its elevated specificity this test may be useful in indicating early surgical exploration of the pelvis in
cases of infertility, dysmenorrhoea or both, which are associated with elevated CA-125
Conflict of interest Not reported
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to assess correlation between serum CA-125 levels and severity of endometriosis
defined by rAFS and to establish diagnostic utility of this test in endometriosis
Participants: women scheduled for laparoscopy or laparotomy for investigation of infertility
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Selection criteria: exclusion criteria: endocrine abnormalities, systemic disease, abnormal laboratory
investigations, uterine fibroids, PID, pelvic pathology other than endometriosis identified at surgery
Study design: cross-sectional, single-gate design, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: infertility, not specified otherwise
Age: median 30 years, range 20-50 years
Number of participants enrolled: 54 women
Number of participants available for analysis: 41 women (menstrual cycle phase not specified)
Setting: University hospital, Federal University of Minas Gerais
Place of study: Belo Horizonte, Brazil
Period of study: January 1992 - June 1993
Language: Portuguese
Index tests Index test: CA-125
Details of the index test procedure as stated: serum CA-125 was measured by ELISA (Cobas Core CA-
125 II, EIA Roche 1992); assay sensitivity < 1 U/ml; procedure and sample handling described
Threshold for positive result: > 16 U/ml and > 35 U/ml, pre-specified
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: Intra- and interobserver CV < 5.3% and < 7.5%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 36/54 (67%): stage I-II 14, stage III-IV 9; controls
n = 18
Reference standard: laparoscopy/laparotomy N = 54 (100%) + histology
Description of positive case definition by reference standard test as reported: diagnosis based on endoscopic
findings, histologic findings or both; staging according to the rAFS classification; surgical procedure
described
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were drawn before surgery
Withdrawals: 13 women were excluded because they met exclusion criteria
Comparative
Key conclusions by the authors In summary, the test is not sensitive enough for discrimination of women with and without en-
dometriosis; observation across several cut-off points revealed that there was a significant lessening
of specificity at the expense of sensitivity
Conflict of interest Not reported
Notes The reported diagnostic estimates for different stages of endometriosis are not included in this
review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Patient sampling Primary objective: to examine the presence and expression of vitamin D binding protein (DBP) in
the peritoneal
fluid (PF) and plasma (PL) of women with endometriosis
Participants: women scheduled for laparoscopy for various indications
Selection criteria: inclusion criteria: pre-menopausal (cycle length 21-35 days), no sign of pelvic
inflammatory disease, no
pregnancy, breastfeeding or abdominal surgery for the last 6 months, have not undergone hysteros-
alpingography in the 2 months prior to the surgical procedure
Study design: cross-sectional two-gate design, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation:study group: infertility - 39.8%, pelvic pain - 28.4%, dysmenorrhoea - 44.
3%, dyspareunia - 22.7%, adnexal mass - 52.3%; controls: infertility - 57.5%, pelvic pain - 12.5%,
dysmenorrhoea - 7.5%, tubal sterilisation - 30%; n = 17/145 women in study group were on OCP
and were analysed separately
Age: mean age 32.1 ± 5.0 years (endometriosis group), 32.6 ± 6.2 years (controls)
Number of participants enrolled: 145 women
Number of participants available for analysis: 145 women (76 in follicular and 69 in luteal menstrual
cycle phase)
Setting: university hospital, San Martino Hospital, University of Genoa and St. Bartholomew’s
Hospital, St Bartholomew’s School of Medicine and Dentistry
Place of study: Genoa, Italy and London, UK
Period of study: not reported
Language: English
Index tests Index test: DBP
Details of the index test procedure as stated: plasma DPB expression was assessed by using 2-D
PAGE (referenced to the previously published method): provisional identification was performed by
matching with the human plasma 2-D PAGE protein map of ExPASy and subsequently confirmed
by western blotting onto PVDF membranes (Hybond-P, Amersham Pharmacia Biotech) that was
performed at 30 V for 18 hours using Towbin’s transfer buffer; sample handling and laboratory
methods described
Threshold for positive result: not provided
Examiners: 2 independent investigators who were blinded to the clinical status of the patients
Interobserver variability: the interassay CV was < 10%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 105/145 (72%): stage I-II 43, stage III-IV 62; controls
- 40
Reference standard: laparoscopy N = 145 (100%) + histology
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Ferrero 2005a (Continued)
Description of positive case definition by reference standard test as reported: visual inspection with
subsequent histological confirmation in all patients; staging according to the rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were drawn at surgery
Withdrawals: none reported
Comparative
Key conclusions by the authors The decreased level of DBPE in the PF but not in PL of women with untreated endometriosis
suggests that this molecule may be relevant in the pathogenesis of this disease
Conflict of interest Not reported
Notes For DBP there was no statistically significant difference between the groups - no data available for
meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in
interpretation of the result of
index test?
Yes
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High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to assess the diagnostic performance of urocortin determination in distinguishing
endometriomas from other benign ovarian cysts
Participants: women who underwent laparoscopic excision of ovarian cysts
Selection criteria: not stated (only severe endometriosis included)
Study design: cross-sectional single-gate design, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: ovarian cyst - 80 women, chronic pelvic pain - 20 women
Age: mean age 34.1 ± 7.4 years (endometriosis), 35.2 ± 7.2 years (controls)
Number of participants enrolled: 80 women
Number of participants available for analysis: 80 women (menstrual cycle phase not specified)
Setting: University of Siena academic hospital
Place of study: Siena, Italy
Period of study: March 2004 - January 2006
Language: English
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Index tests Index test: urocortin, CA-125
Details of the index test procedure as stated: plasma urocortin levels were measured in a blinded
fashion in a single assay according to published methodology (referenced to the original source) with
delayed addition of tracer to improve assay sensitivity (~50 pg/ml); serum CA-125 concentration
was assessed by Cobas Core CA 125 enzyme-immunoassay analysis kit (Roche, Basel, Switzerland)
with assay sensitivity < 1 U/l; procedure and sample handling described
Threshold for positive result: Urocortin > 33 pg/ml and 29 pg/ml; CA-125 > 36U/l and 30 U/l, not
pre-specified
Examiners: no information provided; blinded to the results of reference standard
Interobserver variability: Intra- and interassay CV for urocortin < 8%, for CA-125 < 5.6% and < 7.
8%
Target condition and reference
standard(s)
Target condition: endometriosis (ovarian and ovarian + pelvic)
Prevalence of target condition in the sample: n = 40/80 (50%): all stage III-IV; controls n = 40
Reference standard: laparoscopy N = 80 (100%) + histology
Description of positive case definition by reference standard test as reported: surgical visualisation and
histopathology, staging according to the rAFS classification
Examiners: no information provided




Key conclusions by the authors Immunolocalisation of urocortin and its higher levels in the cystic content than in peritoneal fluid
and plasma suggest that it may be secreted by the endometriotic tissue. Urocortin is a sensitive and
specific marker for the differential diagnosis of endometrioma compared with other benign ovarian
cysts
Conflict of interest The authors have no potential conflicts of interest to disclose; supported in part by grant #
2004068714-004 from the Italian Ministry of University and Scientific Research (MURST) and
the University of Siena
Notes The reported diagnostic estimates for subgroup of endometrioma with no peritoneal implants are
not included in this review
For CA-125 - the cohort overlaps with Florio 2009, but a different threshold is presented, hence it
is included as separate evaluation
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
204Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)





Patient sampling Primary objective: to quantify the concentration of follistatin and CA-125 in the serum of women
with ovarian endometrioma and other benign cysts; to evaluate the follistatin levels in the cystic
content and PF of a subset of patients with ovarian endometriotic cyst; to investigate the use of
follistatin as a marker in the differential diagnosis of benign ovarian cysts
Participants: women who underwent laparoscopic excision of benign ovarian cysts detected by
ultrasound
Selection criteria: inclusion criteria: reproductive age, persistent, large ( > 5 cm) or complex pelvic
mass without evidence ofmalignancy or pelvic pain not responding tomedication; exclusion criteria:
use of steroid hormones during the past 3 months, known pituitary, thyroid, renal, liver or adrenal
disorders (only severe endometriosis included)
Study design: cross-sectional single-gate design prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: ovarian cyst - 104 women, regular menstrual cycle - 90%, nulliparous - 100%;
symptoms and other history not specified
Age: mean age 34.0 ± 6.0 years (endometrioma), 32.0 ± 4.0 years (controls)
Number of participants enrolled: 104 women
Number of participants available for analysis: 104 women (all in follicular phase of menstrual cycle)
Setting: University of Siena academic hospital
Place of study: Siena, Italy
Period of study: September 2004 - August 2006
Language: English
Index tests Index test: follistatin, CA-125
Details of the index test procedure as stated: follistatin concentrations were measured in duplicates
using a commercially available enzyme-linked immunosorbent assay (ELISA) with assay detection
limit of 29 pg/ml (range 250 to 16 000 pg/ml); serum CA-125 concentration was assessed by Cobas
Core CA 125 enzyme-immunoassay analysis kit (Roche, Basel, Switzerland) with assay sensitivity
< 1 U/l; sample handling and laboratory technique for Follistatin described
Threshold for positive result: urocortin levels: > 33 pg/ml and 29 pg/ml; CA-125 levels > 36 U/l and
30 U/l, not pre-specified
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: Intra- and interassay CV for follistatin < 3.0 and < 9.0%; for CA-125 < 5.
6% and < 7.8%
Target condition and reference
standard(s)
Target condition: ovarian endometriosis
Prevalence of target condition in the sample: n = 52/104 (50%): all stage III-IV 52; controls n = 52
Reference standard: laparoscopy N = 104 (100%) + histology
Description of positive case definition by reference standard test as reported: surgical visualisation and
histopathology, staging according to the rAFS classification
Examiners: no information provided
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Key conclusions by the authors In conclusion, serum follistatin levels are increased in women with ovarian endometriosis. Follistatin
seems to fulfil the requirements of sensitivity, specificity and reproducibility in order to become
a useful clinical marker of late stage ovarian endometriosis. Further studies, including a blind
validation in a cohort series, will be required to support the clinical use of follistatin in the diagnosis
of endometriosis
Conflict of interest Not reported; the workwas supported by grants from the ItalianMinistry ofUniversity and Scientific
Research (MURST) and the University of Siena
Notes Originally, this was a a two-gate design study, which also includes healthy controls (N = 27) and
women with non-ovarian endometriosis (N = 11), these groups seem to be separately enrolled and
the data for these groups or for the whole cohort are not available - not included in the review
The reported diagnostic estimates for ’Endometrioma versus no ovarian cyst’ are not included in
this review, because number of participants and analysed subgroups are unclear
For CA-125 - the cohort overlaps with Florio 2007, but different threshold is presented, hence
included as separate evaluation
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
No




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
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Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to determine the clinical usefulness of IL-6, TNF-α, CA-125, Hs-CRP and VEGF
levels in infertile women with pelvic pain as markers of the early stages of peritoneal endometriosis
during which imaging is not effective
Participants: infertile women complaining of chronic pelvic pain undergoing laparoscopy
Selection criteria: inclusion criteria: reproductive age, regular menstrual cycles, do not smoke or drink
alcohol; exclusion criteria: age > 35 years, any current infection (genital or systemic), any medication
within 1 month prior to laparoscopy, minimal amount or bloody peritoneal fluid, patients using
IUD
Study design: cross-sectional single-gate design prospective sample collection
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Patient characteristics and set-
ting
Clinical presentation: infertility - 95women; dysmenorrhoea - 37women; dyspareunia - 15; dyschezia
- 9; pelvic/abdominal pain - 43; menorrhagia - 22; urinary symptoms - 10
Age: range 18-35 years
Number of participants enrolled: 95 women
Number of participants available for analysis: 95 women (all in follicular phase of menstrual cycle,
days 5-10)
Setting: Department of O&G, Mansoura University Hospital
Place of study: Mansoura, Egypt
Period of study: January 2009 - May 2010
Language: English
Index tests Index test: IL-6, CA-125, TNF-α, Hs-CRP VEGF
Details of the index test procedure as stated: IL-6 and TNF-α levels were estimated by using a com-
mercially available enzyme-linked immunosorbent assay (ELISA, DRG, Germany); CA-125 and
Hs-CRP were measured by automated electro-chemiluminescent immunoassay instrument (Elecsys
2010, Roche, Germany); VEGF was determined by a competitive enzyme immunoassay technique
using Accucyte human VEGF kit; lower detection limit of IL-6, CA-125, TNF-α, Hs-CRP &
VEGF kits were 2 pg/ml, < 1 IU/ml, 2.2 pg/ml, 65 ng/ml and 5 pg/ml respectively; sample collec-
tion and storage described
Threshold for positive result: IL-6 > 12.2 pg/ml; CA-125 > 17.6 IU/ml; TNF-α > 12.45 pg/ml; Hs-
CRP >438 µg/ml; VEGF > 236 pg/ml; the thresholds were not pre-specified
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: interassay CV for IL-6, CA-125, TNF-α, Hs-CRP & VEGF kits were <
4%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 65/95 (68%); stage I-II 37, stage III-IV 28; controls
n = 30
Reference standard: laparoscopy N = 95 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rAFS system
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood was collected the day before laparoscopy
Withdrawals: none
Comparative
Key conclusions by the authors Serum IL-6 and TNF-α levels can be used to discriminate between patients with or without en-
dometriosis. Also, minimal-mild endometriosis patients display higher serum IL-6 and TNF-α level
than moderate-severe endometriosis or the control cases; this sheds light on markers of the early
stages of the disease. CA-125, VEGF and Hs-CRP appear to be advantageous only for the diagnosis
of severe endometriosis and positively correlate with the stage of the disease; very low levels might
serve as a marker for an absence of endometriosis
Conflict of interest The authors have no potential conflicts of interest to disclose
Notes The reported cost analysis: cost of the markers per case was about EGP 110, much less than the
costs of the hospital stay and diagnostic laparoscopy
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate the value and potential use of CA-125 determinations in the diagnosis
and management of endometriosis
Participants: patients of reproductive age undergoing laparotomy or laparoscopy for pelvic mass
Selection criteria: not provided
Study design: cross-sectional, single-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: pelvic mass, not specified
Age: median age 34 years, range 20-51 years (endometriosis); median age 32 years, range 27-42
years (controls)
Number of participants enrolled: 120 women
Number of participants available for analysis: 46 women (cycle phase not specified)
Setting: Department of O&G, University of Pavia, 2nd School of Medicine
Place of study: Varese, Italy
Period of study: June 1991 - December 1992
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serum CA-125 levels assessed by radioimmunoassay;
sample processing and laboratory technique not described
Threshold for positive result: > 35 IU/ml, pre-specified
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 37/120 (31%): stage I-II 13, stage III-IV 24; controls
- 9
Reference standard: laparoscopy/laparotomy N = 120 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rAFS classification
Examiners: no information provided
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Flow and timing Time interval between index test and reference standard: blood was collected “immediately before
surgery”
Withdrawals: 74 women were excluded from analysis (only patients with endometriosis and patients
with normal pelvis were included)
Comparative
Key conclusions by the authors Serum CA-125 levels correlated significantly with disease severity, but the low sensitivity of the test
precludes its use as a screening procedure for endometriosis
Conflict of interest Not reported
Notes The reported diagnostic estimates per degree of severity of endometriosis are not presented in this
review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to determine whether the proportion of several leukocyte subsets is modulated in
the endometrium of patients with endometriosis and, if so, whether it can be used for diagnostic
purposes
Participants: women who were scheduled to undergo laparoscopy or laparotomy at 1 of the 8 clinical
institutions in the Montreal area
Selection criteria: inclusion criteria: patients of pre-menopausal age who had never been pregnant,
luteal phase of the menstrual cycle (based on the last period and further confirmed by histology),
regular cycles (21-35 days), not acute salpingitis, no hormonal treatment or intrauterine device in
previous 3 months
Study design: multicentre study of two-gate design, prospective recruitment, random sample of
patients (participation rate 94%)
Patient characteristics and set-
ting
Clinical presentation: infertility (7% controls, 16% cases); pain (19% controls, 33% cases); pelvic
mass (8% controls, 13% cases); fibroids (9% controls, 15% cases); menorrhagia (2% controls, 4%
cases); tubal ligation (60%controls, 25%cases); hysterectomy (19%controls, 32%cases); diagnostic
laparoscopy (20% controls, 43% cases); history of endometriosis (3% controls, 16% cases)
Age: random sampling from a population with mean age of 37.3 ± 6.4 years
Number of participants enrolled: 368 women
Number of participants available for analysis: 368 women (in luteal phase of menstrual cycle)
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Gagne 2003a (Continued)
Setting: biotech firm - MetrioGene BioSciences (a subsidiary of PROCREA BioSciences)
Place of study: Montreal, Canada
Period of study: July 1997 - May 2001
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serum CA-125 level was determined by using a one
step-sandwich radioimmunoassay (Fujirebio America Inc.) with assay sensitivity 0.4 U/ml; sample
handling and laboratory procedure described in details. The bootstrap method validation was per-
formed by drawing 200 replicate samples with replacement from the original data set
Threshold for positive result: CA-125 > 12.8 U/ml and > 35 U/ml, not pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: Inter- and intra-assay variations < 5%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 173/368 (47%): stage I-II 78%, stage III-IV 22%;
controls n = 195
Reference standard: laparoscopy/laparotomy N = 368 (100%)
Description of positive case definition by reference standard test as reported: cases were defined by the
presence of endometriotic lesions confirmed at the time of surgical examination; staging according
to the ASRM system
Examiners: gynaecologists collaborating in the study were trained surgeons experienced with the
management of endometriosis who were skilled in detecting and identifying all forms of endometri-
otic lesions




Key conclusions by the authors The predictive model represents a novel diagnostic tool to identify women with a high likelihood
of suffering from endometriosis
Conflict of interest All the authors except RM are (or were) employees of PROCREA BioSciences; supported by the
Industrial Research Assistance Program (IRAP) fromNSERC grant #15453Q and internal resources
at PROCREA BioSciences
Notes The reported diagnostic estimates of the predictive model based on the combination of blood and
endometrial test with clinical and demographic data are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Gagne 2003a (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Patient sampling Primary objective: to determine whether high levels of VEGF could also be found in the serum of
patients with endometriosis
Participants: women who were scheduled to undergo laparoscopy or laparotomy at 1 of the 8 clinical
institutions in the Montreal area
Selection criteria: inclusion criteria: pre-menopausal age, no past pregnancy, luteal phase of the
menstrual cycle (based on the last period and further confirmed by histology), regular cycles (21-
35 days), no acute salpingitis, no hormonal treatment or IUD in previous 3 months
Study design: multicentre study of two-gate design, prospective recruitment, random sample of
patients (participation rate > 90%)
Patient characteristics and set-
ting
Clinical presentation: infertility (11% controls, 28% cases); pain (19% controls, 34% cases); tubal
ligation (60%controls, 26%cases); hysterectomy (18%controls, 35%cases); diagnostic laparoscopy
(22% controls, 39% cases); history of acute infections (30% controls, 34% cases); smoking (63%
controls, 53% cases)
Age: sampling from a population with mean age of 37.3 ± 6.4 years
Number of participants enrolled: 277 women
Number of participants available for analysis: 277 women (all in luteal cycle phase)
Setting: biotech firm - MetrioGene BioSciences (a subsidiary of PROCREA BioSciences)
Place of study: Montreal, Canada
Period of study: July 1997 - May 2001
Language: English
Index tests Index test: VEGF
Details of the index test procedure as stated: serum VEGF levels were measured using a commercially
available ELISA kit (R&DSystems, Minneapolis, MN) according to themanufacturer’s instruction;
assay sensitivity <9.0 pg/ml; sample handling and laboratory procedure described in details
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: Inter- and intra-assay CV <10%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 131/277 (47%): stages I-IV, numbers not specified;
controls n = 146
Reference standard: laparoscopy/laparotomy N = 277 (100%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to the ASRM classification
Examiners: gynaecologists collaborating in the study were trained surgeons experienced with the
management of endometriosis who were skilled in detecting and identifying all forms of endometri-
otic lesions
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Key conclusions by the authors Although VEGF seems to play a pivotal role locally in the implantation and development of en-
dometriotic lesions, the disease is not associated with a significant modulation in the levels of cir-
culating VEGF
Conflict of interest Not reported (the authors’ affiliation is MetrioGene BioSciences, a biotech firm)
Notes For VEGF there was no difference between the groups - no data available for meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate the role of IL-8 in the pathogenesis of endometriosis in relation to the
stage of disease
Participants: patients undergoing laparoscopic surgery for benign gynaecological indications
Selection criteria: not specified
Study design: cross-sectional, two-gate design, prospective collection of samples, consecutive patients
Patient characteristics and set-
ting
Clinical presentation: indications for surgery: abdominal pain (n= 21), sterilisation (n= 11), infertility
(n = 18); none of the patients had been on medication at least 1 month prior to the laparoscopy
and none was on any long-acting drugs
Age: mean age 28 ± 8.1 years (endometriosis group) and 29 ± 6.9 years (controls)
Number of participants enrolled: 50 women
Number of participants available for analysis: 47 (23 in follicular, 24 in luteal cycle phase)
Setting: not specified, the authors’ affiliations are 2 university hospitals: LiverpoolWomen’sHospital,
University of Liverpool and Department of O&G, University of Aberdeen
Place of study: Aberdeen and Liverpool, UK
Period of study: not provided
Language: English
217Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gazvani 1998 (Continued)
Index tests Index test: IL-8
Details of the index test procedure as stated: IL-8 levels were measured using an enzyme-linked im-
munosorbent assay (CYTokit Red; CYTimmune Sciences, USA) according to the manufacturer’s
instructions; sample processing described
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 25/105 (24%): stage I-II 14, stage III-IV 11; controls
n = 22
Reference standard: laparoscopy N = 105 (100%) + histology
Description of positive case definition by reference standard test as reported: visualisation at surgery: the
condition of tubes, ovaries, pouch of Douglas, and bowels were inspected; staging according to the
AFS system
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: not specified, but from the context, samples
were obtained at surgery
Withdrawals: 3 patients were excluded before analysis because of inadequate peritoneal fluid sample
Comparative
Key conclusions by the authors Peripheral blood concentrations did not correlate with peritoneal fluid concentrations of IL-8 or
the presence of endometriosis. IL-8 (in PF) is an important factor that may contribute to the
pathogenesis of endometriosis possibly by promoting neovascularisation
Conflict of interest Not reported
Notes For IL-8 there was no statistically significant difference between the groups - no data available for
meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
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Gazvani 1998 (Continued)
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to evaluate IL-18 levels in the serum and peritoneal fluid of infertile women with
minimal-mild endometriosis in order to determine association of IL-18 with infertility
Participants: women with minimal or mild endometriosis submitted to laparoscopy to investigate
infertility (endometriosis group) and patients who underwent laparoscopy for tubal ligation (con-
trols)
Selection criteria: inclusion criteria: first menstrual phase, no hormonal medications for at least 3
months prior to surgery
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified; all controls were fertile and none had a significant past medical
history
Age: mean age 31.51 ± 4.54 years (endometriosis group) and 34.23 ± 3.56 years (controls)
Number of participants enrolled: 78 women
Number of participants available for analysis: 78 women (in follicular phase of menstrual cycle)
Setting: Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul
Place of study: Porto Alegre, Brazil
Period of study: March 2006 - December 2007
Language: English
Index tests Index test: IL-18
Details of the index test procedure as stated: serum IL-18 levels were measured using the Human IL-
18 ImmunoAssay ELISA kit (MBL Co.Ltd, Japan); assay sensitivity 12.5 pg/ml, minimal estimated
detection 12.5 ± 6.25 pg/ml
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 56/78 (72%): all stage I-II; controls n = 22
Reference standard: laparoscopy N = 78 (100%)
Description of positive case definition by reference standard test as reported: Endometriosis was diagnosed
by visualisation at surgery; staging according to the rAFS classification
Examiners: the same investigator performed all endoscopic procedures




Key conclusions by the authors Women with minimal-mild endometriosis did not show any alteration in the concentration of IL-
18 in serum or peritoneal fluid
Conflict of interest Not reported; supported by CNPq, Fundo de Incentivo à Pesquisa (FIPE) do Hospital de Clínicas
de Porto Alegre, CAPES and FAPERGS
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Notes For IL-18 there was no statistically significant difference between the groups - no data available for
meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the presence of T regulatory cells (Tregs) in the peripheral blood
(PB) and peritoneal fluid (PF) in females with endometriosis
Participants: women who underwent laparoscopy for suspected endometriosis or infertility investi-
gation
Selection criteria: not specified
Study design: cross-sectional, single-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: endometriosis group - not specified; controls - unexplained infertility; all
participants had regular menstrual cycles
Age: mean age 33.58 ± 4.74 years (endometriosis group) and 31.2 ± 5.9 years (controls)
Number of participants enrolled: 42 women
Number of participants available for analysis: 42 women (in follicular phase of menstrual cycle, days
9-12)
Setting: University hospital: Department of Gynaecology, Medical University of Lublin
Place of study: Lublin, Poland
Period of study: not stated
Language: English
Index tests Index test: Tregs, WBC, lymphocytes
Details of the index test procedure as stated: Tregs in peripheral blood were assessed by analysing
expression of CD4 and CD25 cell surface antigens, and intracellular FOXP3 antigen using a BD
FACSCalibur flow cytometer (BD Biosciences, San Jose, USA); the percentage of CD4+ CD25+
FOXP3+ Tregs in the CD4+ T lymphocyte subpopulation was determined using the Human Treg
Flow™ kit (FOXP3 Alexa Fluor® 488/CD4 PE Cy5/CD25 PE) from BioLegend (San Diego,
USA); WBC and lymphocyte counts were determined by using a peroxidase method with ADVIA
2120 system (Siemens)
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: not provided
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Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 22/42 (53%): stage I-II 15, stage III-IV 7; controls
n = 20
Reference standard: laparoscopy N = 42 (100%) + histopathology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histopathology; staging according to the rAFS classification
Examiners: no information provided




Key conclusions by the authors The local host-defence mechanism is deficient in patients with endometriosis, thus endometriosis
should not be treated as an autoimmune condition
Conflict of interest Not reported
Notes For Tregs, WBC, lymphocytes there was no statistically significant difference between the groups -
no data available for meta-analysis
For CA-125 there was statistically significant difference between the groups, but there were insuffi-
cient data to construct 2 x 2 tables - not included in this review
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to establish the concentration of the adhesionmolecules (ICAM-1 and E-Selectin)
in the sera and peritoneal fluids of women with endometriosis in comparison to the control group
Participants: women who underwent laparoscopy for infertility and pelvic pain
Selection criteria: inclusion criteria: luteal phase ofmenstrual cycle (onlyminimal-mild endometriosis
included)
Study design: cross-sectional, single-gate design, prospective collection of samples
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Patient characteristics and set-
ting
Clinical presentation: infertility, pelvic pain
Age: range 26-40 years (endometriosis group) and 20-42 years (controls)
Number of participants enrolled: 20 women
Number of participants available for analysis: 20 women (all in in luteal phase of menstrual cycle)
Setting: 2nd Department & Gynaecological Clinic of Medical Academy in Wroclaw
Place of study: Wroclaw, Poland
Period of study: March 2006 - December 2007
Language: English
Index tests Index test: ICAM-1 and E-Selectin
Details of the index test procedure as stated: the levels of sICAM-1 and sE-selectins were measured
using ELISA (R&D wg) according to the manufacturers protocol
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 11/20 (55%), all stage I-II; controls n = 9
Reference standard: laparoscopy N = 20 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rAFS system
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood was collected at surgery
Withdrawals: none
Comparative
Key conclusions by the authors We did not find any significant differences between the two examined groups, although further
studies should be carried out
Conflict of interest Not reported
Notes For ICAM-1 and E-Selectin there was no statistically significant difference between the groups - no
data available for meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
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DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in
interpretation of the result of
index test?
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to investigate endometrial antigens involved in the autoimmunity of endometriosis
Participants: women who underwent laparoscopy or laparotomy
Selection criteria: not presented
Study design: cross-sectional, unclear if single or two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not presented; none of the study subjects were on oral contraceptives or other
hormones such as
danazol or GnRH agonists
Age: range 20-46 years
Number of participants enrolled: 36 women
Number of participants available for analysis: 36 women (phase of menstrual cycle not specified)
Setting: University Hospital: Department O&G, Yokohama City University School of Medicine
Place of study: Yokohama, Japan
Period of study: not specified
Language: English
Index tests Index test: anti-endometrial antibodies
Details of the index test procedure as stated: the expression of anti-endometrial antibodies was tested
by using Western Blot analysis (endometrial antigens were prepared from endometrium of 6 fertile
women without endometriosis collected at hysterectomy according to Coulam and Ryan method;
anti-human immunoglobulin, biotinylatedwhole antibody from sheepwas used to detect antibodies
bound to the endometrial antigens); sample handling and laboratory technique described in detail
Threshold for positive result: positive test was defined when distinct dark bands were seen on the blot
for at least one antibody; threshold not pre-specified
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 18/36 (50%): stage I-II 4, stage III-IV 14; controls
n = 18
Reference standard: laparoscopy/laparotomy N = 36 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rAFS system
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood was collected at surgery
Withdrawals: none
Comparative
Key conclusions by the authors Autoantibodies reactive against endometrial antigens are present in patients with endometriosis
Conflict of interest Not reported; the work was supported in part by a Grant-in-Aid for Scientific Research from the
Ministry of Education,
Science and Culture, Japan
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Notes For anti-endometrial antibodies with MW of 28, 38, 64 kDa there was no statistically significant
difference between the groups - no data available for meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate the accuracy of CA-19.9 plasma levels (with or without CA-125 levels)
combined with transvaginal ultrasonography in the differential diagnosis of endometriosis
Participants: women undergoing laparoscopy or laparotomy for persistent adnexal mass at the au-
thors’ institution
Selection criteria: inclusion criteria: pre-menopausal, non-pregnant (only moderate-severe en-
dometriosis included)
Study design: cross-sectional, single-gate design, prospective recruitment and collection of samples,
consecutive series
Patient characteristics and set-
ting
Clinical presentation: pelvic mass - 100%, infertility - 53%
Age: mean age 33.3 ± 9.6 years
Number of participants enrolled: 118 women
Number of participants available for analysis: 118 women (only moderate-severe endometriosis in-
cluded; all in follicular cycle phase)
Setting: Department of O&G, University of Cagliari
Place of study: Cagliari, Italy
Period of study: November 1994 - November 1995
Language: English
Index tests Index test: CA-19.9, CA-19.9 + CA-125
Details of the index test procedure as stated: serum CA-125 levels assessed by immunoradiometric
assay (CIS Bio International, Gif sur Yvette, France), limit of detection 0.5 U/ml; serum CA-19.9
levels assessed by immunoradiometric assay (CIS Bio International, Gif sur Yvette, France), limit of
detection 1.5 U/ml; sample processing and laboratory technique not described
Threshold for positive result: CA-125:≥ 25U/ml, pre-specified;CA-19.9≥12U/ml, not pre-specified
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: Intra- and interassay CV for CA-125 3.9% and 4.2%; for CA-19.9 4.6%
and 5.3%
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Target condition and reference
standard(s)
Target condition: ovarian endometriosis
Prevalence of target condition in the sample: n = 39/118 (33%): all stage III-IV; controls n = 79
Reference standard: laparoscopy n = 99/laparotomy n = 19 (N = 118, 100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection with careful
assessment of the ovaries, followed by histopathological diagnosis; surgical staging according to the
rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood was collected on the day of surgery
Withdrawals: none
Comparative
Key conclusions by the authors Transvaginal ultrasonography used alone is the most cost-effective method in the preoperative
differential diagnosis of endometrioma
Conflict of interest Not reported
Notes The reported diagnostic estimates for combination of blood test with ultrasound are not presented
in this review
The diagnostic estimates were available only for combination of CA-125 with CA-19.9 and for
either 1 of the 2 positive markers
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to assess the role of transvaginal ultrasonography combined with CA-125 plasma
levels in the diagnosis of endometrioma
Participants: women undergoing laparoscopy or laparotomy for persistent adnexal mass at the au-
thors’ institution
Selection criteria: inclusion criteria: pre-menopausal, non-pregnant (only moderate-severe en-
dometriosis included)
Study design: cross-sectional, single-gate design, prospective recruitment and collection of samples,
consecutive series
231Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Guerriero 1996b (Continued)
Patient characteristics and set-
ting
Clinical presentation: pelvic mass - 100%, symptoms not specified
Age: range 20-49 years
Number of participants enrolled: 101 women
Number of participants available for analysis: 101 women (only moderate-severe endometriosis in-
cluded; all in follicular cycle phase)
Setting: Department of O&G, University of Cagliari
Place of study: Cagliari, Italy
Period of study: November 1993 - October 1994
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serum CA-125 levels assessed by immunoradiometric
assay (CIS Bio International, Gif sur Yvette, France), limit of detection 0.5 U/ml; sample processing
and laboratory technique not described
Threshold for positive result: 3 pre-selected cut-offs: ≥ 20 U/ml, ≥ 25 U/ml, ≥ 35 U/ml
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: Intra- and interassay CV 3.9% and 4.2%
Target condition and reference
standard(s)
Target condition: ovarian endometriosis
Prevalence of target condition in the sample: n = 29/101 (29%): all stage III-IV; controls n = 72
Reference standard: laparoscopy/laparotomy + histology
Description of positive case definition by reference standard test as reported: visual inspection with careful
assessment of the ovaries, followed by histopathological diagnosis; visual inspection confirmed on
histopathology; histological criteria reported; surgical procedure described; surgical staging accord-
ing to the rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood was collected on the day of surgery
Withdrawals: none
Comparative
Key conclusions by the authors Transvaginal ultrasonography used alone has a better predictive capacity in differentiating en-
dometrioma from other adnexal masses than combined methods
Conflict of interest Not reported
Notes The reported diagnostic estimates for combination of blood test with ultrasound are not presented
in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Guerriero 1996b (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
233Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)





Patient sampling Primary objective: to evaluate possible value of peritoneal fluid CA-125 levels as a more sensitive
marker of minimal (stage I) endometriosis when compared to serum levels measured simultaneously
Participants: women undergoing laparoscopy as part of infertility work-up or tubal sterilisation
Selection criteria: exclusion criteria: patients with more advanced endometriosis (> stage I) or other
pathological findings
Study design: cross-sectional study of two-gate design, prospective recruitment
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: mean age 30.1 ± 2.6 years (endometriosis), 27.9 ± 2.6 years (controls)
Number of participants enrolled: 38 women
Number of participants available for analysis: 38 women (all in mid-secretory phase of menstrual
cycle)
Setting: Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Hacettepe
Place of study: Sihiye-Ankara, Turkey
Period of study: October 1988 - June 1989
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: CA-125 in serum and PF was measured in duplicates
using an immunoradiometric assay assay (ELISA CA-125, Compagnie ORIS Industrie, France);
assay sensitivity 2.4 U/ml; sample handling and laboratory procedure described
Threshold for positive result: > 16 U/ml, not pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: Inter- and intra-assay CV 5.7%-8.1% and 2%-10%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 17/38 (45%) all stage I; controls n = 21
Reference standard: laparoscopy N = 38 (100%)
Description of positive case definition by reference standard test as reported: classification according to
the ASRM classification
Examiners: no information provided




Key conclusions by the authors CA-125 levels have been found to be mildly, but not significantly elevated in sera of patients with
minimal endometriosis; laparoscopic evaluation remains the most reliable method of diagnosis of
minimal endometriosis
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Conflict of interest Not reported
Notes The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to examine whether IGF-I, IGF-II and IGFBP 3 in serum and peritoneal fluid
correlate with the presence and severity of endometriosis
Participants: patients undergoing laparoscopy for various indications
Selection criteria: exclusion criteria: any other pelvic pathology (myoma uteri, ovarian mass or ad-
hesions not secondary to endometriosis), blood-contaminated PF sample, other medical problems
and/or using any medication for at least the last six months before laparoscopy
Study design: cross-sectional, two-gate design, prospective collection of samples, consecutive patients
Patient characteristics and set-
ting
Clinical presentation: indications for surgery: infertility, pelvic pain and tubal sterilisation
Age: mean age 30.8 ± 5.4 years (stage I-II endometriosis), 32 ± 4.2 years (stage III-IV endometriosis)
, 31.7 ±6.7 years (controls)
Number of participants enrolled: 44 women
Number of participants available for analysis: 44 (21 in follicular, 23 in luteal cycle phase)
Setting: O&G Department, Hacettepe University Hospital
Place of study: Sihiye-Ankara, Turkey
Period of study: not stated
Language: English
Index tests Index test: IGF-I, IGF-II and IGFBP 3
Details of the index test procedure as stated: serum levels of IGF-I and II and IGFBP 3 were measured
by using immunoradiometric assay kits (Diagnostic System Laboratories,Texas); assay sensitivities
were 0.8 ng/ml, 0.13 ng/ml and 0.5 ng/ml, respectively; sample handling described
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: the intra- and interassay CV of IGF-I and II and IGFBP 3 assays were 3.
4%, 4.3%, 1.8% and 8.2%, 9.5%, 1.9%, respectively
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 29/44 (66%): stage I-II 15, stage III-IV 14; controls
n = 15
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Reference standard: laparoscopy N = 44 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histopathology; staging according to the rASRM classification
Examiners: all the procedures were performed by a single operator (the first author)
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none
Comparative
Key conclusions by the authors IGF-I is most probably associated with late-stage endometriosis and may be an important mediator
in progression to late-stage disease. IGF-Imay also act as a local factor in persistence of endometriotic
implants in mild cases
Conflict of interest The authors declared no conflict of interest
Notes For IGF-II and IGFBP3 there was no difference between the groups - no data available for meta-
analysis
For IGF-I there was statistically significant difference between the groups, but there were insufficient
data to construct 2 x 2 tables - not included in this review
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
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Was a cycle phase considered in
interpretation of the result of
index test?
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate whether serum HE4 concentration varies within the normal men-
strual cycle and whether common gynaecological hormonal treatments have an effect on HE4 values
Participants: patients undergoing laparoscopy for suspected endometriosis or tubal ligation
Selection criteria: exclusion criteria: suspicion of malignancy, pregnancy or infection
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: endometriosis - not specified; controls - women requesting tubal ligation;
hormonal medication was used by 78 (43.3%) women
Age: mean age 34 years, range 18-48 years
Number of participants enrolled: 180 women
Number of participants available for analysis: 175 (7 in menstrual, 32 in proliferative and 60 in
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secretory cycle phase; 61 had inactive/atrophic endometrium)
Setting: 2 central hospitals and 2 university central hospitals
Place of study: Turku, Finland
Period of study: October 2005 - October 2007
Language: English
Index tests Index test: HE4, CA-125
Details of the index test procedure as stated: serum HE4 and CA-125 concentrations were analysed
by ELISA analysis (Fujirebio Diagnostics inc, Malvern, PA, USA) according to the manufacturer’s
instructions
Threshold for positive result: For HE4 not provided, for CA-125 > 35 U/l, not pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n =123/175 (70%): stages I-IV, the number of participants
per each stage not reported; controls n = 52
Reference standard: laparoscopy N = 175 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histopathology; staging according to the rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected 24 h before
surgery
Withdrawals: 5 women were excluded when endometrial biopsy was non-conclusive regarding cycle
phase
Comparative
Key conclusions by the authors HE4 measurement in healthy pre-menopausal women as well as in women with endometriosis
can be carried out at any phase of the menstrual cycle, and irrespective of hormonal medication,
extending the benefits of HE4 use in clinical practice
Conflict of interest One of the authors received lecture honoraria from several pharmaceutical companies; other authors
declared no conflict of interest; the study was supported by the Finnish Funding Agency for Tech-
nology and Innovation (projects 40343/05 and 599/05); Hormos Medical Ltd, Finland (subsidiary
of QuatRx Pharmaceutical, USA); Biotop Oy, Finland; Genolyze Oy, Finland
Notes For HE4 there was no difference between the groups - no data available for meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Patient sampling Primary objective: to assess endometrial expression of the human telomerase enzyme and telomere
length (TL)
Participants: patients undergoing laparoscopy for suspected endometriosis or tubal ligation
Selection criteria: inclusion criteria: pre-menopausal women (18-46 years), regular menstrual cycle
(25-31 day), no hormonal treatments
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: endometriosis - not specified, controls - healthy fertile women requesting tubal
ligation
Age: mean age 37 ± 5 years (endometriosis group) and 38 ± 5 years (controls)
Number of participants enrolled: 56 women
Number of participants available for analysis: 56 (all in luteal menstrual cycle phase)
Setting: School of Reproductive and Developmental Medicine, University of Liverpool, Liverpool
Women’s Hospital
Place of study: Liverpool, UK
Period of study: not reported
Language: English
Index tests Index test: TL, progesterone, E2
Details of the index test procedure as stated: peripheral blood TL expression was assessed by using RT-
PCT (extracted from peripheral mononuclear cells, reaction by SYBR green chemistry, measured
on iCycler RT PCR system (Bio-Rad Laboratories, Hercules, USA), expressed in base pairs); sample
handling and laboratory method described
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 29/56 (52%): stage I-II 14, stage III-IV 15; controls
n = 27
Reference standard: laparoscopy N = 56 (100%)
Description of positive case definition by reference standard test as reported: surgical diagnosis; staging
according to the rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected immediately
before surgery (personal communication with the author)
Withdrawals: the data for TL was not available for 6 participants (9%); reason not explained
Comparative
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Key conclusions by the authors We speculate that aberrant endometrial expression of telomerase mediates alterations in cell fate
that enhance proliferation, contributing to the pathogenesis of endometriosis
Conflict of interest Not reported; the work was supported by a RDF grant from the University of Liverpool and RCOG
millennium grant
Notes For TL, progesterone and E2 there was no difference between the groups - no data available for
meta-analysis
The data for markers measured in eutopic endometrium are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the clinical value of the serum CA-19.9 level in comparison with
the serum CA-125 level for diagnosing endometriosis
Participants: patients who underwent laparotomy or laparoscopy with the preoperative diagnosis
of infertility, myoma uteri, adenomyosis or endometriosis (cases) and patients who underwent
laparoscopy for infertility investigation (controls)
Selection criteria: exclusion criteria: patients with malignant tumours or inflammatory disease
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: mean age 35.4 ± 6.7 years, range 21-52 years
Number of participants enrolled: 123 women
Number of participants available for analysis: 123 women (menstrual cycle phase not specified)
Setting: Department of Reproductive Medicine, Tokyo Medical and Dental University Hospital
Place of study: Tokyo, Japan
Period of study: not stated
Language: English
Index tests Index test: CA-125, CA-19.9
Details of the index test procedure as stated: serum CA-19.9 and CA-125 levels were measured by
enzyme immunoassay (TFB Co,Tokyo, Japan) and were expressed in arbitrary units based on a
primary reference standard
Threshold for positive result: CA-19.9 > 37.0 U/ml, CA-125 > 35.0 U/ml, pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
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Interobserver variability: not stated
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 101/123 (82%); stage I-II 38, stage III-IV 63; controls
n = 22
Reference standard: laparoscopy/laparotomy N = 123 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rAFS system
Examiners: no information provided




Key conclusions by the authors The mean serum CA-19.9 levels in patients at all stages of endometriosis were significantly higher
than those in patients without endometriosis and significantly correlated with the rASRM classifi-
cation scores. CA-19.9 levels and serum CA-125 levels may prove to be valuable tools for predicting
the severity of endometriosis as diagnosed by laparoscopy
Conflict of interest Not reported; the study was supported by a Science Research Grant (11671599) from the Ministry
of Education, Culture, Sports, Science and Technology of Japan
Notes The reported data enabled to calculate diagnostic estimates for the subgroups by severity of en-
dometriosis - not included in the review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Unclear
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dard?
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the changes in Th1 and Th2 immune responses, characterised by a
change in the levels of IL-2, IL-4, IL-10 and IFN-γ , and determinations of T helper, T suppressor,
NK, and B cells in peripheral blood and peritoneal fluid of different stages of endometriosis
Participants: patients who underwent laparoscopy for pain or infertility (cases) and for tubal ligation
(controls)
Selection criteria: exclusion criteria: any medical treatment employed prior to laparoscopy that may
interfere with the results
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Study design: cross-sectional two-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: controls had no history of infertility and no pelvic pathology during surgical
inspection
Age: mean 30.9 ± 5.6; 29.9 ± 6.7 years (endometriosis stage I-II; III-IV), 30.1 ± 6.7 years (controls)
Number of participants enrolled: 97 women
Number of participants available for analysis: 97 women (all in follicular phase of menstrual cycle)
Setting: O&G Department, Eskisehir Osmangazi University School of Medicine
Place of study: Eskisehir, Turkey
Period of study: 2003-2005
Language: English
Index tests Index test: IL-2, IL-4, IL-10, IFN-γ , and lymphocytes: Th, Ts, AL and NK
Details of the index test procedure as stated: cytokines were measured by using ELISA assay (Cellular
Communication Investigations, BeckmanCoulter,USA); lymphocyteswere assessed by using cluster
determinant-3 (CD-3), CD4, CD8, CD25, CD28, CD45, CD16, CD23, Abs against early T cell
activation antigens such as CD45RA/CD45RO, CD-69 and late activation antigens such as HLA-
DR; sensitivity limits of the kits were 5 pg/ml, 5 pg/ml, 5 pg/ml, and 0.08 pg/ml for IL-2, IL-4,
IL-10, IFN-γ ; sample handling and technique described
Threshold for positive result: not provided
Examiners: experienced technicians blind to the status of cases at laboratory conducted the detection
of both cytokine and immune cell levels
Interobserver variability: Intra- and interassay CVs were < 10% for all assays
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 60/97 (62%): stage I-II 42, stage III-IV 18; controls
n = 37
Reference standard: laparoscopy N = 97 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
histopathologically; staging according to the rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: not clearly stated, but from the context, blood
was collected at surgery
Withdrawals: none
Comparative
Key conclusions by the authors The result of this study did not show any significant difference in peripheral blood and peritoneal
fluid cytokine and lymphocyte subgroups between normal women and those with early and late
stage endometriosis
Conflict of interest All the authors had a conflict of interest (financial or otherwise)
Notes For IL-2, IL-4, IL-10, IFN-γ , Th, Ts, AL, NK there was not statistically significant difference
between the groups - no data available for meta-analysis
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to compare the serum CA-125 concentrations determined by assays in women
with and without endometriosis, and to determine if the new assay improves the clinical utility of
CA-125 in the diagnosis of endometriosis
Participants: patients with the preoperative diagnosis of endometriosis, pelvic pain, or infertility
recruited from 2 fertility units
Selection criteria: not specified
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: not specified; all patients had menstrual cycles; implies reproductive age
Number of participants enrolled: 123 women
Number of participants available for analysis: 123 women (in follicular phase of menstrual cycle)
Setting: 2 teaching hospitals: Fertility Unit of Brigham andWomen’s Hospital and the Reproductive
Endocrine/Infertility Service of the Cooper Hospital University Medical Center
Place of study: Boston, MA, USA and Camden, NJ, USA
Period of study: not stated
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serum CA-125 concentrations were determined by im-
munoradiometric assay (Centocor, Malvern, PA, USA): older assay and the new, a second-genera-
tion assay, which utilises M-II murine monoclonal OC125 antibody
Threshold for positive result: CA-125 > 35.0 U/ml, not pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: the intra- and interassay CVs were 8.3% and 12.1% for the older assay and
5.2% and 7.5% for the new CA-125 assay
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 74/123 (60%); stage I-II 54, stage III-IV 20; controls
n = 49
Reference standard: laparoscopy N = 123 (100%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to the rAFS classification
Examiners: no information provided; the operating surgeon was not sure of the patients’ CA-125
concentration at the time of surgery
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Key conclusions by the authors The sensitivity and specificity were slightly improved using the new CA-125 assay; however, this
assay did not dramatically improve detection of endometriosis
Conflict of interest Not reported; the work was supported in part by a grant from Centocor, Inc, Malvern, PA, USA
Notes Only the diagnostic estimates for a new generation assay were included in this review because they
were the closest to the currently used technique
The reported diagnostic estimates for stage III-IV endometriosis are not included in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to assess whether the IgG anti-laminin-1 auto-Abs in infertile patients are associ-
ated with reproductive disorders, particularly during pre- and peri-implantation stages
Participants: infertile patients who underwent laparoscopy or laparotomy as part of their infertility
investigation
Selection criteria: not specified
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility
Age: mean age 33.7 years, range: 26-45 years
Number of participants enrolled: 68 women
Number of participants available for analysis: 68 women (menstrual cycle phase not specified)
Setting: Okayama University Hospital and at Nagoya City University Hospital
Place of study: Okayama and Nagoya, Japan
Period of study: not stated
Language: English
Index tests Index test: IgG anti-laminin-1 auto-Abs
Details of the index test procedure as stated: detection of IgG anti-laminin-1 Abs was performed using
ELISA (referenced to the original source); laboratory technique described in details
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Threshold for positive result: 1.0 U/ml, not pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: the inter and intra-assay CV < 3.1% and 6.9%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 42/68 (62%); stage I-II 14, stage III-IV 28; controls
n= 26
Reference standard: laparoscopy/laparotomy N = 68 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histopathology; staging according to the rASRM classification
Examiners: no information provided




Key conclusions by the authors The assessment of IgG anti-laminin auto-Abs might prove useful for the diagnosis and medical
treatment of endometriosis
Conflict of interest Not reported
Notes The presented data enabled calculation of the diagnostic estimates according to severity of en-
dometriosis - not included in this review
We did not consider a group of separately recruited healthy controls (N = 39) that did not have
surgery and were not included in the calculations of the diagnostic estimates
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
Unclear
251Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Inagaki 2003 (Continued)
the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate cell-mediated immunity in endometriosis
Participants: women who underwent laparoscopy or laparotomy for infertility or benign adnexal
mass
Selection criteria: not specified
Study design: cross-sectional single-gate, prospective collection of samples
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Patient characteristics and set-
ting
Clinical presentation: infertility or adnexal mass
Age: mean age 34.8 ± 6.9 years (endometriosis group), 32.3 ± 3.8 years (controls)
Number of participants enrolled: 45 women
Number of participants available for analysis: 45 women (all in mid-follicular menstrual cycle phase)
Setting: Department of O&G, School of Medicine, Keio University
Place of study: Keio, Japan
Period of study: not stated
Language: English
Index tests Index test: lymphocyte subsets and NK activity
Details of the index test procedure as stated: subsets of lymphocytes in peripheral blood were analysed
with flow cytometry FACS scan by using several combinations of monoclonal Abs (Becton Dickin-
son, CA); NK cytotoxicity was assessed in K562 cell line; sample handling and laboratory methods
described
Threshold for positive result: not reported
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 19/45 (42%); stage I-II 16, stage III-IV 3; controls
n= 26
Reference standard: laparoscopy/laparotomy N = 45 (100%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to the rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none
Comparative
Key conclusions by the authors An alteration in cell-mediated immunity may be among the pathogenetic, or developing, factors in
endometriosis
Conflict of interest Not reported
Notes For suppressor-T cells, cytotoxic-T cells, activated-T cells and NK activity, there was a statistically
significant difference between the groups, but there was insufficient data to construct 2 x 2 tables -
not included in this review
For T-lymphocytes, B-lymphocytes, inducer-T cells, helper-T cells, non-MHC restricted T cells
and NK cells, there was no statistically significant difference between the groups - no data available
for meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to assess whether sCD163 and IL-6 could be used as serum markers for discrim-
inating ovarian endometriomas from other benign ovarian masses
Participants: women who had adnexal cystic tumours and underwent adnexal surgery either via
laparoscopy or laparotomy
Selection criteria: exclusion criteria: patients who had ≥ 2 pathologic diagnoses, recent history of
any inflammatory disease (only moderate-severe endometriosis included)
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: dysmenorrhoea - 54.5%ofwomenwith endometrioma; not specified otherwise
Age: reproductive age (values presented for each type of ovarian neoplasm)
Number of participants enrolled: 95 women
Number of participants available for analysis: 95 women (menstrual cycle phase not specified)
Setting: Seoul National University Bundang Hospital
Place of study: Seoul, Korea
Period of study: July 2003 - November 2004
Language: English
Index tests Index test: sCD163 and IL-6
Details of the index test procedure as stated: serum levels of sCD163 and IL-6 were determined with a
commercial ELISA kit (Soluble CD163 ELISA; Cedarlane Laboratories, Canada) and IL-6 ELISA
kit (DuoSet ELISA Development System; R&D System Inc, USA) according to the manufacturer’s
instructions; assay sensitivity for sCD163 is 0.15 ng/ml, for
IL-6, 0.7 pg/ml; sample processing and laboratory techniques described in details
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: intra- and interassay CV sCD163 < 5%; for IL-6, 2.5% and 4.5%
Target condition and reference
standard(s)
Target condition: ovarian endometriosis
Prevalence of target condition in the sample: n = 44/95 (46%), all stage III-IV; controls n = 51
Reference standard: laparoscopy/laparotomy n = 95 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to the rAFS classification; histopathology of the specimens was proven by pathologists
Examiners: no information provided
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Key conclusions by the authors Serum levels of sCD163 as well as IL-6 are not useful markers for ovarian endometriomas
Conflict of interest Not reported
Notes For sCD163 and IL-6 there was no difference between the groups - no data available for meta-
analysis
ForCA-125 therewas statistically significant difference between the groups, but therewas insufficient
data to construct 2 x 2 tables - not included in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate the feasibility of using plasma microRNAs as a non-invasive diagnostic
test for the detection of endometriosis
Participants: women who underwent laparoscopy for various indications, including pelvic masses,
pelvic pain, infertility and uterine leiomyoma
Selection criteria: exclusion criteria: postmenopausal status, previous hormonal use within 3 months,
adenomyosis or malignancy (only moderate-severe endometriosis included)
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: indications for surgery: pelvic pain, infertility, pelvic mass, uterine fibroids
Age: mean age: 34.1 ± 5.03, range: 25-44 years (endometriosis); 32.1 ± 6.95 years, range 22-45
years (controls)
Number of participants enrolled: 46 women
Number of participants available for analysis: 40 women (31 in follicular and 9 in luteal cycle phase)
Setting: Department of O&G, Peking Union Medical College Hospital
Place of study: Beijing, PR China
Period of study: January 2012 - May 2012
Language: English
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Index tests Index test: miR-17-5p, miR-20a and miR-22
Details of the index test procedure as stated: plasma miRNA expression by RT-PCR (normalised to
miR-16 levels and calculated using the 2
−11Ctmethod); sampleprocessingandlaboratorytechniquedescribedindetails
Threshold for positive result: miR-17-5p: 0.9057, miR-20a: 0.6879, miR-22: 0.5647; not pre-speci-
fied
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 20/40 (50%): all stage III-IV; controls n = 20
Reference standard: laparoscopy N = 46 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection with a
thorough inspection of the abdominopelvic cavity to detect any typical or atypical endometriotic
lesion; all possible lesions were excised and sent for pathological examination; staging according to
the rASRM system
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood was collected “immediately before
administration of anaesthesia”
Withdrawals: 6 samples (3 endometriosis and 3 controls) were used for preliminary screening ex-
periment and were not included in the final single-plex analysis
Comparative
Key conclusions by the authors PlasmamiR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis, which
raises the potential clinical utility of plasma microRNA profiling in endometriosis diagnosis
Conflict of interest The authors declared no conflict of interest; supported by grants from the National Natural Science
Foundation of China (81170548) and Key Project for Clinical Faculty Foundation, Ministry of
Health, China
Notes The reported data for combination of miRs was insufficient to construct 2 x 2 tables and hence are
not resented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes
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DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to determine whether a concentration of PEP or other specific proteins in serum
or PF is altered in endometriosis and, if so, whether this alteration is associated with development
of an antibody response
Participants: untreated pre-menopausal womenwhounderwent diagnostic laparoscopy for infertility,
dysmenorrhoea or tubal ligation
Selection criteria: not specified
Study design: cross-sectional two-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: Pre-menopausal, not specified
Number of participants enrolled: 55 women
Number of participants available for analysis: 55 women (35 in proliferative, 20 in secretory cycle
phase)
Setting: not stated; the authors’ affiliations: Department of O&G Albany Medical College and
Baylor College of Medicine
Place of study: Albany, NY and Houston, TX, USA
Period of study: not stated
Language: English
Index tests Index test: PEP and total proteins in follicular and luteal phase of menstrual cycle
Details of the index test procedure as stated: PEP in serum was assessed with a specific RIA; protein
profiles were examined by polyamide gel electrophoresis (SDS PAGE); specific assays were developed
to detect and quantify anti-PEP and anti-EG; sample processing and laboratory techniques described
in details
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 36/55 (66%): stage I-II 21, stage III-IV 15; controls
n = 19
Reference standard: laparoscopy N = 55 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rAFS system
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: not specified, from context - blood samples
were collected short time before surgery
Withdrawals: none
Comparative
Key conclusions by the authors Levels of PEP were not different in serum from women with moderate-severe or mild endometriosis
or from disease-free cycling controls
Conflict of interest Not reported
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Notes For PEP there was no statistically significant difference between the groups - no data available for
meta-analysis
The data for total proteins were reported only for peritoneal fluid - not assessed in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to compare the concentration of the cytokines: IL-6, IL-8, IL-1β, VEGF, TNF-
α, MCP-1, RANTES, PDGF, sFas, sFasL in both biological fluids (PF and serum) in women with
and without endometriosis
Participants: women undergoing laparoscopy for unexplained infertility
Selection criteria: exclusion criteria: active PID, hydrosalpinges, any autoimmune disease, hormonal
treatment or hysterosalpingography in the 2 months preceding laparoscopy, pregnancy in the last 6
months (only minimal-mild endometriosis included)
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility
Age: mean 31.0 ± 6.5 years (endometriosis group) and 30.5 ± 6 years (controls)
Number of participants enrolled: 57 women
Number of participants available for analysis: 40 or 35 women - number of participants varied for
different assays (all in luteal phase of menstrual cycle)
Setting: Assisted Conception Unit, St Helier University Hospital
Place of study: Carshalton, Surrey, UK
Period of study: not stated
Language: English
Index tests Index test: IL-6, IL-8, IL-1β, TNF-α, RANTES, PDGF, VEGF, MCP-1, sFasL, sFas
Details of the index test procedure as stated: PDGF, sFas, RANTES, MCP-1 were determined in
duplicate by quantitative sandwich EIA using commercial Quantikine kits (R&D systems, USA);
the sensitivity was 15 pg/ml, 20 pg/ml and 8 pg/ml, 4.7 pg/ml, respectively. FasL was determined
in duplicate by EIA kits (Diaclone, France); sensitivity < 12.5 pg/ml. IL-6, IL-8, IL-1β and TNF-
α were determined using an ’IMMULITE’ analyser (DPC, USA); sensitivity was 5.0 pg/ml, 2 pg/
ml, 1.5 pg/ml, 1.7 pg/ml, respectively. VEGF was determined by the Neogen (Lexington, USA)
immunoassay, limit of detection was 18.6 pg/ml; sample handling described
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
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Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 26/57 (46%), all stage I-II; controls n = 31
Reference standard: laparoscopy N = 57 (100%)
Description of positive case definition by reference standard test as reported: visual inspection: positive
diagnosis was defined as red endometriotic lesions - red vesicles, red flame-like lesions or gland-like
lesions; staged according to the rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were obtained before anaes-
thesia
Withdrawals: samples of 8-11 participants from control group and 9-11 participants from en-
dometriosis group were not available (number of missing samples varied for each assay due to limi-
tation of sample quantity)
Comparative
Key conclusions by the authors The elevated levels of MCP-1, IL-6, and IL-8 in peritoneal fluid but not serum may indicate the
importance of local macrophage activating factors in the pathogenesis of endometriosis
Conflict of interest Not reported
Notes For IL-6, IL-8, IL-1β, TNF-α, RANTES, PDGF and sFas, there was no statistically significant
difference between the groups - no data available for meta-analysis
For VEGF, MCP-1, sFasL the data was not available (insufficient sample to assay)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
No




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to examine the peritoneal fluid (PF) and serum concentrations of hepatocyte
growth factor (HGF) in different r-ASRM staging and morphologic appearances of endometriosis
in an attempt to determine whether HGF can be clinically useful to predict the activity of pelvic
endometriosis
Participants: women undergoing laparoscopy for infertility, pelvic pain or benign ovarian mass
Selection criteria: exclusion criteria: controls - fibroid uterus, PID
Study design: cross-sectional single-gate, prospective collection of samples
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Patient characteristics and set-
ting
Clinical presentation: infertility, dysmenorrhoea or pelvic pain (endometriosis), benign ovarian cyst
(controls); none of the participants had been on hormonal medication in the 3/12 months prior to
surgery; all women had regular menstrual cycles (28/32 days)
Age: range 15-43 years (endometriosis group) and 17-39 years (controls)
Number of participants enrolled: 194 women
Number of participants available for analysis: 58 women (21 in follicular and 37 in luteal phase of
menstrual cycle)
Setting: Department of O&G, Nagasaki University School of Medicine, Nagasaki Municipal Hos-
pital
Place of study: Nagasaki, Japan
Period of study: not stated
Language: English
Index tests Index test: HGF
Details of the index test procedure as stated: serum concentrations of HGF were measured using
a commercially available ELISA kit (Quantikine, R&D system, Minneapolis, MN); the limit of
detection was 40.0 pg/ml
Threshold for positive result: not provided
Examiners: no information provided; assay was performed in blind fashion
Interobserver variability: the intra- and interassay CV were < 10%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 37/57 (65%): stage I-II 19, stage III-IV 18; controls
n = 21
Reference standard: laparoscopy N = 57 (100%) + histopathology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
onhistopathology: peritoneal lesions of endometriosiswere diagnosed according to published criteria
(referenced to the primary source) and categorised as red, black, and white lesions; peritoneal lesions
and chocolate cysts were measured; staged according to the rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were obtained at surgery
Withdrawals: 136 participants did not consent for blood collection and were not included in the
study
Comparative
Key conclusions by the authors Women with early or advanced endometriosis as measured by rASRM scoring system are not
associated with an increase in either serum or PF concentrations of HGF. Rather HGF levels in
serum and PF were significantly increased in women harbouring blood-filled red peritoneal lesions
and may be clinically useful to predict the activity of pelvic endometriosis
Conflict of interest Not reported
Notes For HGF there was no statistically significant difference between the groups - no data available for
meta-analysis
The data for HGF measured in peritoneal fluid are not presented in this review
The data for HGF expression stratified by type of endometriotic lesions, severity of endometriosis
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or cycle phase are not included in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to measure PGE2 levels in different body fluids; namely MF, PF and sera derived
from women with and without endometriosis and to investigate effect of PGE2 on the replication
of E. coli in a bacteria culture and on growth of PBLs derived from women with and without
endometriosis
Participants: women undergoing laparoscopy for infertility, pelvic pain or benign ovarian mass
Selection criteria: exclusion criteria: induced menstrual cycles
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility, dysmenorrhoea or pelvic pain (endometriosis), benign ovarian cyst
(controls); none of the participants had been on hormonal medication in the 3/12 months prior to
surgery; all women had regular menstrual cycles (28/32 days)
Age: mean age 30.2 ± 3.5 years, range 20-42 years (endometriosis group); 28.4 ± 3.9 years, range
18-32 years (controls)
Number of participants enrolled: 86 women
Number of participants available for analysis: 86 women (30 in proliferative, 47 in secretory and 9
in menstrual cycle phase)
Setting: Department of O&G,Nagasaki University School of Medicine, Saiseikai Nagasaki Hospital
Place of study: Nagasaki, Japan
Period of study: not stated
Language: English
Index tests Index test: PGE2
Details of the index test procedure as stated: serum concentrations of PGE2 were measured using
ELISA (Quantikine, R&D system, Minneapolis, MN); the limit of detection was 8.25 pg/ml
Threshold for positive result: not provided
Examiners: no information provided; assay was performed in blind fashion
Interobserver variability: the intra- and interassay CV were < 10%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 58/86 (67%): stage I-II 35, stage III-IV 23; controls
n = 28
Reference standard: laparoscopy n = 86 (100%) + histopathology
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Description of positive case definition by reference standard test as reported: visual inspection confirmed
on histopathology; staged according to the rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: not specified, the context suggests that the
samples were collected short time before surgery
Withdrawals: none reported
Comparative
Key conclusions by the authors PGE2 promotes bacterial growth in women with endometriosis
Conflict of interest The authors declared no conflict of interests; the work was supported by grants-in-aid for Scientific
Research (grant
no. 16591671 and 18591837) from the Ministry of Education, Sports, Culture, Science and Tech-
nology of Japan
Notes For PGE2 there was no statistically significant difference between the groups - no data available for
meta-analysis
The data for HGF measured in menstrual blood or peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
268Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Khan 2012 (Continued)
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to measure measure the HSP70 levels in sera, menstrual and peritoneal fluid
collected from women with and without endometriosis, to examine the role of LPS in the produc-
tion of HSP70 by eutopic endometrium and to investigate the effects of LPS and HSP70 on the
production of cytokines by peritoneal macrophages in endometriosis
Participants: women undergoing laparoscopy for infertility, pelvic pain or benign ovarian mass
Selection criteria: not specified
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility, dysmenorrhoea or pelvic pain (endometriosis), benign ovarian cyst
(controls); none of the participants had been on hormonal medication in the 3/12 months prior to
surgery; all women had regular menstrual cycles (28/32 days)
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Age: mean age 29.8 ± 4.6 years, range 20-42 years (endometriosis group); 28.6 ± 3.8 years, range
18-32 years (controls)
Number of participants enrolled: 63 women (16 in proliferative, 31 in secretory and 12 in menstrual
cycle phase)
Number of participants available for analysis: 50 women
Setting: Department of O&G,Nagasaki University School of Medicine, Saiseikai Nagasaki Hospital
Place of study: Nagasaki, Japan
Period of study: not stated
Language: English
Index tests Index test: HSP70
Details of the index test procedure as stated: serum concentrations of HSP70 were measured using a
commercially available ELISA (StressXpressTM, EKS-700; Stressgen Victoria, Canada) according
to the manufacturer’s instructions; the limit of detection was 200 pg/ml
Threshold for positive result: not provided
Examiners: no information provided; assay was performed in blind fashion
Interobserver variability: the intra- and interassay CV were < 10%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 43/63 (68%): stage I-II 28, stage III-IV 15; controls
n = 20
Reference standard: laparoscopy N = 63 (100%) + histopathology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
on histopathology; staged according to the rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected before and at
surgery
Withdrawals: 13 participants (21%) were not included in the analysis, presumably blood samples
were not available
Comparative
Key conclusions by the authors A crosstalk between local inflammation and tissue stress reaction in the pelvic environment may be
involved in TLR4-mediated growth of endometriotic cells
Conflict of interest The authors declared no conflict of interests; the work was supported by grants-in-aid for Scientific
Research (grant
no. 16591671 and 18591837) from the Ministry of Education, Sports, Culture, Science and Tech-
nology of Japan
Notes For HSP70 there was no statistically significant difference between the groups - no data available
for meta-analysis
The data for HGF measured in menstrual blood, peritoneal fluid and eutopic endometrium are not
presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Khan 2013 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to compare serum phospholipid fatty acid profile in endometriosis patients with
controls, and to explore the correlation of this profile with the severity of the disease
Participants: women undergoing laparoscopy or laparotomy for various indications
Selection criteria: exclusion criteria: anti-inflammatory drugs during 3/12 months before surgery,
any diseases (endometritis, gastrointestinal or urological disease with pelvic pain, liver or endocrine
autoimmune disease, previous endometriosis or
neoplastic disorders and chronic PID)
Study design: cross-sectional two-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified; surgical diagnosis in controls: uterine myoma, dermoid cyst,
serous cyst, paraovarian cyst or mucinous cyst; all women had regular menstrual cycles
Age: mean age 30.57 ± 5.04 years (endometriosis group) and 30.57 ± 5.71 years (controls)
Number of participants enrolled: 138 women
Number of participants available for analysis: 138 women (in proliferative or secretory cycle phase)
Setting: university Hospital: Alzahra Hospital, Tabriz University of Medical Sciences and Sarem
Hospital
Place of study: Tabriz, Iran and Tehran, Iran
Period of study: not stated
Language: English
Index tests Index test: phospholipid fatty acids
Details of the index test procedure as stated: serum phospholipid fatty acids were purified of the total
phospholipids by using TLC technique and measured using a gas chromatograph (Buck Scientific
model 610, USA); the relative amount of each fatty acid was stated as the percentage of total area
on chromatograms
Threshold for positive result: not provided
Examiners: no information provided; assay was performed in blind fashion
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 64/138 (46%): stage I-II 46, stage III-IV 18; controls
n = 74
Reference standard: laparoscopy/laparotomy N = 138 (100%) + histopathology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
on histopathology; staged according to the rAFS classification
Examiners: no information provided
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Flow and timing Time interval between index test and reference standard: blood samples were collected before surgery
Withdrawals: none reported
Comparative
Key conclusions by the authors Levels of fatty acids in serum total phospholipids do not seem to be a marker for endometriosis, but
the EPA to AA ratio was a relevant factor indicating severity of illness
Conflict of interest The authors declared no conflict of interests
Notes For most of the total phospholipid fatty acids (N = 16) there was no statistically significant difference
between the groups - no data available for meta-analysis
For 18:0 (stearic acid) there was statistically significant difference between the groups, but there was
insufficient data to construct 2 x 2 tables - not included in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate CRP levels as a marker of inflammatory process in serum and
peritoneal fluid of patients with endometriosis
Participants: patients subjected to laparoscopy for the evaluation of infertility or pelvic pain
Selection criteria: exclusion criteria: patients with hypertension, coronary arterial diseases, diabetes,
renal diseases, active pelvic inflammatory disease or polycystic ovarian syndrome
Study design: cross-sectional, single-gate design, prospective collection of samples, non-consecutive
enrolment
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, infertility
Age: mean age 28.9 years, range: 19-44 years (endometriosis group), 30.2 years, range: 24-42 years
(controls)
Number of participants enrolled: 179 women
Number of participants available for analysis: 179 women (166 in follicular, 13 in luteal cycle phase)
Setting: Isfahan Fertility and Infertility Center, Isfahan University
Place of study: Isfahan, Iran
Period of study: 2009-2011
Language: English
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Index tests Index test: CRP
Details of the index test procedure as stated: serum concentrations of CRP weremeasured using enzyme
immunoassay kit (Monobind Inc, CA, USA); absorbance at 450 nmwas determined by plate reader;
sample processing and experiment described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 90/179 (50%): stages not specified; controls n = 89
Reference standard: laparoscopy N = 179 (100%)
Description of positive case definition by reference standard as reported: not reported
Examiners: no information provided




Key conclusions by the authors Measurement of CRP in patients’ serum or plasma cannot be used to diagnose endometriosis. It is
further recommended that a combination of different markers might be helpful in this regard that
could be studied in future
Conflict of interest The authors declared no conflict of interests
Notes For CRP there was no statistically significant difference between the groups - no data available for
meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to determine the serum and PF levels of VEGF in endometriosis patients, and to
compare with normal subjects
Participants: patients subjected to laparoscopy for the evaluation of infertility or pelvic pain
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Selection criteria: exclusion criteria: patients with hypertension, coronary arterial diseases, diabetes,
renal diseases, active pelvic inflammatory disease or polycystic ovarian syndrome
Study design: cross-sectional, single-gate design, prospective collection of samples, non-consecutive
enrolment
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, infertility
Age: mean age 28.9 years, range: 19-44 years (endometriosis group), 30.2 years, range: 24-42 years
(controls)
Number of participants enrolled: 179 women
Number of participants available for analysis: 179 women (166 in follicular, 13 in luteal cycle phase)
Setting: Isfahan Fertility and Infertility Center, Isfahan University
Place of study: Isfahan, Iran
Period of study: 2009-2011
Language: English
Index tests Index test: VEGF
Details of the index test procedure as stated: serum concentrations of VEGF were measured using
ELISA kit (Immuno-Biological Laboratory Co, Japan); absorbance at 450 nm was determined by
plate reader; concentration was determined using standard curve; sample processing and experiment
described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 90/179 (50%): stages not specified; controls n = 89
Reference standard: laparoscopy N = 179 (100%)
Description of positive case definition by reference standard as reported: not reported
Examiners: no information provided




Key conclusions by the authors According to our findings, endometriosis is not associated with change in the level of circulating
VEGF
Conflict of interest Not reported
Notes For VEGF there was no statistically significant difference between the groups - no data available for
meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Patient sampling Primary objective: to investigate the associations between endometriosis and the G(-2518)A poly-
morphism of monocyte chemotactic protein-1 (MCP-1), and serum and peritoneal fluid MCP-1
levels in Korean women
Participants: women who underwent laparoscopy for investigation of pelvic pain, ovarian mass, or
infertility
Selection criteria: not reported
Study design: cross-sectional, single-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, ovarian mass, or infertility; no patient had received any medication
associated with endometriosis or had any history of pelvic surgery; all women had regular menstrual
cycles
Age: range 20-40 years
Number of participants enrolled: 206 women
Number of participants available for analysis: 170 women (all in follicular cycle phase)
Setting: Department of O&G, College of Medicine, Seoul National University
Place of study: Seoul, Korea
Period of study: not reported
Language: English
Index tests Index test: MCP-1
Details of the index test procedure as stated: serum concentrations of MCP-1 measured by using a
Quantikine (M) enzyme-linked immunosorbent assay kit (R&D, Minneapolis, USA), according to
the manufacturer’s instructions; the kit
sensitivity was 5 pg/ml; sample processing and laboratory technique described
Threshold for positive result: not reported
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: the intra- and interassay CV 4.7% and 5.8%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 94/170 (55%): stage I-II 55, stage III-IV 39; controls
n = 76
Reference standard: laparoscopy, N = 170 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection followed
by histologic examination; staging according to the rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were drawn immediately after
surgery
Withdrawals: 36 participants (17%) were not included in the analysis, the reason for exclusion not
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Key conclusions by the authors Serum and peritoneal fluid MCP-1 levels and the G (-2518)A MCP-1 polymorphism were found
not to be associated with endometriosis in Korean women
Conflict of interest Not reported; the work was supported by the Korea Research Foundation Grant funded by the
Korean Government
(MOEHRD) (KRF-2005-041-E00224)
Notes The reported data for MCP-1 polymorphism are not presented in this review
For MCP-1 there was no statistically significant difference between the groups - no data available
for meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate the diagnostic significance of CA-125 for endometriosis without
ovarian endometriomas
Participants: patients who underwent laparoscopy or laparotomy and were diagnosed with en-
dometriosis, adenomyosis, leiomyomas, or a normal pelvis
Selection criteria: inclusion criteria: reproductive age, cyclic menstruation patterns; exclusion criteria:
endocrine therapy, including GnRH agonists, danazol, or combination oestrogen-progestin therapy
for at least 6 months before enrolment; patients diagnosed with other uterine neoplasms, ovarian
neoplasms, pelvic inflammation, or pregnancy
Study design: cross-sectional, unclear if two- or single-gate design, prospective collection of samples,
consecutive series
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: reproductive age, not specified
Number of participants enrolled: 775 women
Number of participants available for analysis: 775women (in follicular or in luteal cycle phase, number
of women in each phase is not reported)
Setting: O&G Department, Kyoto Prefectural University of Medicine
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Place of study: Kyoto, Japan
Period of study: January 1999 - December 2003
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serum concentrations of CA-125 measured by an im-
munoradiometric assay kit (Centocor, Malvern, USA) and expressed in arbitrary units based on a
primary standard; sample processing and laboratory technique described in details
Threshold for positive result: > 20U/ml, > 26 U/ml, > 30 U/ml; not pre-specified
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: the intra- and interassay CV 5.3% and 3.4%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 433/775 (57%): stage I-II 141, stage III-IV 292;
controls n = 342: normal pelvis - 101, other pelvic pathologies - 241
Reference standard: laparoscopy/laparotomy N = 775 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection followed
by histologic examination; staging according to the rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: “Blood samples were drawn before surgery
on days other than those during menstruation” suggests shortly before surgery
Withdrawals: none
Comparative
Key conclusions by the authors In the diagnosis of endometriosis without endometriomas, combined use of two cut-off values for
CA-125, 20 and 30 U/ml, provides improved diagnostic performance. However, the accuracy of
using only CA-125 testing for diagnosis is still limited.
Serum CA-125 testing can be done during initial screenings of women with possible endometriosis
Conflict of interest Not reported; supported in part by Grants-in-Aid for Scientific Research (15591772, 15790903
and 16790965) from the Ministry of Education, Culture, Sports, Science and Technology, Japan
Notes The reported data for CA-125 in diagnosing endometriosis without endometriomas is not presented
in this review
The diagnostic estimates were calculated for the all the women with versus all the women without
endometriosis (regardless of presence of other pelvic pathologies), based on the raw data provided
by the authors
The diagnostic estimates for the widely used cut-off > 35 U/ml was also provided for the data set,
even though this cut-off was not originally assessed by the authors
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
283Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kitawaki 2005 (Continued)






Patient sampling Primary objective: to evaluate serum and peritoneal fluid glycodelin-A concentrations in women
with ovarian endometriosis
Participants: women undergoing surgery for various indications at the authors’ institution
Selection criteria: not specified
Study design: observational, two-gate design, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: endometriosis: not specified, 24/57 were on OCP; controls: indication for
surgery was benign ovarian cysts or tubal ligation, 16/42 were using OCP
Age: mean age 32.9 ± 5.6 years (endometriosis group), 38.4 ± 5.8 years (controls)
Number of participants enrolled: 99 women
Number of participants available for analysis: 99 women (57 in follicular and 42 in luteal cycle phase)
Setting: Faculty of Medicine, University of Ljubljana
Place of study: Ljubljana, Slovenia
Period of study: not stated
Language: English
Index tests Index test: glycodelin-A
Details of the index test procedure as stated: serum glycodelin level were determined by using ELISA
commercial kit (Bio-Serv Dispolab, Switzerland); sample handling described, referenced to the
source describing the laboratory technique
Threshold for positive result: > 2.07 ng/ml, not pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: ovarian endometriosis
Prevalence of target condition in the sample: n = 57/99 (58%): stage I-II, 12; stage III-IV, 45; controls
n = 42
Reference standard: surgery (type of surgery not stated) + histopathology
Description of positive case definition by reference standard test as reported: visual inspection and
histopathology, staging according to the rAFS classification
Examiners: not stated
Flow and timing Time interval between index test and reference standard: the samples were collected at surgery
Withdrawals: none
Comparative
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Key conclusions by the authors Our data show significantly increased glycodelin-A concentrations in serum and PF in women
suffering from ovarian endometriosis. Our results suggest that glycodelin-A is a potentially useful
biomarker for ovarian endometriosis, most
likely in combination with other molecules
Conflict of interest The authors report no declarations of interest; funded by the Slovenian Human Resources Devel-
opment and Scholarship and a J3-9448 grant from the Slovenian Research Agency
Notes The reported diagnostic estimated for serum glycodelin-A were adjusted for age and BMI
The reported diagnostic estimates for peritoneal glycodelin-A are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate PLA2G2AmRNA and protein levels in tissue samples (endometriomas
and normal endometrium) and in serum and peritoneal fluid of ovarian endometriosis patients and
control women
Participants: women undergoing surgery for various indications at the authors’ institution
Selection criteria: not specified
Study design: observational, two-gate design, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: endometriosis group: ovarian endometriosis; controls: women with benign
ovarian cysts and women who were undergoing tubal sterilisation; 14 patients with endometriosis
and 4 control women took NSAID or other analgesics in the last week before blood collection
Age: mean age 32.9 ± 6.2 years (endometriosis group), 39.5 ± 3.8 years (controls)
Number of participants enrolled: 116 women (68 in follicular and 43 in luteal cycle phase; for 5
women information on cycle phase was not available)
Number of participants available for analysis: 91 women
Setting: Faculty of Medicine, University of Ljubljana
Place of study: Ljubljana, Slovenia
Period of study: 2008-2011
Language: English
Index tests Index test: PLA2G2A
Details of the index test procedure as stated: serum PLA2G2A levels were determined by using com-
mercially available ELISA kits (Cat. #585000; Cayman Chemicals, PA); the limit of detection was
15 pg/ml, and the linear range was 0-1000 pg/ml; sample handling described, referenced to the
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source describing the laboratory technique
Threshold for positive result: not reported
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: ovarian endometriosis
Prevalence of target condition in the sample: n = 70/116 (60%): stages I-II 18, stage III-IV 48; not
available 4; controls n = 46
Reference standard: laparoscopy, N = 116 (100%) + histopathology
Description of positive case definition by reference standard test as reported: visual inspection and
histopathology, staging according to the rAFS classification
Examiners: not stated
Flow and timing Time interval between index test and reference standard: not specified; from the context appears that
the samples were collected at surgery
Withdrawals: In 25 women (22%) blood samples were not collected
Comparative
Key conclusions by the authors PLA2G2A is implicated in the pathophysiology of ovarian endometriosis, but that it cannot be used
as a diagnostic biomarker
Conflict of interest The authors report no declarations of interest; the study was supported by a Slovenian Human
Resource Scholarship and a J3-4135 grant from the Slovenian Research Agency
Notes The reported data for PLA2G2A in peritoneal fluid and endometrium are not presented in this
review
For PLA2G2A there was no statistically significant difference between the groups - no data available
for meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate biglycan expression at the protein level in tissue, serum and peritoneal
fluid (PF) from ovarian endometriosis patients, patients with benign ovarian cysts and healthy
women
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Participants: women undergoing surgery for various indications at the authors’ institution
Selection criteria: not specified
Study design: observational, two-gate design, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: endometriosis group: ovarian endometriosis; controls: benign ovarian cyst (n=
10) and tubal sterilisation (n=30)
Age: Reproductive age
Number of participants enrolled: 96 women
Number of participants available for analysis: 96 women (in proliferative or secretory cycle phase)
Setting: Faculty of Medicine, University of Ljubljana
Place of study: Ljubljana, Slovenia
Period of study: 2008-2011
Language: English
Index tests Index test: biglycan
Details of the index test procedure as stated: serum Biglycan level was measured by ELISA using
rabbit (Sigma-Aldrich HPA003157) and goat (R&D Systems, MN, USA) anti-biglycan polyclonal
antibodies and the recombinant biglycan protein (R&D Systems 2667-ICM-050); assay sensitivity
was 10 pg/ml with a linear detection range 10 pg/ml - 100 ng/ml; sample handling described
Threshold for positive result: not reported
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: ovarian endometriosis
Prevalence of target condition in the sample: n = 56/96 (58%): stages I-IV; controls n = 40
Reference standard: laparoscopy, n = 96 (100%) + histopathology
Description of positive case definition by reference standard test as reported: visual inspection and
histopathology
Examiners: not stated
Flow and timing Time interval between index test and reference standard: not specified; from the context appears that
the samples were collected at surgery
Withdrawals: none
Comparative
Key conclusions by the authors Biglycan appears to be involved in ovarian pathologies and probably has different roles in benign
cysts as compared to ovarian endometriomas
Conflict of interest The authors report nodeclarations of interest; the studywas supported by a SloveneHumanResource
Scholarship 2011 and a J3-4135 grant from the Slovenian Research Agency
Notes The reported data for biglycan in peritoneal fluid and endometrium are not presented in this review
For biglycan there was no statistically significant difference between the groups - no data available
for meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate clinical examination during menstruation and plasma CA-125 con-
centration to diagnose endometriosis
Participants: women scheduled for laparoscopy for suspected endometriosis
Selection criteria: exclusion criteria: hormonal treatment or medical treatment for endometriosis in
the 3 months preceding laparoscopy, refusal a clinical examination during menstruation (only DIE
considered)
Study design: cross-sectional single-gate, prospective recruitment and collection of samples, consec-
utive series
Patient characteristics and set-
ting
Clinical presentation: infertility (n = 33), pain (n = 13), infertility + pain (n = 6), hydrosalpinx (n =
1), ovarian cyst (n= 2)
Age: range 20-45 years (personal communication with the author)
Number of participants enrolled: 61 women
Number of participants available for analysis: 55 women (only DIE, endometrioma and severe pelvic
adhesions included; all in menstrual, follicular and early luteal phase of menstrual cycle)
Setting: division of endoscopic surgery, University Hospital Gasthiusberg, University of Leuven
Place of study: Leuven, Belgium
Period of study: not stated
Language: English
Index tests Index test: CA-125 in mid-follicular phase
Details of the index test procedure as stated: CA-125 assay by second generation IRMA kit (CA-125
II, Centocor, Malvern, Pa); all the samples assayed in duplicate using kits from the same production
batch
Threshold for positive result: > 35 U/ml, not pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: intra- and interassay variation < 5% and < 8%
Target condition and reference
standard(s)
Target condition: deep infiltrating endometriosis and ovarian endometrioma
Prevalence of target condition in the sample: n = 38/55 (69%): stage I-II 29, stage III-IV 9; deep
endometriosis 13, endometrioma 9, deep endometriosis + severe cul-de-sac adhesions + endometri-
oma 24; controls n = 17
Reference standard: laparoscopy N = 55 (100%)
Description of positive case definition by reference standard test as reported: visual inspection, deep
endometriosis classified as type I and type II, reference to the source with diagnostic criteria and
described; staging according to the rAFS classification
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Examiners: not stated
Flow and timing Time interval between index test and reference standard: the samples were collected up to 4 months
before surgery (personal communication with the author)
Withdrawals: in 6 women (11%) the surgery was cancelled for various reasons
Comparative
Key conclusions by the authors Clinical examination during menstruation can reliably diagnose deep infiltrating endometriosis,
cystic ovarian endometriosis or cul-de-sac adhesions. This test, preferentially combined with a
follicular phase CA-125 assay, should be used to decide whether a preparation for bowel surgery
should be given
Conflict of interest Not reported
Notes The reported diagnostic estimates for clinical examination or for a combination of clinical exami-
nation with blood test are not presented in this review
The presented diagnostic estimates are for DIE, ovarian endometrioma and severe cul-de-sac ad-
hesions; the authors also report separate diagnostic estimates for each of these conditions - not
presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
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Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to define markers that can be used in the diagnosis and follow-up of patients
with endometriosis by determining serum CA-125, transforming growth factor beta1 (TGF-β1),
interleukin 6 (IL-6), and IL-12 levels
Participants: women who underwent laparoscopy for suspected endometriosis or tubal ligation
Selection criteria: exclusion criteria: myoma uteri, dermoid cysts, ovarian cystic structures > 3 cm
other than endometrioma, pelvic inflammatory disease, any malignancy, oral contraceptives, GnRH
analogues, progestin, danazol or any other hormonal therapy
Study design: observational, two-gate design, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: dysmenorrhoea: 42/61 (endometriosis), 2/12 (controls); chronic pelvic pain:
29/61 (endometriosis), 2/12 (controls); dyspareunia: 22/61 (endometriosis); infertility: 20/61 (en-
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dometriosis), 4/12 (controls); none of the patients had taken anti-inflammatory medications or had
been diagnosed with an inflammation or infection in previous 6/12 months before the study
Age: range 18-40 years
Number of participants enrolled: 73 women
Number of participants available for analysis: 73 women (all in follicular cycle phase)
Setting: Department of Obstetrics and Gynaecology, Gazi University School of Medicine,
Place of study: Ankara, Turkey
Period of study: not reported
Language: English
Index tests Index test: CA-125, TGF-β1, IL-6, IL-12
Details of the index test procedure as stated: serumCA-125 levels weremeasured by chemiluminescence
using IMMULITE 2000 hormone analyser (Diagnostic Products Corporation, CA, USA); serum
TGF-β1, IL-6, and IL-12 levels were measured by using ELISA kits (Biosource International, USA)
; sample processing described
Threshold for positive result: not reported
Examiners: no information provided; unclear if were blinded to the results of reference standard
Interobserver variability: the intra- and interassay CV were < 10% for all assays
Target condition and reference
standard(s)
Target condition: endometriosis (peritoneal and ovarian)
Prevalence of target condition in the sample: n = 61/73 (84%): stage I-II 14, stage III-IV 47; controls
n = 12
Reference standard: laparoscopy N = 73 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection followed
by histologic examination; same protocol was used in diagnostic phase of surgery: inspection of
pelvic and peritoneal organs,
peritoneal washings and staging according to the rASRM classification
Examiners: all the procedures were performed by the same team of 2 experienced laparoscopists
Flow and timing Time interval between index test and reference standard: blood samples were drawn at surgery
Withdrawals: none
Comparative
Key conclusions by the authors TGF-β1 and IL-6 measurements might be a promising alternative in adjunct to CA-125 for the
non-invasive diagnosis of endometrioma. However CA-125, TGF-β1, IL-6 and IL-12 seem not to
have the diagnostic value in the diagnosis of early stage endometriosis. Of all the serum markers
studied, only TGF-β1 was found to be correlated with the stage of endometriosis
Conflict of interest The authors declared no conflict of interests
Notes The data for association between the biomarkers levels and type of endometriosis or clinical findings
are not presented in this review
For IL-12 there was no statistically significant difference between the groups - no data available for
meta-analysis
For CA-125, TGF-β1, IL-6 there was statistically significant difference between the groups, but
there was insufficient data to construct 2 x 2 tables - not included in this review
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to determine the serum and PF levels of VEGF in endometriosis patients and to
compare with normal subjects
Participants: women undergoing diagnostic or therapeutic laparoscopy because of suspected en-
dometriosis, pelvic pain of unknown origin, benign adnexal masses or leiomyoma uteri
Selection criteria: inclusion criteria: pre-menopausal age (18-50 years), written informed consent;
exclusion criteria: known infectious or chronic autoimmune diseases
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, infertility, pelvic mass and other not specified; hormonal therapy
during 3/12 months before surgery - 8/44 in endometriosis and 4/32 in control group
Age: mean age 33.9 ± 7.8 years (endometriosis group), 36.8 ± 7.4 years (controls)
Number of participants enrolled: 76 women
Number of participants available for analysis: 76 women (49 in follicular, 27 in luteal cycle phase)
Setting: Department of O&G, Medical University of Vienna
Place of study: Vienna, Austria
Period of study: not provided
Language: English
Index tests Index test: CK19
Details of the index test procedure as stated: serum concentrations of CK19 were measured using a
sandwich ELISA TM-Cyfra21-1 (DRG Instruments GmbH, Germany); the lower limit of quan-
tification was 1.5 ng/ml, defined as the lowest step in a dilution series of the standard where CV
was still < 30%; sample processing described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 44/76 (58%): stages not specified; controls n = 32
Reference standard: laparoscopy N = 76 (100%) + histopathology
Description of positive case definition by reference standard as reported: visual inspection and diagnosis
was proven histologically
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected during surgery
Withdrawals: none
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Comparative
Key conclusions by the authors In this study, the promising data reported in the recent literature about CK19 serving as a sufficient
biomarker for endometriosis could not be verified when tested in a larger sample size. Further studies
are warranted to explore the usefulness of CK19 in the diagnosis of endometriosis
Conflict of interest Not reported; supported by Bayer Pharma AG
Notes For CK19 there was no statistically significant difference between the groups - no data available for
meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to clarify the value of serum CA-19.9 in the clinical evaluation of endometriosis
Participants: women undergoing laparoscopy or laparotomy or various indications at the authors’
institution
Selection criteria: exclusion criteria: suggested or ascertained diagnosis of myoma uteri, adenomyosis,
pelvic inflammatory disease or malignancy, salpingitis, other benign ovarian tumour and refusal to
participate in the study
Study design: cross-sectional two-gate, prospective recruitment and collection of samples
Patient characteristics and set-
ting
Clinical presentation: indications for surgery: suspected pelvic and ovarian endometriosis, infertility,
adnexal cystic mass,
chronic pelvic pain, desire for sterilisation
Age: mean age 31.12 ± 5.97 years (endometriosis group), 33.46 ± 9.48 years (controls)
Number of participants enrolled: 179 participants
Number of participants available for analysis: 127 participants (cycle phase not specified)
Setting: Department of Obstetrics and Gynecology, Gazi University School of Medicine
Place of study: Ankara, Turkey
Period of study: January 2002 - March 2005
Language: English
Index tests Index test: CA-19.9, CA-125 in serum
Details of the index test procedure as stated: not reported
Threshold for positive result: CA-125 > 35.0 U/ml; CA-19.9 > 37.0 U/ml - pre-specified
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Examiners: not stated
Interobserver variability: not stated
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 101/127 (80%): stage I-II 26, stage III-IV 75; pelvic
endometriosis - 86, ovarian endometrioma - 15; controls n = 26
Reference standard: laparoscopy/laparotomy N = 127 (100%) + histopathology
Description of positive case definition by reference standard test as reported: visual inspection and histo-
logical examination of all excised surgical material; staging according to the rASRM classification
Examiners: not stated
Flow and timing Time interval between index test and reference standard: blood samples were collected immediately
before surgery
Withdrawals: 52 patients from control group were excluded (48 for benign ovarian mass and 4 for
salpingitis)
Comparative
Key conclusions by the authors Both CA-125 and CA-19.9 had high sensitivity with relatively low specificity in the detection of
endometriosis. However, the predictive values of CA-125 and CA-19.9 seem high only to predict
severe (stages III and IV) disease
Conflict of interest Not reported; supported by Gazi University, Unit of Scientific Research Projects, Turkey, grant
number 01/2003-42
Notes The presented data enabled calculation of the diagnostic estimates for different stages of endometrio-
sis - not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate the hypothesis of increased systemic oxidative stress in patients with
endometriosis
Participants: women of reproductive undergoing laparoscopy for unexplained infertility, pelvic pain,
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adnexal mass, or tubal ligation
Selection criteria: exclusion criteria: treatment with antioxidants or anti-inflammatory or hormonal
preparations for at least 6 months before laparoscopy; elevated CRP level or WBC or basal body
temperature > 37 C° on admission
Study design: cross-sectional two-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility, pelvic pain, adnexal mass
Age: mean 33.1 ± 6.0 years (endometriosis group) and 34.9 ± 9.2 years (controls)
Number of participants enrolled: 90 women
Number of participants available for analysis: 66 women (phase of menstrual cycle not specified)
Setting: Department of O&G, Aretaieion Hospital, University of Athens
Place of study: Athens, Greece
Period of study: January 2006 - November 2006
Language: English
Index tests Index test: oxidative stress proteins: HSP70, HSP70’, TRX, IMA
Details of the index test procedure as stated: serum levels of HSP70, HSP70’, TRX, IMA were deter-
mined in ELISA commercial kits (Hsp 70 ELISA Kit,Stressgen Bioreagents, Canada), (Hsp 70b’
ELISA Kit, Stressgen), (TRX ELISA Kit; Redox Bioscience Inc, Japan),(Albumin Cobalt Binding
test; Inverness Medical Professional Diagnostics, CO); the sensitivity of HSP70, HSP70’, TRX,
IMA assays was 0.5 ng/ml, 0.06 ng/ml, 0.25 ng/ml, 28.00 U/ml; sample handling described
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: For HSP70 and HSP70’ intra- and interassay CV < 10%; for TRX intra-
and interassay, CV was 8.3% and 12.2%; for IMA intra- and interassay, CV was 1.7% and 3.5%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 45/66 (68%), stage I-II 13, stage III-IV 32; controls
n = 21
Reference standard: laparoscopy N = 66 (100%)
Description of positive case definition by reference standard test as reported: visual inspection (a thorough
search for endometriotic foci in each patient); staging according to the rAFS classification
Examiners: all laparoscopic procedures were performed by the same surgeon, who was blinded to
the indication of laparoscopy
Flow and timing Time interval between index test and reference standard: blood sampling was performed 48 h before
surgery
Withdrawals: 24 of recruited participants were not eligible and were excluded from the study
Comparative
Key conclusions by the authors Women with endometriosis have evidence of increased systemic oxidative stress expressed by higher
levels of HSP70b’. The stage of the disease is not associated with circulating HSP70b’
Conflict of interest Not reported
Notes For HSP70, IMA, TRX there was no statistically significant difference between the groups - no data
available for meta-analysis
For HSP70b’ there was statistically significant difference between the groups, but there was insuffi-
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cient data to construct 2 x 2 tables - not included in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
No




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate associations between survivin promoter polymorphisms and the risk
of endometriosis, as well as to compare the immunoreactivity to survivin in sera of patients with
and without endometriosis
Participants: women undergoing laparoscopy for infertility, pelvic pain and suspected endometriosis
Selection criteria: not specified
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: endometriosis group - not specified; controls: infertility (n = 35) or pelvic pain
(n = 12)
Age: mean 30.9 ± 6.5 years (endometriosis group) and 30.0 ± 6.1 years (controls)
Number of participants enrolled: 196 women
Number of participants available for analysis: 145 women (phase of menstrual cycle not specified)
Setting: Department of O&G, University of Tartu
Place of study: Tartu, Estonia
Period of study: not reported
Language: English
Index tests Index test: anti-survivin antibodies
Details of the index test procedure as stated: serum anti-survivin antibodies were detectedwith a specific
ELISA kit (Uscn Life Science Inc, Wuhan, China) according to the manufacturer’s protocol
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 98/145 (68%): stage I-II 55, stage III-IV 43; controls
n = 47
Reference standard: laparoscopy N = 145 (100%) + histopathology
Description of positive case definition by reference standard test as reported: Surgically and histologically
confirmed endometriosis; staging according to the rAFS classification
Examiners: no information provided
303Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lamp 2012 (Continued)
Flow and timing Time interval between index test and reference standard: blood samples were obtained before surgery
Withdrawals: 51 of recruited participants with endometriosis were not included in anti-survivin
antibody testing, reason not explained
Comparative
Key conclusions by the authors Survivin promoter polymorphisms are not associated with susceptibility to endometriosis in the
Estonian population, and though the expression of survivin is increased in endometriotic lesions,
autoimmune reactivity against it is similar in women with and without the disease
Conflict of interest Not reported; the work was funded by the European Union Regional Development Fund and by
Enterprise Estonia,
Grant no. EU30200, by the Estonian Science Foundation (grants 6573 and 6585) and by the
Estonian Ministry of
Education and Research (core grants SF0180044s09 and SF0180035s08)
Notes For anti-survivin antibodies there was no statistically significant difference between the groups - no
data available for meta-analysis
The data for survivin promoter region polymorphisms are not included in this review
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
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Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate CA-125 in serum and peritoneal fluid of women with various stages
of endometriosis and in the control subjects
Participants: women undergoing laparoscopy for infertility or pelvic pain during luteal phase of the
cycle
Selection criteria: exclusion criteria: peritoneal fluid positive for mycoplasma and chlamydia
Study design: longitudinal single-gate, prospective recruitment and collection of samples, consecutive
series
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, infertility or both
Age: mean age 30 ± 6.5 years, range 19-44 years (endometriosis group), 30 ± 6.9 years, range 19-41
years (controls)
Number of participants enrolled: 270 participants
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Number of participants available for analysis: 119 participants (all in luteal cycle phase)
Setting: Department of O&G, Universita Catolica del Sacro Cuore
Place of study: Rome, Italy
Period of study: January 1987 - December 1988
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serum CA-125 levels measured with radioimmunoassay
(CIS Diagnostici); all samples from the same patient were assayed at the same time
Threshold for positive result: CA-125 > 35.0 U/ml - pre-specified
Examiners: not stated
Interobserver variability: the inter- and intra-assay CV were 8% and 15%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 81/270 (30%): stage I-II 31, stage III-IV 50; controls
n = 38
Reference standard: laparoscopy N = 270 (100%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to the rAFS classification
Examiners: not stated
Flow and timing Time interval between index test and reference standard: blood samples were collected immediately
before surgery
Withdrawals: 151 participants were excluded (reason not explained)
Comparative
Key conclusions by the authors The measurement of serumCA-125 does not appear to be useful for the diagnosis and management
of endometriosis.Therefore, at present, laparoscopy should be considered the most specific and
sensitive method of detecting and following the disease
Conflict of interest Not reported
Notes The reported estimates for peritoneal fluid and the estimates following medical treatment for en-
dometriosis are not presented in this review
The reported diagnostic estimates per stages of severity of endometriosis are not presented in this
review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to investigate the function of T-lymphocyte subsets in patients with endometriosis
Participants: women with endometriosis confirmed by laparoscopy and a group of women who
underwent tubal ligation or anastomosis with a normal pelvis at laparoscopy
Selection criteria: exclusion criteria: autoimmune diseases, allergic diseases and acute inflammation,
no steroid treatment 3 months prior to surgery
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: mean age 35 ± 7 years (endometriosis group), 38 ± 4 years (controls)
Number of participants enrolled: 50 participants (10women with fibroid uterus in whom endometrial
samples were assessed comprised separate control group and were not included in this review)
Number of participants available for analysis: 50 participants (cycle phase not reported)
Setting: Department of O&G, Qingdao Eighth People’s Hospital
Place of study: Qingdao, China
Period of study: September 2001 - September 2002
Language: Chinese
Index tests Index test: IL-2 and IL-6
Details of the index test procedure as stated: serum IL-2 and IL-6 were measured with ELISA kits
(LIFEFEY BioMeditech Corporation USA), working assay range or minimal detection limit are not
included in the paper; sample handling described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: no information provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 30/50 (60%): stage I-II 9, stage III-IV 21; controls
n = 20
Reference standard: laparoscopy N = 50 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histopathology; staging according to the rASRM classification
Examiners: no information provided




Key conclusions by the authors The levels of IL-6 in the serum and peritoneal fluid of patients with endometriosis are increased,
implying that IL-6 might play a role in the pathophysiology of endometriosis. The ratio of IL-2/IL-
6 in the serum and peritoneal fluid was decreased in patients with endometriosis compared with the
control group, suggesting shift of Th1 cell toward Th2 cell in patients with endometriosis. Stronger
expression of IL-2 and IL-6 in the ectopic endometrial tissues may contribute to the disturbed
immune regulation in patients with endometriosis
Conflict of interest Not reported
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Notes The data for markers measured in peritoneal fluid and endometrium are not reported in this review
For IL-2 there was no statistically significant difference between the groups - no data available for
meta-analysis
The levels of IL-6 were statistically significantly higher in endometriosis, but there were no data to
construct 2 x 2 tables - not included in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to determine FSH, LH, E2, progesterone, and Hi concentrations in serum, PF
and FF of women with and without endometriosis
Participants: women undergoing laparoscopy for infertility and/or pelvic pain (cases) and tubal
sterilisation (controls)
Selection criteria: inclusion criteria: secretory cycle phase, no medical treatment for at least three
months preceding surgery, absence of other gynaecological diseases, absence of pelvic pain, age
between 18 and 40 years
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, infertility (cases); asymptomatic fertile women requesting sterili-
sation (controls)
Age: mean age 33.9 ± 7.8 years (endometriosis group), 36.8 ± 7.4 years (controls)
Number of participants enrolled: 49 women
Number of participants available for analysis: 49 women (all in luteal cycle phase)
Setting: Department of O&G, Hospital das Clinicas, Faculty of Medicine of Ribeirão Preto, Uni-
versity of São Paulo
Place of study: São Paulo, Brazil
Period of study: 2002-2004
Language: Portuguese
Index tests Index test: FSH , LH, E2, progesterone
Details of the index test procedure as stated: serum concentrations of FSH, LH, E2 and progesterone
were measured using a commercial kit (DPC Imm Sys, California) by chemiluminescence; sample
processing described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: Intra- and interassay CV were for FSH 7.9% and 6.5%, for LH 8.8% and
11.3%, for E2 8.4% and 9.3%, for P 5.8% and 10.3%
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Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 28/49 (57%): stage I-II 18, stage III-IV 10; controls
n = 21
Reference standard: laparoscopy n = 49 (100%)
Description of positive case definition by reference standard as reported: visual inspection; staging ac-
cording to the rASRM classification
Examiners: no information provided




Key conclusions by the authors Ovary dysfunction in women with endometriosis, with reduction on E, P and Hi concentrations,
which may contribute to the subfertility often associated with the disease
Conflict of interest Not reported
Notes For LH and FSH there was no statistically significant difference between the groups - no data
available for meta-analysis
For E2 and progesterone there was statistically significant difference between the groups, but there
was insufficient data to construct 2 x 2 tables - not included in this review
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the role of interleukin-16 (IL-16) in the pathogenesis of endometrio-
sis
Participants: women with suspected endometriosis who underwent laparoscopy
Selection criteria: exclusion criteria: autoimmune diseases, no steroid treatment or immunosuppres-
sant treatment 6 months prior to surgery
Study design: cross-sectional, single-gate design, prospective collection of samples
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Patient characteristics and set-
ting
Clinical presentation: not specified
Age: mean age 37 ± 10.3 years (endometriosis group), 36.8 ± 12.1 years (controls)
Number of participants enrolled: 44 participants
Number of participants available for analysis: 44 participants (cycle phase not reported)
Setting: Department of O&G, College of Medicine, Zhejiang University
Place of study: Hangzhou, China
Period of study: September 2001 - June 2002
Language: Chinese
Index tests Index test: IL-16
Details of the index test procedure as stated: serum IL-16 was measured with enzyme-linked im-
munosorbent assay (ELISA) (human IL-16 BMS 248, Bender Medsystems, Vienna, Austria); no
working ranges were reported; sample handling described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: CV < 10%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 22/44 (50%): stage I-II 8, stage III-IV 14; controls
n = 22
Reference standard: laparoscopy/laparotomy N = 44 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histopathology; staging according to the rASRM classification
Examiners: no information provided




Key conclusions by the authors Reduced levels of IL-16 in peritoneal fluid and serum of women with advanced stage endometriosis
may imply a role of IL-16 in the development and progression of endometriosis
Conflict of interest Not reported
Notes The data for markers measured in peritoneal fluid are not reported in this review
For IL-16 there was no statistically significant difference between the groups - no data available for
meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Patient sampling Primary objective: to establish the diagnostic model for endometriosis by screening the plasma
biomarkers of endometriosis using surface enhanced laser desorption/ionisation time of flight mass
spectrometry (SELDI-TOF-MS) coupled with bioinformatic
Participants: women undergoing laparoscopy for infertility, pelvic pain or benign ovarian mass
Selection criteria: not reported
Study design: cross-sectional, single-gate, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, infertility or adnexal mass
Age: mean age 33.6 ±4.7 years (training set), 34.2 ± 3.6 years (test set) (endometriosis group); 32.5
± 3.2 years (training set), 33.0 ± 2.8 years (test set) (controls)
Number of participants enrolled: 102 participants (71 women - training set; 31 women - test set)
Number of participants available for analysis: 102 participants (cycle phase not reported)
Setting: Department of O&G, Peking Union Medical Colledge Hospital
Place of study: Beijing, China
Period of study: January 2007 - October 2007
Language: Chinese
Index tests Index test: proteome by SELDI-TOF-MS (3 protein peaks with the molecular weight of 3,956.00
Da, 11,710.00 Da and 6,986.00 Da)
Details of the index test procedure as stated: surface-enhanced laser desorption/ionisation coupled to
time-of-flight mass spectrometry (detection analysis of protein chips was done with ProteinChip
Biotechnology System mass spectrometer (PBS-II, Ciphergen Co, America); bioinformatic analysis
by using ProteinChip Software 3.1.1 and Biomarker Pattern Software; CART model for training
set (70%) with double blind validation on test set (30%); sample handling and procedure described
in details
Threshold for positive result: presence of specific protein peaks intensities, not pre-specified
Examiners: not stated, blinded to the clinical outcomes
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 52/102 (51%): stage I-II 23, stage III-IV 29; controls
n = 50
Reference standard: laparoscopy N = 102 (100%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to rAFS classification
Examiners: not stated
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none reported
Comparative
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Key conclusions by the authors SELDI-TOF-MS is a newapproach for screeningmarkers of endometriosis. Its clinical value deserves
further investigation
Conflict of interest Not reported
Notes The diagnostic estimates for the validation test set are reported in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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of the results of the index tests?
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the univariable and multivariable performances of the mRNA levels
of MMP-3, MMP-9, VEGF and survivin in peripheral blood and the serum levels of CA-125, CA-
19.9 to diagnose or exclude the endometriosis and to differentiate between deep infiltrating and
ovarian endometriosis
Participants: women of reproductive age undergoing laparoscopy for suspected endometriosis or
non-malignant conditions (myoma, tubal ligation, and ovarian biopsy)
Selection criteria: exclusion criteria: suspected or ascertained diagnosis of systemic pathologies (ma-
lignancies, autoimmune diseases, liver diseases) or pregnancy
Study design: cross-sectional two-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: range 26-40 years
Number of participants enrolled: 60 women
Number of participants available for analysis: 60 women (all in the follicular phase of the menstrual
cycle)
Setting: theMinimally InvasiveGynecological SurgeryUnit, S.Orsola-MalpighiHospital,University
of Bologna
Place of study: Bologna, Italy
Period of study: February 2007 - May 2008
Language: English
Index tests Index test: MMP-3 mRNA, MMP-9 mRNA, VEGF mRNA, survivin mRNA, CA-125, CA19-9
Details of the index test procedure as stated: detection of serum CA-125 and CA-19.9 was performed
using a commercially available chemiluminescent immunometric assay (Roche Diagnostics GmbH,
Germany) by using the Elecsys Analyzer; sensitivity for both assays was 0.6 IU/ml. All other biomark-
ers in peripheral blood were detected by qRT-PCR with gene-specific primers on the ABI PRISM
7900 Sequence Detection System (PE Applied Biosystems); laboratory techniques and sample pro-
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cessing described in details
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 40/60 (67%) (DIE and ovarian endometrioma);
controls n = 20
Reference standard: laparoscopy N = 60 (100%)
Description of positive case definition by reference standard test as reported: diagnosis of endometriosis
was surgical and histological
Examiners: no information provided




Key conclusions by the authors A combination of serum and molecular markers could allow a better diagnosis of endometriosis
Conflict of interest The authors declare that they have no conflict of interest
Notes For VEGF and MMP9 there was no difference between the groups - no data available for meta-
analysis
ForMMP3 there was statistically significant difference between the groups, but there was insufficient
data to construct 2 x 2 tables - not included in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate host immunologic response to endometriosis in terms of intercellular
adhesion molecule (ICAM)-1 expression by macrophages and killer cell inhibitory receptor (KIR)
expression by natural killer (NK) cells
Participants: women undergoing laparoscopy for various indications
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Selection criteria: exclusion criteria: history of pregnancy or history of treatment with GnRH ana-
logues within 3 years, complications from apparent pelvic inflammatory disease
Study design: cross-sectional, two-gate, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: endometriosis group - not specified; controls: benign ovarian cysts - 12, uterine
myoma - 7, infertility - 4, paraovarian cysts - 2, carcinoma in situ of uterine cervix - 1
Age: mean age 32.8 ± 7.5 years (endometriosis group), 35.0 ± 8.9 years (controls)
Number of participants enrolled: 54 participants
Number of participants available for analysis: 54 participants (all in early follicular cycle phase)
Setting: Department of O&G, Kochi Medical School
Place of study: Kochi, Japan
Period of study: April 1999 - August 2000
Language: English
Index tests Index test: PBMC (CD3, CD4, CD8, CD19, CD16, CD14), ICAM-1, KIR2DL1+NK, KIR2DL2
+NK
Details of the index test procedure as stated:peripheral blood mononuclear cells were measured by flow
cytometry using specific mononuclear antibodies (FITC-labelled anti-CD3, anti-CD4 mAb and
PE-labelled anti-CD8 mAb as T cell markers, PE-labelled anti-CD19 mAb as B cell marker, FITC-
labeled anti-CD16 mAb as NK cell and FITC-labelled anti-CD14 mAb as monocyte/macrophage
marker, PE-labeled anti-CD54 (ICAM-1) mAb as marker for monocyte/macrophage activation,
and PE-labelled anti-CD158a, anti-CD158b, and CD94 as markers for KIRs (all from Beckman-
Coulter, Fullerton, CA); laboratory technique described
Threshold for positive result: not reported
Examiners: not information provided, unclear if were blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 28/54 (52%): stage I-II 11, stage III-IV 17; controls
n = 26
Reference standard: laparoscopy, N = 54 (100%)
Description of positive case definition by reference standard test as reported: staging according to rAFS
classification
Examiners: not stated
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none reported
Comparative
Key conclusions by the authors Properties of macrophages and NK cells in women with endometriosis promote immunotolerance
to implanted tissue in the peritoneal environment. Increased KIR(+)NK cells in peripheral blood
may represent a risk factor for endometriosis
Conflict of interest Not reported
Notes For PBMC (CD3,CD4,CD8, CD19,CD16,CD14) there was no statistically significant difference
between the groups - no data available for meta-analysis
For KIR2DL2+NK the data reported in larger overlapping study (Maeda 2002b)
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For ICAM-1 and KIR2DL1+NK there was statistically significant difference between the groups,
but there was insufficient data to construct 2 x 2 tables - not included in this review
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the host immunologic response to endometriosis in terms of killer
inhibitory receptor (KIR) expression by natural killer (NK) cells
Participants: women undergoing laparoscopy for various indications
Selection criteria: exclusion criteria: history of pregnancy or history of treatment with GnRH ana-
logues within 3 years, complications from apparent pelvic inflammatory disease
Study design: cross-sectional, two-gate, p
rospective sample collection
Patient characteristics and set-
ting
Clinical presentation: endometriosis group - not specified; controls: benign ovarian cysts - 15, uterine
myoma - 14, infertility - 7, paraovarian cysts - 2, carcinoma in situ of uterine cervix - 2
Age: mean age 32.0 ± 7.2 years (endometriosis group), 35.0 ± 9.2 years (controls)
Number of participants enrolled: 82 participants
Number of participants available for analysis: 82 participants (cycle phase not reported)
Setting: Department of O&G, Kochi Medical School
Place of study: Kochi, Japan
Period of study: April 1999 - January 2001
Language: English
Index tests Index test: KIR2DL1+NK, KIR2DL2+NK, CD94+NK cells
Details of the index test procedure as stated: NK cells were measured by flow cytometry using specific
mononuclear antibodies (FITC-labeled anti-CD16 mAb as NK cell, PE-labelled anti-CD158a and
anti-CD158b as markers for KIR subfamilies KIR2DL1 and KIR2DL2 expressed on NK cells
and CD94 as lectin-like receptor marker on NK cells (all from Beckman-Coulter, Fullerton, CA);
laboratory technique described
Threshold for positive result: not reported
Examiners: not information provided, unclear if were blinded to the result of reference standard
Interobserver variability: not reported
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Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 42/82 (51%): stage I-II 12, stage III-IV 30; controls
n = 40
Reference standard: laparoscopy, N = 82 (100%)
Description of positive case definition by reference standard test as reported: staging according to rAFS
classification
Examiners: not stated
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none reported
Comparative
Key conclusions by the authors The proportion of KIR2DL1(+)NK cells was increased in peritoneal fluid and peripheral blood
in women with endometriosis; this difference is probably related to NK cell suppression in en-
dometriosis. This increase in KIR2DL1 expression by NK cells may represent a risk factor in the
pathogenesis of endometriosis
Conflict of interest Not reported
Notes For KIR2DL2+NK and CD94+NK there was no statistically significant difference between the
groups - no data available for meta-analysis
For KIR2DL1+NK there was statistically significant difference between the groups, but there was
insufficient data to construct 2 x 2 tables - not included in this review
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Unclear






Patient sampling Primary objective: to evaluate if serum CA-125 levels correlate with rAFS and whether serum CA-
125 measurement should be performed in the routine work-up of dysmenorrhoea and dyspareunia
Participants: women who underwent laparoscopy for infertility, ovarian cyst or suspected en-
dometriosis (endometriosis group) and women operated for ovarian cysts and confirmed not to have
endometriosis (controls)
Selection criteria: exclusion criteria: patients with malignant tumours or inflammatory disease
Study design: cross-sectional two-gate, prospective collection of samples
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Patient characteristics and set-
ting
Clinical presentation: In endometriosis group: dysmenorrhoea - 52%, dyspareunia - 26%, asymp-
tomatic - 22%; controls - ovarian cysts
Age: mean age 33.6 ± 7.3 years, range 21-54 years
Number of participants enrolled: 86 women
Number of participants available for analysis: 86 women (in follicular phase of menstrual cycle)
Setting: obstetrics and gynaecology units, Civic Hospital
Place of study: Paleromo, Italy
Period of study: not stated
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serum CA-125 levels were measured by enzyme im-
munoassay and were expressed in arbitrary units based on a primary reference standard; no other
information provided
Threshold for positive result: > 35 U/ml, pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 69/86 (79%): stage I-II 14, stage III-IV 55; controls
n = 17
Reference standard: laparoscopy N = 86 (100%)
Description of positive case definition by reference standard test as reported: surgical diagnosis, rASRM
classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: not specified, but statement ’preoperative
blood sample’ implies short time before surgery
Withdrawals: none
Comparative
Key conclusions by the authors CA-125 levels are related to endometriosis and rAFS score in the evaluated patient series; no corre-
lation was found between CA-125 and pelvic pain with endometriosis
Conflict of interest Not reported
Notes The presented diagnostic estimates according to severity of endometriosis are not included in this
review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
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Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Patient sampling Primary objective: to analyse PF and peripheral blood for concentration of both RANTES and TNF-
α in a group of women with and without endometriosis
Participants: patients undergoing routine gynaecological treatment in hospital for non-malignant
conditions
Selection criteria: not specified
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: reproductive age (personal communication with the authors)
Number of participants enrolled: 32 women
Number of participants available for analysis: 32 women (cycle phase not specified)
Setting: Department of O&G, Queen Elizabeth II Research Institute for Mothers and Infants,
University of Sydney
Place of study: Sydney, Australia
Period of study: not specified
Language: English
Index tests Index test: RANTES, TNF-α
Details of the index test procedure as stated: serum concentrations of RANTES were measured using a
commercial sandwich ELISA (R&D Systems, USA) with assay sensitivity 2.5 pg/ml; TNF-α levels
were measured by “in house amplified ELISA sandwich” assay with sensitivity of 1.0 pg/ml; sample
processing described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: Inter- and intra-assay CV for RANTES < 6%, for TNF-α < 9%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 23/32 (72%): stage I-II 11, stage III-IV 12; controls
n = 9
Reference standard: laparoscopy N = 32 (100%)
Description of positive case definition by reference standard as reported: staging according to the rAFS
score
Examiners: no information provided




Key conclusions by the authors We found that RANTES concentrations in blood or peritoneal fluid are unlikely to be helpful as a
potential marker for endometriosis
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Conflict of interest Not reported
Notes For RANTES there was no statistically significant difference between the groups - no data available
for meta-analysis
For TNF-α there was statistically significant difference between the groups, but there was insufficient
data to construct 2 x 2 tables - not included in this review
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate whether serum IL-6 levels could serve as a marker of the early stages
of endometriosis and to determine the value of CA-125 as a diagnostic marker
Participants: women undergoing laparoscopy for various indications at the authors’ institution
Selection criteria: inclusion criteria: reproductive age and regular menstrual cycles; exclusion criteria:
administration of any medication over the previous 2 years, acute inflammatory diseases or neo-
plasms, 2 or more concomitant findings at laparoscopy
Study design: cross-sectional two-gate, prospective recruitment and collection of samples
Patient characteristics and set-
ting
Clinical presentation: indications for laparoscopy were pelvic pain (n = 5), infertility (n = 11), tubal
sterilisation
(n = 37),myomas (n = 16), suspicion of endometrioma (n = 33) and other benign ovarian pathologies
(n = 26)
Age: reproductive age
Number of participants enrolled: 128 women
Number of participants available for analysis: 119 women (all in follicular cycle phase)
Setting: Department of O&G, Hospital Universitario Dr Peset
Place of study: Valencia, Spain
Period of study: February 2003 - February 2005
Language: English
Index tests Index test: CA-125 and IL-6
Details of the index test procedure as stated: serum CA-125 levels were measured by enzyme im-
munoassay and were expressed in arbitrary units based on a primary reference standard; no other in-
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formation provided. Serum IL-6 measured by immunoassay (Quantikine, R&D Systems Inc, MN,
USA), minimum detectable value of 0.7 pg/ml. Serum CA-125 level performed using a commer-
cially available chemiluminescent microparticle immunoassay (ARCHITECT CA-125 II Abbott
Diagnositics, Spain) with assay sensitivity of < 1.0 IU/ml
Threshold for positive result: IL-6 > 25.75 pg/ml U/ml, CA-125 > 35 IU/ml - not pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: Inter- and intra-assay CV for IL-6 6.4 and 4.2%, for CA-125 ≤ 10%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 47/119 (40%): stage I-II 11, stage III-IV 36; controls
n = 72
Reference standard: laparoscopy N = 119 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples collected up to 3 months
before surgery
Withdrawals: 9 women were excluded before the analysis as did not meet inclusion criteria (4 refused
surgery, 2 had adhesions related to PID, 3 had fibroid uterus + endometriosis)
Comparative
Key conclusions by the authors Serum IL-6 is a reliable, non-invasive marker of minimal and mild endometriosis. Combined with
clinical data, this will allow doctors to detect which women are at risk of having early stages of the
disease
Conflict of interest Not reported
Notes The diagnostic estimates for IL-6 were reported only for minimal-mild endometriosis and for CA-
125 reported only for moderate-severe endometriosis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes
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DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to investigate the soluble levels of the angiogenic factors VEGF, EGF-R, GM-CSF,
IGF-1, IFN-γ in women with and without endometriosis and to investigate whether administration
of danazol and leuprorelin depot to patients with endometriosis regulates their expression
Participants: women selected from a cohort of 387 women undergoing laparoscopy at the authors’
institution
Selection criteria: inclusion criteria: pre-menopausal, not-pregnant
Study design: longitudinal, single-gate, prospective collection of samples, selected group from larger
cohort
Patient characteristics and set-
ting
Clinical presentation: indications for surgery - infertility and suspected endometriosis; infertility
work-up (ovulation, cervical mucus, tubal patency and semen analysis) were normal in all women
Age: mean 28.2 ± 5.6 years (endometriosis group) and 29.3 ± 5.8 years (controls)
Number of participants enrolled: 48 women
Number of participants available for analysis: 48 women (phase of menstrual cycle not specified)
Setting: Department of O&G, the University Hospital of Crete
Place of study: Crete, Greece
Period of study: 1991-1999
Language: English
Index tests Index test: angiogenic factors VEGF, EGF-R, GM-CSF, IGF-1, IFN-γ
Details of the index test procedure as stated: serum levels of GM-CSF and IFN-γ were measured
with commercial kits (Endogen, MA); by using using ELISA method as specified by the suppliers
at test and reference wavelengths of 450 and 550 nm, respectively. Serum levels of IGF-1, VEGF,
EGF-R were measured with the affinity-purified goat polyclonal IGF-1 (G-17, sc-1422, Santa Cruz
Biotechnology, CA) and the mouse monoclonals for VEGF (Ab-3; JH121, NeoMarkers, CA) and
EGFR (Ab-4; clone F4, NeoMarkers, CA); sample handling and laboratory technique described
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 28/48 (58%): stage I-II 17, stage III-IV 11; controls
- 20
Reference standard: laparoscopy N = 48 (100%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to the rAFS system
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were taken before laparoscopy
Withdrawals: 24 of recruited participants were not eligible and were excluded from the study
Comparative
Key conclusions by the authors EGF-R, GM-CSF, IFN-γ and IGF-1 are being released at high rates in both healthy and endometri-
otic subjects indicating that they do not actively participate in the disease but not excluding, how-
ever, other regulatory roles. VEGF may be associated with the disease process
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Conflict of interest Not reported
Notes For EGF-R, GM-CSF, IGF-1 and IFN-γ there was no statistically significant difference between
the groups - no data available for meta-analysis
For VEGF there was statistically significant difference between the groups, but there were insufficient
data to construct 2 x 2 tables - not included in this review
The reported data for the biomarkers following medical treatment are not included in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the effects of danazol and leuprorelin acetate on CA-125 levels
during treatment for endometriosis
Participants: women who underwent laparoscopy for pelvic pain, infertility or both
Selection criteria: not specified
Study design: longitudinal, single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, infertility or both
Age: mean 28.6 ± 5.2 years (endometriosis group) and 29.4 ± 5.3 years (controls)
Number of participants enrolled: 100 women
Number of participants available for analysis: 100 women (phase of menstrual cycle not specified)
Setting: Department of O&G, the University Hospital of Crete
Place of study: Crete, Greece
Period of study: 1991-1999
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serum levels of CA-125 weremeasured by radioimmunoas-
say with commercial kits (CIS Biointernational, France); kit sensitivity was 1.0 U/ml; sample han-
dling and laboratory technique described
Threshold for positive result: > 33 U/ml, not pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: the intra- and interassay CV were 4.9% and 5.9%
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Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 50/100 (50%): stage I-II 29, stage III-IV 21; controls
- 50
Reference standard: laparoscopy n = 100 (100%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to the rAFS system
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were taken before laparoscopy
Withdrawals: none reported
Comparative
Key conclusions by the authors Danazol and leuprorelin acetate are equally effective in the treatment of endometriosis. Moreover,
the results support the view that the determination of CA-125 levelsmay assist in evaluating progress
of endometriosis treatment
Conflict of interest Not reported
Notes The reported data for the biomarkers following medical treatment are not included in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
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Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate inhibitory and activation motif expression of killer immunoglob-
ulin-like receptor (KIR) by natural killer (NK) cells, which may be pathogenetically involved in
endometriosis
Participants: women undergoing laparoscopy for various indications
Selection criteria: exclusion criteria: history of pregnancy or history of treatment with GnRH ana-
logues within previous year, complications from apparent pelvic inflammatory disease
Study design: cross-sectional, two-gate, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: infertility; all women had regular ovulatory menstrual cycles
Age: mean age 30.6 years, range 26-35 years
Number of participants enrolled: 119 participants
Number of participants available for analysis: 119/74 participants (in follicular or luteal cycle phase)
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, different number of samples for different tests
Setting: National research centre of mother and child health, Ministry of Health
Place of study: Moscow, Russia
Period of study: not reported
Language: Russian
Index tests Index test: PBMC (CD3, CD4, CD8, CD2), IgA, IgM, IgG
Details of the index test procedure as stated: PBMC were measured by flow cytometry using FACScan
(Becton Dickinson, USA); serum immunoglobulins were determined by using Manchini method;
laboratory technique described
Threshold for positive result: not reported
Examiners: no information provided, unclear if were blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 62/119 (52%): all stage I-II; controls n = 57
Reference standard: laparoscopy, n= 119 (100%)
Description of positive case definition by reference standard test as reported: staging according to rAFS
classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: data were not reported for up to 45 participants for some of the index tests, reason
not explained
Comparative
Key conclusions by the authors The tested cells did notmarkedly differ from those in control fertile patients. Serumconcentrations of
immunoglobulin Mwere increased in women with endometriosis. Immunoglobulin concentrations
widely varied in the peritoneal fluid, with a statistically significant elevation of IgA and IgM in
women with tubal-peritoneal infertility
Conflict of interest Not reported
Notes For PBMC (CD3, CD4, CD8, CD2), IgA and IgG there was no statistically significant difference
between the groups - no data available for meta-analysis
For IgM there was statistically significant difference between the groups, but there were insufficient
data to construct 2 x 2 tables - not included in this review
The data for markers measured in peritoneal fluid are not presented in this review
The data for a group of healthy women (n = 10) who did not have laparoscopy are not presented in
this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Matveeva 1990 (Continued)
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
338Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Matveeva 1990 (Continued)






Patient sampling Primary objective: to assess immunological variables, T-cell apoptosis and oxidative stress markers
in the peripheral blood and peritoneal fluid of women with and without endometriosis
Participants: women undergoing laparoscopy for infertility or for tubal ligation
Selection criteria: exclusion criteria: PID, autoimmune disease, endocrine metabolic disease; use of
antioxidant medication in the last year, mononuclear peritoneal cell viability < 80% and a final
reconstituted peritoneal cell
number < 2 x 106 cells/ml
Study design: cross-sectional, two-gate, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: endometriosis group - infertility, had never received any hormonal treatment;
controls: healthy women requesting tubal ligation, had not taken contraceptive hormones in the
last 3/12 months
Age: mean age 32.7 ± 2.5 years (endometriosis group), 33.8 ± 5.4 years (controls)
Number of participants enrolled: 62 participants
Number of participants available for analysis: 62 participants (all in peri-ovulatory cycle phase)
Setting: National Institute of Perinatology
Place of study: Mexico City, Mexico
Period of study: not reported
Language: English
Index tests Index test: intracellular cytokines (CD4+/IFN-γ , CD4+/IL-2, CD8+/IFN-γ , CD8+/IL-2), apop-
totic cells, and oxidant markers (malondialdehyde and ascorbic acid)
Details of the index test procedure as stated: lymphocyte subsets were measured by flow cytometry;
degree of apoptosis in T lymphocytes was analysed using a FACS Calibur instrument (BD Bio-
sciences, San Jose, CA, USA) equipped
with CellQuest 3.3 software; concentrations of thiobarbituric acid reactive substances were deter-
mined according to the method developed by Ohkawa et al; cytokines were measured by using Bio-
Plex human cytokine assay (Bio-Plex, Hercules, USA); sample handling and laboratory technique
described in details
Threshold for positive result: not reported
Examiners: not information provided, unclear if were blinded to the result of reference standard
Interobserver variability: Intra- and interassays CV for malondialdehyde were 3.5% and 7.5%, for
ascorbic acid were 5.0% and 8.0%, for cytokines were 2.0%-7.0% and 3.5%-12.0%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 32/62 (52%): all stage I-II; controls n = 30
Reference standard: laparoscopy, N= 62 (100%)
Description of positive case definition by reference standard test as reported: staging according to rASRM
classification
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Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none reported
Comparative
Key conclusions by the authors The alterations observed in women with endometriosis were associated with a diminished peritoneal
T helper type 1 immune response. Pro-inflammatory, chemotactic, angiogenic and oxidative stress
markers were altered in the peritoneal milieu of women with endometriosis
Conflict of interest Not reported; the workwas supported byConsejoNacional deCiencia y Tecnología: Grant SALUD-
2002-C-01-7615/A-1
Notes For intracellular cytokines (CD4+/IL-2, CD8+/IFN-γ , CD8+/IL-2), apoptotic cells, and oxidant
markers (malondialdehyde and ascorbic acid) there was no statistically significant difference between
the groups - no data available for meta-analysis
For CD4+/IFN-γ there was statistically significant difference between the groups, but there was
insufficient data to construct 2 x 2 tables - not included in this review
For lymphocyte subsets (CD3, CD19, CD4, CD8, CD16+56) there was no statistically significant
difference between the groups, but there was insufficient data to confirm negative findings - not
included in this review
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate the combined performance of 6 potential plasma biomarkers in the
diagnosis of endometriosis
Participants: women who underwent laparoscopy for subfertility with or without pain at the authors’
institution - identified through electronic database of the bio bank samples
Selection criteria: exclusion criteria: samples collected from women who were on hormonal medica-
tion or had other pelvic inflammatory disease or general diseases at the time of collection, surgery
within 6 months prior to the time of collection
Study design: cross-sectional single-gate, prospective collection of samples, retrospective selection of
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cases
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, infertility or both
Age: reproductive age
Number of participants enrolled: 294 women
Number of participants available for analysis: 294 women (59 in menstrual, 119 in follicular, 116 in
luteal cycle phase)
Setting: Department of O&G, University Hospital Gasthuisberg
Place of study: Leuven, Belgium
Period of study: not specified; samples collected since 1999
Language: English
Index tests Index test: IL-6, IL-8, TNF-α, hsCRP, CA-125, CA-19.9
Details of the index test procedure as stated: plasma concentrations of IL-6, IL-8 and TNF-α were
determined by
using commercially available ELISA kits (BD Biosciences, Erembodegem,Belgium) according to
the manufacturer’s instructions. Plasma concentrations of CA-125, CA-19.9 and hsCRP levels
were measured by automated assays on a Roche Modular P or Modular E170 instruments (Roche,
Vilvoorde, Belgium) at the central laboratories of the university
Hospitals Leuven (Gasthuisberg, Leuven). The predictive model was built by using a multivariate
analysis (stepwise logistic regression with and without LSSVM analysis
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 201/294 (68%): stage I-II 132, stage III-IV 69;
controls n = 93
Reference standard: laparoscopy n = 294 (100%) + histopathology
Description of positive case definition by reference standard test as reported: visual inspection with
histological confirmation for most of the samples; rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples collected before anaesthesia
Withdrawals: none
Comparative
Key conclusions by the authors Advanced statistical analysis of a panel of 6 selected plasma biomarkers on samples obtained during
the secretory
phase or during menstruation allows the diagnosis of both minimal-mild and moderate-severe
endometriosis with high sensitivity and clinically acceptable specificity
Conflict of interest Not reported; supported by a TBM (Toegepast Biomedisch Onderzoek met Primair Maatschap-
pelijke Finaliteit) grant from the Institute for Innovative Science and Technology IWT (Innovatie
door Wetenschap en technologie) in Flanders, Belgium
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Notes The reported diagnostic estimates according to severity of endometriosis are not presented in this
review
The diagnostic estimates for each individual marker were reported only for luteal cycle phase and
were the result of univariate logistic regression model
The diagnostic estimates for the combination of biomarkers were reported for the overall group and
for each cycle phase and were the results of multivariate logistic regression and LS-SVM models
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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of the results of the index tests?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate the role of serum level of VEGF-A in comparison to CA-125 in the
diagnosis and detection of recurrence of patients, with advanced endometriosis after conservative
laparoscopic surgery
Participants: women referred for laparoscopy for unexplained primary infertility, chronic pelvic pain
or both
Selection criteria: inclusion criteria: regularmenses, follicular cycle phase; only patientswith advanced
disease selected; exclusion criteria: hormonal treatment for 3 months prior to surgery, history of
ovarian cancer, ovarian failure, pelvic inflammatory disease or other gynaecological pathologies,
previous pelvic surgery, obesity, smokers
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: endometriosis group: chronic pelvic pain - 30 women, dysmenorrhoea - 26
women, history of PID - 7 women; controls: chronic pelvic pain - 2 women, dysmenorrhoea - 9
women, history of PID - 5 women
Age: range 18-40 years
Number of participants enrolled: 60 women
Number of participants available for analysis: 60 women (all in in follicular phase of menstrual cycle)
Setting: Cytogenetic and Endoscopy Unit, Department O&G, Zagazig University Hospital
Place of study: Zagazig, Egypt
Period of study: April 2008 - August 2010
Language: English
Index tests Index test: CA-125 and VEGF-A
Details of the index test procedure as stated: serumVEGFwas measured byHuman VEGFQuantikine
ELISA Kit (DVE00, R&D Systems, Minneapolis, MN) and CA-125 was measured by ELISA kit
for Can-Ag CA-125 (Fujirebio Diagnostics, Inc, Goteborg, Sweden) according to manufacturer
instructions (expected value 5.06-47.9 U/ml)
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Threshold for positive result: CA-125 > 35 µg/ml, VEGF-A > 680 pg/ml; not pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 30/60 (50%), all stage III-IV; controls n = 30
Reference standard: laparoscopy + histology N = 60 (100%)
Description of positive case definition by reference standard test as reported: surgical diagnosis - reference
to the source onmorphologic criteria; confirmed by histopathology; staging according to the rASRM
classification
Examiners: no information provided




Key conclusions by the authors The use of VEGF-A for diagnosis of advanced endometriosis at cut-off 680 pg/ml and for follow-
up is better than CA-125
Conflict of interest The authors reported no conflict of interest
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate CA-125 and CA-72 prior to diagnostic laparoscopy in women with
infertility
Participants: consecutive patients undergoing laparoscopy for infertility investigation
Selection criteria: not specified
Study design: cross-sectional single-gate, prospective recruitment and collection of samples, consec-
utive series
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Number of participants enrolled: 35 women
Number of participants available for analysis: 35 women (all in late proliferative phase - mid-cycle
phase)
Setting: Department of O&G, Rush Medical College and Rush-Presbyterian-St Luke’s Medical
Centre
Place of study: Chicago, IL
Period of study: not specified
Language: English
Index tests Index test: CA-125, CA-72
Details of the index test procedure as stated: plasma concentrations of CA-125 and CA-72 were
measured by radioimmunoassay (Contocor Inc, Malvern, PA)
Threshold for positive result: CA-125 > 35 U/ml, CA-72 > 4 U/ml, pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 19/35 (54%): stages not specified; controls n = 16
Reference standard: laparoscopy N = 35 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection (en-
dometriosis defined as classic powder burn lesion, areas of hypervascularity, petechial lesions, clear
lesions and pseudoperitoneal pockets; suspicious areas confirmed by histopathology; staging accord-
ing to rAFS classification
Examiners: no information provided




Key conclusions by the authors There was no advantage in using CA-125 and CA-72 preoperatively to determine the likelihood of
pelvic endometriosis. There is no evidence that these tumour-associated antigens are helpful in the
routine work-up of the female infertility patient
Conflict of interest Not reported
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Patient sampling Primary objective: to evaluate the concentrations of MIF in the peripheral blood of normal women
and patients with endometriosis
Participants: women undergoing laparoscopy for infertility, pelvic pain, or tubal ligation
Selection criteria: inclusion criteria: no other pelvic pathology and no treatment with any anti-
inflammatory or hormone medication at least 3 months before laparoscopy
Study design: cross-sectional two-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: endometriosis group: pain - 42/55, infertility - 34/55; controls - fertile women
requesting tubal ligation or reanastomosis
Age: mean age 33.6 ± 4.7 years (endometriosis) and 36.7 ± 6.2 years (controls)
Number of participants enrolled: 93 women
Number of participants available for analysis: 93 women (47 in follicular and 45 in luteal cycle phase)
Setting: University hospital, Saint-Francois d’Assise hospital Universite Laval
Place of study: Quebec, Canada
Period of study: not specified
Language: English
Index tests Index test: MIF
Details of the index test procedure as stated: serum concentrations of MIF measured by ELISA samples
run in duplicate; concentrations extrapolated from a standard curve using recombinant human
MIF; sample handling and laboratory method described
Threshold for positive result: > 0.57 ng/ml, not pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: the inter- and intra-assay CV 2.9% and 3.8%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 55/93 (54%): stage I-II 36, stage III-IV 19; controls
n = 38
Reference standard: laparoscopy N = 93 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rAFS classification
Examiners: no information provided
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Key conclusions by the authors This study showed a marked increase in MIF concentrations in the peripheral blood of women with
endometriosis and a relationship with disease progress, and suggests that MIF may be involved in
endometriosis-related pain and infertility
Conflict of interest Not reported; supported by grant MOP-37921 from The Canadian Institutes for Health Research.
AA is a Chercheur-Boursier National of the Fonds de la Recherche en Santé du Québec (FRSQ)
Notes The presented data enabled calculation of diagnostic estimated per severity of endometriosis - not
presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to verify the clinical usefulness of CA-125, TAG-72 and CA-15.3 in the diagnosis
of endometriosis either by themselves, or when combined
Participants: women who underwent laparoscopy for infertility, pelvic pain or both at the authors’
institution
Selection criteria: not specified
Study design: cross-sectional single-gate, prospective collection of samples, non-consecutive series
Patient characteristics and set-
ting
Clinical presentation: infertility, pelvic pain or both
Age: mean age 30 ± 6 years, range 19-41 years (endometriosis) and 29 ± 5 years, range 19-44 years
(controls)
Number of participants enrolled: 119 women
Number of participants available for analysis: 119 women (all in luteal cycle phase)
Setting: Department of O&G, Universiti Cattolica, S. Cuore
Place of study: Rome, Italy
Period of study: January 1089 - February 1990
Language: English
Index tests Index test: CA-123, CA-15.3 and TAG-72
Details of the index test procedure as stated: serum concentrations of CA-125 and CA-15.3 measured
by using a commercially available radioimmunoassay (CIS Diagnostici); serum levels of TAG-
72 assessed by using a solid-phase double-determinant radio immunometric assay (Centocor); all
assays were performed in duplicate; concentration assessed with a standard curve; sample handling
described
351Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Muscatello 1992 (Continued)
Threshold for positive result: CA-125 > 35 U/ml; CA-15.3 > 30 U/ml; TAG-72 > 6 U/ml; all pre-
specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: the intra-and interassay CV 8% and 15% for CA-125
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 81/119 (68%): stage I-II 31, stage III-IV 50; controls
n = 38
Reference standard: laparoscopy N = 119 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rAFS classification
Examiners: no information provided




Key conclusions by the authors Measurement of serumCA-15.3 andTAG-72 in addition toCA-125does not provide any advantage
for the diagnosis of endometriosis
Conflict of interest Not provided
Notes The presented data enabled calculation of diagnostic estimated per severity of endometriosis - not
presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Unclear
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dard?
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate the serum concentration of sCD23 and the serum endometrial IgG
antibody in patients with endometriosis to determine if B cell activation occur in these patients
Participants: fertile patients with chronic pelvic painwho underwent laparoscopy andwere diagnosed
with endometriosis (endometriosis group) and fertile pain-free patients who at laparoscopic tubal
sterilisation were found to have normal pelvis (controls)
Selection criteria: not specified
Study design: cross-sectional two-gate, prospective collection of samples
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Patient characteristics and set-
ting
Clinical presentation: not specified; all patients have regular menstrual cycle (22-35 days)
Age:mean age 33.5 ± 5.7, range 21-45 years (endometriosis); 32.6 ± 6.8, range 25-45 years (controls)
Number of participants enrolled: 97 women
Number of participants available for analysis: 97 women (55 follicular and 42 luteal phase)
Setting: University Department, Jessop Hospital for Women
Place of study: Sheffield, UK
Period of study: not stated
Language: English
Index tests Index test: sCD23 (soluble CD23) and endometrial IgG auto-Ab
Details of the index test procedure as stated: serum sCD23 concentrationwas estimated by chemilumes-
cent ELISA; endometrial Ab was measured with ELISA, laboratory techniques described in details
Threshold for positive result: positivity defined as absorbance value of the ELISA > than the plate
control mean ± SD (male and postmenopausal serum); threshold pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Reference standard: laparoscopy + histology, N = 97 (100%)
Prevalence of target condition in the sample: n = 57/97 (59%): stage I-II 40, stage III-IV 17; controls
n = 40
Reference standard: laparoscopy + histology N = 97 (100%)
Description of positive case definition by reference standard test as reported: surgical diagnosis confirmed
by histology; staging according to the rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood was taken at the time of laparoscopy
Withdrawals: none
Comparative
Key conclusions by the authors These data suggest the existence of B cell activation in patients with endometriosis with a signif-
icant correlation between endometrial antibodies and sCD23. Mild endometriosis appears to be
immunologically more active than the severe form. The value of sCD23 in the management of
endometriosis needs further evaluation
Conflict of interest Not reported; financial assistance from Lederle Laboratories, Gosport, England
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
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Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Patient sampling Primary objective: to determine if serum concentration of serum IL-8 can be found in ovarian
endometrioma and if this is a useful tool for diagnosing this disease
Participants: women who underwent laparoscopy or laparotomy for endometrioma or other benign
ovarian cysts
Selection criteria: inclusion criteria: preoperative imaging suggestive of ovarian cyst; exclusion criteria:
suspected infectious diseases, chronic or acute inflammatory diseases, malignancy, autoimmune
diseases, artificial grafts or ruptured endometrioma
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: mean 35.5 ± 8.0, range 20-48 years (endometriosis); 36.0 ± 10.6, range 20-50 years (controls)
Number of participants enrolled: 91 women
Number of participants available for analysis: 91 women (44 follicular and 37 luteal phase)
Setting: Tottori University Hospital
Place of study: Yonago, Japan
Period of study: 2001-2006
Language: English
Index tests Index test: IL-8 and CA-125
Details of the index test procedure as stated: serum concentrations were measured with immunoas-
says: IL-8 (Quantikine; R&D Systems Inc, Minneapolis, MN), range 3.5-2,000 pg/ml; CA-125
(ChemiLumi ACS-CA-125 II; Bayer Medical Co. Ltd, Tokyo, Japan), range 2 to 600 U/ml; sample
processing and laboratory techniques described
Threshold for positive result: IL-8 ≥ 25 pg/ml; CA-125 ≥ 30 U/ml, not pre-specified
Examiners: no information provided; unclear if blinded to the results of reference standard
Interobserver variability: Inter- and intra-assay CV < 10% for both tests
Target condition and reference
standard(s)
Target condition: ovarian endometriosis
Prevalence of target condition in the sample: n = 70/91 (77%), all stage III-IV; controls n = 21
Reference standard: laparoscopy/laparotomy + histology N = 91 (100%)
Description of positive case definition by reference standard test as reported: Surgical diagnosis confirmed
by pathologic examination; staging according to the rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were obtained before surgery
Withdrawals: for CA-125 the data was missing for 5 cases and 3 controls, withdrawals not explained
Comparative
Key conclusions by the authors Serum levels of IL-8 could improve diagnostic reliability; further studies are needed for IL-8 to be
used as a reliable serum marker in the clinical management of endometriosis
356Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ohata 2008 (Continued)
Conflict of interest Not reported
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to elucidate the role of IL-18 in the pathogenesis of endometriosis
Participants: women undergoing surgery for suspected endometriosis, ovarian mass or infertility
Selection criteria: not specified
Study design: observational, single-gate design, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: endometriosis: not specified, controls: benign ovarian cysts - 13, fibroid uterus
- 2, infertility - 4; all the women had normal ovulatory cycles and did not take hormonal medication
for at least 3/12 months before surgery
Age: mean age 33.8 ± 6.8 years, range 24-48 years (endometriosis group), 31.7 ± 6.7 years, range
20-46 years (controls)
Number of participants enrolled: 58 women
Number of participants available for analysis: 58 women (all in follicular cycle phase)
Setting: Department of O&G, Institute for Advanced Medical Sciences and Hyogo College of
Medicine
Place of study: Hyogo, Japan
Period of study: not stated
Language: English
Index tests Index test: IL-18, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, GM-CSF and IFN-γ
Details of the index test procedure as stated: serum IL-18 levels were determined by using ELISA
commercial kit (MBL Co. Ltd, Nagoya, Japan); IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α,
GM-CSF and IFN-γ were determined by Bio-Plex Protein Array System (Bio-Rad Laboratories,
Hercules, CA) using Human Cytokine Assay reagents (Bio-Rad)
Threshold for positive result: not reported
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 39/58 (67%): stage I-II 6, stage III-IV 33; controls
n = 19
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Reference standard: Surgery (type of surgery not stated), N = 58 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rASRM classification .
Examiners: not stated
Flow and timing Time interval between index test and reference standard: the samples were collected at surgery
Withdrawals: none
Comparative
Key conclusions by the authors The elevation of IL-18 in the peritoneal fluid of endometriosis patients and the induction of COX-
II in peritoneal monocytes by IL-18 suggest that IL-18 plays a pathogenic role in endometriosis
Conflict of interest Not reported
Notes For IL-18 and IL-1β there was no statistically significant difference between the groups - no data
available for meta-analysis
For IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, GM-CSF and IFN-γ there was no statistically significant
difference between the groups, but there was insufficient information to confirm negative findings
- not included in the review
The reported diagnostic estimates for peritoneal fluid biomarkers are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
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Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the levels of CD4+ CD25+FOXP3+ Treg cells in the peripheral
blood and peritoneal fluid of patients with endometriosis
Participants: women undergoing laparoscopy for suspected endometriosis or ovarian cyst
Selection criteria: not specified
Study design: cross-sectional, single-gate, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: endometriosis group - not specified; controls - indications for surgery: benign
ovarian cysts or diagnostic laparoscopy; none of the participants suffered from any other chronic
inflammatory or autoimmune disorder and was not subjected to pharmacological treatment which
would affect immune response for at least 3/12 months prior to the study
Age: mean age 31 years, range 19-39 years (endometriosis group), 34 years, range 18-46 years
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(controls)
Number of participants enrolled: 32 participants
Number of participants available for analysis: 32 participants (all in follicular cycle phase, day 5-10)
Setting: Department of O&G, Militay institute of Medicine and research laboratory, Medical Uni-
versity of Warsaw
Place of study: Warsaw, Poland
Period of study: not reported
Language: English
Index tests Index test: CD4+ CD25+ FOXP3+ regulatory T cells (Treg cells)
Details of the index test procedure as stated: Treg cells were measured by flow cytometry using chloro-
phyll protein-conjugated anti-CD4 and allophycocyanin conjugated anti-CD25 monoclonal anti-
bodies (all from BD Biosciences, San Jose, USA); followed by intracellular staining of FOXP3 using
the fluorescein isothiocyanate (FITC) Anti-Human Foxp3
Staining Set (eBioscience Inc, SanDiego, USA) according to themanufacturer’s instructions; sample
handling and laboratory technique described
Threshold for positive result: not reported
Examiners: not information provided, unclear if were blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: ovarian endometriosis
Prevalence of target condition in the sample: n = 17/32 (53%): all stage III-IV; controls n = 15
Reference standard: laparoscopy, N = 32 (100%) + histopathology
Description of positive case definition by reference standard test as reported: visual inspection with
histological confirmation; staging according to rAFS classification
Examiners: not reported
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none reported
Comparative
Key conclusions by the authors Treg cells may play a part in immunopathogenesis of endometriosis, being responsible for abrogated
local cellular immune responses and facilitation and development of autoimmune reactions. Treg
cells may be thus a potential target in the treatment of endometriosis
Conflict of interest The authors declared no conflict of interests; the work was supported by 1M15/N/2011 andNK1W
grants from the I Faculty of Medicine, Warsaw Medical University
Notes For CD25+ FOXP3+ and CD25low FOXP3+ cells, there was no statistically significant difference
between the groups - no data available for meta-analysis
For CD4+ and CD4+ CD25+ Treg cells. there was no statistically significant difference between the
groups, but there was insufficient data to confirm negative findings - not included in this review
For CD25high FOXP3+, there was statistically significant difference between the groups, but there
was insufficient data to construct 2 x 2 tables - not included in this review
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to test the ability of a group of serum cytokines, either individually or in combi-
nation, to serve as biomarkers for the non-surgical diagnosis of endometriosis
Participants: women undergoing laparoscopy for the evaluation of infertility or pelvic pain
Selection criteria: inclusion criteria: regular menstrual cycles, not on hormonal medications at least
3 months prior to enrolment, not been pregnant or hysterosalpingography done at least 3 months
prior to enrolment
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility, pelvic pain
Age: median 34.0, range 29.0-38.5 years (endometriosis group) and 32.0, range 28.5-36.5 years
(controls)
Number of participants enrolled: 131 women
Number of participants available for analysis: 131 women (60 in follicular, 78 in luteal cycle phase)
Setting: gynaecologic endoscopy unit, institution not specified
Place of study: not stated; authors’ affiliations include universities in USA, Germany, Egypt
Period of study: not stated
Language: English
Index tests Index test: MCP-1, IL-6, VEGF, TNF-α, GM-CSF, INF-γ
Details of the index test procedure as stated: serum cytokine concentrations were determined using
the Bio-Plex Protein Array System (Bio-Rad, Hercules, CA, USA) with cytokine-specific antibody-
coated beads (Bio-Rad) detecting range 0.2-32,000 pg/ml; sample processing and laboratory tech-
niques described
Threshold for positive result: IL-6 > 1.03 pg/ml, > 1.9 pg/ml, > 2.6 pg/ml; not pre-specified
Examiners: no information provided; unclear if blinded to the results of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 68/138 (49%): stage I-II 32, stage III-IV 36; controls
n= 70
Reference standard: laparoscopy + histology n = 138 (100%)
Description of positive case definition by reference standard test as reported: surgical diagnosis confirmed
by pathologic examination, reference to the source on morphological criteria; staging according to
the rASRM classification
Examiners: no information provided
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Flow and timing Time interval between index test and reference standard: blood samples were obtained before surgery
Withdrawals: none
Comparative
Key conclusions by the authors Serum IL-6 provided a good means of discrimination between subjects with endometriosis and
controls; adding MCP-1 and IFN-γ to IL-6 did not improve the discrimination between subjects
with endometriosis and controls over that achieved by using IL-6 alone
Conflict of interest Not reported
Notes For VEGF, TNF-α, GM-CSF there was no statistically significant difference between the groups -
no data available for meta-analysis
For MCP-1 and INF-γ there was statistically significant difference between the groups, but there
was insufficient data to construct 2 x 2 tables - not included in this review
For IL-2, IL-8, IL-15 the concentrations were below the detection limit of the assay in each group
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in
interpretation of the result of
index test?
Yes
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High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the diagnostic potentials of the serum levels of 9 different biomarkers
in endometriosis
Participants: women undergoing laparoscopy or laparotomy for evaluation of chronic pelvic pain,
severe dysmenorrhoea, infertility, pelvic endometriosis or pelvic mass
Selection criteria: exclusion criteria: autoimmune diseases, pelvic inflammatory disease, any ma-
lignancy, a history of delivery or abortion within the last 6/12 months, any endocrine disease,
menopause, premature ovarian failure, menses, other pelvic masses out of endometrial adhesions or
endometrioma, any anti-inflammatory or hormone medication within 3/12 months of operation
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility, pelvic pain, dysmenorrhoea, ovarian mass
Age: mean age 32.3 ± 7.01 years (endometriosis group) and 34.2 ± 6.88 years (controls)
Number of participants enrolled: 80 women
Number of participants available for analysis: 80 women (cycle phase not reported)
Setting: Department of O&G, University of Ondokuz Mayis
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Place of study: Samsun, Turkey
Period of study: over 1 year, dates not reported
Language: English
Index tests Index test: enolase, MIF, leptin, IL-8, AEA, PDPK1, CA-125, STX-5, LN-1
Details of the index test procedure as stated: serum biomarkers were measures using micro-ELISA
method by the ELISA reader (awareness technology well model, USA); detection range for Enolase
1.25-80.00 ng/ml, for MIF 125-8000 pg/ml, for leptin > 0,04 ng/ml, for IL-8 > 1,1 pg/ml, for
PDPK1 0.156-10.00 ng/ml, for CA-125 15-300 U/ml, for STX-5 23.4-1500.0 ng/ml, for LN-1
78-5000 pg/ml; sample processing described
Threshold for positive result: CA-125 > 43 U/ml, STX-5 > 55 ng/ml, LN-1 > 1110.0 pg/ml; not pre-
specified
Examiners: no information provided; unclear if blinded to the results of reference standard
Interobserver variability: the intra- and interassay CV for enolase, MIF and STX-5 was < 8% and <
10%; for AEA, < 15%; for PDPK1 and LN-1, < 10% and < 12%, for CA-125, < 15% and < 20%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 60/80 (75%): stage I-II - 18, stage III-IV - 42; controls
n = 20
Reference standard: laparoscopy/ laparotomy N = 80 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rASRM classification
Examiners: no information provided




Key conclusions by the authors Concurrent measurement of CA-125, syntaxin-5 and laminin-1 might be a useful non-invasive test
in strengthening the diagnosis of endometriosis and in predicting its severity
Conflict of interest Not reported; the study was supported by the scientific research funding of the University of
Ondokuz Mayis: PYO.TIP.1904.12.038
Notes For enolase, MIF, leptin, IL-8, AEA and PDPK1 there was no statistically significant difference
between the groups - no data available for meta-analysis
When the data are available for the whole group of endometriosis versus controls, the diagnostic
estimates for separate stages of endometriosis are not included
ForCA-125 and LN-1 the diagnostic estimates were reported only for certain stages of endometriosis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Patient sampling Primary objective: to develop a test to discriminate between women suffering from pelvic pain
associated with presence or absence of endometriosis, using symptom visual analogue scale (VAS)
scores, demographic and lifestyle factors and known and novel plasma biomarkers
Participants: women undergoing laparoscopy for evaluation of chronic pelvic pain, dysmenorrhoea,
or dyspareunia
Selection criteria: exclusion criteria: women on current hormonal therapy, failure to complete ques-
tionnaire,
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, dysmenorrhoea, dyspareunia
Age: mean age 27 years, range 18-44 years (endometriosis group) and 30 years, range 19-43 years
(controls)
Number of participants enrolled: 172 women
Number of participants available for analysis: 101 women (in menstrual, proliferative or secretory
cycle phase)
Setting: Department of O&G, Royal Women’s Hospital, University of Melbourne
Place of study: Melbourne, Australia
Period of study: May 2006 - February 2009
Language: English
Index tests Index test: CA-125, MIF, GM-CSF, MCP-1, VEGF, IL-17, CNTF, GDNF, SOD3, GSH, NT4,
vitamin E, annexin V, glycodelin, nitrotyrosine, NGF, leptin, sICAM
Details of the index test procedure as stated: serum CA-125 and MIF were measures using 2-plex
magnetic human circulating cancer biomarker panel, GM-CSF, MCP-1, VEGF, IL-1 - using 4-
plex magnetic human cytokine panel kit (Millipore, USA), CNTF, GDNF, SOD3, GSH, NT4,
vitamin E, annexin V, glycodelin, nitrotyrosine, NGF - using ELISA kits (Life Research, Australia)
and leptin, sICAM - using ELISA kits (R&D Systems, USA); detection limit for CA-125 - 0.26
pg/ml, MIF - 30 pg/ml, CNTF - 3.2 pg/ml, GDNF - 39 pg/ml, SOD3 - 3.9 pg/ml, GSH - 0.8
ug/ml, NT4 - 0.3 ng/ml, vitamin E - 0.2 µmol/ml, annexin V - 1.6 ng/ml, glycodelin - 0.78 ng/
ml, nitrotyrosine - 0.16 ng/ml, NGF - 78 pg/ml, leptin - 31 pg/ml, sICAM - 24 pg/ml; laboratory
methods and sample processing described
Threshold for positive result: not reported
Examiners: no information provided; unclear if blinded to the results of reference standard
Interobserver variability: the intra- and interassay CV < 10%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 69/101 (68%): stage I-II 45, stage III-IV 24; controls
n = 32
Reference standard: laparoscopy N = 101 (100%) + histopathology
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Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histological demonstration of endometrial glands and stroma; staging according to the rASRM
classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were obtained preoperatively
Withdrawals: 71 participants were excluded: 16 due to current hormone treatment, 31 - not com-
pleted questionnaire, 24 - no samples available due to laboratory freezer failure
Comparative
Key conclusions by the authors Combining symptom scores, historical measures and CA-125 provides a reasonable means to dis-
criminate between women with pelvic pain associated with presence or absence of endometriosis,
but greater specificity is needed before such a model could replace laparoscopy
Conflict of interest The authors declared no conflict of interests; the study was supported by several research grants
Notes For MIF, GM-CSF,MCP-1, VEGF, IL-17, CNTF, GDNF, SOD3, GSH, NT4, vitamin E, annexin
V, glycodelin, nitrotyrosine, NGF, leptin, sICAM there was no statistically significant difference
between the groups - no data available for meta-analysis
ForCA-125 therewas statistically significant difference between the groups, but therewas insufficient
data to construct 2 x 2 tables solely for this marker - not included in this review
The diagnostic estimates for a diagnostic model based on combination of demographic data, symp-
toms and CA-125 are not included in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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Paiva 2014 (Continued)
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to determine the efficacy of CA-125 measurements as a screening procedure for
endometriosis
Participants: women who underwent laparoscopy
Selection criteria: inclusion criteria: no systemic diseases
Study design: cross-sectional two-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: indications for surgery: infertility - 44%, pain - 10%, elective sterilisation -
43%, premature ovarian failure - 2.6%
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Age: mean 30.5 years, range 16-48 years
Number of participants enrolled: 113 women
Number of participants available for analysis: 113 women (menstrual cycle phase not specified)
Setting: Department of O&G, Mayo Clinic, tertiary care centre
Place of study: Rochester, Minnesota
Period of study: January 1985 - June 1985
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serumCA-125 levels weremeasured using radioimmunoas-
say (RIA); sample handling and laboratory techniques not described, but referenced to a primary
source (referenced to the original source)
Threshold for positive result: CA-125 > 35 U//ml; unclear if pre-specified
Examiners: no information provided; unclear if blinded to the results of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 37/113 (33%): stage I-II - 22, stage III-IV - 15;
controls n = 76: normal pelvis - 45, adhesions - 26, other - 5
Reference standard: laparoscopy + histology N = 113 (100%)
Description of positive case definition by reference standard test as reported: surgical diagnosis confirmed
by pathologic examination; endometriosis, pelvic adhesions, or other pelvic pathology were prospec-
tively recorded; staging according to the rASRM classification
Examiners: no information provided




Key conclusions by the authors The analysis of proteins with antigenic determinant CA-125 in patients with endometriosis and
other disorders may be useful
Conflict of interest Not reported
Notes The reported diagnostic estimates for advanced endometriosis (stage III-IV) are nor presented in
this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
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Patton 1986 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Patient sampling Primary objective: to evaluate whether the levels of the circulating factors involved in gynaecologic
cancers, such as AFP, IGFBP-3, c-erbB-2 and EGF are modulated in the serum of patients with
endometriosis
Participants: womenwho were scheduled to undergo laparoscopy or celiotomy at one of the 8 clinical
institutions of the Montreal area (for various indications)
Selection criteria: inclusion criteria: pre-menopausal age, not currently menstruating, regular men-
strual cycles, no acute salpingitis, not pregnant, not under hormonal treatment for the past 3months
Study design: cross-sectional two-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: indications for surgery: tubal ligation or reanastomosis - 40%, hysterectomy/
ovariectomy - 22%, diagnostic laparoscopy - 38%; symptoms not specified; history of acute infection
- 39% controls, 36% cases; leiomyoma - 11% controls, 17% cases
Age: mean 35.2 ± 6.5 years (endometriosis group) and 36.3 ± 5.4 years (controls)
Number of participants enrolled: 72 women
Number of participants available for analysis: 72 women (all in luteal phase of menstrual cycle)
Setting: biotech firm - MetrioGene BioSciences (a subsidiary of PROCREA BioSciences)
Place of study: Montreal, Quebec, Canada
Period of study: not specified
Language: English
Index tests Index test: AFP, IGFBP-3, c-erbB-2, EGF
Details of the index test procedure as stated: serum levels of AFP, IGFBP-3, c-erbB-2, EGF were
determined in ELISA commercial kits (AFP and IGFBP-3Diagnostic Systems Laboratories, TX), (c-
erB-2 Bender MedSystems, Austria), (EGF Quantikine, R&rDdingaSlystems, MN); the sensitivity
of AFP, IGFBP-3, c-erbB-2, EGF assays was 0.7 pg/ml, 0.04 ng/ml, 0.1 ng/ml, 0.7 pg/ml; sample
handling and laboratory techniques described
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: Intra-and interassay CVs < 10% for all the assays
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 36/72 (50%), stage I-II 26, stage III-IV 10; controls
- 36
Reference standard: laparoscopy/laparotomy N = 72 (100%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to the rAFS system
Examiners: gynaecologists collaborating in this study were trained surgeons experienced with the
management of endometriosis and skilled to detect and identify all forms of endometriotic lesions
Flow and timing Time interval between index test and reference standard: blood samples were collected before anaes-
thesia
Withdrawals: none
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Philippoussis 2004 (Continued)
Comparative
Key conclusions by the authors Although AFP, IGFBP-3, c-erbB-2, and EGF are not altered in the circulation of patients with
endometriosis, their involvement in the development of endometriotic lesions cannot be excluded
Conflict of interest Not reported; the authors are affiliated to the biomedical company; supported by a grant #15453Q
of IRAP from the NSERC and by internal resources at PROCREA BioSciences, Canada
Notes For AFP, IGFBP-3, c-erbB-2, and EGF there was no statistically significant difference between the
groups - no data available for meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
No




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to determine whether serum CA-125 would be useful in differentiating between
pelvic pain caused by endometriosis and that from other causes
Participants: reproductive-aged women scheduled for laparoscopy or laparotomy for investigation
of chronic pelvic pain with or without infertility
Selection criteria: inclusion criteria: reproductive age, pain lasting at least 3 months
Study design: cross-sectional single-gate design, prospective recruitment
Patient characteristics and set-
ting
Clinical presentation: pelvic pain ± infertility
Age: mean age 28.9 years, range 16-39 (endometriosis) and 26.7 years, range 14-44 years (controls)
Number of participants enrolled: 180 women
Number of participants available for analysis: 163 women (all in in late follicular phase of menstrual
cycle, day 7-10)
Setting: Section on Reproductive Endocrinilogy, Wake Forest School of Medicine, tertiary referral
centre
Place of study: Winston Salem, North Carolina, USA
Period of study: over 30 months period, dates not provided
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serum CA-125 was measured in duplicate in using an
immunoradiometric assay (Centocor,Malvern, PA); sample handling described, reference to a source
describing laboratory technique
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Threshold for positive result: CA-125 ≥16 U/ml; pre-specified
Examiners: no information provided; operators of index test were blinded to surgical data
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 82/163 (50%): stage I-II 54, stage III-IV 28; controls
n = 81: normal pelvis - 15, adhesions - 27, chronic PID - 28, other - 11
Reference standard: laparoscopy n = 163 (100%)
Description of positive case definition by reference standard test as reported: surgical diagnosis; staging
according to the rASRM classification
Examiners: no information provided; CA-125 levels were not known at the time of surgery
Flow and timing Time interval between index test and reference standard: preoperative 7-10 days before onset of last
menses
Withdrawals: 17 women were excluded from the study (were still menstruating on a day of sample
collection)
Comparative
Key conclusions by the authors Determination of CA-125 may assist in the evaluation and treatment of women with chronic pelvic
pain
Conflict of interest Not reported
Notes The reported data enabled calculation of the diagnostic estimates per severity of endometriosis - not
presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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dard?
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to analyse the interaction between Th1 and Th2 immune response patterns and
endometriosis by evaluating a panel of cytokines
Participants: women undergoing laparoscopy for suspected endometriosis
Selection criteria: inclusion criteria: age 18-40 years, histologically confirmed endometriosis (study
group), absence of
autoimmune disease, menstrual cycles of 26-32 days, no use of hormone therapy in 3/12 months
before surgery
377Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Podgaec 2007 (Continued)
Study design: cross-sectional single-gate, prospective collection of samples, consecutive patients
Patient characteristics and set-
ting
Clinical presentation: clinically suspected endometriosis
Age: mean age 32.1 ± 5.4 years (endometriosis group), 32.9 ± 5.1 years (controls)
Number of participants enrolled: 98 women
Number of participants available for analysis: 98 women (in follicular or luteal cycle phase)
Setting: endometriosis clinic, Department of O&G, Universidade de São Paulo
Place of study: São Paulo, Brazil
Period of study: January 2004 - November 2005
Language: English
Index tests Index test: TNF-α, IFN-γ , IL-2, IL-4, IL-10
Details of the index test procedure as stated: serum biomarkers assessed by using the BD Cytometric
Bead Array (CBA), (Pharmingen, Becton Dickinson, USA) and carried out using a flow cytometer
(BD FACSCalibur, USA); sample handling and laboratory methods described
Threshold for positive result: presence or absence of the selected mass protein peaks, not pre-specified
Examiners: no information provided
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 63/98 (66%): stage I-II - 28, stage III-IV - 37; controls
n = 33
Reference standard: laparoscopy N = 98 (100%) + histopathology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
on histopathology; staging according to the rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none reported
Comparative
Key conclusions by the authors Endometriosis is an inflammatory disease involving a possible shift towards Th2 immune response
component, as demonstrated by the relative increase in cytokines characteristic of this pattern of
immune response
Conflict of interest Not reported; the work was supported by grant 05/01218-3 from the SP State Foundation
Notes For TNF-α, IFN-γ , IL-2, IL-4 and IL-10, there was no statistically significant difference between
the groups - no data available for meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Patient sampling Primary objective: to evaluate serum concentrations of CA-125 and soluble CD-23 and to correlate
them with clinical symptoms, localisation and stage of pelvic endometriosis and histological classi-
fication of the disease
Participants: patients undergoing laparoscopy for suspected endometriosis based on symptoms,
examination or imaging findings
Selection criteria: inclusion criteria: age 18-45 years, no hormone therapy within 3 months prior
to consultation, no autoimmune diseases confirmed by history and laboratory tests, evidence of
ovarian function
Study design: cross-sectional, single-gate design, prospective collection of samples; consecutive series
Patient characteristics and set-
ting
Clinical presentation: chronic pelvic pain - 59/104, deep dyspareunia - 43/104, dysmenorrhoea -
82/104
Age: range 18-45 years
Number of participants enrolled: 104 women
Number of participants available for analysis: 102 women (all in menstrual and all in late proliferative
cycle)
Setting: endometriosis division, Department of O&G, Universidade de São Paulo
Place of study: São Paulo, Brazil
Period of study: June 2007 - October 2010
Language: English
Index tests Index test: CA-125, sCD-23
Details of the index test procedure as stated: serum concentrations of CA-125 and sCD-23 were mea-
sured by using a a commercial sandwich ELISA kit (Elecsys®, Roche, USA and Bender MedSys-
tems, Vienna, Austria) according to manufacturer’s instructions; the analyte range of CA-125 and
sCD-23 is 25-35 IU/ml and 10-91 U/ml, respectively; sample processing described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 44/102 (43%): stage I-II 19, stage III-IV 25; controls
n = 58
Reference standard: laparoscopy n = 102 (100%) + histology
Description of positive case definition by reference standard as reported: visual inspection, histology of the
excised lesions; classification according to the rASRM score; referenced to the source of histological
criteria
Examiners: no information provided
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Flow and timing Time interval between index test and reference standard: blood samples were collected up to 3 months
before surgery
Withdrawals: 2 participants left the study
Comparative
Key conclusions by the authors The concentrations of CA-125 were higher in patients with endometriosis than in patients without
the disease. There were no significant differences for soluble CD-23 levels between groups
Conflict of interest Not reported
Notes For sCD-23 there was no statistically significant difference between the groups - no data available
for meta-analysis
For CA-125 there was no statistically significant difference between the groups, but there were
insufficient data to construct 2 x 2 tables - not included in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the relationship between laparoscopic diagnosis of endometriosis
and results of a serum anti-endometrial antibody (AEA) assay
Participants: patients presenting to their physicians with dysmenorrhoea, chronic pelvic pain or
infertility, who subsequently underwent laparoscopy
Selection criteria: not specified
Study design: cross-sectional single-gate, multicentre, prospective recruitment and collection of sam-
ples
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, dysmenorrhoea or both, n = 145, infertility, n = 382
Age: mean age 31.8 ± 6.5 years
Number of participants enrolled: 2609 women
Number of participants available for analysis: 527 women (cycle phase not specified)
Setting: several medical centres - not specified; the authors’ institutions includeDepartment of O&G
West Virginia University School of Medicine; Fertility and Endocrinology Center, Bristol, TN; the
New Hope Center for Reproductive Medicine, Virginia; Canterbury Women Health Care, Fresno,
CA; Abingdon Healthcare for Women; Appalachian Ob/Gyn Associates, Kingsport, TN
Place of study: USA
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Period of study: not specified
Language: English
Index tests Index test: IgG anti-endometrial Abs
Details of the index test procedure as stated: anti-endometrial Ab immunoreactivity measured by indi-
rect immunofluorescence assay, which utilised frozen sections of endometrium from hysterectomy
specimens (performed for pelvic pain); AEA reactions were ranked as negative, positive or strongly
positive based on fluorescence difference between negative controls and tested sera; sample handling
and laboratory technique described
Threshold for positive result: positive results were defined as glandular epithelial immunofluorescence
greater than background as seen in negative female controls (male serum was utilised to assist in
selection of female negative controls); threshold pre-specified
Examiners: same laboratory investigator performed all analyses without prior knowledge of patient
history
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 278/527 (53%): stage not specified; controls n = 249
Reference standard: laparoscopy N = 527 (100%)
Description of positive case definition by reference standard test as reported: not reported
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were taken within 1 year before
surgery
Withdrawals: 2082 women did not undergo surgery and were excluded
Comparative
Key conclusions by the authors The AEA assay is a very good screening test for patients suspected of having endometriosis and
should be utilised prior to laparoscopy in diagnostic categories of dysmenorrhoea or chronic pelvic
pain and infertility
Conflict of interest Not provided
Notes The reported data for women with pain, infertility or both who did not undergo laparoscopy are
not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
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DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to test local (PF) and systemic inflammatory markers in order to explore what
parts of inflammation are activated in endometriosis, and test whether this was related to stage and
symptoms of the disease
Participants: patients with histologically confirmed endometriosis and controls undergoing surgery
for benign gynaecological disorders
Selection criteria: not specified
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: dyspareunia - 12/32, dysmenorrhoea - 21/32, other pelvic pain - 19/32, in-
fertility, fibroids
Age: median age (95% CI): 33 (29-36) years (endometriosis group), 37 (31-43) years (controls)
Number of participants enrolled: 32 women (14 in follicular, 14 in luteal cycle phase; 3 women were
menopausal and 1 had undetermined cycle phase due to AUB)
Number of participants available for analysis: 30 women
Setting: Department of O&G, St. Olavs University Hospital
Place of study: Trondheim, Norway
Period of study: not provided
Language: English
Index tests Index test: CA-125, CRP
Details of the index test procedure as stated: serum concentrations of CA-125 and CRP were measured
by using the commercial kits (Elecsys, CA-125II Roche/Roche/Hitachi Modular Analytics E170,
Germany and Tina-quant
CRPLX,Roche/HitachiModular Analytics E170,Roche) on the day of collection; sample processing
not described
Threshold for positive result: CA-125 > 35 kU/l, not pre-specified
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 18: stage I - 10, stage III-IV - 8; controls n = 14
Reference standard: laparoscopy n = 32 (100%)
Description of positive case definition by reference standard as reported: staging according to the rAFS
score
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: 2 women were excluded (1 - ovarian abscess diagnosed at surgery, 1 - on NSAIDs for
rheumatoid arthritis)
Comparative
Key conclusions by the authors Neutrophil granulocytes in endometriosis patients may have a lowered ability to respond to weak
activation signals, while in
more extensive endometriosis stronger neutrophil activation may be related to a pro-inflammatory
effect of endometriotic
tissue
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Conflict of interest Not reported
Notes For CA-125 and CRP there was no statistically significant difference between the groups - no data
available for meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes




Rosa E Silva 2007
Study characteristics
Patient sampling Primary objective: to define the serum CA-125 values that best indicate the presence and stage of
endometriosis
Participants: pre-menopausal women who had undergone diagnostic laparoscopy for pelvic pain or
infertility
Selection criteria: exclusion criteria were ovarian tumour (except endometriomas), pregnancy, PID,
myomas or adenomyosis on echographic examination and hormonal treatment in the preceding 3
months
Study design: cross-sectional single-gate design, prospective sample collection, consecutive series
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, infertility or both
Age: range 18-40 years
Number of participants enrolled: 201 women
Number of participants available for analysis: 201 women (all in follicular phase of menstrual cycle)
Setting: Division of Human Reproduction and Gynecological Endoscopy, University of São Paulo,
a tertiary referral centre
Place of study: São Paulo, Brazil
Period of study: not stated
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: no information provided
Threshold for positive result: CA-125 > 10 IU/ml; > 20 U/ml; not pre-specified
Examiners: no information provided
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 148/201 (74%): stage I-II 63, stage III-IV 85; controls
n = 53
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Reference standard: laparoscopy N = 201 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rASRM classification
Examiners: no information provided




Key conclusions by the authors In conclusion, it is not advisable to use serum levels of CA-125 as a diagnostic tool; sensitivity of
CA-125 as a marker can be increased if used with other non-invasive methods such as TVUS or
MRI
Conflict of interest Not reported
Notes The reported diagnostic estimates per severity of endometriosis are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in
interpretation of the result of
index test?
Yes
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High Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes




Rosa E Silva 2014
Study characteristics
Patient sampling Primary objective: to assess the changes secondary to chronic inflammation in women with and
without pelvic endometriosis by the determination of serum thiols and carbonyls
Participants: women undergoing laparoscopy for suspected endometriosis or tubal ligation
Selection criteria: exclusion criteria: smoking, use of anti-inflammatory medications in 2/12 months
before surgery, ovarian tumour, PID, adenomyosis, fibroid uterus, pregnancy, hormonal therapy in
3/12 months preceding surgery
Study design: cross-sectional two-gate, prospective collection of samples, consecutive patients
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, dyspareunia, dysmenorrhoea, infertility; controls - symptomatic
or asymptomatic women requesting tubal ligation
Age: mean age 33.22 ± 6.22 years (endometriosis group), 32.49 ± 4.74 years (controls)
Number of participants enrolled: 138 women
Number of participants available for analysis: 108 women (cycle phase not specified)
Setting: University Hospitals: Division of O&G, Faculty of Medicine of Ribeirao Preto, University
of São Paulo and hospital Santa Casa de Misericordia of Curitiba
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Place of study: São Paulo, Brazil
Period of study: not stated
Language: English
Index tests Index test: antioxidant substances: total thiols and carbonyls
Details of the index test procedure as stated: serum thiols and carbonyls were determined using DTNB
method; sample handling and laboratory methods described
Threshold for positive result: thiols <396.44 µM; carbonyls <14.9 µM; not pre-specified
Examiners: no information provided
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 67/108 (62%): stages of endometriosis not specified;
controls n = 41
Reference standard: laparoscopy N = 108 (100%) + histopathology
Description of positive case definition by reference standard test as reported: endometriosis diagnosed at
laparoscopy with histologic confirmation
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected immediately
before surgery (personal communication with the authors)
Withdrawals: 30 women were excluded before analysis due to haemolysis or high lipid concentration
in the samples
Comparative
Key conclusions by the authors The serum thiol levels revealed an increase in oxidative stress related to the development of pelvic
endometriosis
Conflict of interest Not reported
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to evaluate non-invasive and practical diagnostic methods by measuring serum
and peritoneal fluid CA-125 levels in patients with endometriosis
Participants: women who underwent laparoscopy because of infertility, chronic pelvic pain, or
recurrent abortion
Selection criteria: exclusion criteria: hormonal therapieswithin 6months prior to laparoscopy, ovarian
neoplasia and other cancers, PID or large uterine myomas
Study design: cross-sectional single-gate, multicentre, prospective recruitment and collection of sam-
ples
Patient characteristics and set-
ting
Clinical presentation: primary infertility - 46/60, secondary infertility - 10/60, chronic pelvic pain -
7/60, dysmenorrhoea - 23/60, dyspareunia - 10/60, recurrent abortion - 3/60 patients
Age: mean age 28.94 ± 4.34 years (endometrioma group), 28.36 ± 4.02 years (controls)
Number of participants enrolled: 60 women
Number of participants available for analysis: 60 women (all in early follicular cycle phase)
Setting: Infertility and ReproductiveHealth Research Centre, Shahid BeheshtiUniversity ofMedical
Sciences
Place of study: Tehran, Iran
Period of study: 2008-2009
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serum CA-125 levels measured in duplicate by using a
2010 Elecsys kit (Roche Diagnostic GmbH, USA) by ECLIA method with sensitivity of assay of 0.
60 IU/ml; sample handling described
Threshold for positive result: > 14.70 IU/ml - not pre-specified
Examiners: no information provided
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 35/60 (58%): stage I-II 25, stage III-IV 10; controls
n = 25
Reference standard: laparoscopy N = 60 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by pathologic evaluation of the biopsy specimen; staging according to the rASRM classification
Examiners: no information provided




Key conclusions by the authors Serum and peritoneal fluid CA-125 levels are simple and non-surgical tools for diagnosing and
staging pelvic endometriosis. These markers are of greater diagnostic value in higher stages of the
disease
Conflict of interest Not reported
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Notes The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate whether a combination of putative markers of inflammation and CA-
125 could serve as a multiple-marker screening test for endometriosis in a heterogeneous population
of patients
Participants: women undergoing laparoscopy for infertility, pelvic pain, tubal sterilisation or tubal
reversal, or other benign aetiology
Selection criteria: inclusion criteria: reproductive age, at least stage II of endometriosis
Study design: cross-sectional two-gate, prospective recruitment and collection of samples
Patient characteristics and set-
ting
Clinical presentation: pain 61/141, infertility 27/141, BTL 27/141, other benign conditions 6/141;
OCP use 31/141
Age: mean age 34 years, range 18-48 years (endometriosis group), 33 years, range 23-48 years
(controls)
Number of participants enrolled: 197 women
Number of participants available for analysis: 141 women (91 in follicular, 25 in luteal and 25 in
unknown cycle phase)
Setting: Center forResearch inReproduction andWomen’sHealth,Department ofO&G,University
of Pennsylvania School of Medicine
Place of study: Philadelphia, Pennsylvania
Period of study: December 2003 - November 2005
Language: English
Index tests Index test: IL-6, TNF-α, MIF, MCP-1, IFN-γ , leptin, and CA-125
Details of the index test procedure as stated: serum concentrations of 7 markers evaluated by using
commercially available ELISA kits (R&D Systems, Inc, MN and Panomics, Inc, CA for CA-125);
the sensitivities of the IL-6, TNF-α, MIF, MCP-1, IFN-γ , leptin, and CA-125 ELISAs were 0.70,
1.60, 0.017, 5.00, 8.00, and 780.00 pg/ml and 5.0 U/ml, respectively; sample handling described;
diagnostic performance of the markers then was evaluated jointly by using CART analysis with
automatic self-validation procedures
Threshold for positive result: CA-125 > 20 mIU/ml; MCP-1 > 76.4 pg/ml, > 152.744 pg/ml, > 53.
451 pg/ml; leptin >3.14 pg/ml, > 29.1 pg/ml; MIF >14.7 ng/ml - all not pre-specified
Examiners: no information provided
Interobserver variability: not provided
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Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 63/141 (45%): stage II - 22, stage III-IV - 41; controls
n = 78
Reference standard: laparoscopy N = 141 (100%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to the rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: serum was obtained on the day of surgery
Withdrawals: 56 participants were excluded before analysis (diagnosed with stage I endometriosis)
Comparative
Key conclusions by the authors Using the serum concentration of 4 markers in a 2-tiered decision rule, nearly half of the subjects in
this population would have been diagnosed (and could have avoided surgery) with 93% accuracy
Conflict of interest Not reported
Notes The diagnostic estimates were reported only for the combination of biomarkers
The reported diagnostic estimates were calculated by using a marker classification tree
For TNF-α and IL-6 levels, there was no difference between the groups, and these markers were not
included in the diagnostic model; there were insufficient data available to present these 2 markers
in the review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to identify potential novel biomarkers that differ between subjects with and
without endometriosis and
that might aid in developing a non-invasive, serum-based diagnostic test
Participants: women undergoing laparoscopy for the indications of infertility, pelvic pain, tubal
sterilisation or tubal reversal, or other benign aetiology
Selection criteria: inclusion criteria: reproductive age, at least stage II of endometriosis
Study design: cross-sectional two-gate, prospective recruitment and collection of samples
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Patient characteristics and set-
ting
Clinical presentation: pain 61/141, infertility 27/141, BTL 27/141, other benign conditions 6/141;
OCP use 31/141
Age: mean age 34 years, range 18-48 years (endometriosis group), 33 years, range 23-48 years
(controls)
Number of participants enrolled: 197 women
Number of participants available for analysis: 139 women (91 in follicular, 25 in luteal and 25 in
unknown cycle phase)
Setting: Center forResearch inReproduction andWomen’sHealth,Department ofO&G,University
of Pennsylvania School of Medicine
Place of study: Philadelphia, Pennsylvania
Period of study: December 2003 - November 2005
Language: English
Index tests Index test: serum proteome by SELDI-TOF-MS (5 proteins with molecular mass of 1629.00 Da,
3047.00 Da, 3526.00 Da, 3774.00 Da, 5046.00 Da and 5068.00 Da)
Details of the index test procedure as stated: serum proteome assessed by using 8-spot CM10 chip
arrays. Mass spectrometry analysis was performed using a PBS-II ProteinChip reader (Ciphergen
Biosystems, CA); spectra were collected using ~ 165 laser shots (laser intensity of 170, detector
sensitivity of 8, molecular mass range of 1000-10,000 Da); autodetection settings for peak deter-
mination with signal-to-noise ratio 5:1 on first pass and 2:1 of second pass; sample handling and
method described; diagnostic performance of themarkers thenwas evaluated jointly by using CART
analysis with automatic self-validation procedures and 10-fold cross validation
Threshold for positive result:presence or absence of the selected mass protein peaks, not pre-specified
Examiners: no information provided
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 63/141 (45%): stage II - 22, stage III-IV - 41; controls
n = 78
Reference standard: laparoscopy n = 141 (100%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to the rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: serum was obtained on the day of surgery
Withdrawals: 56 participants were excluded before analysis (diagnosed with stage I endometriosis)
and 2 participants excluded due to poor sample quality
Comparative
Key conclusions by the authors This study is the critical first step in the identification of potential novel biomarkers of endometriosis.
Future identification of the proteins and further validation in a second population is needed before
applying these findings in clinical practice
Conflict of interest Not reported
Notes The reported diagnostic estimates were calculated by using a 2-step classification tree
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the hypothesis that sICAM-1 may be used as a new serum marker
of endometriosis
Participants: women who underwent gynaecologic laparoscopy at the authors’ institution
Selection criteria: inclusion criteria: reproductive age, no hormonal treatment for at least 3 months
before surgery; no history of endometritis or autoimmune, liver, endocrine, or neoplastic disorders;
exclusion criteria: laparoscopic diagnosis of PID or malignancy
Study design: cross-sectional single-gate, prospective recruitment and collection of samples, consec-
utive series
Patient characteristics and set-
ting
Clinical presentation: endometriosis group - not specified; control group: pelvic pain, infertility or
both - 13/49, uterine fibroids - 7/49, benign ovarian cysts - 25
Age: reproductive age, not specified
Number of participants enrolled: 120 women
Number of participants available for analysis: 120 women (different cycle phases, not specified)
Setting: an academic department specialising in gynaecologic laparoscopy - University of Milan,
Istituto Auxologico Italiano, and Istituti Clinici di Perfezionamento
Place of study: Milan, Italy
Period of study: December 1998 - January 2000
Language: English
Index tests Index test: sICAM-1, CA-125
Details of the index test procedure as stated: serum sICAM-1 levels assessed by using a commercially
available ELISA kit (Bender MedSystem, Austria); serum CA-125 level measured by using a com-
mercially available chemiluminescent immunometric assay (Diagnostic Products Corporation, CA)
; sample handling described
Threshold for positive result: sICAM-1 > 381 ng/ml; CA-125 > 37 IU/ml - not pre-specified
Examiners: no information provided
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 71/120 (59%): stage I-II - 24, stage III-IV - 47, DIE
- 21; controls n = 49)
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Reference standard: laparoscopy N = 120 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection (DIE,
defined as lesions infiltrating to a depth of at least 5 mm beneath the peritoneal surface), histological
confirmation of other benign pelvic conditions; staging according to the rASRM classification
Examiners: surgery was performed by 1 of the 3 physicians active in the evaluation and treatment
of endometriosis




Key conclusions by the authors Although the present study tends to support a role of sICAM-1 in the development of endometriosis,
serum concentrations of this molecule do not seem to be an effective indicator for the diagnosis of
either the early or advanced stage of endometriosis. However, an integrated clinical and laboratory
approach using both CA-125 and sICAM-1 may be helpful in specifically identifying women with
deep peritoneal endometriosis
Conflict of interest Not reported
Notes For sICAM-1 levels there was no statistically significant difference between the groups - no data
available for meta-analysis
The reported diagnostic estimates for CA-125 and sICAM were calculated for a subgroup with
DIE versus the remaining cohort (women with and without endometriosis) and the estimates for
endometriosis versus controls were not available, hence these estimates were not included in the
review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Unclear
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dard?
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to verify the clinical value of serum CA-125, CA-19.9 and IL-6 levels, either by
themselves or combined, in the detection of endometriosis
Participants: womenwhounderwent gynaecologic laparoscopy for benign gynaecological pathologies
Selection criteria: inclusion criteria: reproductive age, gynaecological indications for laparoscopic
surgery; exclusion criteria: suspected or ascertained diagnosis of malignancy, pregnancy, menopausal
age, refusal to participate in the study
Study design: cross-sectional single-gate, prospective recruitment and collection of samples, consec-
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utive series
Patient characteristics and set-
ting
Clinical presentation: endometriosis group: not specified, other concomitant pathologies (fibroids,
benign ovarian masses) - 14/45; control group: the main diagnoses were PID - 6/35, ovarian cysts
- 19/35, myomas - 2/35, normal pelvis in patients with infertility/ pelvic pain - 5/35
Age: mean age 32.0 ± 4.2 years (endometriosis group), 32.6 ± 6.4 years (controls)
Number of participants enrolled: 80 women
Number of participants available for analysis: 80 women (11 in menstrual, 12 in peri-ovulatory, 23
in luteal cycle phase; for 27 participants cycle phase was not determined)
Setting: an academic department specialising in gynaecologic laparoscopy - Department of O&G,
Clinica L.Mangiagalli, University of Milano
Place of study: Milan, Italy
Period of study: October 2002 - January 2003
Language: English
Index tests Index test: CA-125, IL-6, CA-19.9
Details of the index test procedure as stated: serum levels of CA-125 and CA-19.9 assessed by using
a commercially available chemiluminescent immunometric assay (Roche Diagnostics GmbH, Ger-
many) with assay sensitivity 0.6 IU/ml; serum IL-6 levels assessed by using 2 methods: a commer-
cially available ELISA kit (R&DSystems, Inc, USA) with assay sensitivity 0.7 pg/ml and a sequential
immunometric assay (Diagnostic Prod Corp, Medical Systems, Italy); sample handling described
Threshold for positive result: CA-125 >35 IU/ml, CA-19.9 >37 IU/ml, IL-6 >2 pg/ml - all pre-
specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability:Intra-and interassay CV for IL-6: 2.5% and 4.5% (ELISA); 4% and 7%
(immunometric assay)
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 45/80 (59%): stage I-II - 14, stage III-IV - 31; controls
n = 35)
Reference standard: laparoscopy N = 80 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
rASRM classification
Examiners: the surgerieswere performed at the department specialising in gynaecological laparoscopy




Key conclusions by the authors The concomitant dosage of CA-125, CA-19.9 and IL-6 does not add significant information with
respect to the CA-125 test
alone in diagnosing either early or advanced stages of endometriosis
Conflict of interest Not reported
Notes For IL- and CA- 19.9 levels there was no statistically significant difference between the groups, but
the diagnostic estimates were reported by the authors and presented in this review
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to compare themeasurements of serum levels of IGF-1, sTNFR-1 and angiogenin
in serum of patients with endometriosis and controls
Participants: patients who underwent laparoscopy or laparotomy for different indications
Selection criteria: inclusion criteria: pre-menopausal age, not currently menstruating, regular men-
strual cycles (21-35 days), no acute salpingitis, no pregnancy, hormonal treatment or IUD for the
last 3 months
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified; indications for surgery included diagnostic evaluation, tubal
ligation or reanastomosis, or hysterectomy
Age: mean age 37.5 ± 5.9 years (endometriosis group), 35.7 ± 6.3 years (controls)
Number of participants enrolled: 148 women
Number of participants available for analysis: 148 women (77 in follicular, 71 in luteal cycle phase)
Setting: MetrioGene BioSciences (a subsidiary of PROCREA BioSciences; patients recruited from
several collaborating medical institutions - not specified
Place of study: Montreal, Quebec, Canada
Period of study: not provided
Language: English
Index tests Index test: IGF-1, sTNFR-1, angiogenin
Details of the index test procedure as stated: serum concentrations were measured by using the com-
mercial ELISA kits for sTNFR-1, angiogenin (Quantikine; R&D Systems, MN, USA) and for
IGF-1 (Diagnostic Systems Laboratories, TX, USA); sample processing and laboratory methods
described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 77/148 (52%): stage I-II - 52, stage III-IV - 25;
controls n = 71
Reference standard: laparoscopy n = 148 (100%)
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Description of positive case definition by reference standard as reported: staging according to the rAFS
score
Examiners: no information provided




Key conclusions by the authors sTNFR-1 and angiogenin represent potential blood markers for endometriosis
Conflict of interest Not reported (the authors’ affiliation is MetrioGene BioSciences, a biotech firm)
Notes For IGF-1 there was no statistically significant difference between the groups - no data available for
meta-analysis
For sTNFR-1 and Angiogenin in follicular cycle phase there was statistically significant difference
between the groups, but there were insufficient data to construct 2 x 2 tables - not included in this
review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
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Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the modulatory role of IL-10 in the development of endometriosis
Participants: patients who underwent surgery for various indications
Selection criteria: exclusion criteria: any autoimmune disease, allergic disease,malignancy, or hepatitis
B virus or hepatitis C virus infection, or any medical treatment or surgery within 3 months before
the study-related surgery
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: indications for surgery: endometriosis group - for the treatment of advanced
endometriosis; controls - for benign gynaecological conditions; all controls had regular menstrual
cycles
Age: mean age 34.0 ± 7.1 years (endometriosis group), 36.6 ± 7.9 years (controls)
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Number of participants enrolled: 67 women
Number of participants available for analysis: 67 women (cycle phase not specified)
Setting: Departments of O&G and Medical Research, Kaohsiung Medical University Hospital
Place of study: Kaohsiung, Taiwan
Period of study: not provided
Language: English
Index tests Index test: IL-6, IL-12, IL-10
Details of the index test procedure as stated: serum levels of IL-10 and IL-6 were determined using
ELISA, with 2.0 pg/ml as the limit of detection; sample processing described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 41/67 (61%): all stage III-IV; controls n = 26
Reference standard: surgery, not specified N = 67 (100%)
Description of positive case definition by reference standard as reported: staging according to the rASRM
classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected within 24 h
before surgery (personal communication with the authors)
Withdrawals: none reported
Comparative
Key conclusions by the authors IL-10 may suppress immunity against endometrial implants, contributing to development of en-
dometriosis
Conflict of interest Not reported; the work supported by grants NSC-99-2628-B-037-009-MY3, NSC100-2314-B-
037-043 and NSC 102-2628-B-037-011-MY3 from the National Science Council (Taiwan), and
by grants KMUH101-1R27, KMUH100-0R24, KMUH
99-9I04 and KMUH 99-9R30 from Kaohsiung Medical University Hospital
Notes For IL-6 and IL-12 there was no statistically significant difference between the groups - no data
available for meta-analysis
For IL-10 there was statistically significant difference between the groups, but there were insufficient
data to construct 2 x 2 tables - not included in this review
The data for healthy controls (N = 11) who did not undergo abdominal surgery were not included
in this review
The data for animal model of endometriosis are not included in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Patient sampling Primary objective: to measure the levels of anti-gamete antibodies in serum and peritoneal fluid of
women with endometriosis, infertility or both
Participants: women who underwent laparoscopy for infertility, suspected endometriosis, chronic
pelvic pain
Selection criteria: not specified (only patients with minimal endometriosis were included)
Study design: cross-sectional, single-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility, chronic pelvic pain or both
Age: mean age 29 years, range 23-38 years
Number of participants enrolled: 98 women
Number of participants available for analysis: 98 women (all in luteal cycle phase)
Setting: Clinic of Reproduction, Institute of Gynaecology and Obstetrics Poznan
Place of study: Poznan, Poland
Period of study: not provided
Language: English
Index tests Index test: anti-gamete Abs (anti-ZP Abs and antisperm Abs)
Details of the index test procedure as stated: serum levels of anti-gamete Abs were assessed by using the
quantitative ELISA (absorbance at 492 nm was determined by Multiscan Plus spectrophotometer
(Labsystems Multiscan, Finland) and standard curve was plotted; protein concentration was was
extrapolated from the standard curve and calculated per cell in both performed assays; sample
processing and laboratory methods described in details
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 50/98 (51%): all stage I; controls n = 48
Reference standard: laparoscopy N = 98 (100%)
Description of positive case definition by reference standard as reported: staging according to the rAFS
score
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected before surgery
Withdrawals: none
Comparative
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Key conclusions by the authors Antizona antibodies locally produced in the peritoneal fluid have diagnostic value for infertility
status; however, they cannot be treated as a marker or prognostic factor for minimal endometriosis
or its treatment
Conflict of interest Not reported; supported by the Committee of Scientific Research of Poland and the Ministry of
Health, Warsaw, Poland
Notes For serum anti-ZP and anti-sperm antibodies there was no statistically significant difference between
the groups - no data available for meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to measure the levels of anti-gamete antibodies in serum and peritoneal fluid of
women with endometriosis, infertility or both
Participants: women who underwent laparoscopy for suspected endometriosis or endometriosis
recurrence
Selection criteria: inclusion criteria: regular menstrual cycles, no hormonal therapy for 3/12 months
preceding surgery
Study design: cross-sectional, single-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: pelvic pain
Age: mean age 29 years, range 23-38 years
Number of participants enrolled: 64 women
Number of participants available for analysis: 64 women (all in luteal cycle phase)
Setting: Clinic of Reproduction, Institute of Gynaecology and Obstetrics Poznan
Place of study: Poznan, Poland
Period of study: 1998-1999
Language: Polish
Index tests Index test: IL-12
Details of the index test procedure as stated: serum levels of IL-12 were assessed by using ELISA; sample
processing and laboratory methods described in details
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not provided
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Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 53/64 (83%): stage I-II - 21, stage III-IV - 20;
recurrent endometriosis 12; controls n = 11
Reference standard: laparoscopy n = 64 (100%) + histopathology
Description of positive case definition by reference standard as reported: visual inspectionwith histological
confirmation; staging according to the rAFS score
Examiners: no information provided




Key conclusions by the authors There were no statistically significant differences in IL-12 levels in peritoneal fluid nor in serum in
any of studied groups
Conflict of interest Not reported
Notes For serum IL-2 there was no statistically significant difference between the groups - no data available
for meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
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Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate CA-125 in serum and peritoneal fluid (PF) as an indicator of en-
dometriosis
Participants: patients admitted for diagnostic or therapeutic laparoscopy
Selection criteria: exclusion criteria: any conditions known as influencing CA-125 concentration and
with ovarian malignancy established by intraoperative histopathological examination; luteal phase
of the cycle
Study design: cross-sectional single-gate, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: adnexal mass, infertility, pelvic pain, suspected endometriosis
Age: reproductive age
Number of participants enrolled: 59 women
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Number of participants available for analysis: 59 women (all in follicular cycle phase)
Setting: Department of O&G, Clinic of Gynaecological Surgery and Oncology, Medical University
of Lodz
Place of study: Lodz, Poland
Period of study: not provided
Language: English
Index tests Index test: CA-125
Details of the index test procedure as stated: serum CA-125 levels were measured in accordance with
the manufacturer’s instructions (VIDAS CA-125 II).; sample handling described
Threshold for positive result: CA-125 > 11 U/ml - not pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 44/59 (75%): stage I-II 22, stage III-IV 22; controls
n = 15
Reference standard: laparoscopy N = 59 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection, in some
cases peritoneal biopsy or ovarian cyst excision was conducted; staging according to the ASRM
classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none
Comparative
Key conclusions by the authors CA-125 cut-off value in serum suggesting endometriosis with 68% sensitivity is 11 U/ml. This
value is normal range for CA-125 concentration
Conflict of interest Not reported; the study was supported by grant no. 2431/B/P01/2009/37 from Polish Ministry of
Science and Higher Education
Notes The diagnostic estimates for the subgroups by severity of endometriosis are not included in the
review
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes
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DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to evaluate these two processes inwomenwith endometriosis who had been treated
with danazol to determine the sensitivity of a non-invasive test in diagnosing endometriosis
Participants: patients admitted for diagnostic or therapeutic laparoscopy for infertility, pelvic pain
or both
Selection criteria: not reported
Study design: cross-sectional single-gate, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: infertility, pelvic pain; 9 patients (13%) with endometriosis did not report any
pain; none had any disorders in the pelvis minor that may have increased the concentrations of the
markers under investigation (e.g. ovarian cysts, ovarian tumours or myomas)
Age: mean age 31.76 ± 5.09 years (median 31 years; range 22-47 years)
Number of participants enrolled: 103 women
Number of participants available for analysis: 102-84 women; number of the samples varied for
different tests (all in follicular cycle phase)
Setting: Department of O&G, Clinic of Gynaecological Surgery and Oncology, Medical University
of Lodz
Place of study: Lodz, Poland
Period of study: February-November 2010
Language: English
Index tests Index test: CA-125, VEGF, IL-1β, CRP
Details of the index test procedure as stated: serum CA-125 levels were measured in accordance with
the manufacturer’s instructions (VIDAS CA-125 II); plasma CRP concentrations were determined
using an immunoturbidimetric assay (PROTILINE kit; bioMérieux, Poland), CA-125 was assessed
by enzyme immunofluorescence (VIDAS II automatic quantitative test; bioMérieux, France); VEGF
and IL-1β were analysed by ELISA (the QUANTIKINE Human immunoassays; R&D Systems,
MN, USA); sample handling and laboratory methods described
Threshold for positive result: CA-125 > 11 U/ml - not pre-specified
Examiners: no information provided; biomarkers were evaluated before laparoscopy
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: peritoneal endometriosis
Prevalence of target condition in the sample: n = 71/103 (69%): stages I-IV, number per subgroups
of severity not reported; controls n = 32
Reference standard: laparoscopy N = 103 (100%)
Description of positive case definition by reference standard test as reported: staging according to the
ASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: “Blood samples were collected prior to surgery
and evaluated before laparoscopy”, time frame not reported, but the context suggests short time
before surgery
Withdrawals: some samples were missing from the analysis (n = 1 for CA-125 and CRP; n = 19 for
VEGF, n = 18 for IL-1β) - reason not explained
Comparative
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Key conclusions by the authors For the diagnosis of endometriosis, none of the combinations of given markers had a sensitivity >
60%. Danazol treatment is highly effective in relieving pain and decreasing CA-125 concentrations
in the plasma. Higher plasma concentrations of VEGF after treatment could imply stimulation of
angiogenesis
Conflict of interest Not reported; the study was supported by grant no. 2431/B/P01/2009/37 from the Polish Ministry
of Science and Higher Education, a grant from European Funds for Foundation for Polish Science
and a doctoral grant from Polfarma Scientific Foundation
Notes For CRP and IL-1β there was no statistically significant difference between the groups - no data
available for meta-analysis
For CA-125 and VEGF there was statistically significant difference between the groups, but there
was insufficient data to construct 2 x 2 tables - not included in this review
The data for markers measured in peritoneal fluid and endometrium are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate CA-125 in serum and peritoneal fluid (PF) as an indicator of en-
dometriosis
Participants: non-pregnant patients < 42 years old who underwent pelvic surgery
Selection criteria: exclusion criteria: visually diagnosed with endometriosis the absence of histologic
confirmation
Study design: cross-sectional two-gate, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: dysmenorrhoea, dyspareunia, non-cyclic pelvic pain, gastro and urinary com-
plains; 224 women from endometriosis group had previous surgery for endometriosis; controls
underwent surgeries for various reasons (ovarian cysts, n = 117; tubal defects, n = 81; fibroids, n =
172; and other benign conditions, n = 94); no infectious or inflammatory diseases at the time of
serum collection
Age: mean age 31.9 ± 5.3 years (endometriosis group), 32.2 ± 5.8 years (controls)
Number of participants enrolled: 1439 women
Number of participants available for analysis: 834 women (215 in follicular and 207 in luteal cycle
phase; in 412 cycle phase was unclear)
Setting: Department ofO&GandReproductiveMedicine, CentreHospitalierUniversitaire Cochin,
a tertiary care university hospital
Place of study: Paris, France
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Period of study: January 2005 - December 2009
Language: English
Index tests Index test: hs-CRP
Details of the index test procedure as stated: CRP levels were assayed in fresh serum using the hs-CRP
method, performed on a Cobas Integra 400 Plus analyser using a particle-enhanced immunotur-
bidimetric technique (Roche Diagnostics, Germany); the lower detection limit of assay was 0.03
mg/L with functional sensitivity of 0.11 mg/l; sample handling described
Threshold for positive result: > 10 ng/ml, not pre-specified
Examiners: all measurements were performed in the same laboratory (Laboratoire Port Royal, Paris)
preoperatively
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 370/834 (44%): stage I-II - 130, stage III-IV - 240;
controls n = 464
Reference standard: surgery (not specified) n = 834 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histopathology in all cases, in some cases peritoneal biopsy or ovarian cyst excision was conducted;
histological criteria for different types of endometriosis described; staging according to the ASRM
classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were acquired and analysed
before surgical intervention
Withdrawals: 605 women were excluded: 133 refused to participate, 365 - missing serum samples,
21 - incomplete surgical excision of endometriosis, 86 - no histologic proof of endometriosis
Comparative
Key conclusions by the authors Although endometriosis is an inflammatory disease, we failed to identify any systemic changes in hs-
CRP serum levels; therefore, hs-CRP analysis appears to be irrelevant to the diagnosis and staging
of endometriosis
Conflict of interest Not reported
Notes The diagnostic estimates for the subgroups by severity of endometriosis are not included in the
review
The data for different anatomical distributions of endometriosis are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
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Patient sampling Primary objective: to establish the value of a new molecule, urocortin, in the diagnosis of endometri-
oma and compare with CA-125 to identify superiority of urocortin
Participants: patients who underwent laparoscopy for adnexal mass in the authors’ institution
Selection criteria: not specified (only moderate-severe endometriosis included)
Study design: cross-sectional single-gate, multicentre, prospective recruitment and collection of sam-
ples
Patient characteristics and set-
ting
Clinical presentation: adnexal mass, infertility - 28/88, concurrent diseases - 30/88
Age: mean age 34.3 ± 7.7 years (endometrioma group), 33.2 ± 11.8 years (controls)
Number of participants enrolled: 88 women
Number of participants available for analysis: 88 women (all in follicular cycle phase)
Setting: Department of Reproductive Endocrinology, Zekai Tahir Burak Women’s Health Research
and Education
Hospital
Place of study: Ankara, Turkey
Period of study: January 2009 - June 2009
Language: English
Index tests Index test: urocortin, CA-125
Details of the index test procedure as stated: plasma urocortin levels measured by using urocortin
(Human) EIA kit (range 0-100 ng/dl), Phoenix Pharmaceuticals Inc, Burlingame, CA, USA); serum
CA-125 levels were measured with the electro chemiluminescence immunoassay method (Roche
Elecsys 1010/2010,Roche Diagnostics, Germany); sample handling described
Threshold for positive result: urocortin > 4.16 ng/dl; CA-125 > 21.38 U/l - not pre-specified
Examiners: biomarkers were analysed at theHospital Biochemistry Laboratory; no other information
provided
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: ovarian endometriosis
Prevalence of target condition in the sample: n = 42/88 (48%): all stage III-IV; controls n = 46
Reference standard: laparoscopy n = 88 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection: the
diameter of all the ovarian cysts was measured and peritoneal invasion; staging according to the AFS
classification; for pathological examination specimens were obtained by total cystectomy, partial
cystectomy or biopsy
Examiners: no information provided
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Key conclusions by the authors Urocortin was not found to be efficient in distinguishing endometrioma from other benign ovarian
cysts or to be superior to CA-125 in the diagnosis of endometrioma
Conflict of interest The authors have no conflicts of interest
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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of the results of the index tests?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to determine whether serum copeptin levels were altered in women with en-
dometriosis and played a role in the pathophysiology of the disease
Participants: women who had undergone laparoscopy or laparotomy due to suspected ovarian en-
dometriosis, infertility and pelvic pain
Selection criteria: inclusion criteria: reproductive age, regular menstrual cycle; exclusion criteria:
postmenopausal FSH levels, pregnancy, suspicion of a malignant ovarian disease, history of any
hormone therapy in past 3/12 months, presence of any non-endometriotic ovarian cyst/mass
Study design: cross-sectional single-gate, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: adnexal mass, infertility, pelvic pain; none had a history of a previous ovarian
surgery and any other endocrine or autoimmune disease
Age: mean age 31.9 ± 8.2 years (endometrioma group), 30.7 ± 7.8 years (controls)
Number of participants enrolled: 92 women
Number of participants available for analysis: 86 women (menstrual cycle phase not reported)
Setting: Department of O&G, Istanbul University Cerrahpasa School of Medicine
Place of study: Istanbul, Turkey
Period of study: May 2012 - July 2013
Language: English
Index tests Index test: Copeptin, CRP, WBC, CA-125, CA-19.9, CA-15.3
Details of the index test procedure as stated: serum CA-125, CA-19.9, CA-15.3 were measured using
an IMMULITE 2000 (DPC, Los Angeles, CA): chemiluminescent immunometric assay for CA-
125 and CA-15-3 and immunometric assay for CA-19.9; serum copeptin was measured by using
Human Vasopressin-neurophysin 2-copeptin ELISA kit (EIAab Wuhan EIAab Science Co. Ltd,
China); with minimum detectable dose of Human Vasopressin-neurophysin 2-copeptin was < 10
pg/ml, detection rate of 15.6-1000.0 pg/ml; CRP was measured using an automated CRPLX Tina-
quant C-Reactive Protein
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(Latex) assay (Roche, Belgium) with lower detection limit of 0.425 mg/L and the functional sensi-
tivity of 0.88 mg/L; sample handling described
Threshold for positive result: CA-125 > 26.29 IU/ml, CA-19.9 >10.67 IU/ml, CA-15-5 >15.04 IU/
ml; copeptin >251.18 pg/ml - not pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 50/86 (58%): stage I-II - 27, stage III-IV - 23; controls
n = 36
Reference standard: laparoscopy/laparotomy n = 88 (100%) + histology
Description of positive case definition by reference standard test as reported: thorough examination of the
abdominopelvic cavity with histological confirmation; staging according to the ASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected immediately
before surgery
Withdrawals: 5 patients were excluded (met exclusion criteria)
Comparative
Key conclusions by the authors Serum copeptin levels were significantly higher in patients with endometriosis as compared to
healthy controls and severity of the disease was correlated with serum copeptin levels
Conflict of interest The authors disclosed no conflict of interests
Notes For CRP and WBC there was no statistically significant difference between the groups - no data
available for meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to determine whether in vivo levels of tumour necrosis factor a in plasma and
peritoneal fluid differ in infertile subjects with and without endometriosis
Participants: women undergoing laparoscopy for infertility
Selection criteria: inclusion criteria: regular menstrual cycles, no previous pelvic surgery, no hormonal
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treatment in preceding 3 months
Study design: cross-sectional, single-gate design, prospective recruitment and collection of samples,
consecutive patients
Patient characteristics and set-
ting
Clinical presentation: primary infertility - 70/94, secondary infertility - 24/94
Age: mean age 30 ± 6 years (endometriosis group), 29 ± 5 years (controls)
Number of participants enrolled: 94 women
Number of participants available for analysis: 94 women (cycle phase not specified)
Setting: Department of O&G, University of Milano
Place of study: Milan, Italy
Period of study: not provided
Language: English
Index tests Index test: TNF-α
Details of the index test procedure as stated: plasma levels of TNF-α were assessed by using enzyme
immunoassay test (Biokine, T Cell Sciences, Mas, USA); sensitivity 10 pg/ml; sample processing
described
Threshold for positive result: not provided
Examiners: no information provided; blinded to the result of reference standard
Interobserver variability: intra-assay CV < 10%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 46/94 (49%): stage I-II 38, stage III-IV 8; controls
n = 48
Reference standard: laparoscopy n = 94 (100%)
Description of positive case definition by reference standard as reported: staging according to the rAFS
score
Examiners: no information provided




Key conclusions by the authors In our series, plasma and peritoneal tumour necrosis factor a levels were not different in infertile
women with and without endometriosis
Conflict of interest Not reported; supported by Italian National Research Council, grant N 91.00131.PF41.115.05532
Notes For plasma TNF-α there was no statistically significant difference between the groups - no data
available for meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Patient sampling Primary objective: to compare the serum PON-1 activity in women with endometriosis versus
controls and to assess whether PON-1 activity can be used as a diagnostic test for endometriosis
Participants: women undergoing laparoscopy or laparotomy for evaluation of infertility, pelvic pain,
pelvic mass, tubal ligation or endometriosis
Selection criteria: inclusion criteria: reproductive age, regular menstrual cycle; exclusion criteria:
age > 35 years, pregnancy, hormonal therapy, smoking, alcohol drinking, CAD, unstable angina,
myocardial infarction, any operation or cardiovascular intervention within the previous 3 months,
hypertension, hyperlipidaemia, rheumatological or endocrine conditions, liver diseases, renal dys-
function, anaemia, obesity, parasitic diseases, systemic or local infection, any history of cancer in the
past 5 years and therapeutic interventions known to influence antioxidants such as supplemental
vitamins
Study design: cross-sectional two-gate, prospective recruitment and collection of samples, consecutive
series
Patient characteristics and set-
ting
Clinical presentation: preoperative indications: infertility 50 (57.5%), pelvic pain 9 (10.3%), pelvic
mass 16 (18.4%), tubal ligation 12 (13.8%)
Age: mean age 24.4 ± 4.0 years (endometriosis group), 24.8 ± 3.8 years (controls)
Number of participants enrolled: 87 women
Number of participants available for analysis: 87 women (all in follicular cycle phase)
Setting: tertiary referral centre - Department of O&G, Harran University Faculty of Medicine
Place of study: Sanliurfa, Turkey
Period of study: November 2006 - May 2007
Language: English
Index tests Index test: PON-1
Details of the index test procedure as stated: PON-1 enzymatic activity determined by using paraoxon
as a substrate and measured by increases in the absorbance at 412 nm due to the formation of 4-
nitrophenol (referenced to the primary source); sample handling and laboratory technique described
Threshold for positive result: < 141.5 U/l, not pre-specified (different thresholds for diagnosis of
minimal-mild and moderate-severe disease)
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: Intra-and interassay CV 3%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 47/87 (54%): stage I-II - 24, stage III-IV - 23; controls
n = 40
Reference standard: laparoscopy n = 71 (81.6%)/laparotomy 16 (18.4%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to the rAFS classification
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Examiners: all procedures were performed by the same surgeon in a tertiary referral centre
Flow and timing Time interval between index test and reference standard: blood samples were collected less than 12
months before surgery (personal communication with the author)
Withdrawals: none
Comparative
Key conclusions by the authors Reduced serum PON-1 activity and increased LOOH might contribute to the increased suscep-
tibility for the development of atherosclerosis. PON-1 activity can be used as a diagnostic test to
detect endometriosis
Conflict of interest Not reported; no financial support was accepted for this study
Notes The reported diagnostic estimates per severity of endometriosis are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
No




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate whether leptin may be used as a new serum marker of endometriosis
Participants: women who underwent laparoscopy for infertility, pelvic pain or adnexal mass
Selection criteria: inclusion criteria: reproductive age (17-46 years), normal regular menstrual cycle
(25-35 d), day 5 LH/FSH <2, no hormone therapy for at least 3 months before surgery, no evidence
of endometritis or previous autoimmune, liver, endocrine or malignant disease; exclusion criterion:
intraoperative diagnosis of malignancy
Study design: cross-sectional, single-gate design, prospective collection of samples, consecutive pa-
tients
Patient characteristics and set-
ting
Clinical presentation: infertility, pelvic pain, adnexal mass
Age: median age 32.2 years, range 23-46 years (endometriosis), 33 years, range 17-40 years (controls)
Number of participants enrolled: 67 women
Number of participants available for analysis: 67 women (8 in menstrual, 28 in follicular, 31 in luteal
cycle phase)
Setting: II Department of O&G, University of Milan
Place of study: Milan, Italy
Period of study: February 2000 - October 2000
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Language: English
Index tests Index test: leptin
Details of the index test procedure as stated: serum levels of leptin were assessed by using using a
commercially available RIA kit (DRG Instruments GmbH, Germany) with a sensitivity of 0.5 ng/
ml; sample processing described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: Intra- and interassay CV 3.4%-8.3% and 6.5%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 42/67 (63%): stage I-II 20, stage III-IV 22; controls
n = 25
Reference standard: laparoscopy N = 67 (100%) + histology
Description of positive case definition by reference standard as reported: visualisation and histological
confirmation in all cases of atypical, deep and adnexal lesions; classification according to the rASRM
score
Examiners: 3 physicians active in the evaluation and treatment of endometriosis




Key conclusions by the authors Serum concentrations of the obese gene product, leptin, cannot reliably be used for the diagnosis
of endometriosis
Conflict of interest Not reported; supported by the EndoBank program of Arevia GmbH
Notes For leptin there was no statistically significant difference between the groups - no data available for
meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to study a prevalence of endometriosis in women of reproductive age presenting
with dysmenorrhoea, infertility or both; to evaluate relationship between CA-125 and laparoscopic
finding and to identify the most frequent grade endometriosis by age group
Participants: women who underwent laparoscopy for dysmenorrhoea and pelvic pain not responding
to medical management, with or without infertility
Selection criteria: not specified
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: chronic pelvic pain, dysmenorrhoea, infertility
Age: mean age 28.16, range 16-41 years
Number of participants enrolled: 49 women
Number of participants available for analysis: 49 women (different phases of menstrual cycle, not
specified)
Setting: Research Center of Reproductive Health at the Pontificia Catholic University Chile
Place of study: Santiago, Chile
Period of study: not provided
Language: Spanish
Index tests Index test: CA-125
Details of the index test procedure as stated: CA-125 levels analysed by the IRMA-COUNTOM-MA
method; sample handling and laboratory technique not described
Threshold for positive result: > 35 IU/ml, pre-specified
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 45/49 (92%): stages I-IV, number of patients per
group provided only for stage IV - 20; controls n = 4
Reference standard: laparoscopy N = 49 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histopathology; staging according to the rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: not specified, but the context suggests that
the samples were taken peri-operatively
Withdrawals: 1 patient excluded from the analysis (reason not specified)
Comparative
Key conclusions by the authors CA-125 is not correlated with the presence and staging of endometriosis. Laparoscopy remains the
best alternative
Conflict of interest Not reported
Notes Translated from Spanish
The reported diagnostic estimates per age group (< 25 years and 26-41 years) are not reported in
this review
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to compare the diagnostic performance of the hs-CRP assay and the classical CRP
assay to detect low grade inflammation in plasma of women with endometriosis
Participants: women who underwent laparoscopy for subfertility with or without pain - identified
through electronic database of the biobank samples
Selection criteria: exclusion criteria: samples collected from women who were on hormonal medica-
tion at the time of collection, who had been operated within 6 months prior to the time of collection
or who had other pelvic inflammatory disease or general diseases at the time of collection
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, infertility or both
Age: reproductive age
Number of participants enrolled: 295 women
Number of participants available for analysis: 295 women (60 in menstrual, 119 in follicular and 116
in luteal cycle phase)
Setting: Department of O&G, University Hospital Gasthuisberg
Place of study: Leuven, Belgium
Period of study: not specified; samples collected since 1999
Language: English
Index tests Index test: CRP and hsCRP
Details of the index test procedure as stated: plasma CRP level was measured twice by 2 methods:
the classical automated CRPLX Tina-quant assay (Roche, Vilvoorde, Belgium) (CRP), and HS
Tina-quant high sensitive assay (Roche, Vilvoorde, Belgium) (hsCRP), both performed on a Roche
Modular P instrument; the lower detection limit was 0.425 mg/L (CRP) and 0.03 mg/L (hsCRP);
sample handling and method described
Threshold for positive result: CRP > 0.71 mg/l; hs-CRP > 0.62 mg/l all phases, > 0.70 ng/ml for
luteal phase, > 0.61 for follicular phase, > 0.73 for menstrual phase; not pre-specified
Examiners: the assays were performed at the central laboratories of the University Hospitals Leuven
Interobserver variability: the within-run CV was 1.34%-0.28% for hs-CRP and 2.5%-0.76% for
CRP; total imprecision CV was 5.70%-2.51% for hsCRP and 2.53%-1.8% for CRP
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Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 204/295 (69%): stage I-II 135, stage III-IV 69;
controls n = 91
Reference standard: laparoscopy N = 295 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection with
histological confirmation for most of the samples; staging according to the rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples collected before anaesthesia
Withdrawals: none
Comparative
Key conclusions by the authors The hsCRP assay was superior to the classical CRP assay for the detection of low CRP levels and
for revealing subclinical inflammation in plasma of women with endometriosis
Conflict of interest The authors declare that they have no competing interests; supported by a TBM (Toegepast
Biomedisch Onderzoek met
PrimairMaatschappelijke Finaliteit) grant from the Institute for Innovative Science and Technology
IWT (Innovatie door Wetenschap en technologie) in Flanders, Belgium
Notes The reported diagnostic estimates according to severity of endometriosis are not presented in this
review
The reported diagnostic estimates for CRP assay are demonstrated as inferior to hs-CRP, since both
assays test the same marker - less accurate classical CRP is not presented in this review
The diagnostic estimates for hs-CRP were reported for the overall group and per menstrual cycle
phase
The diagnostic estimates for hs-CRP in luteal cycle phase were also reported for the same cohort in
Mihalyi 2010 but the cut-off threshold in the later study was not provided, therefore the data from
both studies are included but not combined in the meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes
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DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to develop and validate a non-invasive diagnostic test with a high sensitivity (80%
or more) for symptomatic endometriosis patients, without ultrasound evidence of endometriosis,
since this is the group most in need of a non-invasive test
Participants: women who underwent laparoscopy for subfertility with or without pain - identified
through electronic database of the biobank samples
Selection criteria: inclusion criteria: minimal sample volume (2.5 ml) and essential clinical informa-
tion available; exclusion criteria: samples collected fromwomen who were on hormonal medication,
had other pelvic inflammatory disease or general diseases at the time of collection or who had been
operated within 6 months prior to collection
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: pelvic pain, infertility or both
Age: mean age 31.2 ± 4.02 years, range 24-44 years (endometriosis), 31.7 ± 5.28 years, range 19-46
years (controls)
Number of participants enrolled: 353 women - independent training and test set, with equal distri-
bution of controls (34%) and endometriosis (66%) patients
Number of participants available for analysis: 296 women (67 in menstrual, 111 in follicular and 118
in luteal cycle phase; all had normal preoperative ultrasound)
Setting: Department of O&G, University Hospital Gasthuisberg
Place of study: Leuven, Belgium
Period of study: not specified; samples collected since 1999
Language: English
Index tests Index test: Panel of 28 bio markers: IL-1β, IL-4, IL-6, IL-8, IL-10, IL-17, TNF-α, RANTES,
NGF, β-FGF, IFN-γ , MIF, MCP-1, VCAM, VEGF, M-CSF, HGF, osteopontin, IGFBP-3, leptin,
sICAM-1, follistatin, annexin V, IL-21, glycodelin, CA-125, CA-19.9, hs-CRP
Details of the index test procedure as stated: plasma levels of the biomarkers were assessed by using Bio-
Plex Protein Array System (Bio-Rad Laboratories, USA) for IL-1β, IL-4, IL-6, IL-8, IL-10, IL-17,
TNF-α, RANTES,NGF,β-FGF, IFN-γ ,MIF;multiplexing sandwich-ELISA (AushonBiosystems,
USA) for osteopontin, IGFBP-3, leptin; single ELISAs for sICAM-1 and follistatin (R&D Systems,
USA), annexin V (American Diagnostica, Inc, USA), IL-21 (Bender Med Systems, Austria) and
glycodelin (Bioserv Diagnostics, Germany); automated immunoassays (Roche, Vilvoorde, Belgium)
for CA-125, CA-19.9 and hs-CRP; the analyses were performed separately for training and for test
sets using univariate analysis for individual markers as well as the multivariate logistic regression
and LS-SVM models for predictive models of the combined biomarkers
Threshold for positive result: CA-125 > 12.5 U/ml, glycodelin > 18 ng/ml, VEGF > 1.5 pg/ml,
IGFBP-3 > 210 ng/ml, sICAM-1 < 243 ng/ml (all phases) and < 254.6 ng/ml (menstrual), CA-19.
9 > 9.5 IU/ml CRP > 0.71 mg/l; hs-CRP > 0.62 mg/l all phases, > 0.70 ng/ml for luteal phase, >
0.61 for follicular phase, > 0.73 for menstrual phase; pre-specified (for validation test set)
Examiners: the assays were performed at the central laboratories of the University Hospitals Leuven
Interobserver variability: glycodelin: intra- and interassay CV 12.6%-15.3% and 6.8%-18.8%, not
reported for other tests
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 175/296 (59%): stage I-II 146, stage III-IV 29;
controls n = 121
Reference standard: laparoscopy N = 296 (100%) + histopathology
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Description of positive case definition by reference standard test as reported: visual inspection with
histological confirmation for most of the samples; staging according to the rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples collected before anaesthesia
Withdrawals: 57 women were excluded prior to analysis as had endometriosis-related findings on
preoperative ultrasound (outside the study objectives)
Comparative
Key conclusions by the authors The hs-CRP assay was superior to the classical CRP assay for the detection of low CRP levels and
for revealing subclinical inflammation in plasma of women with endometriosis
Conflict of interest The authors declare that they have no competing interests; supported by a TBM grant from the
Institute for Innovative Science and Technology in Flanders, Belgium, Research Council KUL:
ProMeta, GOA MaNet, CoE EF/05/007 SymBioSys, GOA 08/16 KUL PFV/10/016 SymBioSys,
START 1, several PhD/postdoc and fellow grants Flemish Government (the list is not presented in
full)
Notes The reported diagnostic estimates according to severity of endometriosis are not presented in this
review
The reported diagnostic estimates for each marker are presented for only for ultrasound-negative
endometriosis (univariate analysis for single markers and multivariate analysis/LS-SVM model for
combination of the biomarkers)
The diagnostic estimates are presented only for validation test set except for CA-19.9 (only data for
training set available)
The diagnostic estimates are presented for the overall group, per specific menstrual cycle phase or
both only for the best performing markers, as selected for reporting by the authors
The diagnostic estimates for CA-125 for each cycle phase were also reported in the overlapping
but not identical cohort in Mihalyi 2010, but the cut-off threshold in that study was not provided,
therefore the data from both studies are included but not combined in a meta-analysis
IL-4, NGF and M-CSF were not detectable in 90% of the samples and have been excluded from
the statistical analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes
Was a ’two-gate’ design
avoided?
Yes
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High Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to analyse the plasma metabolomes of endometriosis patients by comparing them
with healthy controls
Participants: patients with ovarian endometriosis who underwent laparoscopic surgery and a control
group of
healthy women who underwent sterilisation
Selection criteria: not specified
Study design: cross-sectional two-gate, prospective recruitment and collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified; concomitant findings: adenomyosis - 1; fibroids - 5 in en-
dometriosis group; fibroids - 3 in controls; not on hormonal treatment - 75% endometriosis group,
62% controls
Age: mean age 33.3 ± 6.06 years, range 22-44 years (endometriosis group), 40.6 ± 3.1 years, range
32-45 years (controls)
Number of participants enrolled: 111 women
Number of participants available for analysis: 92 women (29 in follicular, 19 in late follicular/early
luteal, 41 in luteal cycle phase; for 3 participants cycle phase was not determined)
Setting: Department of O&G, University Clinical Centre, University of Ljubljana
Place of study: Ljubljana, Slovenia
Period of study: March 2008 - October 2009
Language: English
Index tests Index test: metabolome (model of SMOH C16:1+ PCaa C36:2/ PCae C34:2, corrected for age and
BMI)
Details of the index test procedure as stated: plasma metabolome evaluated by electrospray ionisation
mass spectrometry (ESI-MS/MS)measurements with the AbsoluteIDQTMp150 kit (BIOCRATES
Life Sciences AG, Austria); referenced to the sources with description of the assay and quality
measures; experiments sample handling described; diagnostic model defined by using backward
stepwise-regression selection procedure
Threshold for positive result: not provided
Examiners: no information provided; blinded to the result of reference standard; “randomly assigned
samples”
Interobserver variability: CV < 0.25 (otherwise excluded)
Target condition and reference
standard(s)
Target condition: ovarian endometriosis
Prevalence of target condition in the sample: n = 40/92 (44%): all stage III-IV; controls n = 52
Reference standard: laparoscopy N = 92 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histopathology; staging according to the rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected on the day of
surgery
Withdrawals: 19 patients were excluded prior to analysis for the following reasons: the absence of
ovarian endometriosis (11 patients), pregnancy (1 control), menopause (1 patient), surgery did not
take place (2 controls) and errors in the sampling procedure (2 patients and 2 controls)
Comparative
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Key conclusions by the authors Endometriosis is associated with elevated levels of sphingomyelins and phosphatidylcholines, which
might contribute to the suppression of apoptosis and affect lipid-associated signalling pathways
Conflict of interest The authors have nothing to disclose; supported by a J3-4135 grant from the Slovenian Research
Agency and by the Deutsche Forschungsgemeinschaft grant AD127/10-1
Notes The evaluated diagnostic model was selected by using multiple regression procedure
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to detect the serum microRNAs that are differentially expressed between en-
dometriosis patients and negative controls to evaluate the potential of these microRNAs as diagnos-
tic markers for endometriosis
Participants: patients attending the hospital with complaints of severe dysmenorrhoea and pelvic
mass as well as infertility and subsequently underwent laparoscopy
Selection criteria: inclusion criteria: aged 20-60 years, no hormone therapy for at least 3/12 months,
non-smoker, no history of other inflammatory disease; exclusion criteria: malignancy, benign ovarian
cyst except endometrioma, severe PID, known
chronic, systemic, metabolic, and endocrine disease including PCOS
Study design: cross-sectional single-gate, prospective recruitment and collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility - 48/85, dysmenorrhoea - 44/85
Age: mean age 33.3 ± 6.06 years, range 22-44 years (endometriosis), 40.6 ± 3.1 years, range 32-45
years (controls)
Number of participants enrolled: 85 women
Number of participants available for analysis: 85 women (64 in follicular, 21 in luteal cycle phase)
Setting: Department of O&G, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University
Place of study: Guangzhou, China
Period of study: 2011
Language: English
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Index tests Index test: miRNAome with subsequent validation (miR-199a, miR-122, miR-145*, miR-141*,
miR-542-3p, miR-9*)
Details of the index test procedure as stated: plasma microRNA expression evaluated by RT-PCR
(screening with Taq-
Man microRNA array in pooled samples followed by validation with single assays (SYBR Premix
Ex Taq II-based (Takara, Japan) quantified with Roche Light Cycler 480II (Roche, Switzerland));
experiments run in triplicates, normalised to U6; sample handling described; discriminant analysis
was used to built the diagnostic model
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 60/85 (71%): stage I-II stage 22, III-IV 38, peritoneal
endometriosis - 19, ovarian endometriosis - 41, DIE - 18; controls n = 25
Reference standard: laparoscopy N = 85 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histopathology; staging according to rAFS classification
Examiners: no information provided




Key conclusions by the authors The circulating microRNAs miR-199a, miR-122, miR-145*, and miR-542-3p could potentially
serve as non-invasive biomarkers for endometriosis. miR-199a may also play an important role in
the progression of the disease
Conflict of interest The authors have nothing to declare; supported by the funds fromNational Science and Technology
Department (973, 2011CB811301) and National Science Foundation of China (81270629 and
30500578)
Notes The predictive models based on combination of microRNAs were defined by discriminant analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes
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DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to investigate the relationship between circulating angiogenic cells (CACs) and
the presence of endometriosis in women, so as to determine whether CACs could be used as a disease
biomarker
Participants: women scheduled for laparoscopy for symptoms or signs suggestive of endometriosis
Selection criteria: not specified
Study design: cross-sectional single-gate, prospective recruitment and collection of samples
Patient characteristics and set-
ting
Clinical presentation: chronic pelvic pain - 44, subfertility - 36, ovarian cysts - 15; all women were
free of exogenous hormones in the preceding 3/12 months
Age: mean age 35.6 ± 5.0 years (endometriosis group), 32.9 ± 7.3 years (controls)
Number of participants enrolled: 64 women
Number of participants available for analysis: 64 women (9 in menstrual, 21 in follicular, 8 in peri-
ovulatory, 22 in luteal cycle phase; for 4 participants cycle phase was not determined)
Setting: Department of O&G, University of Oxford, Women’s Centre, John Radcliffe Hospital, a
national referral centre for the management of endometriosis
Place of study: Oxford, UK
Period of study: July 2010 - May 2012
Language: English
Index tests Index test: CAC
Details of the index test procedure as stated: Peripheral blood CAC was evaluated by flow cytometry
according to an established protocol for identifying viable CD34brightCD133+CD31+ CD45dim
cells; in a subgroup of women, CAC levels were also assessed using a CFU assay; laboratory methods
referenced to a primary source and described
Threshold for positive result: not provided
Examiners: no information provided, unclear if blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 42/64 (66%): stage I-II - 21, stage III-IV - 21; controls
n = 22
Reference standard: laparoscopy n = 64 (100%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to the rASRM classification
Examiners: surgeon was blinded to laboratory results




Key conclusions by the authors CACs are not a useful biomarker of endometriosis and may be unaffected by the presence of this
disease
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Conflict of interest The authors declared no conflict of interests; supported grants from the MRC (New Investigator
Award, G0601458), the Oxford Partnership Comprehensive Biomedical Research Centre with
funding from the Department of Health’s NIHR Biomedical Research Centres Scheme and the
Oxfordshire Health Services Research Committee
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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of the results of the index tests?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to determine serum and peritoneal fluid leptin levels in women with infertility
due to endometriosis
Participants: women with with infertility or benign ovarian cysts who underwent laparoscopy
Selection criteria: exclusion criteria: steroid treatment or immunosuppressant treatment 3 months
prior to surgery, endometritis, autoimmune disease, endocrine disorders, liver disease, cancer, and
abnormalities in reproductive system; other causes of infertility
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility or ovarian cyst
Age: age range 24-35 years (endometriosis group), 20-35 years (controls)
Number of participants enrolled: 63 participants
Number of participants available for analysis: 63 participants (cycle phase not reported)
Setting: Department of O&G, Gyn Xiangya Hospital of Central South University
Place of study: Changshang, Hunan province, China
Period of study: April 2004 - August 2004
Language: Chinese
Index tests Index test: leptin
Details of the index test procedure as stated: serum leptin was measured with RIA (Beijing East - Asian
Immune Reagent Institute), minimal detection limit was 0.1 pg/ml; sample handling described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n =33/63 (52%): stage I-II - 14, stage III-IV - 19; controls
n = 30 (control group 1 - 15, control group 2 - 15)
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Reference standard: laparoscopy N = 63 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histopathology; staging according to the rASRM classification
Examiners: no information provided




Key conclusions by the authors Peritoneal full leptin level was significantly increased in endometriosis infertility patients, suggesting
that leptin may affect fertility via a localised mechanism
Conflict of interest Not reported
Notes The data for markers measured in peritoneal fluid are not reported in this review
For leptin there was no statistically significant difference between the groups - no data available for
meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
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Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to determine whether antibody detection by utilising endometrial carcinoma cell
line is more sensitive, specific or both than measurement of circulating CA-125 levels
Participants: patients undergoing laparoscopy or laparotomy for infertility investigation
Selection criteria: not specified
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility
Age: mean age 30.7 years, range 18-40 years
Number of participants enrolled: 93 women (36 gynaecology patients and 73 gynaecological oncology
patients were presented as separate groups and not included in this review)
Number of participants available for analysis: 93 women (cycle phase not specified)
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Setting: Hershey Medical Centre, Pennsylvania State University
Place of study: Hershey, Pennsylvania
Period of study: not provided
Language: English
Index tests Index test: IgG anti-endometrial Abs, CA-125
Details of the index test procedure as stated: serumanti-endometrial antibodies evaluated by IIFutilising
monolayered cultures of carcinoma cell line; fluorescence evaluated by using Nicon optics (Nicon
Inc, NY) and ranked by immunofluorescence intensity (0 to 3+); laboratory method described and
referenced to a primary source; serum CA-125 levels determined by IRMA (Centocor, PA)
Threshold for positive result: IgG Abs: positive fluorescence of 1+ to 3+ (ranked by intensity of
immunofluorescence); CA-125: > 16 U/ml; pre-specified
Examiners: single technician, blinded to the surgical findings
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 72/93 (77%): stage I-II stage 51, III-IV 21; controls
n = 21
Reference standard: laparoscopy/laparotomy N = 93 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histopathology; staging according to the rAFS classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected before surgery
Withdrawals: none
Comparative
Key conclusions by the authors These initial results suggest that detection of antibodies might be useful for the diagnosis of en-
dometriosis
Conflict of interest Not reported; supported in part by a contract fromWinthrop Pharmaceuticals Division of Sterling
Drug, NY
Notes The reported data for gynaecological patients (wide age range) and gynaecological oncology patients
are not included in this review
The presented data enabled calculation of the diagnostic estimated according to severity of en-
dometriosis - not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Patient sampling Primary objective: to evaluate evaluate whether distinct patterns of serum proteins in symptomatic
women are of value to predict endometriosis before laparoscopy
Participants: women presenting for diagnosis or treatment of dysmenorrhoea, dyspareunia, chronic
pelvic pain or unexplained infertility
Selection criteria: exclusion criteria: oestrogen-dependent diseases, previous diagnosis of endometrio-
sis or endocrine therapy such as GnRH analogues or danazol
Study design: cross-sectional single-gate, prospective recruitment
Patient characteristics and set-
ting
Clinical presentation: dysmenorrhea - 74/91, dyspareunia - 14/91, chronic pelvic pain - 28/91,
infertility - 31/91
Age: mean age 32.3, range 22 - 47 years
Number of participants enrolled: 91 women
Number of participants available for analysis: 90 (51 proliferative and 39 secretory phase)
Setting: tertiary care centre, institution not specified
Place of study: not stated; authors’ affiliations include universities in Aachen and Luebeck, Germany
and in Peking, China
Period of study: not stated
Language: English
Index tests Index test: proteome by SELDI-TOF MS (5 peaks with molecular weights of 4159.00 Da, 5264.00
Da, 5603.00 Da, 9861.00 Da and 10,533.00 Da)
Details of the index test procedure as stated: serum proteome was profiled by SELDI-TOF MS, by
using Q10 (anionic exchange surface) ProteinChips (Ciphergen, Freemont, CA) and the calibrated
protein biologic system IIc SELDI-ProteinChipReader, ProteinChip 3.1 software (Ciphergen), and
optimised measuring protocol; sample processing, experimental techniques and analyses described
in details; classifying model was created with subsequent cross-validation and application of decision
tree algorithm to optimise the classification
Threshold for positive result: presence or absence of the selected mass protein peaks, not pre-specified
Examiners: no information provided; unclear if were blinded to surgical data
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 51/90 (57%): stage I-II 19, stage III-IV 32; controls
n = 39 women
Reference standard: laparoscopy N = 90 (100%) + histology
Description of positive case definition by reference standard test as reported: laparoscopic visualisation,
followed by histopathologic assessment of putative lesions; staging according to the rAFS classifica-
tion
Examiners: no information provided
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Flow and timing Time interval between index test and reference standard: blood samples were obtained before la-
paroscopy
Withdrawals: 1 sample was excluded as not eligible (not specified)
Comparative
Key conclusions by the authors Screening for serum protein patterns using SELDI-TOF MS before laparoscopy might be of dis-
criminative value in the prediction of disease and partly confirms recently published data. However,
both low sensitivity and low specificity disqualify this method as a ’quick fix’ diagnostic test
Conflict of interest The authors reported no conflict of interest; supported by a research grant from Takeda Pharma
Notes The reported diagnostic estimates according to severity of endometriosis are not presented in this
review
The diagnostic estimates established by a rule-based selection process using a decision tree algorithm
(DTA) are reported in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in
interpretation of the result of
index test?
Yes
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High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the association between concentrations of soluble intercellular ad-
hesion molecule-
1 (ICAM-1) and interferon-gamma (IFN-γ ) with regard to the severity of endometriosis
Participants: women with infertility who underwent laparoscopy for suspected endometriosis
Selection criteria: not specified
Study design: cross-sectional, single-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility
Age: mean age 28.93 ± 2.66 years, range, 24-35 years
Number of participants enrolled: 71 women
Number of participants available for analysis: 71 women (cycle phase not reported)
Setting: Department of O&G, Medical College, National Cheng-Kung University
Place of study: Tainan, Taiwan
Period of study: not provided
Language: English
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Index tests Index test: INF-γ , ICAM-1
Details of the index test procedure as stated: plasma levels of ICAM-1 and serum levels of INF-
γ were assessed by using commercial ELISA kits (Cellfree, ICAM-1 test kit; T Cell Diagnostics,
MA); quantification at absorbance at 490 nm; kit sensitivity of 0.3 ng/ml; sample processing and
laboratory methods described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 36/71 (51%): stage I-II - 22, stage III-IV - 14; controls
n = 35
Reference standard: laparoscopy n = 71 (100%)
Description of positive case definition by reference standard as reported: classification according to
rASRM score
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none
Comparative
Key conclusions by the authors The increased serum levels of ICAM-1 found in patients with endometriosis may indicate the
presence of an active disease process. Further, the increased levels of soluble ICAM-1 in peripheral
blood were inversely correlated with the concentrations of INF-γ in PF and may be associated with
an immunologic feedback response that blocks further infiltration of immune cells. These findings
may be of value in the diagnosis and evaluation of endometriosis
Conflict of interest Not reported; supported by by grant NSC86-2314-B006-080 from the National Science Council,
Taipei, Taiwan
Notes For serum INF-γ there was no statistically significant difference between the groups - no data
available for meta-analysis
For ICAM-1 there was statistically significant difference between the groups, but there was insuffi-
cient data to construct 2 x 2 tables - not included in this review
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
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DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Study characteristics
Patient sampling Primary objective: to evaluate whether the analysis of different pro-inflammatory and angiogenesis-
regulating cytokines in a well-defined patient population can be accurate for the diagnosis of en-
dometriosis at different stages
Participants: patients undergoing laparoscopy for infertility investigation
Selection criteria: exclusion criteria: womenonhormonalmedication, underwent anoperationwithin
6 months, other pelvic inflammatory disease
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility
Age: mean age 31.24 ± 7.24 years (endometriosis group), 26.86 ± 9.13 years (controls)
Number of participants enrolled: 55 women
Number of participants available for analysis: 55 women (cycle phase not specified)
Setting: Department of O&G, Istanbul University School of Medicine
Place of study: Istanbul, Turkey
Period of study: not provided
Language: English
Index tests Index test: CA-125, IL-6, Epo, TNF-α
Details of the index test procedure as stated: plasma concentrations of Epo, IL-6 and TNF-α were
determined by using commercially available ELISA kits (R&D Systems Inc, Minneapolis, USA)
according to the manufacturer’s instructions; plasma levels of the CA-125 were measured using
Microparticle Enzyme Immunoassay (MEIA) Abbott AxSYM instrument (Abbott Diagnostics,
USA)
Threshold for positive result: not provided
Examiners: no information provided
Interobserver variability: Inter- and intra-assay CV were for Epo < 10% and 5.9%; for IL-6, 6.4%
and 4.2%; for TNF-α, 3.5% and 1.8%; for CA-125 < 10%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 33/55 (60%): stage I-II stage 16, III-IV 17; controls
n = 22
Reference standard: laparoscopy n = 55 (100%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to the rAFS classification
Examiners: experienced gynaecologic surgeon




Key conclusions by the authors Progression of endometriosis is associated with the elevated level of serum IL-6. Undoubtedly,
larger well-designed prospective studies are urgently needed to determine the diagnostic potential
of cytokines like IL-6 in endometriosis
Conflict of interest The authors declared no conflict of interests
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Notes For CA-125 and IL-6 levels there was statistically significant difference between the groups but there
were insufficient information to construct 2 x 2 tables - not included in this review
For Epo and TNF-α levels, there was no statistically significant difference between the groups - no
data available for meta-analysis
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to measure levels of CA-125 and endometrial antibodies (EMAb) in serum and
peritoneal fluid
Participants: women who underwent laparoscopy at the authors’ institution for infertility or sus-
pected endometriosis
Selection criteria: not reported
Study design: cross-sectional, single-gate, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: infertility - 40, suspected endometriosis - 2
Age: mean age 31.36 years, range 24-39 years
Number of participants enrolled: 42 participants
Number of participants available for analysis: 42 participants (all in luteal cycle phase)
Setting: Chang Zheng Hospital, Second Military Medical College
Place of study: Shanghai, China
Period of study: July 1992 - December 1992
Language: Chinese
Index tests Index test: CA-125, anti-endometrial antibodies
Details of the index test procedure as stated: CA-125 was measured by emission immunoassay kit
(Syntron Biotech Co, USA) according to manufacturers instructions with a lower limit of detection
of 5000 U/l; endometrial antibodies were assessed with indirect ELISA by using the endometrial
antigens (EMAg) and horseradish peroxidase-labelled staphylococcal protein A (HRP-SPA); sample
handling and laboratory technique described
Threshold for positive result: CA-125 > 35,000 U/l, for anti-endometrial antibodies > 0.3 A (492 nm
wavelength absorbance value), not pre-specified
Examiners: not information provided, unclear if were blinded to the result of reference standard
Interobserver variability: Intra- and inter-observer CV for CA-125 were 4.3%-5.4% and 5.3%-6.
6%; for anti-endometrial antibodies 7.9%-9.2% and 10.1%-11.7%
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Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 28/42 (67%): stage I-II - 19, stage III-IV - 9; controls
n = 14
Reference standard: laparoscopy n = 42 (100%)
Description of positive case definition by reference standard test as reported: staging according to rAFS
classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none reported
Comparative
Key conclusions by the authors The sensitivity of CA-125 and EMAb measurements in the diagnosis of endometriosis were 71.
43% and 82.14%, and the specificity were 57.21% and 57.14% respectively
Conflict of interest Not reported
Notes The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
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Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to compare the preoperative values of mean platelet volume (MPV) and peripheral
systemic inflammatory response (SIR) markers (neutrophil/lymphocyte ratio and platelet/lympho-
cyte ratio) between patients with advanced-stage (stage 3/4) endometriosis having endometrioma
and patients with a non-neoplastic adnexal mass other than endometrioma
Participants: patients who underwent laparotomy or laparoscopy with the pre-diagnosis of infertility
or adnexal mass and who underwent laparoscopic tubal ligation
Selection criteria: exclusion criteria: patients beyond reproductive age, previous medical therapy
for endometriosis, history of past pelvic surgery or PID, myoma uteri, adenomyosis, endometrial
polyp, endometrial hyperplasia or borderline ovarian tumour, infectious disease, chronic or acute
inflammatory disease, smokers, autoimmune or systemic disorder, any malignancy, endometrioma
< 10 mm or other benign adnexal mass < 30 mm
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Study design: cross-sectional two-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility - 10, dyspareunia - 14, dysmenorrhoea - 17, ovarian mass - 61
Age: mean age 36.21 ± 8.37 years
Number of participants enrolled: 94 women
Number of participants available for analysis: 94 women (cycle phase not reported)
Setting: Department of O&G, Düzce University Faculty of Medicine
Place of study: Düzce, Turkey
Period of study: November 2009 - February 2013
Language: English
Index tests Index test: haemoglobin, WBC, platelet count, MPV, neutrophil count, lymphocyte count, NLR,
PLR, CA-125
Details of the index test procedure as stated: haematological parameters were analysed using a haema-
tology analyser (Abbott CELLDYN 3700, Boston, USA); serumCA-125 levels were determined by
using electro chemo-illuminescence method (Roche Hitachi Cobas 6000 E 60, Rotkreuz, Switzer-
land); sample handling described
Threshold for positive result: CA-125 >35 IU/ml, for other biomarkers not reported
Examiners: no information provided; unclear if blinded to the results of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: ovarian endometriosis
Prevalence of target condition in the sample: n = 33/94 (35%): all stage III-IV; controls n= 61: healthy
controls - 33, other ovarian cyst - 28
Reference standard: laparoscopy/laparotomy n = 94 (100%) + histopathology
Description of positive case definition by reference standard test as reported: staging according to the
rASRM classification
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: blood samples were obtained before surgery
Withdrawals: none
Comparative
Key conclusions by the authors MPV, NLR and PLR values are not useful for this purpose in patients with advanced stage en-
dometriosis that are proven to develop severe inflammation at either the cellular or molecular level
Conflict of interest The authors declared no conflict of interests; the study did not receive any financial support
Notes For haemoglobin,WBC, platelet count, MPV, neutrophil count, lymphocyte count, NLR and PLR,
there was no statistically significant difference between the groups - no data available for meta-
analysis
When the data are available for the whole group of endometriosis versus controls, the diagnostic
estimates for separate stages of endometriosis are not included
ForCA-125 therewas statistically significant difference between the groups, but therewas insufficient
data to construct 2 x 2 tables - not included in this review
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to evaluate the diagnostic value of examining endometrial biopsy specimens for
aromatase cytochrome P450 and CA-125 for endometriosis
Participants: patients undergoing laparoscopy or laparotomy for pelvic pain, infertility or both
Selection criteria: inclusion criteria: reproductive age regular menstrual cycle; exclusion criteria:
hormonal treatment for 3/12 months prior reproductive age, preoperative diagnosis of uterine
fibroids, adenomyosis
Study design: cross-sectional single-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: infertility or pelvic pain
Age: mean age 33 ± 4 years, range 26-40 years (endometriosis), 32 ± 4 years, range 25-39 years
(controls)
Number of participants enrolled: 58 women
Number of participants available for analysis: 58 women (31 women in follicular and 27 women in
luteal cycle phase)
Setting: Department of O&G, Third Xiangya Hospital, Central South University
Place of study: Changsha, China
Period of study: March 2003 - February 2004
Language: Chinese
Index tests Index test: CA-125
Details of the index test procedure as stated: serum CA-125 was determined by chemiluminescence
assay; sample handling and laboratory technique not described
Threshold for positive result: > 35 U/ml, not pre-specified
Examiners: no information provided
Interobserver variability: not stated
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 36/58 (62%): stage I-II 20, stage III-IV 16; controls
n = 22
Reference standard: laparoscopy/laparotomy N = 58 (100%)
Description of positive case definition by reference standard test as reported: visual inspection; staging
according to rAFS classification
Examiners: not stated
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Key conclusions by the authors The combination assay of aromatase cytochrome P450 in eutopic endometrium and CA-125 can
be used as a diagnostic test for endometriosis, especially for the early stage of endometriosis, which
is superior to the assay of CA-125
Conflict of interest Not reported
Notes Translated from Chinese
The reported diagnostic estimates for combined test of endometrium and blood markers are not
presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to compare peritoneal fluid and serum IL-16 levels between women with and
without endometriosis
Participants: consecutive patients undergoing laparoscopy
Selection criteria: not specified
Study design: cross-sectional two-gate, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: controls: asymptomatic fertile women undergoing tubal sterilisation; en-
dometriosis: women undergoing surgery for pelvic pain (n = 7), infertility (n = 6) or pelvic mass (n
= 9)
Age: mean age 37.1 ± 10.2 years (endometriosis group) and 38.6 ± 10.9 years (control group)
Number of participants enrolled: 44 women
Number of participants available for analysis: 44 women (25 in follicular and 19 in luteal phase of
menstrual cycle)
Setting: Department of Gynaecology, Women’s hospital, Zhejiang University School of Medicine
Place of study: Hangzhou, China
Period of study: December 2001 - December 2002
Language: English
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Index tests Index test: IL-16
Details of the index test procedure as stated: serum IL-16 analysis was by Human IL-16 ELISA kit
(Human IL-16 BMS 248, Bender Medsystems, Austria); laboratory technique not described
Threshold for positive result: not provided
Examiners: no information provided; unclear if were blinded to the result of reference standard
Interobserver variability: not provided
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 22/44 (50%): stage I-II 8, stage III-IV 14; controls -
22
Reference standard: laparoscopy n = 44 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histological examinations; staging according to the rAFS scoring system
Examiners: no information provided
Flow and timing Time interval between index test and reference standard: venous blood was obtained preoperatively
Withdrawals: none
Comparative
Key conclusions by the authors Our results suggest that IL-16 is not involved in the pathogenesis of pelvic endometriosis
Conflict of interest Not reported
Notes For IL-16 there was no statistically significant difference between the groups - no data available for
meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear




DOMAIN 2: Index Test All tests
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to assess the levels of IL-18 in peritoneal fluid and blood of patients with en-
dometriosis in correlation with the rAFS classification and to understand the role of IL-18 in patho-
genesis of endometriosis
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Participants: women who underwent laparoscopy or laparotomy at the authors’ institution and were
diagnosed with endometriosis, benign ovarian mass or normal pelvis
Selection criteria: inclusion criteria: regular menstrual cycle, no hormonal therapy 3 months before
surgery, no autoimmune diseases and no malignancy
Study design: cross-sectional, unclear if single- or two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: not specified
Age: mean age 33.41 ± 6.53 years, range 23-45 years (endometriosis), 32.49 ± 5.02 years, range 24-
44 years (controls)
Number of participants enrolled: 60 women
Number of participants available for analysis: 60 women (cycle phase not specified)
Setting: Xiangya Hospital, Central South University
Place of study: Changsha, China
Period of study: April 2004 - Septamber 2004
Language: Chinese
Index tests Index test: IL-18
Details of the index test procedure as stated: serum levels of IL-18 were assessed by using a commercial
ELISA kits (Hysen male biological reagents public division) with assay sensitivity of 6 pg/ml; sample
processing described
Threshold for positive result: not provided
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: Intra-assay CV < 10%
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 39/60 (65%): stage I-II - 12, stage III-IV - 27; controls
n = 21
Reference standard: laparoscopy/laparotomy n = 60 (100%) + histopathology
Description of positive case definition by reference standard as reported: visual inspection confirmed by
histopathology; classification according to the rAFS score
Examiners: no information provided




Key conclusions by the authors IL-18 levels in serum and peritoneal fluid did not correlate with a presence or severity of endometrio-
sis
Conflict of interest Not reported
Notes For IL-18 there was no statistically significant difference between the groups - no data available for
meta-analysis
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate inhibitory and activation motif expression of killer immunoglob-
ulin-like receptor (KIR) by natural killer (NK) cells, which may be pathogenetically involved in
endometriosis
Participants: women undergoing laparoscopy for various indications
Selection criteria: exclusion criteria: history of pregnancy or history of treatment with GnRH ana-
logues within previous year, complications from apparent pelvic inflammatory disease
Study design: cross-sectional, two-gate, prospective sample collection
Patient characteristics and set-
ting
Clinical presentation: endometriosis group - not specified; controls: benign ovarian cysts - 21, uterine
myoma - 35, infertility - 6, paraovarian cysts - 2, chronic abdominal pain - 4
Age: mean age 35.1 ± 7.6 years (endometriosis group), 33.9 ± 6.5 years (controls)
Number of participants enrolled: 68 participants
Number of participants available for analysis: 68 participants (menstrual cycle phase not reported)
Setting: Department of O&G, Kochi Medical School
Place of study: Kochi, Japan
Period of study: April 2003 - May 2005
Language: English
Index tests Index test: T cells (CD3, CD3, CD8), B cells (CD 19), NK cells (CD 56), KIR2DL1+NK
(CD158a+NK), KIR2DL2+NK (CD158b+NK), CD94+NK, monocyte/macrophage (CD 14) and
their antigen presentation
Details of the index test procedure as stated: PBMC were measured by flow cytometry using specific
mononuclear antibodies (FITC-labeled anti-CD3 and anti-CD4 mAb and PE-labelled anti-CD8
mAb as T-cell markers; PE-labelled anti-CD19 mAb as B cells marker, FITC-labelled anti-CD56
mAb for NK cells, and FITC-labeled anti-CD14 mAb for monocytes/macrophages; PE-labelled
anti-CD158a and anti-CD158b as markers for KIR subfamilies KIR2DL1 and KIR2DL2 expressed
on NK cells; PE-labeled anti-CD94 mAb for lectin-like receptor; PE-labeled anti-HLA-ABC and
-DR mAbs to assess antigen presentation. PE-labeled anti-CD54 mAb, CD40 mAb, CD58 mAb,
CD80 mAb, and CD86 mAb - to identify co-stimulatory molecules for antigen presentation (all
from Beckman-Coulter Fullerton, CA); laboratory technique described
Threshold for positive result: not reported
Examiners: no information provided, unclear if were blinded to the result of reference standard
Interobserver variability: not reported
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Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 56/124 (45%): stage I-II - 20, stage III-IV - 36;
controls n = 68
Reference standard: laparoscopy N = 124 (100%)
Description of positive case definition by reference standard test as reported: staging according to rAFS
classification assigned by the same operator intraoperatively and later finalised by postoperative
review of video materials
Examiners: surgical team included an expert operator who had performed laparoscopy for more than
20 years
Flow and timing Time interval between index test and reference standard: blood samples were collected at surgery
Withdrawals: none reported
Comparative
Key conclusions by the authors IncreasedCD158a(+)NKcells inPBandPF indicated decreasedNKcell cytotoxicity in endometrio-
sis, while decreased HLA expression on PF macrophages suggested impaired antigen presentation.
Thus, aberrant immune responses by NK cells and macrophages may represent risk factors for en-
dometriosis
Conflict of interest Not reported
Notes For CD3, CD3, CD8, CD 19, CD 56, CD158b+NK, CD94+NK and CD14 there was no statis-
tically significant difference between the groups - no data available for meta-analysis
For CD158a+NK there was statistically significant difference between the groups, but there was
insufficient data to construct 2 x 2 tables - not included in this review
The data for markers measured in peritoneal fluid are not presented in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes






Patient sampling Primary objective: to investigate the levels of soluble intracellular adhesion molecule-1 (sICAM-1)
in serum and peritoneal fluid of patients with or without endometriosis, and to discuss the clinical
significance of serum sICAM-1 in pelvic endometriosis
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Participants: women who underwent surgical treatment for endometriosis or for benign epithelial
ovarian tumours
Selection criteria: exclusion criteria: steroid treatment 3months prior to surgery, pelvic inflammatory
disorder, autoimmune disease, other known internal medicine or surgical disease
Study design: cross-sectional, two-gate design, prospective collection of samples
Patient characteristics and set-
ting
Clinical presentation: endometriosis group - not specified; controls - benign ovarian mass
Age: mean age 38.7 ± 9.5 years (endometriosis group), 36.0 ± 8.6 years (controls)
Number of participants enrolled: 60 participants
Number of participants available for analysis: 60 participants (cycle phase not reported)
Setting: Department of O&G, Renmin Hospital of Wuhan University
Place of study: Wuhan, China
Period of study: September 2004 - March 2005
Language: Chinese
Index tests Index test: sICAM-1
Details of the index test procedure as stated: serum sICAM-1 was measured with human sICAM-1
enzyme-linked immunosorbent assay (ELISA) (R&D Systems Germany), working assay range or
minimal detection limit were not reported; sample handling described
Threshold for positive result: cut-off threshold > 241.46 µg/ml, not pre-specified
Examiners: no information provided; unclear if blinded to the result of reference standard
Interobserver variability: not reported
Target condition and reference
standard(s)
Target condition: endometriosis
Prevalence of target condition in the sample: n = 30/60 (50%): stage I-II 14, stage III-IV 16; controls
n = 30
Reference standard: laparoscopy/laparotomy N = 60 (100%) + histology
Description of positive case definition by reference standard test as reported: visual inspection confirmed
by histopathology; staging according to the rASRM classification
Examiners: no information provided




Key conclusions by the authors The sICAM-1 may participate in the inflammatory process in endometriosis. Serum concentrations
of sICAM-1 seem to be the effective indicator for the diagnosis of endometriosis
Conflict of interest Not reported
Notes The data for markers measured in peritoneal fluid are not reported in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
No
Did the study avoid inappropri-
ate exclusions?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was a cycle phase considered in




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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AA: arachidonic acid; AEA: anti-endometrial antibodies; AUB: abnormal uterine bleeding; BMI: body mass index; BTL: bilateral tubal
ligation;CAD: coronary artery disease;CFU: colony-forming unit;CRP: C-reactive protein;CV: coefficient of variation;Da: dalton;
DIE: deep infiltrating endometriosis; DTA: decision tree algorithm;DTNB: Ellman’s reagent (5.5’-dithiobis-(2-nitrobenzoic acid);
ECLIA: electro-chemiluminescence immunoassay; EIA: enzyme immunoassay; ELISA: enzyme-linked immunosorbent assay; EPA:
eicosapentaenoic acid; ESHRE: European Society of Human Reproduction and Embryology; ESI-MS/MS: electrospray ionization
mass spectrometry FACS: Fluorescence-activated cell sorting; FSH: follicle-stimulating hormone; HGF: hepatocyte growth factor;
hs-CRP: high sensitivity C-reactive protein; IIF: indirect immunofluorescence; IRMA: immunoradiometric assay; IUD: intrauterine
device; kd: kilodalton; KIR: killer inhibitory receptor; LH: luteinising hormone; LOOH: lipid hydroperoxides; LPS: lipopolysac-
charide; LS-SVM: least squares support vector machine; MEIA: microparticle enzyme immunoassay; MF: menstrual fluid; miR:
microRNA;MPV: mean platelet volume;MRI: magnetic resonance imaging; mRNA: messenger RNA;MW: molecular weight; n:
number of events/number in study arm;N: total sample size;NK: natural killer cell;NSAID: nonsteroidal anti-inflammatory drugs;
OCP: oral contraception pill;OD: optical density;O&G: obstetrics and gynaecology; PB: peripheral blood; PBL: peripheral blood
lymphocytes; PCaa: phosphatidylcholine; PCae: etherphospholipid; PCOS: polycystic ovary syndrome; PID: pelvic inflammatory
disease; PF: peritoneal fluid; PL: plasma; SELDI-TOF-MS: surface enhanced laser desorption/ionisation time of flight mass spec-
trometry; (r)AFS: (revised) American Fertility Society; (r)ASRM: (revised) American Society for Reproductive Medicine; RCOG:
Royal College of Obstetricians and Gynaecologists; RIA: radioimmunoassay; RDF: research development fund; RT-PCR: real time
polymerase chain reaction; SD: standard deviation; SMOH: hydroxysphingomyelin; TVUS: transvaginal ultrasound; VAS: visual
analogue scale;WBC: white blood cell.
For a comprehensive list of all biomarkers with their biological annotation, please see Appendix 1.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdallah 2006 Study groups outside inclusion criteria (comparison within endometriosis group pre- and postsurgery;
no control group included)
Abrao 1997 Study design outside inclusion criteria (retrospective collection of samples); insufficient diagnostic test
accuracy information (unable to construct 2 x 2 tables)
Abrao 1999 Study design outside inclusion criteria (retrospective collection of samples)
Acien 2007 Insufficient information of study methods and population (unclear if prospective or retrospective sample
collection); insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Adamyan 1993 Insufficient description of study methods and population (unclear number of participants tested and
if all the controls had abdominal surgery); insufficient diagnostic test accuracy information (unable to
construct 2 x 2 tables)
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Agic 2007 Population outside inclusion criteria (women with pregnancy and malignancy were included)
Alcazar 2011 Index test outside inclusion criteria (lesion level analysis; unable to construct 2 x 2 tables)
Amaral 2006 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Ammendola 2008 Predictive study: test for susceptibility to endometriosis; not for diagnosis of the disease
Anastasi 2013 Target condition outside inclusion criteria (assessment of benign versus malignant ovarian tumours; not
specific for endometriosis); population outside inclusion criteria (postmenopausal women included)
Andrade 2010 Study design outside inclusio criteria (retrospective sample collection)
Andrisani 2014 Reference standard outside inclusion criteria (no abdominal surgery in controls)
Antsiferova 2005 Reference standard outside inclusion criteria (no abdominal surgery in the control group); insufficient
diagnostic test accuracy information (unable to construct 2 x 2 tables)
Arjona Berral 1996 Reference standard outside inclusion criteria (no abdominal surgery in approximately 45% of the control
group); insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Avcioglu 2014 Study groups outside inclusion criteria (comparison within endometriosis group; no control group
included)
Ayers 1987 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Badawy 1984 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables); insufficient description
of study methods and population (unclear if prospective sample collection)
Badawy 1987 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Badawy 1990 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Balasch 1985 Study design outside inclusion criteria (retrospective sample collection)
Barbieri 1986 Population outside inclusion criteria (postmenopausal women included)
Barbieri 1987 Review article
Barrier 2002 Study design outside inclusion criteria (retrospective collection of samples); insufficient diagnostic test
accuracy information (unable to construct 2 x 2 tables)
Basta 2009 Population outside inclusion criteria (postmenopausal women included); insufficient diagnostic test
accuracy information (unable to construct 2 x 2 tables)
Bedaiwy 2006 Index test outside inclusion criteria (focus on genotype of the biomarker, not its levels)
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Berkes 2013 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Bianchi 2003 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Bohler 2007 Reference standard outside inclusion criteria (no abdominal surgery in the control group); insufficient
diagnostic test accuracy information (unable to construct 2 x 2 tables)
Bordin 2010 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Bourlev 2006a Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Bourlev 2006b Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables or to confirm negative
findings)
Bragatto 2013 Study groups outside inclusion criteria (comparison within endometriosis group; no control group
included)
Brinton 1996 Study design outside inclusion criteria (retrospective collection of samples)
Brosens 1978 Reference standard outside inclusion criteria (no abdominal surgery in the control group); study design
outside inclusion criteria (retrospective collection of samples)
Cai 2005 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Carmona 2012 Insufficient diagnostic accuracy information (unable to construct 2 x 2 tables; presented diagnostic
estimates are for ovarian endometriosis versus mixed group of controls and other type of endometriosis;
no separate data for endometriosis versus controls)
Cheng 2002 Population outside inclusion criteria (only participants with positive reference standard included)
Chihal 1986 Study design outside inclusion criteria (retrospective collection of samples)
Cho 2008 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Cho 2009 Reference standard outside inclusion criteria (no abdominal surgery in subset of subjects within the
control group)
Cho 2012 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Chrobak 2004 Reference standard outside inclusion criteria (no abdominal surgery in subset of subjects within the
control group); insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Chun 2012 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Colacurci 1996b Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables); population likely
overlapped with Colacurci 1996a (unable to clarify with the study authors)
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Confino 1990 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Cunha-Filho 2001 Insufficient descriptionof studymethods and population (unclear if prospective sample collection; unable
to clarify with the study authors)
D’Amico 2013 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
D’Cruz 1996 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Darai 2003 Population outside inclusion criteria (postmenopausal women included)
Dawood 1988 Reference standard outside inclusion criteria (no abdominal surgery in the control group); insufficient
diagnostic test accuracy information (unable to construct 2 x 2 tables)
De Sanctis 2011 Insufficient description of study methods and population (unable to contact the study authors)
Di Stefano 1994 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables); insufficient description
of study methods and population (unclear if all the controls had abdominal surgery and if prospective
sample collection)
Dias 2006 Population outside inclusion criteria (only participants with positive reference standard included)
Dias 2012 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Dogan 2006 Review article
Dutta 2012 Study design outside inclusion criteria (retrospective collection of samples)
Dutta 2015 Reference standard outside inclusion criteria (no abdominal surgery in subset of subjects within the
control group)
Ejzenberg 2013 Population outside inclusion criteria (likely only participants with positive reference standard included;
unable to clarify with the study authors); insufficient diagnostic test accuracy information (unable to
construct 2 x 2 tables)
Fallat 1997 Study design outside inclusion criteria (retrospective collection of samples); insufficient diagnostic test
accuracy information (unable to construct 2 x 2 tables)
Fedele 1988 Population overlapped with Fedele 1989
Fernandez-Shaw 1993 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Fernandez-Shaw 1996 Insufficient description of study methods and population (unable to clarify with the study authors)
Ferrero 2005b Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Fisk 1988 Insufficient description of study methods and population (unable to clarify with the study authors)
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Flores 2006 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Fu 2002 Reference standard outside inclusion criteria (no abdominal surgery in the control group); insufficient
diagnostic test accuracy information (unable to construct 2 x 2 tables)
Fujii 2008 Reference standard outside inclusion criteria (no abdominal surgery in the control group); insufficient
diagnostic test accuracy information (unable to construct 2 x 2 tables)
Gagne 2003c Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Gajbhiye 2008 Insufficient description of study methods and population (unable to contact the study authors)
Gajbhiye 2012 Insufficient description of study methods and population (unable to contact the study authors)
Galleri 2009 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Galo 2005 Population outside inclusion criteria (postmenopausal women included); insufficient diagnostic test
accuracy information (unable to construct 2 x 2 tables)
Garcia-Manero 2007 Study groups outside inclusion criteria (comparison within endometriosis group; no control group
included)
Garcia-Velasco 2002 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Garza 1991 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Garzetti 1994 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Gebel 1993 Insufficient description of study methods and population (unclear age group, no separate data for women
with untreated endometriosis; unable to contact the study authors)
Gebel 1995 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables or to confirm negative
findings)
Giudice 1986 Population outside inclusion criteria (postmenopausal women and women with malignancy included)
Gmyrek 2005 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Gorski 2007 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Guerriero 1997 Index test outside inclusion criteria (data for combined blood test and imaging, no separate data for
blood biomarker); population overlapped with Guerriero Guerriero 1996a and Guerriero 1996b
Gunev 1981 Insufficient description of study methods and population (unclear if all the participants had abdominal
surgery and if prospective sample collection; unable to contact the study authors)
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Hammadeh 2003 Study design outside inclusion criteria (retrospective sample collection); reference standard outside in-
clusion criteria (no abdominal surgery in subset of subjects within the control group)
Han 2009 Predictive study (test for susceptibility for endometriosis, not for diagnosis of the disease)
Hatayama 1996 Insufficient description of study methods and population (unable to contact the study authors)
He 1993 Study design outside inclusion criteria (retrospective collection of samples)
Hompes 1996 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Hornstein 1992 Population likely overlapped with Hornstein 1995; unable to contact the study authors
Hrycek 1996 Reference standard outside inclusion criteria (no abdominal surgery in the control group); insufficient
diagnostic test accuracy information (unable to construct 2 x 2 tables)
Hsu 1997 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables or to confirm negative
findings)
Hsu 2014 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Huang 2004 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Hwang 2014 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables); insufficient description
of study methods and population (unclear if prospective sample collection)
Ihlenfeld 2007 Full text not available (unable to contact the study authors)
Illera 2001 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables); insufficient description
of study methods and population
Izumiya 2003 Index test outside inclusion criteria (data for peritoneal fluid to peripheral blood macrophage ratio; no
separate data for blood biomarker)
Jackson 2005 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables); insufficient description
of study methods and population (unclear if prospective sample collection)
Jana 2013 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables); insufficient description
of study methods and population (unclear if prospective sample collection)
Jedryka 2001 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Jerzak 2002 Insufficient description of study methods and population (unclear if all the controls had abdominal
surgery and if prospective sample collection; unable to contact the study authors)
Jing 2009 Reference standard outside inclusion criteria (no surgery in approximately 50% of the control group)
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Kabut 2007 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Kadija 2012 Target condition outside inclusion criteria (assessment of benign versus malignant ovarian tumours; not
specific for endometriosis)
Kafali 2004 Study design outside inclusion criteria (retrospective collection of samples)
Kang 1988 Study design outside inclusion criteria (retrospective collection of samples); insufficient description of
study methods and population (unclear if all the controls had surgery)
Kataoka 2012 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Kharfi 2002 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables or to confirm negative
findings)
KhoshdelRad 2014 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Kichuchi 1993 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Kiechle 1994 Reference standard outside inclusion criteria (no abdominal surgery in subset of subjects within the
control group)
Kilpatrick 1991 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Kim 1995 Population outside inclusion criteria (umbilical cord blood served as control samples)
Kim 2007 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Kim 2014 Study groups outside inclusion criteria (comparison within endometriosis group; no control group
included)
Kinugasa 2011 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables); insufficient description
of study methods and population (unclear if prospective sample collection)
Kobayashi 1987 Reference standard outside inclusion criteria (no abdominal surgery in subset of subjects within the
study and control group); insufficient description of study methods and population (unclear if all the
participants were of reproductive age and time interval between sample collection and surgery)
Kondera-Anasz 2004 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Kondera-Anasz 2005 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Koninckx 1992 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Kopuz 2014 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
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Koumantakis 1994 Insufficient description of study methods and population (unclear if all the controls had abdominal
surgery)
Kralickova 2007 Target condition outside inclusion criteria (assessment of leukaemia-inhibitory factor mutation-positive
versus leukaemia-inhibitory factor mutation-negative women; no separate analysis for endometriosis)
Krasnicki 2001 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Kurt 2014 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Lambert 2014 Unable to locate the full text
Lang 2001 Population outside inclusion criteria (male donors served as controls)
Lee 2014 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Leggieri 2014 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Leng 2002 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Lenhard 2011 Target condition outside inclusion criteria (assessment of benign verus ovarian tumours of lowmalignant
potential; not specific for endometriosis); population outside inclusion criteria (postmenopausal women
included)
Lermann 2010 Insufficient description of study methods and population (unclear age group and if prospective collection
of samples; unable to clarify with the study authors)
Li 2000 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Li 2010 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Linghu 2004 Reference standard outside inclusion criteria (no abdominal surgery in subset of subjects within the
control group)
Liu 2007 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Liu 2013 Study design outside inclusion criteria (retrospective sample collection)
Long 2013 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Luo 2005 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Maeda 2004 Population overlapped with Maeda 2002a and Maeda 2002b
Mahdian 2015 Reference standard outside inclusion criteria (no abdomial surgery in the control group); insufficient
diagnostic accuracy information (unable to construct 2 x 2 tables)
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Malvezzi 2013 Study design outside inclusion criteria (retrospective collection of samples)
Manero 2009 Study groups outside inclusion criteria (comparison within endometriosis group; no control group
included)
Manero 2010 Study groups outside inclusion criteria (comparison within endometriosis group; no control group
included)
Markham 1997b Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Masahashi 1988 Reference standard outside inclusion criteria (no abdominal surgery in the control group); study design
outside inclusion criteria (retrospective collection of samples)
Matalliotakis 1994 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables); insufficient description
of study methods and population (unclear if controls had abdominal surgery)
Matalliotakis 1997 Study design outside inclusion criteria (retrospective sample collection); insufficient information on
study population (unclear if controls had abdominal surgery)
Matalliotakis 2000 Study design outside inclusion criteria (retrospective sample collection)
Matalliotakis 2001a Study design outside inclusion criteria (retrospective sample collection); insufficient diagnostic test ac-
curacy information (unable to construct 2 x 2 tables)
Matalliotakis 2001b Study design outside inclusion criteria (retrospective sample collection); insufficient diagnostic test ac-
curacy information (unable to construct 2 x 2 tables)
Matalliotakis 2003b Study design outside inclusion criteria (retrospective sample collection); insufficient diagnostic test ac-
curacy information (unable to construct 2 x 2 tables)
Matarese 2000 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Mathur 1982 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Mathur 1990 Descriptive study; no focus on diagnostic performance of the test
Mathur 1998 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Mathur 1999 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Mathur 2000 Review article
Matsuoka 2005 Population overlapped with Zhang 2006a
Medl 1997 Population outside inclusion criteria (postmenopausal women included)
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Michaud 2014 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables); insufficient description
of study methods and population (unclear if prospective sample collection)
Moloney 1989 Study design outside inclusion criteria (retrospective collection of samples)
Moretuzzo 1988 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Nabeta 2009 Reference standard outside inclusion criteria (no abdominal surgery in approximately 50% of the control
group); population outside inclusion criteria (women with known malignancy included)
Nabeta 2011 Reference standard outside inclusion criteria (no abdominal surgery in approximately 50% of the control
group); population outside inclusion criteria (women with known malignancy included)
Nagamani 1992 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Nalbanski 2008 Study design outside inclusion criteria (retrospective collection of samples); insufficient diagnostic test
accuracy information (unable to construct 2 x 2 tables)
Nomiyama 1997 Insufficient descriptionof studymethods and population (unclear if prospective sample collection; unable
to contact the study authors)
O’Shaughnessy 1993 Insufficient description of study methods and population (unable to contact the study authors); insuffi-
cient diagnostic accuracy information (unable to construct 2 x 2 tables)
Odukoya 1995a Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Odukoya 1995b Insufficient description of study methods and population (unable to contact the study authors)
Ota 1990 Reference standard outside inclusion criteria (no abdominal surgery in the control group); insufficient
diagnostic test accuracy information (unable to construct 2 x 2 tables)
Ota 1991 Study groups outside inclusion criteria (comparison of endometriosis groupwith adenomyosis; no control
group included)
Ozaksit 1995 Study design outside inclusion criteria (retrospective sample collection)
Ozasa 1987 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Perwira 2009 Full text not available (unable to contact the study authors)
Pittaway 1986 Target condition outside inclusion criteria (evaluation of blood biomarker in various pathological/phys-
iological conditions; unable to obtain separate data for endometriosis)
Pittaway 1987a Population likely overlapped with Pittaway 1989
Pittaway 1987b Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
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Pizzo 2002 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Podgaec 2010 Population overlapped with Podgaec 2007
Pupo-Nogueira 2007 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables or to confirm negative
findings)
Quaranta 2006 Study question outside inclusion criteria: focus on the impact of environmental contaminants on the
dysregulation of
immune function in endometriosis
Rajkumar 1992 Insufficient description of study methods and population (unclear age group; unable to contact the study
authors)
Ramos 2011 Population overlapped with Ramos 2012
Reis 2012 Reference standard outside inclusion criteria (no abdominal surgery in subset of subjects within the
control group)
Santulli 2015 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Sengul 2014 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Seo 2010 Reference standard outside inclusion criteria (no abdominal surgery in subset of subjects within the
control group)
Sha 2009 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Shanti 1999 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Sharma 2010 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Sharpe-Timms 1998 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Signorile 2014 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Slabe 2013 Insufficient descriptionof studymethods and population (unclear if prospective sample collection; unable
to contact the study authors)
Socolov 2011 Population outside inclusion criteria (women with ectopic pregnancy, pelvic inflammatory disease and
other known pathologies included)
Steff 2004b Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Suryawanshi 2013 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Szyllo 2001 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
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Takahashi 1987 Study groups outside inclusion criteria (comparison within endometriosis groups; no controls included)
Takahashi 1988 Reference standard outside inclusion criteria (no abdominal surgery in the control group); study design
outside inclusion criteria (retrospective collection of samples)
Takahashi 1989 Reference standard outside inclusion criteria (no abdominal surgery in the control group); study design
outside inclusion criteria (retrospective collection of samples)
Takemura 2005 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Tanaka 2000 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables); insufficient description
of study methods and population (unclear if retrospective sample collection and if all the controls had
abdominal surgery)
Telimaa 1989 Reference standard outside inclusion criteria (no abdominal surgery in the control group); insufficient
diagnostic test accuracy information (unable to construct 2 x 2 tables)
Tsao 2007 Focus on screening, not on diagnostic performance of the test
Tuten 2014b Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Venturella 2011 Insufficient descriptionof studymethods and population (unclear if prospective sample collection; unable
to clarify with the study authors); insufficient diagnostic test accuracy information (unable to construct
2 x 2 tables)
Vercellini 1992 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Wang 2007 Reference standard outside inclusion criteria (no abdominal surgery in the control group); population
outside inclusion criteria (postmenopausal women included)
Wang 2008 Reference standard outside inclusion criteria (no abdominal surgery in the control group); population
outside inclusion criteria (postmenopausal women included)
Wang 2009 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Wang 2013b Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Watanabe 1990 Reference standard outside inclusion criteria (no abdominal surgery in subset of subjects within the
study and control group); insufficient description of study methods and population (unclear if all the
participants were of reproductive age and time interval between sample collection and surgery)
Wild 1985 Population overlapped with Wild Wild 1991a; insufficient description of methods and population
Wild 1991b Population overlapped with Wild 1991a
Wild 1991c Evaluation of the laboratory techniques; no focus on diagnostic accuracy of the test
488Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Wild 1992 Evaluation of the laboratory techniques; no focus on diagnostic accuracy of the test
Wilson 1994 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Wojcik-Krowiranda 2010 Population outside inclusion criteria (postmenopausal women included)
Xavier 2006 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Yang 2013a Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Yang 2013b Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Yi 2010 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Yin 2000 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Zachariah 2009 Reference standard outside inclusion criteria (no abdominal surgery in the control group); insufficient
diagnostic test accuracy information (unable to construct 2 x 2 tables)
Zhang 2006c Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Zhang 2009 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Zhao 2015 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Zheng 2011 Reference standard outside inclusion criteria (no abdominal surgery in the control group)
Zhu 2007 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Zomer 2013 Study groups outside inclusion criteria (comparison within endometriosis group; no control group
included)
Zong 2003 Insufficient diagnostic test accuracy information (unable to construct 2 x 2 tables)
Characteristics of ongoing studies [ordered by study ID]
JPRN-UMIN000009223
Trial name or title Analysis ofmiRNA inblood for development of diagnostic biomarkers for endometriosis
ClinicalTrials.gov Identifier: JPRN-UMIN000009223
Primary sponsor: Juntendo University Hospital, Department of Obstetrics and Gyne-
cology
Target condition and reference standard(s) Objective: To identify endometriosis-specific microRNAs in blood and to develop a
diagnostic test for endometriosis
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JPRN-UMIN000009223 (Continued)




Index and comparator tests Blood
Starting date February 2013
Contact information Name: Ikuo Mori DVM, Ph.D
Address: 26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, JAPAN Japan
Email: ikuo.mori@takeda.com
Affiliation: Takeda Pharmaceutical Company Limited Integrated Technology Research
Laboratories, Pharmaceutical Research Division
Name: Mari Kitade MD
Address: Hongo 3-1-3, Bunkyo-ku, Tokyo 113-8431, Japan
Telephone: 03-3813-3111
Email: kitade@juntendo.ac.jp
Affiliation: Juntendo University Hospital Department of Obstetrics and Gynecology
Notes Current status - ongoing, recruiting participants
NCT01301885
Trial name or title ENDOMET - Novel diagnostic tools and treatments for endometriosis
ClinicalTrials.gov Identifier: NCT01301885
Other study name: CA125 VAS changes
Target condition and reference standard(s) Objective: To identify expression of endometriosis specific RNAs/proteins
Primary outcome measures: Concentration of protein and DNA in biological fluids
and tissues in association with endometriosis
Study design: Observational case-control, prospective
Target condition: Endometriosis
Reference standard: Laparoscopy
Index and comparator tests Serum, peritoneal fluid, endometrium tissue, healthy peritoneum, tissue of endometrio-
sis (peritoneal, ovarian, deep infiltrating)
Extracted DNA, RNA, cDNA and protein from the above samples
Starting date February 2011
Contact information Responsible party: Antti Perheentupa, Turku University Hospital
Notes Current status - ongoing, but not recruiting participants
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NCT02091557
Trial name or title CA-125 and VAS pain score changes to diagnose endometriosis
ClinicalTrials.gov Identifier: NCT02091557
Other study name: CA125 VAS changes
Target condition and reference standard(s) Objective: To assess the diagnostic accuracy for the noninvasive detection of pelvic
endometriosis of the combination of two simple parameters: modifications of serum
CA-125 and VAS pain score following one dose of GnRH-a
Primary outcome measures: Serum CA-125 level taken in follicular cycle phase (2nd-
3rd day of the menstrual cycle) and VAS score for menstrual pain. During the time
passed on surgery waiting list, patients will receive LAD at a dose of 3.75 mg IM on
the 21st day of the menstrual cycle. One month later, LAD administration, serum CA-
125 levels and VAS score will be assessed again, and then the surgical procedure will be
performed in all these patients
Study design: Observational cohort, prospective
Target condition: Endometriosis
Reference standard: Laparoscopy
Index and comparator tests Blood
Starting date January 2011
Contact information Responsible party: Fulvio Zullo, University Magna Graecia
Notes Current status - completed, results not available
NCT02337816
Trial name or title Role of metabolomics in the diagnosis of endometriosis
ClinicalTrials.gov Identifier: NCT02337816
Other study name: ENDOMETAB01
Target condition and reference standard(s) Objective: To identify an alteration in the expression of the metabolites in women with
endometriosis
Primary outcome measures: Plasma and urine concentration of metabolites (time
frame: at least one month after discontinuation of hormonal therapies and before la-
paroscopic surgery)
Study design: Non-randomised, parallel assignment, open label
Target condition: Endometriosis
Reference standard: Laparoscopy + histopathology
Index and comparator tests Urine and blood
Starting date December 2014
Contact information Responsible party: Stefano Angioni, University of Cagliari
Notes Current status - ongoing, but not recruiting participants
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CA-125: cancer antigen-125; cDNA: complementary DNA;GnRH-a: gonadotropin-releasing hormone analogue; IM: intramuscular;
LAD: leuprolide acetate depot; VAS: visual analogue scale
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D A T A
Presented below are all the data for all of the tests entered into the review.






1 Glycodelin-A (> 2.07 ng/ml) 1 99
2 Glycodelin (> 9.0 ng/ml) 1 45
3 Glycodelin (> 18 ng/ml) 1 99
4 IGFBP-3 (> 200 ng/ml) 1 45
5 IGFBP-3 (> 210 ng/ml) 1 99
6 VEGF (> 1.5 pg/ml) 1 99
7 VEGF (> 236 pg/ml) 1 95
8 VEGF-A (> 680 pg/ml) 1 60
9 Urocortin (> 29 pg/ml),
endometrioma
1 80
10 Urocortin (> 33 pg/ml),
endometrioma
1 80
11 Urocortin (> 41.6 pg/ml),
endometrioma
1 88
12 Survivin (cut-off not reported) 1 60
13 sICAM-1 (< 243 ng/ml) 1 100
14 sICAM-1 (< 254.6 ng/ml) 1 28
15 sICAM-1 (> 241.46 µg/ml) 1 60
16 LN-1 (> 1110.0 pg/ml) 1 73
17 Metabolome by ESI-MS/MS




18 Proteome by SELDI-TOF-MS
(3 peaks with the molecular
weight of 3,956.00, 11,710.00
and 6,986.00 Da)
1 31
19 Proteome by SELDI-TOF MS
(5 peaks with molecular weights
of 4159.00, 5264.00, 5603.00,
9861.00 and 10,533.00 Da)
1 90
20 Proteome by SELDI-TOF
MS (5 peaks with molecular




21 Proteome by SELDI-TOF
MS (5 peaks with molecular
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22 Proteome by SELDI-TOF
MS (5 peaks with molecular




23 Proteome by SELDI-TOF-MS
(6 peaks with molecular




24 Prolactin (> 14.8 ng/ml) 1 97
25 Prolactin (> 20 ng/ml) 1 97
26 Anti-endometrial Abs, IgG 4 759
27 Anti-endometrial Abs (MW
26/34/42 kd)
1 36
28 Anti-laminin auto Abs, IgG (>
1 U/ml)
1 68
29 sCD23 (cut-off not reported) 1 97
30 MCP-1 (> 100 pg/ml) 1 101
31 Copeptin (> 251.18 pg/ml) 1 87
32 hs-CRP (> 0.61 mg/l) 1 119
33 hs-CRP (> 0.62 mg/l) 1 295
34 hs-CRP (> 0.70 mg/l) 1 116
35 hs-CRP (> 0.73 mg/l) 1 60
36 hs-CRP (> 438 µg/ml) 1 95
37 hs-CRP (cut-off not reported) 1 116
38 IFN-γ (< 76 pg/ml) 1 45
39 MIF (> 0.57 ng/ml) 1 93
40 TNF-α (> 12.45 pg/ml) 1 95
41 TNF-α (< 45.6 pg/ml) 1 45
42 TNF-α (cut-off not reported) 1 116
43 Neutrophils (> 4058/ml) 1 100
44 NLR (> 2.19) 1 100
45 WBC (> 6400/ml) 1 100
46 IL-1β (< 0.9 pg/ml) 1 45
47 IL-4 (≥ 3 pg/ml) 1 50
48 IL-6 (> 1.03 pg/ml) 1 138
49 IL-6 (> 1.9 pg/ml) 1 138
50 IL-6 (> 2 pg/ml) 2 171
51 IL-6 (> 2.6 pg/ml) 1 138
52 IL-6 (> 4 pg/ml) 1 91
53 IL-6 (> 7.5 pg/ml) 1 91
54 IL-6 (< 10 pg/ml) 1 45
55 IL-6 (> 12.2 pg/ml) 1 95
56 IL-6 (> 15.4 pg/ml) 1 78
57 IL-6 (> 25.75 pg/ml) 1 83
58 IL-6 (cut-off not reported) 1 116
59 IL-8 (> 24 pg/ml) 1 101
60 IL-8 (≥ 25 pg/ml),
endometrioma
1 91
61 IL-8 (cut-off not reported) 1 116
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62 Follistatin (> 1433 pg/ml),
endometrioma
1 104
63 STX-5 (> 55 ng/ml) 1 80
64 Carbonyls (< 14.9 µM) 1 108
65 PON-1 (< 141.5 U/l) 1 87
66 Thiols (< 396.44 µM) 1 108
67 miR-9* (cut-off not reported) 1 85
68 miR-17-5 (< 0.9057) 1 40
69 miR-20a (< 0.6879) 1 40
70 miR-22 (< 0.5647) 1 40
71 miR-122 (cut-off not reported) 1 85
72 miR-141* (cut-off not
reported)
1 85
73 miR-145* (cut-off not
reported)
1 85
74 miR-199a (cut-off not
reported)
1 85
75 miR-532-3p (cut-off not
reported)
1 85
76 Ca-15.3 (> 15 IU/ml) 1 88
77 Ca-15.3 (> 30 IU/ml) 1 119
78 CA-19.9 (> 7.5 IU/ml) 1 76
79 CA-19.9 (> 9.5 IU/ml) 1 198
80 CA-19.9 (> 10.67 IU/ml) 1 88
81 CA-19.9 (≥ 12 U/ml),
endometrioma
1 118
82 CA-19.9 (> 37 IU/ml) 3 330
83 CA-19.9 (cut-off not reported) 2 176
84 CA-72 (TAG-72) (> 4 U/ml) 1 35
85 CA-72 (TAG-72) (> 6 U/ml) 1 119
86 CA-125 (> 10 IU/ml) 1 201
87 CA-125 (> 11 U/ml) 1 59
88 CA-125 (> 11.5 U/ml) 1 45
89 CA-125 (> 12.5 U/ml) 1 99
90 CA-125 (> 12.8 U/ml) 1 368
91 CA-125 (> 13.5 U/ml) 1 35
92 CA-125 (> 14.7 IU/ml) 1 60
93 CA-125 (> 16 U/ml) 4 335
94 CA-125 (> 17.6 IU/ml) 1 95
95 CA-125 (> 20 IU/ml) 4 1115
96 CA-125 (> 20 U/ml),
endometrioma
2 189
97 CA-125 (> 25 U/ml),
endometrioma
1 101
98 CA-125 (> 26 IU/ml) 2 862
99 CA-125 (> 30 U/ml) 3 943
100 CA-125 (> 30 U/ml),
endometrioma
2 163
101 CA-125 (> 33 U/ml) 1 100
102 CA-125 (> 35 U/ml) 25 3266
103 CA-125 (> 35 U/ml),
endometrioma
1 101
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104 CA-125 (> 36 U/l)
endometrioma
1 80
105 CA-125 (> 42 U/l),
endometrioma
1 104
106 CA-125 (> 43 U/ml) 1 62
107 CA-125 (cut-off not reported) 1 59
108 CA-125 (cut-off not reported) 1 119
109 CA-125 (cut-off not reported) 1 60
110 CA-125 (cut-off not reported) 1 116
111 Combined test (CA-125 ≥
25 U/ml +/or CA-19.9 ≥ 12
U/ml), endometrioma
1 118
112 Combined test (CA-125 ≥ 25
U/ml + Ca-19.9 ≥ 12 U/ml),
endometrioma
1 118
113 Combined test (CA-125 >
19.8 U/l + Prolactin > 14.8
ng/ml)
1 97
114 Combined test (CA-125 > 35
U/l + Prolactin > 20 ng/ml)
1 97
115 Combined test (CA-125 >
17.6 IU/ml + VEGF > 236
pg/ml)
1 95
116 Combined test (CA-125 > 20
U/l + Anti-endometrial Abs >
0.3 A-value)
1 42
117 Combined test (CA-125 x
NLR; (> 43.1)
1 100
118 Combined test (CA-125 > 30
U/ml +/or IL-8 ≥ 25 pg/ml),
endometrioma
1 83
119 Combined test (CA-125 +
IL-8) (cut-off not reported)
1 294
120 Combined test (IL-6 > 12.2
pg/ml + TNF-α > 12.45 pg/ml)
1 96
121 Combined test (IL-6 > 12.2
pg/ml + CRP > 438 µg/ml)
1 95
122 Combined test (TNF-α >
12.45 pg/ml + CRP > 438
µg/ml)
1 95
123 Combined test (miR-199a
+ miR-122) (cut-off not
reported)
1 85
124 Combined test (miR-199a
+ miR-542-3p) (cut-off not
reported)
1 85
125 Combined test (Ca-125 + Ca
19-9 + Survivin) (cut-off not
reported)
1 60
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126 Combined test (CA-125 +
STX-5 + LN-1) (cut-off not
reported)
1 80
127 Combined test (CA-125 >
35 IU/ml +/or CA-19.9 > 37
IU/ml +/or IL-6 > 2 pg/ml)
1 80
128 Combined test (CA-125 >
50 IU/mL +/ or CCR1 > 1.16
+/or MCP-1 > 140 pg/ml)
1 151
129 Combined test (Ca-125 > 20
mIU/ml + MCP-1 > 152.74
pg/ml + Leptin > 3.14 ng/ml)
1 141
130 Combined test CA-125 +
IL-8 + TNF-α) (cut-off not
reported)
1 116
131 Combined test (IL-6 > 12.2
pg/ml + TNF-α > 12.45 pg/ml
+ CRP > 438 µg/ml)
1 95
132 Combined test (CA-125
+ VEGF + annexin V +
glycodelin] - MLR (cut-off not
reported)
1 19
133 Combined test (CA-125
+ VEGF + annexin V +
glycodelin] - LS-SVM (cut-off
not reported)
1 19
134 Combined test (CA-125
+ VEGF + annexin V +
sICAM-1) - MLR or LS-SVM
(cut-off not reported)
1 19
135 Combined test (CA-125 >
20 mIU/ml + MCP-1 > 53.5
pg/ml + Leptin > 29.1 ng/ml +
MIF > 14.7 ng/ml)
1 141
136 Combined test (miR-199a




137 Combined test (CA-125
+ CA-19.9 + IL-6 + IL-8 +
TNF-α + hs-CRP) (cut-off not
reported)
1 294
138 Combined test (CA-125
+ CA-19.9 + IL-6 + IL-8 +
TNF-α + hs-CRP) (cut-off not
reported)
1 59
139 Combined test (CA-125
+ CA-19.9 + IL-6 + IL-8 +
TNF-α + hs-CRP) (cut-off not
reported)
1 119
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140 Combined test (CA-125
+ CA-19.9 + IL-6 + IL-8 +
TNF-α + hs-CRP) (cut-off not
reported)
1 116
141 CA-125 (> 20 U/ml), Bilibio
2014
1 97
142 CA-125 (> 35 U/ml), Bilibio
2014
1 97
143 CA-125 (> 16 U/ml), Ferreira
1994
1 41
144 CA-125 (> 35 U/ml), Ferreira
1994
1 41
145 CA-125 (> 30 U/ml), Florio
2007
1 80
146 CA-125 (> 36 U/ml), Florio
2007
1 80
147 CA-125 (> 12.8 U/ml),
Gagne 2003a
1 368
148 CA-125 (> 35 U/ml), Gagne
2003a
1 368
149 CA-125 (> 20 U/ml),
Guerriero 1996b
1 101
150 CA-125 (≥ 25 U/ml),
Guerriero 1996b
1 101
151 CA-125 (> 35 U/ml),
Guerriero 1996b
1 101
152 CA-125 (> 20 U/ml),
Kitawaki 2005
1 775
153 CA-125 (> 26 U/ml),
Kitawaki 2005
1 775
154 CA-125 (> 30 U/ml),
Kitawaki 2005
1 775
155 CA-125 (> 35 U/ml),
Kitawaki 2005
1 775
156 CA-125 (> 10 U/ml), Rosa E
Silva 2007
1 201
157 CA-125 (> 20 U/ml), Rosa E
Silva 2007
1 201
158 CA-125 (> 20 U/ml), Yang
1994
1 42
159 CA-125 (> 35 U/ml), Yang
1994
1 42
160 IL-6 (> 1.03 pg/ml), Othman
2008
1 138
161 IL-6 (> 1.9 pg/ml), Othman
2008
1 138
162 IL-6 (> 2.6 pg/ml), Othman
2008
1 138
163 IL-6 (> 2 pg/ml), Bedaiwy
2002
1 91
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164 IL-6 (> 4 pg/ml), Bedaiwy
2002
1 91
165 IL-6 (> 7.5 pg/ml), Bedaiwy
2002
1 91
Test 1. Glycodelin-A (> 2.07 ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 1 Glycodelin-A (> 2.07 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kocbek 2013 47 9 10 33 0.82 [ 0.70, 0.91 ] 0.79 [ 0.63, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. Glycodelin (> 9.0 ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 2 Glycodelin (> 9.0 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 20 11 8 6 0.71 [ 0.51, 0.87 ] 0.35 [ 0.14, 0.62 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 3. Glycodelin (> 18 ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 3 Glycodelin (> 18 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 36 23 22 18 0.62 [ 0.48, 0.74 ] 0.44 [ 0.28, 0.60 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. IGFBP-3 (> 200 ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 4 IGFBP-3 (> 200 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 20 12 8 5 0.71 [ 0.51, 0.87 ] 0.29 [ 0.10, 0.56 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. IGFBP-3 (> 210 ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 5 IGFBP-3 (> 210 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 32 23 26 18 0.55 [ 0.42, 0.68 ] 0.44 [ 0.28, 0.60 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 6. VEGF (> 1.5 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 6 VEGF (> 1.5 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 29 16 29 25 0.50 [ 0.37, 0.63 ] 0.61 [ 0.45, 0.76 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 7. VEGF (> 236 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 7 VEGF (> 236 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Foda 2012 60 7 5 23 0.92 [ 0.83, 0.97 ] 0.77 [ 0.58, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 8. VEGF-A (> 680 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 8 VEGF-A (> 680 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mohamed 2013 28 1 2 29 0.93 [ 0.78, 0.99 ] 0.97 [ 0.83, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 9. Urocortin (> 29 pg/ml), endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 9 Urocortin (> 29 pg/ml), endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Florio 2007 39 6 1 34 0.98 [ 0.87, 1.00 ] 0.85 [ 0.70, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 10. Urocortin (> 33 pg/ml), endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 10 Urocortin (> 33 pg/ml), endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Florio 2007 35 4 5 36 0.88 [ 0.73, 0.96 ] 0.90 [ 0.76, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 11. Urocortin (> 41.6 pg/ml), endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 11 Urocortin (> 41.6 pg/ml), endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tokmak 2011 32 25 10 21 0.76 [ 0.61, 0.88 ] 0.46 [ 0.31, 0.61 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 12. Survivin (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 12 Survivin (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mabrouk 2012 3 2 37 18 0.08 [ 0.02, 0.20 ] 0.90 [ 0.68, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 13. sICAM-1 (< 243 ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 13 sICAM-1 (< 243 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 32 21 26 21 0.55 [ 0.42, 0.68 ] 0.50 [ 0.34, 0.66 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 14. sICAM-1 (< 254.6 ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 14 sICAM-1 (< 254.6 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 8 12 3 5 0.73 [ 0.39, 0.94 ] 0.29 [ 0.10, 0.56 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 15. sICAM-1 (> 241.46 µg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 15 sICAM-1 (> 241.46 g/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Zhang 2006b 18 4 12 26 0.60 [ 0.41, 0.77 ] 0.87 [ 0.69, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 16. LN-1 (> 1110.0 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 16 LN-1 (> 1110.0 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ozhan 2014 38 6 15 14 0.72 [ 0.58, 0.83 ] 0.70 [ 0.46, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 17. Metabolome by ESI-MS/MS (SMOH C16:1 + PCaa C36:2/ PCae C34:2) age-/BMI-adjusted.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 17 Metabolome by ESI-MS/MS (SMOH C16:1 + PCaa C36:2/ PCae C34:2) age-/BMI-adjusted
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vouk 2012 36 8 4 44 0.90 [ 0.76, 0.97 ] 0.85 [ 0.72, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 18. Proteome by SELDI-TOF-MS (3 peaks with the molecular weight of 3,956.00, 11,710.00 and
6,986.00 Da).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 18 Proteome by SELDI-TOF-MS (3 peaks with the molecular weight of 3,956.00, 11,710.00 and 6,986.00 Da)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Liu 2009 14 3 2 12 0.88 [ 0.62, 0.98 ] 0.80 [ 0.52, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 19. Proteome by SELDI-TOF MS (5 peaks with molecular weights of 4159.00, 5264.00, 5603.00,
9861.00 and 10,533.00 Da).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 19 Proteome by SELDI-TOF MS (5 peaks with molecular weights of 4159.00, 5264.00, 5603.00, 9861.00 and 10,533.00 Da)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wolfler 2009 40 16 11 23 0.78 [ 0.65, 0.89 ] 0.59 [ 0.42, 0.74 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 20. Proteome by SELDI-TOF MS (5 peaks with molecular weight of 9,926.31, 10,072.2, 6,753.04,
4,302.67, 9,328.49 Da).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 20 Proteome by SELDI-TOF MS (5 peaks with molecular weight of 9,926.31, 10,072.2, 6,753.04, 4,302.67, 9,328.49 Da)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Fassbender 2012 18 4 27 18 0.40 [ 0.26, 0.56 ] 0.82 [ 0.60, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 21. Proteome by SELDI-TOF MS (5 peaks with molecular weight of 2,831.02, 7,554.66, 4,241.29,
2,953.25, 9,927.73 Da).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 21 Proteome by SELDI-TOF MS (5 peaks with molecular weight of 2,831.02, 7,554.66, 4,241.29, 2,953.25, 9,927.73 Da)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Fassbender 2012 25 5 40 28 0.38 [ 0.27, 0.51 ] 0.85 [ 0.68, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 22. Proteome by SELDI-TOF MS (5 peaks with molecular weight of 11,366.3, 5,712.69, 10,070.7,
3,017.68, 3,824.44 Da).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 22 Proteome by SELDI-TOF MS (5 peaks with molecular weight of 11,366.3, 5,712.69, 10,070.7, 3,017.68, 3,824.44 Da)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Fassbender 2012 29 6 26 27 0.53 [ 0.39, 0.66 ] 0.82 [ 0.65, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 23. Proteome by SELDI-TOF-MS (6 peaks with molecular weights of 1629.00 3047.00, 3526.00,
3774.00, 5046.00 and 5068.00 Da).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 23 Proteome by SELDI-TOF-MS (6 peaks with molecular weights of 1629.00 3047.00, 3526.00, 3774.00, 5046.00 and 5068.00 Da)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Seeber 2010 40 1 21 77 0.66 [ 0.52, 0.77 ] 0.99 [ 0.93, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 24. Prolactin (> 14.8 ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 24 Prolactin (> 14.8 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bilibio 2014 28 2 35 32 0.44 [ 0.32, 0.58 ] 0.94 [ 0.80, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 25. Prolactin (> 20 ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 25 Prolactin (> 20 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bilibio 2014 13 0 50 34 0.21 [ 0.11, 0.33 ] 1.00 [ 0.90, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 26. Anti-endometrial Abs, IgG.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 26 Anti-endometrial Abs, IgG
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Odukoya 1996 32 3 25 37 0.56 [ 0.42, 0.69 ] 0.93 [ 0.80, 0.98 ]
Randall 2007 243 32 35 217 0.87 [ 0.83, 0.91 ] 0.87 [ 0.82, 0.91 ]
Wild 1991a 61 7 11 14 0.85 [ 0.74, 0.92 ] 0.67 [ 0.43, 0.85 ]
Yang 1994 23 6 5 8 0.82 [ 0.63, 0.94 ] 0.57 [ 0.29, 0.82 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 27. Anti-endometrial Abs (MW 26/34/42 kd).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 27 Anti-endometrial Abs (MW 26/34/42 kd)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Gorai 1993 18 11 0 7 1.00 [ 0.81, 1.00 ] 0.39 [ 0.17, 0.64 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 28. Anti-laminin auto Abs, IgG (> 1 U/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 28 Anti-laminin auto Abs, IgG (> 1 U/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Inagaki 2003 17 3 25 23 0.40 [ 0.26, 0.57 ] 0.88 [ 0.70, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 29. sCD23 (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 29 sCD23 (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Odukoya 1996 14 3 43 37 0.25 [ 0.14, 0.38 ] 0.93 [ 0.80, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 30. MCP-1 (> 100 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 30 MCP-1 (> 100 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Akoum 1996 37 17 20 27 0.65 [ 0.51, 0.77 ] 0.61 [ 0.45, 0.76 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 31. Copeptin (> 251.18 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 31 Copeptin (> 251.18 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tuten 2014a 33 15 18 21 0.65 [ 0.50, 0.78 ] 0.58 [ 0.41, 0.74 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 32. hs-CRP (> 0.61 mg/l).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 32 hs-CRP (> 0.61 mg/l)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2011 45 18 38 18 0.54 [ 0.43, 0.65 ] 0.50 [ 0.33, 0.67 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 33. hs-CRP (> 0.62 mg/l).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 33 hs-CRP (> 0.62 mg/l)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2011 126 40 78 51 0.62 [ 0.55, 0.68 ] 0.56 [ 0.45, 0.66 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 34. hs-CRP (> 0.70 mg/l).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 34 hs-CRP (> 0.70 mg/l)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2011 47 13 33 23 0.59 [ 0.47, 0.70 ] 0.64 [ 0.46, 0.79 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 35. hs-CRP (> 0.73 mg/l).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 35 hs-CRP (> 0.73 mg/l)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2011 28 10 13 9 0.68 [ 0.52, 0.82 ] 0.47 [ 0.24, 0.71 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 36. hs-CRP (> 438 µg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 36 hs-CRP (> 438 g/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Foda 2012 54 4 11 26 0.83 [ 0.72, 0.91 ] 0.87 [ 0.69, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 37. hs-CRP (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 37 hs-CRP (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mihalyi 2010 32 11 46 27 0.41 [ 0.30, 0.53 ] 0.71 [ 0.54, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 38. IFN-γ (< 76 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 38 IFN- (< 76 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 19 6 9 11 0.68 [ 0.48, 0.84 ] 0.65 [ 0.38, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 39. MIF (> 0.57 ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 39 MIF (> 0.57 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Morin 2005 36 13 19 25 0.65 [ 0.51, 0.78 ] 0.66 [ 0.49, 0.80 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 40. TNF-α (> 12.45 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 40 TNF- (> 12.45 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Foda 2012 58 4 7 26 0.89 [ 0.79, 0.96 ] 0.87 [ 0.69, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 41. TNF-α (< 45.6 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 41 TNF- (< 45.6 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 19 11 9 6 0.68 [ 0.48, 0.84 ] 0.35 [ 0.14, 0.62 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 42. TNF-α (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 42 TNF- (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mihalyi 2010 62 10 16 28 0.79 [ 0.69, 0.88 ] 0.74 [ 0.57, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 43. Neutrophils (> 4058/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 43 Neutrophils (> 4058/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dayangan Sayan 2013 34 20 16 30 0.68 [ 0.53, 0.80 ] 0.60 [ 0.45, 0.74 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 44. NLR (> 2.19).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 44 NLR (> 2.19)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dayangan Sayan 2013 38 9 12 41 0.76 [ 0.62, 0.87 ] 0.82 [ 0.69, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 45. WBC (> 6400/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 45 WBC (> 6400/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dayangan Sayan 2013 32 23 18 27 0.64 [ 0.49, 0.77 ] 0.54 [ 0.39, 0.68 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 46. IL-1β (< 0.9 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 46 IL-1 (< 0.9 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 23 11 5 6 0.82 [ 0.63, 0.94 ] 0.35 [ 0.14, 0.62 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 47. IL-4 (≥ 3 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 47 IL-4 (≥ 3 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Drosdzol-Cop 2012b 21 6 12 11 0.64 [ 0.45, 0.80 ] 0.65 [ 0.38, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 48. IL-6 (> 1.03 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 48 IL-6 (> 1.03 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Othman 2008 55 34 13 36 0.81 [ 0.70, 0.89 ] 0.51 [ 0.39, 0.64 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 49. IL-6 (> 1.9 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 49 IL-6 (> 1.9 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Othman 2008 48 24 20 46 0.71 [ 0.58, 0.81 ] 0.66 [ 0.53, 0.77 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 50. IL-6 (> 2 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 50 IL-6 (> 2 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bedaiwy 2002 50 12 6 23 0.89 [ 0.78, 0.96 ] 0.66 [ 0.48, 0.81 ]
Somigliana 2004 9 7 36 28 0.20 [ 0.10, 0.35 ] 0.80 [ 0.63, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 51. IL-6 (> 2.6 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 51 IL-6 (> 2.6 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Othman 2008 41 21 27 49 0.60 [ 0.48, 0.72 ] 0.70 [ 0.58, 0.80 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 52. IL-6 (> 4 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 52 IL-6 (> 4 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bedaiwy 2002 48 7 8 28 0.86 [ 0.74, 0.94 ] 0.80 [ 0.63, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 53. IL-6 (> 7.5 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 53 IL-6 (> 7.5 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bedaiwy 2002 45 5 11 30 0.80 [ 0.68, 0.90 ] 0.86 [ 0.70, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 54. IL-6 (< 10 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 54 IL-6 (< 10 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 20 14 8 3 0.71 [ 0.51, 0.87 ] 0.18 [ 0.04, 0.43 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 55. IL-6 (> 12.2 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 55 IL-6 (> 12.2 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Foda 2012 62 5 3 25 0.95 [ 0.87, 0.99 ] 0.83 [ 0.65, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 56. IL-6 (> 15.4 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 56 IL-6 (> 15.4 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Elgafor el Sharkwy 2013 34 7 4 33 0.89 [ 0.75, 0.97 ] 0.83 [ 0.67, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 57. IL-6 (> 25.75 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 57 IL-6 (> 25.75 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Martinez 2007 8 12 3 60 0.73 [ 0.39, 0.94 ] 0.83 [ 0.73, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 58. IL-6 (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 58 IL-6 (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mihalyi 2010 46 9 32 29 0.59 [ 0.47, 0.70 ] 0.76 [ 0.60, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 59. IL-8 (> 24 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 59 IL-8 (> 24 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dayangan Sayan 2013 31 14 19 37 0.62 [ 0.47, 0.75 ] 0.73 [ 0.58, 0.84 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 60. IL-8 (≥ 25 pg/ml), endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 60 IL-8 (≥ 25 pg/ml), endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ohata 2008 50 4 20 17 0.71 [ 0.59, 0.82 ] 0.81 [ 0.58, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 61. IL-8 (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 61 IL-8 (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mihalyi 2010 38 11 40 27 0.49 [ 0.37, 0.60 ] 0.71 [ 0.54, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 62. Follistatin (> 1433 pg/ml), endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 62 Follistatin (> 1433 pg/ml), endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Florio 2009 48 4 4 48 0.92 [ 0.81, 0.98 ] 0.92 [ 0.81, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 63. STX-5 (> 55 ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 63 STX-5 (> 55 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ozhan 2014 47 6 13 14 0.78 [ 0.66, 0.88 ] 0.70 [ 0.46, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 64. Carbonyls (< 14.9 µM).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 64 Carbonyls (< 14.9 M)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rosa E Silva 2014 63 20 4 21 0.94 [ 0.85, 0.98 ] 0.51 [ 0.35, 0.67 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 65. PON-1 (< 141.5 U/l).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 65 PON-1 (< 141.5 U/l)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Verit 2008 46 8 1 32 0.98 [ 0.89, 1.00 ] 0.80 [ 0.64, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 66. Thiols (< 396.44 µM).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 66 Thiols (< 396.44 M)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rosa E Silva 2014 49 8 18 33 0.73 [ 0.61, 0.83 ] 0.80 [ 0.65, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 67. miR-9* (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 67 miR-9* (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wang 2013a 41 1 19 24 0.68 [ 0.55, 0.80 ] 0.96 [ 0.80, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 68. miR-17-5 (< 0.9057).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 68 miR-17-5 (< 0.9057)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jia 2013 14 6 6 14 0.70 [ 0.46, 0.88 ] 0.70 [ 0.46, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 69. miR-20a (< 0.6879).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 69 miR-20a (< 0.6879)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jia 2013 12 2 8 18 0.60 [ 0.36, 0.81 ] 0.90 [ 0.68, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 70. miR-22 (< 0.5647).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 70 miR-22 (< 0.5647)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jia 2013 18 4 2 16 0.90 [ 0.68, 0.99 ] 0.80 [ 0.56, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 71. miR-122 (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 71 miR-122 (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wang 2013a 48 6 12 19 0.80 [ 0.68, 0.89 ] 0.76 [ 0.55, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 72. miR-141* (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 72 miR-141* (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wang 2013a 43 1 17 24 0.72 [ 0.59, 0.83 ] 0.96 [ 0.80, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 73. miR-145* (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 73 miR-145* (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wang 2013a 42 1 18 24 0.70 [ 0.57, 0.81 ] 0.96 [ 0.80, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 74. miR-199a (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 74 miR-199a (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wang 2013a 47 6 13 19 0.78 [ 0.66, 0.88 ] 0.76 [ 0.55, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 75. miR-532-3p (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 75 miR-532-3p (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wang 2013a 48 2 12 23 0.80 [ 0.68, 0.89 ] 0.92 [ 0.74, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 76. Ca-15.3 (> 15 IU/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 76 Ca-15.3 (> 15 IU/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tuten 2014a 33 14 18 23 0.65 [ 0.50, 0.78 ] 0.62 [ 0.45, 0.78 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 77. Ca-15.3 (> 30 IU/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 77 Ca-15.3 (> 30 IU/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Muscatello 1992 3 3 78 35 0.04 [ 0.01, 0.10 ] 0.92 [ 0.79, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 78. CA-19.9 (> 7.5 IU/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 78 CA-19.9 (> 7.5 IU/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 32 14 12 18 0.73 [ 0.57, 0.85 ] 0.56 [ 0.38, 0.74 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 79. CA-19.9 (> 9.5 IU/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 79 CA-19.9 (> 9.5 IU/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 64 34 53 47 0.55 [ 0.45, 0.64 ] 0.58 [ 0.47, 0.69 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 80. CA-19.9 (> 10.67 IU/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 80 CA-19.9 (> 10.67 IU/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Tuten 2014a 33 14 18 23 0.65 [ 0.50, 0.78 ] 0.62 [ 0.45, 0.78 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 81. CA-19.9 (≥ 12 U/ml), endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 81 CA-19.9 (≥ 12 U/ml), endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Guerriero 1996a 24 24 15 55 0.62 [ 0.45, 0.77 ] 0.70 [ 0.58, 0.79 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 82. CA-19.9 (> 37 IU/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 82 CA-19.9 (> 37 IU/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Harada 2002 34 0 67 22 0.34 [ 0.25, 0.44 ] 1.00 [ 0.85, 1.00 ]
Kurdoglu 2009 35 1 66 25 0.35 [ 0.25, 0.45 ] 0.96 [ 0.80, 1.00 ]
Somigliana 2004 19 10 26 25 0.42 [ 0.28, 0.58 ] 0.71 [ 0.54, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 83. CA-19.9 (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 83 CA-19.9 (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mabrouk 2012 21 2 19 18 0.53 [ 0.36, 0.68 ] 0.90 [ 0.68, 0.99 ]
Mihalyi 2010 28 11 50 27 0.36 [ 0.25, 0.48 ] 0.71 [ 0.54, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 84. CA-72 (TAG-72) (> 4 U/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 84 CA-72 (TAG-72) (> 4 U/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Molo 1994 1 4 18 12 0.05 [ 0.00, 0.26 ] 0.75 [ 0.48, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 85. CA-72 (TAG-72) (> 6 U/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 85 CA-72 (TAG-72) (> 6 U/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Muscatello 1992 7 4 74 34 0.09 [ 0.04, 0.17 ] 0.89 [ 0.75, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 86. CA-125 (> 10 IU/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 86 CA-125 (> 10 IU/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rosa E Silva 2007 95 10 53 43 0.64 [ 0.56, 0.72 ] 0.81 [ 0.68, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 87. CA-125 (> 11 U/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 87 CA-125 (> 11 U/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Szubert 2012 30 5 14 10 0.68 [ 0.52, 0.81 ] 0.67 [ 0.38, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 88. CA-125 (> 11.5 U/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 88 CA-125 (> 11.5 U/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 24 6 4 11 0.86 [ 0.67, 0.96 ] 0.65 [ 0.38, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 89. CA-125 (> 12.5 U/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 89 CA-125 (> 12.5 U/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 48 24 10 17 0.83 [ 0.71, 0.91 ] 0.41 [ 0.26, 0.58 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 90. CA-125 (> 12.8 U/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 90 CA-125 (> 12.8 U/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Gagne 2003a 133 127 40 68 0.77 [ 0.70, 0.83 ] 0.35 [ 0.28, 0.42 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 91. CA-125 (> 13.5 U/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 91 CA-125 (> 13.5 U/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 15 11 4 5 0.79 [ 0.54, 0.94 ] 0.31 [ 0.11, 0.59 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 92. CA-125 (> 14.7 IU/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 92 CA-125 (> 14.7 IU/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Salehpour 2009 23 8 12 17 0.66 [ 0.48, 0.81 ] 0.68 [ 0.46, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 93. CA-125 (> 16 U/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 93 CA-125 (> 16 U/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ferreira 1994 8 5 15 13 0.35 [ 0.16, 0.57 ] 0.72 [ 0.47, 0.90 ]
Gurgan 1990 12 6 5 15 0.71 [ 0.44, 0.90 ] 0.71 [ 0.48, 0.89 ]
Pittaway 1989 66 5 16 76 0.80 [ 0.70, 0.88 ] 0.94 [ 0.86, 0.98 ]
Wild 1991a 21 1 51 20 0.29 [ 0.19, 0.41 ] 0.95 [ 0.76, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 94. CA-125 (> 17.6 IU/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 94 CA-125 (> 17.6 IU/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Foda 2012 39 0 26 30 0.60 [ 0.47, 0.72 ] 1.00 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 95. CA-125 (> 20 IU/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 95 CA-125 (> 20 IU/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bilibio 2014 32 3 31 31 0.51 [ 0.38, 0.64 ] 0.91 [ 0.76, 0.98 ]
Kitawaki 2005 347 141 86 201 0.80 [ 0.76, 0.84 ] 0.59 [ 0.53, 0.64 ]
Rosa E Silva 2007 45 1 103 52 0.30 [ 0.23, 0.38 ] 0.98 [ 0.90, 1.00 ]
Yang 1994 20 6 8 8 0.71 [ 0.51, 0.87 ] 0.57 [ 0.29, 0.82 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 96. CA-125 (> 20 U/ml), endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 96 CA-125 (> 20 U/ml), endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Guerriero 1996b 23 32 6 40 0.79 [ 0.60, 0.92 ] 0.56 [ 0.43, 0.67 ]
Tokmak 2011 37 17 5 29 0.88 [ 0.74, 0.96 ] 0.63 [ 0.48, 0.77 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 97. CA-125 (> 25 U/ml), endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 97 CA-125 (> 25 U/ml), endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Guerriero 1996b 22 24 7 48 0.76 [ 0.56, 0.90 ] 0.67 [ 0.55, 0.77 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 98. CA-125 (> 26 IU/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 98 CA-125 (> 26 IU/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kitawaki 2005 307 108 126 234 0.71 [ 0.66, 0.75 ] 0.68 [ 0.63, 0.73 ]
Tuten 2014a 44 5 6 32 0.88 [ 0.76, 0.95 ] 0.86 [ 0.71, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 99. CA-125 (> 30 U/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 99 CA-125 (> 30 U/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Acien 1989 23 1 31 13 0.43 [ 0.29, 0.57 ] 0.93 [ 0.66, 1.00 ]
Dayangan Sayan 2013 32 6 18 44 0.64 [ 0.49, 0.77 ] 0.88 [ 0.76, 0.95 ]
Kitawaki 2005 275 89 158 253 0.64 [ 0.59, 0.68 ] 0.74 [ 0.69, 0.79 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 100. CA-125 (> 30 U/ml), endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 100 CA-125 (> 30 U/ml), endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Florio 2007 30 6 10 34 0.75 [ 0.59, 0.87 ] 0.85 [ 0.70, 0.94 ]
Ohata 2008 37 1 28 17 0.57 [ 0.44, 0.69 ] 0.94 [ 0.73, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 101. CA-125 (> 33 U/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 101 CA-125 (> 33 U/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Matalliotakis 2004 20 0 30 50 0.40 [ 0.26, 0.55 ] 1.00 [ 0.93, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 102. CA-125 (> 35 U/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 102 CA-125 (> 35 U/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barbati 1994 8 3 10 24 0.44 [ 0.22, 0.69 ] 0.89 [ 0.71, 0.98 ]
Bilibio 2014 17 1 46 33 0.27 [ 0.17, 0.40 ] 0.97 [ 0.85, 1.00 ]
Chen 1998 80 3 51 21 0.61 [ 0.52, 0.69 ] 0.88 [ 0.68, 0.97 ]
Colacurci 1996a 8 2 10 20 0.44 [ 0.22, 0.69 ] 0.91 [ 0.71, 0.99 ]
Fedele 1989 15 0 87 52 0.15 [ 0.08, 0.23 ] 1.00 [ 0.93, 1.00 ]
Ferreira 1994 1 2 22 16 0.04 [ 0.00, 0.22 ] 0.89 [ 0.65, 0.99 ]
Franchi 1993 19 11 18 72 0.51 [ 0.34, 0.68 ] 0.87 [ 0.78, 0.93 ]
Gagne 2003a 35 16 138 179 0.20 [ 0.15, 0.27 ] 0.92 [ 0.87, 0.95 ]
Hallamaa 2012 47 0 76 52 0.38 [ 0.30, 0.47 ] 1.00 [ 0.93, 1.00 ]
Harada 2002 49 0 52 22 0.49 [ 0.38, 0.59 ] 1.00 [ 0.85, 1.00 ]
Hornstein 1995 17 3 57 46 0.23 [ 0.14, 0.34 ] 0.94 [ 0.83, 0.99 ]
Kitawaki 2005 253 71 180 271 0.58 [ 0.54, 0.63 ] 0.79 [ 0.75, 0.83 ]
Koninckx 1996 12 4 12 27 0.50 [ 0.29, 0.71 ] 0.87 [ 0.70, 0.96 ]
Kurdoglu 2009 58 2 43 24 0.57 [ 0.47, 0.67 ] 0.92 [ 0.75, 0.99 ]
Lanzone 1991 43 5 38 33 0.53 [ 0.42, 0.64 ] 0.87 [ 0.72, 0.96 ]
Maiorana 2007 46 1 23 16 0.67 [ 0.54, 0.78 ] 0.94 [ 0.71, 1.00 ]
Martinez 2007 17 2 19 70 0.47 [ 0.30, 0.65 ] 0.97 [ 0.90, 1.00 ]
Mohamed 2013 21 5 9 25 0.70 [ 0.51, 0.85 ] 0.83 [ 0.65, 0.94 ]
Molo 1994 0 1 19 15 0.0 [ 0.0, 0.18 ] 0.94 [ 0.70, 1.00 ]
Muscatello 1992 43 5 38 33 0.53 [ 0.42, 0.64 ] 0.87 [ 0.72, 0.96 ]
Patton 1986 5 5 32 71 0.14 [ 0.05, 0.29 ] 0.93 [ 0.85, 0.98 ]
Somigliana 2004 12 1 33 34 0.27 [ 0.15, 0.42 ] 0.97 [ 0.85, 1.00 ]
Vigil 1999 20 1 25 2 0.44 [ 0.30, 0.60 ] 0.67 [ 0.09, 0.99 ]
Yang 1994 10 2 18 12 0.36 [ 0.19, 0.56 ] 0.86 [ 0.57, 0.98 ]
Zeng 2005 16 4 20 18 0.44 [ 0.28, 0.62 ] 0.82 [ 0.60, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 103. CA-125 (> 35 U/ml), endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 103 CA-125 (> 35 U/ml), endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Guerriero 1996b 17 15 12 57 0.59 [ 0.39, 0.76 ] 0.79 [ 0.68, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 104. CA-125 (> 36 U/l) endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 104 CA-125 (> 36 U/l) endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Florio 2007 26 4 14 36 0.65 [ 0.48, 0.79 ] 0.90 [ 0.76, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 105. CA-125 (> 42 U/l), endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 105 CA-125 (> 42 U/l), endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Florio 2009 23 5 29 47 0.44 [ 0.30, 0.59 ] 0.90 [ 0.79, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 106. CA-125 (> 43 U/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 106 CA-125 (> 43 U/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ozhan 2014 42 4 0 16 1.00 [ 0.92, 1.00 ] 0.80 [ 0.56, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 107. CA-125 (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 107 CA-125 (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mihalyi 2010 29 4 11 15 0.73 [ 0.56, 0.85 ] 0.79 [ 0.54, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 108. CA-125 (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 108 CA-125 (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mihalyi 2010 54 10 29 26 0.65 [ 0.54, 0.75 ] 0.72 [ 0.55, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 109. CA-125 (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 109 CA-125 (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mabrouk 2012 33 2 7 18 0.83 [ 0.67, 0.93 ] 0.90 [ 0.68, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 110. CA-125 (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 110 CA-125 (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mihalyi 2010 53 11 25 27 0.68 [ 0.56, 0.78 ] 0.71 [ 0.54, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 111. Combined test (CA-125 ≥ 25 U/ml +/or CA-19.9 ≥ 12 U/ml), endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 111 Combined test (CA-125 ≥ 25 U/ml +/or CA-19.9 ≥ 12 U/ml), endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Guerriero 1996a 35 47 4 32 0.90 [ 0.76, 0.97 ] 0.41 [ 0.30, 0.52 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 112. Combined test (CA-125 ≥ 25 U/ml + Ca-19.9 ≥ 12 U/ml), endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 112 Combined test (CA-125 ≥ 25 U/ml + Ca-19.9≥ 12 U/ml), endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Guerriero 1996a 21 8 18 71 0.54 [ 0.37, 0.70 ] 0.90 [ 0.81, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 113. Combined test (CA-125 > 19.8 U/l + Prolactin > 14.8 ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 113 Combined test (CA-125 > 19.8 U/l + Prolactin > 14.8 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bilibio 2014 49 4 14 30 0.78 [ 0.66, 0.87 ] 0.88 [ 0.73, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 114. Combined test (CA-125 > 35 U/l + Prolactin > 20 ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 114 Combined test (CA-125 > 35 U/l + Prolactin > 20 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bilibio 2014 28 1 35 33 0.44 [ 0.32, 0.58 ] 0.97 [ 0.85, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 115. Combined test (CA-125 > 17.6 IU/ml + VEGF > 236 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 115 Combined test (CA-125 > 17.6 IU/ml + VEGF > 236 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Foda 2012 50 2 15 28 0.77 [ 0.65, 0.86 ] 0.93 [ 0.78, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
546Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)
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Test 116. Combined test (CA-125 > 20 U/l + Anti-endometrial Abs > 0.3 A-value).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 116 Combined test (CA-125 > 20 U/l + Anti-endometrial Abs > 0.3 A-value)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Yang 1994 17 3 11 11 0.61 [ 0.41, 0.78 ] 0.79 [ 0.49, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 117. Combined test (CA-125 x NLR; (> 43.1).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 117 Combined test (CA-125 x NLR; (> 43.1)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dayangan Sayan 2013 40 7 10 43 0.80 [ 0.66, 0.90 ] 0.86 [ 0.73, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 118. Combined test (CA-125 > 30 U/ml +/or IL-8 ≥ 25 pg/ml), endometrioma.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 118 Combined test (CA-125 > 30 U/ml +/or IL-8≥ 25 pg/ml), endometrioma
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ohata 2008 56 5 9 13 0.86 [ 0.75, 0.93 ] 0.72 [ 0.47, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 119. Combined test (CA-125 + IL-8) (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 119 Combined test (CA-125 + IL-8) (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mihalyi 2010 143 27 58 66 0.71 [ 0.64, 0.77 ] 0.71 [ 0.61, 0.80 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 120. Combined test (IL-6 > 12.2 pg/ml + TNF-α > 12.45 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 120 Combined test (IL-6 > 12.2 pg/ml + TNF- > 12.45 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Foda 2012 46 0 20 30 0.70 [ 0.57, 0.80 ] 1.00 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 121. Combined test (IL-6 > 12.2 pg/ml + CRP > 438 µg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 121 Combined test (IL-6 > 12.2 pg/ml + CRP > 438 g/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Foda 2012 49 0 16 30 0.75 [ 0.63, 0.85 ] 1.00 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 122. Combined test (TNF-α > 12.45 pg/ml + CRP > 438 µg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 122 Combined test (TNF- > 12.45 pg/ml + CRP > 438 g/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Foda 2012 48 0 17 30 0.74 [ 0.61, 0.84 ] 1.00 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 123. Combined test (miR-199a + miR-122) (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 123 Combined test (miR-199a + miR-122) (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wang 2013a 48 5 12 20 0.80 [ 0.68, 0.89 ] 0.80 [ 0.59, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 124. Combined test (miR-199a + miR-542-3p) (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 124 Combined test (miR-199a + miR-542-3p) (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wang 2013a 58 3 2 22 0.97 [ 0.88, 1.00 ] 0.88 [ 0.69, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 125. Combined test (Ca-125 + Ca 19-9 + Survivin) (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 125 Combined test (Ca-125 + Ca 19-9 + Survivin) (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mabrouk 2012 35 2 5 18 0.88 [ 0.73, 0.96 ] 0.90 [ 0.68, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 126. Combined test (CA-125 + STX-5 + LN-1) (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 126 Combined test (CA-125 + STX-5 + LN-1) (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ozhan 2014 57 6 3 14 0.95 [ 0.86, 0.99 ] 0.70 [ 0.46, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 127. Combined test (CA-125 > 35 IU/ml +/or CA-19.9 > 37 IU/ml +/or IL-6 > 2 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 127 Combined test (CA-125 > 35 IU/ml +/or CA-19.9 > 37 IU/ml +/or IL-6 > 2 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Somigliana 2004 19 10 26 25 0.42 [ 0.28, 0.58 ] 0.71 [ 0.54, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 128. Combined test (CA-125 > 50 IU/mL +/ or CCR1 > 1.16 +/or MCP-1 > 140 pg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 128 Combined test (CA-125 > 50 IU/mL +/ or CCR1 > 1.16 +/or MCP-1 > 140 pg/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Agic 2008 94 9 8 40 0.92 [ 0.85, 0.97 ] 0.82 [ 0.68, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 129. Combined test (Ca-125 > 20 mIU/ml + MCP-1 > 152.74 pg/ml + Leptin > 3.14 ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 129 Combined test (Ca-125 > 20 mIU/ml + MCP-1 > 152.74 pg/ml + Leptin > 3.14 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Seeber 2008 31 5 32 73 0.49 [ 0.36, 0.62 ] 0.94 [ 0.86, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 130. Combined test CA-125 + IL-8 + TNF-α) (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 130 Combined test CA-125 + IL-8 + TNF- ) (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mihalyi 2010 70 11 8 27 0.90 [ 0.81, 0.95 ] 0.71 [ 0.54, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 131. Combined test (IL-6 > 12.2 pg/ml + TNF-α > 12.45 pg/ml + CRP > 438 µg/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 131 Combined test (IL-6 > 12.2 pg/ml + TNF- > 12.45 pg/ml + CRP > 438 g/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Foda 2012 41 0 24 30 0.63 [ 0.50, 0.75 ] 1.00 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 132. Combined test (CA-125 + VEGF + annexin V + glycodelin] - MLR (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 132 Combined test (CA-125 + VEGF + annexin V + glycodelin] - MLR (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 9 2 2 6 0.82 [ 0.48, 0.98 ] 0.75 [ 0.35, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 133. Combined test (CA-125 + VEGF + annexin V + glycodelin] - LS-SVM (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 133 Combined test (CA-125 + VEGF + annexin V + glycodelin] - LS-SVM (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 9 3 2 5 0.82 [ 0.48, 0.98 ] 0.63 [ 0.24, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 134. Combined test (CA-125 + VEGF + annexin V + sICAM-1) - MLR or LS-SVM (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 134 Combined test (CA-125 + VEGF + annexin V + sICAM-1) - MLR or LS-SVM (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Vodolazkaia 2012 9 2 2 6 0.82 [ 0.48, 0.98 ] 0.75 [ 0.35, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 135. Combined test (CA-125 > 20 mIU/ml + MCP-1 > 53.5 pg/ml + Leptin > 29.1 ng/ml + MIF > 14.7
ng/ml).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 135 Combined test (CA-125 > 20 mIU/ml + MCP-1 > 53.5 pg/ml + Leptin > 29.1 ng/ml + MIF > 14.7 ng/ml)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Seeber 2008 63 51 0 27 1.00 [ 0.94, 1.00 ] 0.35 [ 0.24, 0.46 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 136. Combined test (miR-199a + miR-122 + miR-145* + miR-542-3p) (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 136 Combined test (miR-199a + miR-122 + miR-145* + miR-542-3p) (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wang 2013a 56 1 4 24 0.93 [ 0.84, 0.98 ] 0.96 [ 0.80, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 137. Combined test (CA-125 + CA-19.9 + IL-6 + IL-8 + TNF-α + hs-CRP) (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 137 Combined test (CA-125 + CA-19.9 + IL-6 + IL-8 + TNF- + hs-CRP) (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mihalyi 2010 181 44 20 49 0.90 [ 0.85, 0.94 ] 0.53 [ 0.42, 0.63 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 138. Combined test (CA-125 + CA-19.9 + IL-6 + IL-8 + TNF-α + hs-CRP) (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 138 Combined test (CA-125 + CA-19.9 + IL-6 + IL-8 + TNF- + hs-CRP) (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mihalyi 2010 36 5 4 14 0.90 [ 0.76, 0.97 ] 0.74 [ 0.49, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 139. Combined test (CA-125 + CA-19.9 + IL-6 + IL-8 + TNF-α + hs-CRP) (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 139 Combined test (CA-125 + CA-19.9 + IL-6 + IL-8 + TNF- + hs-CRP) (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mihalyi 2010 48 10 35 26 0.58 [ 0.46, 0.69 ] 0.72 [ 0.55, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 140. Combined test (CA-125 + CA-19.9 + IL-6 + IL-8 + TNF-α + hs-CRP) (cut-off not reported).
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 140 Combined test (CA-125 + CA-19.9 + IL-6 + IL-8 + TNF- + hs-CRP) (cut-off not reported)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mihalyi 2010 67 11 11 27 0.86 [ 0.76, 0.93 ] 0.71 [ 0.54, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 141. CA-125 (> 20 U/ml), Bilibio 2014.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 141 CA-125 (> 20 U/ml), Bilibio 2014
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bilibio 2014 32 3 31 31 0.51 [ 0.38, 0.64 ] 0.91 [ 0.76, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 142. CA-125 (> 35 U/ml), Bilibio 2014.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 142 CA-125 (> 35 U/ml), Bilibio 2014
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bilibio 2014 17 1 46 33 0.27 [ 0.17, 0.40 ] 0.97 [ 0.85, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 143. CA-125 (> 16 U/ml), Ferreira 1994.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 143 CA-125 (> 16 U/ml), Ferreira 1994
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ferreira 1994 8 5 15 13 0.35 [ 0.16, 0.57 ] 0.72 [ 0.47, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 144. CA-125 (> 35 U/ml), Ferreira 1994.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 144 CA-125 (> 35 U/ml), Ferreira 1994
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ferreira 1994 1 2 22 16 0.04 [ 0.00, 0.22 ] 0.89 [ 0.65, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 145. CA-125 (> 30 U/ml), Florio 2007.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 145 CA-125 (> 30 U/ml), Florio 2007
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Florio 2007 30 6 10 34 0.75 [ 0.59, 0.87 ] 0.85 [ 0.70, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 146. CA-125 (> 36 U/ml), Florio 2007.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 146 CA-125 (> 36 U/ml), Florio 2007
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Florio 2007 26 4 14 36 0.65 [ 0.48, 0.79 ] 0.90 [ 0.76, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 147. CA-125 (> 12.8 U/ml), Gagne 2003a.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 147 CA-125 (> 12.8 U/ml), Gagne 2003a
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Gagne 2003a 133 127 40 68 0.77 [ 0.70, 0.83 ] 0.35 [ 0.28, 0.42 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 148. CA-125 (> 35 U/ml), Gagne 2003a.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 148 CA-125 (> 35 U/ml), Gagne 2003a
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Gagne 2003a 35 16 138 179 0.20 [ 0.15, 0.27 ] 0.92 [ 0.87, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 149. CA-125 (> 20 U/ml), Guerriero 1996b.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 149 CA-125 (> 20 U/ml), Guerriero 1996b
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Guerriero 1996b 23 32 6 40 0.79 [ 0.60, 0.92 ] 0.56 [ 0.43, 0.67 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 150. CA-125 (≥ 25 U/ml), Guerriero 1996b.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 150 CA-125 (≥ 25 U/ml), Guerriero 1996b
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Guerriero 1996b 22 24 7 48 0.76 [ 0.56, 0.90 ] 0.67 [ 0.55, 0.77 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 151. CA-125 (> 35 U/ml), Guerriero 1996b.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 151 CA-125 (> 35 U/ml), Guerriero 1996b
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Guerriero 1996b 17 15 12 57 0.59 [ 0.39, 0.76 ] 0.79 [ 0.68, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 152. CA-125 (> 20 U/ml), Kitawaki 2005.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 152 CA-125 (> 20 U/ml), Kitawaki 2005
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kitawaki 2005 347 141 86 201 0.80 [ 0.76, 0.84 ] 0.59 [ 0.53, 0.64 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 153. CA-125 (> 26 U/ml), Kitawaki 2005.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 153 CA-125 (> 26 U/ml), Kitawaki 2005
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kitawaki 2005 307 108 126 234 0.71 [ 0.66, 0.75 ] 0.68 [ 0.63, 0.73 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 154. CA-125 (> 30 U/ml), Kitawaki 2005.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 154 CA-125 (> 30 U/ml), Kitawaki 2005
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kitawaki 2005 275 89 158 253 0.64 [ 0.59, 0.68 ] 0.74 [ 0.69, 0.79 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 155. CA-125 (> 35 U/ml), Kitawaki 2005.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 155 CA-125 (> 35 U/ml), Kitawaki 2005
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kitawaki 2005 253 71 180 271 0.58 [ 0.54, 0.63 ] 0.79 [ 0.75, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 156. CA-125 (> 10 U/ml), Rosa E Silva 2007.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 156 CA-125 (> 10 U/ml), Rosa E Silva 2007
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rosa E Silva 2007 95 10 53 43 0.64 [ 0.56, 0.72 ] 0.81 [ 0.68, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 157. CA-125 (> 20 U/ml), Rosa E Silva 2007.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 157 CA-125 (> 20 U/ml), Rosa E Silva 2007
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rosa E Silva 2007 45 1 103 52 0.30 [ 0.23, 0.38 ] 0.98 [ 0.90, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 158. CA-125 (> 20 U/ml), Yang 1994.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 158 CA-125 (> 20 U/ml), Yang 1994
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Yang 1994 20 6 8 8 0.71 [ 0.51, 0.87 ] 0.57 [ 0.29, 0.82 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 159. CA-125 (> 35 U/ml), Yang 1994.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 159 CA-125 (> 35 U/ml), Yang 1994
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Yang 1994 10 2 18 12 0.36 [ 0.19, 0.56 ] 0.86 [ 0.57, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 160. IL-6 (> 1.03 pg/ml), Othman 2008.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 160 IL-6 (> 1.03 pg/ml), Othman 2008
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Othman 2008 55 34 13 36 0.81 [ 0.70, 0.89 ] 0.51 [ 0.39, 0.64 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 161. IL-6 (> 1.9 pg/ml), Othman 2008.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 161 IL-6 (> 1.9 pg/ml), Othman 2008
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Othman 2008 48 24 20 46 0.71 [ 0.58, 0.81 ] 0.66 [ 0.53, 0.77 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 162. IL-6 (> 2.6 pg/ml), Othman 2008.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 162 IL-6 (> 2.6 pg/ml), Othman 2008
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Othman 2008 41 21 27 49 0.60 [ 0.48, 0.72 ] 0.70 [ 0.58, 0.80 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 163. IL-6 (> 2 pg/ml), Bedaiwy 2002.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 163 IL-6 (> 2 pg/ml), Bedaiwy 2002
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bedaiwy 2002 50 12 6 23 0.89 [ 0.78, 0.96 ] 0.66 [ 0.48, 0.81 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 164. IL-6 (> 4 pg/ml), Bedaiwy 2002.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 164 IL-6 (> 4 pg/ml), Bedaiwy 2002
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bedaiwy 2002 48 7 8 28 0.86 [ 0.74, 0.94 ] 0.80 [ 0.63, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 165. IL-6 (> 7.5 pg/ml), Bedaiwy 2002.
Review: Blood biomarkers for the non-invasive diagnosis of endometriosis
Test: 165 IL-6 (> 7.5 pg/ml), Bedaiwy 2002
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bedaiwy 2002 45 5 11 30 0.80 [ 0.68, 0.90 ] 0.86 [ 0.70, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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A D D I T I O N A L T A B L E S




< 1 cm 1-3 cm > 3 cm
Peritoneum Superficial 1 2 4
Deep 2 4 6
Ovary R Superficial 1 2 4
Deep 4 16 20
L Superficial 1 2 4
Deep 4 16 20
Posterior cul-de-sac obliteration Partial Complete
4 40
Adhesions < 1/3 Enclosure 1/3-2/3 Enclosure > 2/3 Enclosure
Ovary R Filmy 1 2 4
Dense 4 8 16
L Filmy 1 2 4
Dense 4 8 16
Tube R Filmy 1 2 4
Dense 4a 8a 16
L Filmy 1 2 4
Dense 4a 8a 16
Stage ·1 (Minimal) - score 1-5; Stage II (Mild) - score 6-15; Stage III (Moderate) - score 16-40; Stage IV (Severe) - score >40
aIf the fimbriated end of the fallopian tube is completely enclosed, change the point assignment to 16 (ASRM 1997)
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Table 2. Blood biomarkers evaluated in this review
Biomarker
Angiogenesis and growth factors and their receptors
Glycodelin-A (PP14 or PAEP) (or placental protein 14 or pro-
gestogen-associated endometrial protein)a
VEGF (vascular endothelial growth factor)a




Cell adhesion molecules and other matrix-related proteins





Immune system and inflammatory markers
Autoantibodies
• Anti-endometrial Abs (anti-endometrial auto antibodies)a
• Anti-laminin-1 Abs (anti-laminin auto antibodies)
Immune cells
• Neutrophilsa
• NLR (neutrophil-to-lymphocyte ratio)a
• WBC (white blood cells)a
Chemokines
• CCR1 (C-C motif receptor 1)
• MCP-1 (monocyte chemotactic protein-1)a
Interleukins
• IL-1β (interleukin - 1β)a
• IL-4 (interleukin - 4)a
• IL-6 (interleukin - 6)a
• IL-8 (interleukin - 8)a
Other cytokines
• IFN-γ (interferon-gamma)a
• MIF (macrophage migration inhibitory factor)a
• TNF-α (tumour necrosis factor alpha)a
Other immune/inflammatory markers
• sCD23 (soluble CD23, low-affinity IgE receptor)a
• Copeptin, vasopressin surrogate
• hs-CRP (high sensitive C-reactive protein)a
Other peptides and proteins shown to influence key events implicated in endometriosis
Follistatin, activin-binding protein; involved in diverse activities from embryonic development to cell secretion
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Table 2. Blood biomarkers evaluated in this review (Continued)











CA-15.3 (cancer antigen-15.3) CA-72 (TAG-72) (cancer antigen-72 or (tumour associated gly-
coprotein-72])
CA-19.9 (cancer antigen-19.9)a CA-125 (cancer antigen-125)a
Blood biomarkers that did not exhibit differential expression in endometriosis and for which diagnostic performance was not
assessed
Angiogenesis and growth factors and their receptors
Angiogenic activity of serum IGF-1 (insulin-like growth factor-1)
CAC (circulating angiogenic cells) IGF-2 (insulin-like growth factor-2)
EGF (epidermal growth factor) IGFBP-3 (insulin-like growth factor binding protein-3)a
sEGF-R (soluble epidermal growth factor-receptor) Leptina
sFlt-1 (sVEGFR-1] (soluble fms-like tyrosine kinase or variant of
VEGF receptor 1)
PDGF (platelet derived growth factor)
Glycodelin-A (PP14 or PAEP] (or placental protein 14 or pro-
gestogen-associated endometrial protein)a
VEGF (vascular endothelial growth factor)a
HGF (hepatocyte growth factor)
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Table 2. Blood biomarkers evaluated in this review (Continued)
Apoptosis markers
Annexin Va sFas (soluble Fas)
Apoptotic cells anti-survivin Abs (anti-survivin antibodies)
Cell adhesion molecules and other matrix-related proteins
Biglycan sE-selectin (soluble E selectin)
sICAM-1 (soluble form of intercellular-adhesion molecule-1)a MMP-9 (matrix metalloproteinase-9)
Cytoskeleton molecules
CK 19 (Cytokeratin-19)
DNA-repair and telomere maintenance molecules
TL (telomere length)
Hormonal markers
E2 (oestradiol) LH (luteinizing hormone)
FSH (follicle stimulating hormone) Progesterone
Immune system and inflammatory markers
Autoantibodies
• Anti-endometrial Abs (anti-endometrial auto antibodies)a
• Anti-sperm Abs (anti-sperm auto antibodies)
















• MCP-1 (monocyte chemotactic protein-1)a
other Cytokines
• Epo (erythropoietin)
• GM-CSF (granulocyte/macrophage-colony stimulating
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Table 2. Blood biomarkers evaluated in this review (Continued)
factor)
• IFN-γ (interferon-gamma)a MIF (macrophage migration
inhibitory factor)a
• TNF-α (tumour necrosis factor alpha)a
Immune cells
• Peripheral blood mononuclear cells:




◦ NLR (neutrophil-to-lymphocyte ratio)a
◦ NK (natural killer cells)
◦ NKR (natural killer cells receptors)
◦ Tregs (Regulatory T cells)
◦ WBC (white blood cells)a
• Other blood cells and blood cell parameters
◦ Haemoglobin
◦ MPV (mean platelet volume)
◦ Platelet count
◦ PLR (platelet/lymphocyte ratio
Other immune/inflammatory markers
• C3a (anaphylatoxin)
• sCD23 (soluble CD23, low-affinity IgE receptor)a
• sCD163 (soluble haemoglobin scavenger receptor)
• CRP (C-reactive protein)a
• sHLA-I (soluble human leukocyte class I antigens)
• Immunoglobulins: IgA, IgG
• MPO (myeloperoxidase)
• NAG (N-acetyl-b-Dglucosaminidase)
• PGE2 (prostaglandin E2)
• Phospholipid fatty acids
• PLA2G2A (phospholipase A2 group IIA)
• RANTES (regulated on activation, normal T cell expressed
and secreted)
Nerve growth markers
CNTF (ciliary Neurotrophic Factor) NGF (nerve growth factor)
GDNF (glial cell-derived neurotrophic factor) NT4 (neurotrophin 4)
Other peptides and proteins shown to influence key events implicated in endometriosis
DBP (vitamin D binding protein), component of Gc-globulin and is the major plasma carrier protein of vitamin D metabolites, responsible
for the transport of fat and endotoxins, important factor in the actin scavenging system, plays an important role in the immune system
Enolase (phosphopyruvate hydratase], a glycolytic enzyme, frequently associated with autoimmune diseases
PDPK1 (phosphoinositide dependent protein kinase 1), a master kinase involved in the signalling pathways
activated by several growth factors and hormones (glucose metabolism, cellular proliferation, cellular survival, and angiogenesis)
Oxidative stress markers
Ascorbic acid Nitrotyrosine
GSH (glutathione) SOD3 (superoxide dismutase-3)
HSP70 (heat shock protein 70) TRX (Thioredoxin)
IMA (Ischemia-modified albumin) Vitamin E
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Table 2. Blood biomarkers evaluated in this review (Continued)
Malondialdehyde
Tumour markers
AFP (alpha-fetoprotein) c-erbB-2 (HER-2/neu] (erythroblastosis oncogene B or human
epidermal growth factor receptor-2 derived from glioblastoma)
CA-19.9 (cancer antigen-19.9)a HE4 (human epididymal secretory protein E4)
CA-125 (cancer antigen-125)a
a Biomarkers that belong to both groups (evaluated as a diagnostic test for endometriosis in some studies and did not exhibit differential
expression in endometriosis in the other studies)
For a comprehensive list of all biomarkers with their biological annotation, please see Appendix 1.
Table 3. Application of the QUADAS-2 tool for assessment of methodological quality of the included studies
Domain 1 - Patient selection
Description Describe methods of patient selection and in-
cluded patients
Type of bias assessed Selection bias, spectrum bias
Review Question Women of reproductive age with clinically sus-
pected endometriosis (symptoms, clinical exam-
ination ± presence of pelvic mass), scheduled for
surgical exploration of pelvic/abdominal cavity
for confirmation of the diagnosis ± treatment
Informaton collected Study objectives, study population, selection (in-
clusion/exclusion criteria), study design, clinical
presentation, age, number of enrolled and num-
ber of available for analysis, setting, place and
period of the study
Signalling question 1 Was a consecutive or random sample of pa-
tients enrolled?
Yes If a consecutive sample or a random sample
of the eligible participants was included in the
study
No If a consecutive sample or a random sample of
the eligible participants was not included in the
study
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Table 3. Application of the QUADAS-2 tool for assessment of methodological quality of the included studies (Continued)
Unclear If this information was unclear
Signalling question 2 Did the study avoid inappropriate exclusions?
Yes If inclusion and exclusion criteria were presented
and all participants with suspected endometrio-
sis were included, with an exception for those
who either had a history ofmedical conditions or
were on medical therapy that would have poten-
tially interfered with interpretation of index test
(e.g. malignancy, pregnancy, autoimmune dis-
orders, infectious diseases, treatment with hor-
monal or immunomodulator substances); re-
fused to participate in the study; or were unfit
for surgery
No If the study excluded the participants based
on education level, psychosocial factors, genetic
testing or phenotype or excluded participants
with any comorbidities commonly present in
general population, including a population that
could have undergone a testing for endometrio-
sis in clinical setting (hypertension, asthma, obe-
sity, benign gastrointestinal or renal disease, etc)
Unclear If the study did not provide clear definition of
the selection (inclusion/exclusion) criteria and
’no’ judgement was not applicable
Signalling question 3 Was a ’two-gate’ design avoided?
Yes If the study had a single set of inclusion crite-
ria, defined by the clinical presentation (i.e. only
participants in whom the target condition is sus-
pected) - a single-gate design
No If the study had more than one set of inclusion
criteria in respect to clinical presentation (i.e.
participants suspected of target condition and
participants with alternative diagnosis in whom
the target condition would not be suspected in
clinical practice) - a two-gate study design
Unclear If it was unclear whether a two-gate deign was
avoided or not
Risk of bias Could the selection of patients have intro-
duced bias?
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Table 3. Application of the QUADAS-2 tool for assessment of methodological quality of the included studies (Continued)
Low If ’yes’ classification for all the above 3 questions
High If ’no’ classification for any of the above 3 ques-
tions
Unclear If ’unclear’ classification for any of the above
3 questions and ’high risk’ judgement was not
applicable
Concerns about applicability Are there concerns that the included patients
do not match the review question?
Low If the study includes only clinically relevant pop-
ulation that would have undergone index test in
real practice and includes representative form of
target condition
High If the study population differed from the pop-
ulation defined in the review question in terms
of demographic features and comorbidity (e.g.
studies with multiple sets of inclusion criteria
with respect to clinical presentation including
either healthy controls or alternative diagnosis
controls that would not have undergone index
test in real practice). Further, if target condi-
tion diagnosed in the study population was not
representative of the entire spectrum of disease,
such as limited spectrum of severity (e.g. only
mild forms) or limited type of endometriosis (e.
g. only deep infiltrating endometriosis)
Unclear If this information was unclear (e.g. severity of
endometriosis was not reported)
Domain 2 - Index test
Description Describe the index test, how it was conducted
and interpreted
Type of bias assessed Test review bias, clinical review bias, interob-
server variation bias
Review question Any type of blood-based biomarker
Informaton collected Index test name, description of positive case def-
inition by index test as reported, threshold for
positive result, examiners (number, level of ex-
pertise, blinding), interobserver variability, con-
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Table 3. Application of the QUADAS-2 tool for assessment of methodological quality of the included studies (Continued)
flict of interests
Signalling question 1 Were the index test results interpreted without
knowledge of the results of the reference stan-
dard?
Yes If the operators performing/interpreting index
test were unaware of the results of the reference
standard
No If the operators performing/interpreting index
test were not blinded to the results of the refer-
ence standard
Unclear If this information was unclear
Signalling question 2 If a threshold was used, was it pre-specified?
Yes If study clearly provided a threshold for positive
result and was defined before execution/inter-
pretation of index test
No If a threshold for positive result was not provided
or not defined prior to test execution
Unclear If it was unclear whether a threshold was pre-
specified or not
Signalling question 3 Was a menstrual cycle phase considered in in-
terpreting the index test?
Yes If all the included participants were in the same
phase of menstrual cycle, if the study reported
subgroup analyses per cycle phase, or if study re-
ported the pooled estimates after impact of the
cycle phase on biomarker expression was not de-
tected
No If study included participants in different phases
of menstrual cycle, but effect of cycle phase on
index test was not assessed
Unclear If the cycle phase was not reported
Risk of bias Could the conduct or interpretation of the
index test have introduced bias?
Low If ’yes’ classification for all the above 3 questions
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Table 3. Application of the QUADAS-2 tool for assessment of methodological quality of the included studies (Continued)
High If ’no’ classification for any of the above 3 ques-
tions
Unclear If ’unclear’ classification for any of the above
3 questions and ’high risk’ judgement was not
applicable
Concerns about applicability Are there concerns that the index test, its con-
duct, or interpretation differ from the review
question?
Low We considered all types of blood-based biomark-
ers as eligible, therefore all the included studies
were classified as ’low concern’, unless ’unclear’
judgement was applicable
High We did not consider the studies where index
tests other than blood-based biomarkers were in-
cluded (or excluded information on other index
tests reported in addition to blood tests) or where
index test looked at other target conditions not
specified in the review (e.g. studies aimed at clas-
sifying pelvic masses as benign and malignant);
therefore none of the included studies was clas-
sified as ’high concern’
Unclear If study reported, but did not present sufficient
information on any of the following: laboratory
method, sample handling, reagents used or ex-
perience of the test operators
Domain 3 - Reference standard
Description Describe the reference standard, how it was con-
ducted and interpreted
Type of bias assessed Verification bias, bias in estimation of diagnostic
accuracy due to inadequate reference standard
Review question Target condition - pelvic endometriosis, ovar-
ian endometriosis, deep infiltrating endometrio-
sis. Reference standard - visualisation of en-
dometriosis at surgery (laparoscopy or laparo-
tomy) with or without histological confirmation
Informaton collected Target condition, prevalence of target condition
in the sample, reference standard, description of
positive case definition by reference test as re-
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Table 3. Application of the QUADAS-2 tool for assessment of methodological quality of the included studies (Continued)
ported, examiners (number, level of expertise,
blinding), interobserver variability, conflict of
interests
Signalling question 1 Is the reference standard likely to correctly
classify the target condition?
Yes If the study reported at least one of the following:
surgical procedure was described in sufficient de-
tail; criteria for positive reference standard were
stated; diagnosis was confirmed by histopathol-
ogy; or the procedure was performed by a team
with high level of expertise in diagnosis/surgical
treatment of target condition, including tertiary
referral centres for endometriosis
No If reference standard did not classify target con-
dition correctly; considering the inclusion crite-
ria and nature of the reference standard, none of
the studies were classified as ’no’ for this item
Unclear If information on execution of the reference
standard, its interpretation or operators was un-
clear
Signalling question 2 Were the reference standard results inter-
preted without knowledge of the results of the
index tests?
Yes If operators performing the reference test were
unaware of the results of the index test
No If operators performing the reference test were
aware of the results of the index test
Unclear If this information was unclear
Risk of bias Could the reference standard, its conduct, or
its interpretation have introduced bias?
Low If ’yes’ classification for both of the above 2 ques-
tions
High If ’no’ classification for any of the above 2 ques-
tions
Unclear If ’unclear’ classification for any of the above
2 questions and ’high risk’ judgement was not
applicable
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Table 3. Application of the QUADAS-2 tool for assessment of methodological quality of the included studies (Continued)
Concerns about applicability Are there concerns that the target condition
as defined by the reference standard does not
match the question?
Low Considering the inclusion criteria, all the studies
were classified as ’low concern’, unless ’unclear’
judgement was applicable
High We excluded the studies where participants
did not undergo surgery for diagnosis of en-
dometriosis; therefore none of the included stud-
ies were classified as ’high concern’
Unclear Only studies where laparoscopy/laparotomy
served as a reference test were included; there-
fore none of the included studies were classified
as ’unclear concern’
Domain 4 - Flow and timing
Description Describe any participants who did not receive
the index tests or reference standard or who were
excluded from the 2 x 2 table; describe the in-
terval and any interventions between index tests
(sample collection) and the reference standard
Type of bias assessed Disease progression bias, bias of diagnostic per-
formance due to missing data
Review question Less than 12-month interval between index test
(sample collection) and reference standard - en-
dometriosis may progress over the time, so we
had chosen an arbitrary time interval of 12
months as an acceptable time interval between
the index test and surgical confirmation of diag-
nosis
Informaton collected Time interval between index test (sample collec-
tion) and reference standard, withdrawals (over-
all number of reported and if explanation)
Signalling question 1 Was there an appropriate interval between in-
dex test (sample collection) and reference stan-
dard?
Yes If time interval was reported and was less than
12 months
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Table 3. Application of the QUADAS-2 tool for assessment of methodological quality of the included studies (Continued)
No We excluded all the studies where time interval
was longer than 12 months; therefore none of
the included studies were classified as ’no’ for
this item
Unclear If time interval was not stated clearly, but authors
description allowedus to assume that the interval
was reasonably short
Signalling question 2 Did all patients receive the same reference
standard?
Yes If all participants underwent laparoscopy/la-
parotomy as a reference standard. Considering
the inclusion criteria, all the studies were classi-
fied as ’yes’ for this item, as anticipated
No If all participants did not undergo surgery or had
alternative reference standard or if only a subset
of participants had surgery as reference standard,
but the information on this population was not
available in isolation
Unclear If this information was unclear. Considering the
inclusion criteria, none of the included studies
were classified as ’unclear’ for this item
Signalling question 3 Were all patients included in the analysis?
Yes If all the participants were included in the anal-
ysis or if the participants were excluded because
they did not meet inclusion criteria prior to ex-
ecution of index test or if the withdrawals were
less than 5% of the enrolled population (arbi-
trary selected cut-off )
No If any participants were excluded from the anal-
ysis because of uninterpretable results, inability
to undergo either index test or reference stan-
dard, or unclear reasons
Unclear If this information was unclear
Risk of bias Could the patient flow have introduced bias?
Low If ’yes’ classification for all the above 3 questions
High If ’no’ classification for any of the above 3 ques-
tions
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Table 3. Application of the QUADAS-2 tool for assessment of methodological quality of the included studies (Continued)
Unclear If ’unclear’ classification for any of the above
3 questions and ’high risk’ judgement was not
applicable
Table 4. Blood biomarkers to be validated for their diagnostic potential in endometriosis
Blood biomarkers1 Replacement test SnOUT triage test SpIN triage test
1. Angiogenesis and growth markers
VEGF > 680 pg/ml ± ± +
VEGF > 236 pg/ml ± ±
2. High-throughput markers
Metabolome by ESI-MS/MS





of 1.63, 3.05, 3.53, 3.77, 5.05
and 5,07 Da)
+
3. Immune system and inflammatory markers
IL-6 > 12.2 pg/ml + +
4. Oxidative stress markers
PON-1 < 141.5 U/l + +
Carbonyls < 14.9 µM ±




miR-20a < 0.69 ±
miR-22 < 0.56 ± ±
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Table 4. Blood biomarkers to be validated for their diagnostic potential in endometriosis (Continued)
miR-532-3p ±
6. Tumour markers
CA-125 (cut-off value > 43 U/
ml)
+ +
7. Combined blood tests
IL-6 > 12.2 pg/ml + TNF-α >
12.45 pg/ml
+
IL-6 > 12.2 pg/ml + CRP > 438
µg/ml
+
TNF-α > 12.45 pg/ml + CRP
> 438 µg/ml
+
miR-199a + miR-542-3p + +
CA-125 + STX-5 + LN-1 ± +
IL-6 > 12.2 pg/ml + TNF-α >
12.45 pg/ml + CRP > 438 µg/
ml
+
miR-199a + miR-122 + miR-
145* + miR-542-3p
± ± +
CA-125 > 17.6 IU/ml + VEGF
> 236 pg/ml
±
CA-125 + CA-19-9 + survivin ±
CA-125>50 IU/ml +/orCCR1
> 1.16 +/or MCP-1 > 140 pg/
ml
± ±
CA-125 > 20 IU/ml + MCP-1
> 152.744 pg/ml + leptin > 3.
14 ng/ml
±
CA-125 + IL-8 + TNF-α ±
CA-125 + CA-19.9 + IL-6 + IL-
8 + TNF-α + hs-CRP (in men-
strual phase of the cycle)
± ±
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Table 4. Blood biomarkers to be validated for their diagnostic potential in endometriosis (Continued)
8. Tests that specifically differentiate endometrioma from other benign ovarian cysts in women of reproductive age
Urocortin > 29 pg/ml + +
Urocortin > 33 pg/ml ±
Follistatin > 1433 pg/ml ± ± ±
CA-125 > 30U/ml and > 36 U/
ml
+




+ meets the criteria
• Replacement test:
sensitivity ≥ 94 and specificity
≥ 79
• SnOUT triage test:
sensitivity ≥ 95 and specificity
≥ 50
• SpIN triage test:
sensitivity ≥ 50 and specificity
≥ 95
± approaches the
criteria (within 5% of the pre-
defined criteria)
1 This group included: tests with an adequate diagnostic performance, but insufficient data to confidently comment on their diagnostic
role (less than 3 studies with the diagnostic estimates meeting the criteria for either a replacement or triage test); and tests where the
diagnostic estimates were approaching the criteria for replacement or triage tests in a small number of studies, and it is possible that
they would reach this criteria if further studies were performed (less than 3 studies with the diagnostic estimates within 5% of the
criteria for either replacement or triage tests).
For a comprehensive list of all biomarkers with their biological annotation, please see Appendix 1.
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A P P E N D I C E S
Appendix 1. Alphabetical list of blood biomarkers
Biomarker Biological group Biological subgroup 1 Biological subgroup 2
1 Angiogenic activity of serum Angiogenesis and growth fac-
tors and their receptors
2 Annexin V Apoptosis markers
3 Anti-endometrial Abs or AEA
(anti-endometrial
autoantibodies)
Immune system and inflam-
matory markers
Autoantibodies
4 Anti-laminin-1 Abs (anti-
laminin autoantibodies)
Immune system and inflam-
matory markers
Autoantibodies
5 Anti-sperm Abs (anti-sperm
autoantibodies)
Immune system and inflam-
matory markers
Autoantibodies
6 Anti-survivin Abs (anti-sur-
vivin antibodies)
Apoptosis markers
7 Anti-ZP Abs (anti-zona pellu-
cida autoantibodies)
Immune system and inflam-
matory markers
Autoantibodies
8 Apoptotic cells Apoptosis markers
9 Ascorbic acid Oxidative stress markers
10 Biglycan Cell adhesion molecules and
other matrix-related proteins
11 B-lymphocytes Immune system and inflam-
matory markers
Immune cells Peripheral blood mononu-
clear cells (PBMC)




13 CA-125 (cancer antigen-125) Tumour markers
14 CA-15.3 (cancer antigen-15.
3)
Tumour markers
15 CA-19.9 (cancer antigen-19.
9)
Tumour markers
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(Continued)
16 CA-72 (TAG-72) (cancer
antigen-72 or (tumour associ-
ated glycoprotein-72))
Tumour markers
17 CAC (circulating angiogenic
cells)
Angiogenesis and growth fac-
tors and their receptors
18 Carbonyls Oxidative stress markers
19 CCR1 (C-Cmotif receptor 1) Immune system and inflam-
matory markers
Chemokines
20 c-erbB-2 (HER-2/neu) (ery-
throblastosis oncogene B or
human epidermal growth fac-
tor receptor-2 derived from
glioblastoma)
Tumour markers
21 CK 19 (cytokeratin-19) Cytoskeleton molecules
22 CNTF (ciliary neurotrophic
factor)
Nerve growth markers




24 CRP (C-reactive protein) or
hs-CRP (high sensitive C-re-
active protein)




25 DBP (vitamin Dbinding pro-
tein)
Other peptides/proteins
shown to influence key events
implicated in endometriosis
26 E2 (oestradiol) Hormonal markers
27 EGF (epidermal growth fac-
tor)
Angiogenesis and growth fac-
tors and their receptors
28 Enolase Other peptides/proteins
shown to influence key events
implicated in endometriosis
29 Epo (erythropoietin) Immune system and inflam-
matory markers
Other cytokines
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(Continued)
30 Follistatin Other peptides/proteins
shown to influence key events
implicated in endometriosis
31 FSH (follicle stimulating hor-
mone)
Hormonal markers
32 GDNF (glial-derived neu-
rotrophic factor)
Nerve growth markers
33 glycodelin-A (PP14 or PAEP)
(placental protein 14 or pro-
gestogen-associated endome-
trial protein)
Angiogenesis and growth fac-
tors and their receptors
34 GM-CSF (granulocyte
macrophage-colony stimulat-




Immune system and inflam-
matory markers
Other cytokines
35 GSH (glutathione) Oxidative stress markers
36 Haemoglobin Immune system and inflam-
matory markers
Immune cells Other blood cells and blood
cell parameters
37 HE4 (human epididymal se-
cretory protein E4)
Tumour markers
38 HGF (hepatocyte growth fac-
tor)
Angiogenesis and growth fac-
tors and their receptors






Immune system and inflam-
matory markers
Other cytokines
41 IGF-1 (insulin-like growth
factor-1) or sIGF-1 (soluble
Insulin-like growth factor-1)
Angiogenesis and growth fac-
tors and their receptors
42 IGF-2 (insulin-like growth
factor-2)
Angiogenesis and growth fac-
tors and their receptors
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(Continued)
43 IGFBP-3 (insulin-like growth
factor binding protein-3)
Angiogenesis and growth fac-
tors and their receptors
44 IL-1β Immune system and inflam-
matory markers
Interleukins
45 IL-2 Immune system and inflam-
matory markers
Interleukins
46 IL-4 Immune system and inflam-
matory markers
Interleukins
47 IL-6 Immune system and inflam-
matory markers
Interleukins
48 IL-8 Immune system and inflam-
matory markers
Interleukins
49 IL-10 Immune system and inflam-
matory markers
Interleukins
50 IL-12 Immune system and inflam-
matory markers
Interleukins
51 IL-13 Immune system and inflam-
matory markers
Interleukins
52 IL-15 Immune system and inflam-
matory markers
Interleukins
53 IL-16 Immune system and inflam-
matory markers
Interleukins
54 IL-17 Immune system and inflam-
matory markers
Interleukins
55 IL-18 Immune system and inflam-
matory markers
Interleukins
56 IL-23 Immune system and inflam-
matory markers
Interleukins
57 IMA (ischemia-modified al-
bumin)
Oxidative stress markers
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(Continued)
59 Leptin Angiogenesis and growth fac-
tors and their receptors
60 LH (luteinizing hormone) Hormonal markers
61 LN-1 (laminin-1) Cell adhesion molecules and
other matrix-related proteins
62 Lymphocytes Immune system and inflam-
matory markers
Immune cells Peripheral blood mononu-
clear cells (PBMC)
63 Malondialdehyde Oxidative stress markers
64 MCP-1 (monocyte chemo-
tactic protein-1)
Immune system and inflam-
matory markers
Chemokines
65 Metabolome High-throughput molecular
markers
66 MIF (macrophage migration
inhibitory factor)




regulators of gene expression
(microRNAs)
68 miR-141* Post-transcriptional
regulators of gene expression
(microRNAs)
69 miR-145* Post-transcriptional
regulators of gene expression
(microRNAs)
70 miR-17-5 Post-transcriptional
regulators of gene expression
(microRNAs)
71 miR-199a Post-transcriptional
regulators of gene expression
(microRNAs)
72 miR-20a Post-transcriptional
regulators of gene expression
(microRNAs)
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(Continued)
73 miR-22 Post-transcriptional
regulators of gene expression
(microRNAs)
74 miR-532-3p Post-transcriptional
regulators of gene expression
(microRNAs)
75 miR-9* Post-transcriptional
regulators of gene expression
(microRNAs)
76 MMP-9 (matrix metallopro-
teinase-9)
Cell adhesion molecules and
other matrix-related proteins
77 Monocytes/macrophages Immune system and inflam-
matory markers
Immune cells Peripheral blood mononu-
clear cells (PBMC)




79 MPV (mean platelet volume) Immune system and inflam-
matory markers








81 Neutrophils Immune system and inflam-
matory markers
Immune cells Peripheral blood mononu-
clear cells (PBMC)
82 NGF (nerve growth factor) Nerve growth markers
83 Nitrotyrosine Oxidative stress markers
84 NK (natural killer cells) Immune system and inflam-
matory markers





2DL2 on NK cells)
Immune system and inflam-
matory markers
Immune cells Peripheral blood mononu-
clear cells (PBMC)
86 NKR CD94 + (lectin-like re-
ceptor on natural killer cells)
Immune system and inflam-
matory markers




Immune system and inflam-
matory markers
Immune cells Peripheral blood mononu-
clear cells (PBMC)
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(Continued)
88 NT4 (neurotrophin 4) Nerve growth markers
89 PAEP (glycodelin) (progesta-
gen-associated endometrial
protein)
Angiogenesis and growth fac-
tors and their receptors
90 PDGF (platelet derived
growth factor)
Angiogenesis and growth fac-
tors and their receptors
91 PDPK1 (phosphoinositide
dependent protein kinase 1)
Other peptides/proteins
shown to influence key events
implicated in endometriosis








94 PLA2G2A (phospholipase A2
group IIA)




95 Platelet count Immune system and inflam-
matory markers
Immune cells Other blood cells and blood
cell parameters
96 PLR (platelet/lymphocyte ra-
tio)
Immune system and inflam-
matory markers
Immune cells Other blood cells and blood
cell parameters
97 PON-1 (paraoxonase-1) Oxidative stress markers
98 Progesterone Hormonal markers
99 Prolactin Hormonal markers
100 Proteome High-throughput molecular
markers
101 RANTES (regulated on ac-
tivation, normal T cell ex-
pressed and secreted)




102 sCD163 (soluble haemoglo-
bin scavenger receptor)




103 sCD23 (soluble CD23, low-
affinity IgE receptor)
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(Continued)




105 sE-selectin (soluble E selectin) Cell adhesion molecules and
other matrix-related proteins
106 sFas (soluble Fas) Apoptosis markers
107 sFlt-1 (sVEGFR-1) (soluble
fms-like tyrosine kinase or
(variant of VEGF receptor 1)
Angiogenesis and growth fac-
tors and their receptors
108 sHLA-I (soluble human
leukocyte class I antigens)




109 sICAM-1 (soluble form of in-
tercellular adhesionmolecule-
1)
Cell adhesion molecules and
other matrix-related proteins
110 SOD3 (superoxide dismu-
tase)
Oxidative stress markers
111 STX-5 (syntaxin-5) Other peptides/proteins
shown to influence key events
implicated in endometriosis
112 Survivin Apoptosis markers
113 Thiols Oxidative stress markers
114 TL (telomere length) DNA-repair/telomere main-
tenance molecules
115 T-lymphocytes Immune system and inflam-
matory markers
Immune cells Peripheral blood mononu-
clear cells (PBMC)
116 TNF-α (tumour necrosis fac-
tor alpha)
Immune system and inflam-
matory markers
Other cytokines
117 Tregs (regulatory T cells) Immune system and inflam-
matory markers
Immune cells Peripheral blood mononu-
clear cells (PBMC)
118 TRX (thioredoxin) Oxidative stress markers
119 Urocortin Angiogenesis and growth fac-
tors and their receptors
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(Continued)
120 VEGF (vascular endothelial
growth factor)
Angiogenesis and growth fac-
tors and their receptors
121 Vitamin E Oxidative stress markers
122 WBC (white blood cells) Immune system and inflam-
matory markers
Immune cells Peripheral blood mononu-
clear cells (PBMC)
Appendix 2. Search strategy for MEDLINE (OVID platform)
Database: MEDLINE (Ovid) <1946 to February, week 2 2015 (16.2.2015)>
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
Search Strategy:
--------------------------------------------------------------------------------
1 (biomarker$ or marker$).tw. (605002)
2 Laboratory Test$.tw. (29839)
3 growth factor$.tw. (272049)
4 scatter factor$.tw. (1287)
5 cytokine$.tw. (250618)
6 hepatocyte growth factor.tw. (8053)
7 (FGF or fibroblast growth factor$).tw. (31798)
8 (PDGF or platelet derived growth factor$).tw. (19864)
9 (EGF or epidermal growth factor$).tw. (58069)
10 (IGF-I or insulin-like growth factor$ or IGF1).tw. (43539)
11 (TGF-a or transforming growth factor alfa or TGFa).tw. (281)
12 (TGF-b or transforming growth factor beta or TGFb).tw. (28842)
13 (EGFR or epidermal growth factor receptor$).tw. (41719)
14 (VEGF or vascular endothelial growth factor$).tw. (53588)
15 exp Luteinizing Hormone/bl (Blood] (24587)
16 leptin$.tw. (24994)
17 exp Progesterone/bl (Blood] (18412)
18 Proteolytic enzyme$.tw. (9768)
19 expmatrixmetalloproteinase 1/ or expmatrixmetalloproteinase 2/ or expmatrixmetalloproteinase 3/ or expmatrixmetalloproteinase
9/ (22968)
20 matrix metalloproteinase$.tw. (34522)
21 MMP$.tw. (44439)
22 TIMP$.tw. (10777)
23 exp “tissue inhibitor of metalloproteinase-1”/ or exp “tissue inhibitor of metalloproteinase-2”/ (6146)
24 exp Glycoproteins/ (637149)
25 (Ca-125 or Ca125 or cancer antigen 125).tw. (6761)
26 (Ca-19-9 or Ca19-9 or cancer antigen 19-9).tw. (4194)
27 (PP 14 or PP14).tw. (229)
28 serum placental protein$.tw. (33)
29 exp Follistatin/ (1134)
30 Osteopontin$.tw. (6769)
31 exp intercellular adhesion molecule-1/ or exp selectins/ (25302)
32 soluble intercellular adhesion.tw. (1588)
33 Soluble adhesion molecule$.tw. (779)
34 sICAM.tw. (2258)
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35 sVCAM$.tw. (1277)
36 (sEcadherin or soluble E-cadherin).tw. (95)
37 (sEselectin or soluble E-selectin).tw. (689)
38 exp t-lymphocytes/ or exp natural killer t-cells/ (272580)
39 Immune cells alteration$.tw. (1)
40 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (21275)
41 Total complement level$.tw. (23)
42 Autoantibodies.tw. (33457)
43 exp Antibodies, Antiphospholipid/ (7522)
44 Anti-endometrial.tw. (23)
45 Antiphospholipid$.tw. (9974)
46 exp hla antigens/ or exp hla-a1 antigen/ or exp hla-a2 antigen/ (64462)
47 (HLA or human leucocyte antigen$).tw. (80501)
48 Anti-laminin-1.tw. (33)
49 Anti-thyroid.tw. (1414)
50 Anti-Thomsen Friedenreich antigen$.tw. (6)
51 Anti-transferrin.tw. (275)
52 Anti-LDL.tw. (181)
53 (Anti-2HSG or Heremans-Schmidt glycoprotein).tw. (3)
54 interleukin$.tw. (175195)
55 (MCP-I or monocyte chemoattractant protein-I).tw. (44)
56 (MIF or migration inhibitory factor$).tw. (4479)
57 (TNF-a or tumour necrosis factor$ alfa).tw. (1344)
58 Fas ligand$.tw. (6032)
59 Endometrial marker$.tw. (11)
60 CAMs.tw. (1756)
61 cell adhesion molecule$.tw. (20903)




66 Aromatase P450.tw. (180)
67 estrogen receptor$.tw. (38819)
68 progesterone receptor$.tw. (16623)
69 MTMMP$.tw. (7)
70 cyr61.tw. (559)
71 exp Cysteine-Rich Protein 61/ (386)
72 cysteine-rich heparin-binding protein$.tw. (9)
73 (ANXA 1 or ANXA1).tw. (313)
74 (Annexin 1 or Annexin1).tw. (339)
75 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2096)
76 serum marker$.tw. (5429)
77 neural marker$.tw. (925)
78 cell surface marker$.tw. (4456)





84 (endometri$ adj2 biops$).tw. (3411)
85 Follistatin$.tw. (1663)
86 Vascular Endothelial Growth Factor A/ (35738)
87 Vitamin D-Binding Protein/ (1282)
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88 exp Cytokines/ (547522)
89 exp interleukins/ or exp interleukin-1/ or exp interleukin-6/ or exp interleukin-8/ or exp interleukin-12/ or exp interleukin-13/
(188479)
90 exp Epidermal Growth Factor/ (21298)
91 exp Fibroblast Growth Factors/ (25075)
92 Platelet-Derived Growth Factor/ (11030)
93 Keratin-19/ (1090)
94 exp Clinical Laboratory Techniques/ (2132820)
95 (Luteinizing Hormone$ or LH).tw. (56679)
96 cytokeratin-19.tw. (1469)
97 (VDBP or vitamin D-binding protein$).tw. (1158)
98 urinary peptide$.tw. (137)
99 VDBP-Cr.tw. (1)
100 urinary VDBP corrected for creatinine expression.tw. (1)
101 urinary marker$.tw. (638)
102 or/1-101 (4086291)
103 Endometriosis/di (Diagnosis] (3354)
104 102 or 103 (4088946)
105 exp Endometriosis/ (17244)
106 Endometrio$.tw. (21492)
107 105 or 106 (24940)
108 104 and 107 (10490)
109 (animals not (humans and animals)).sh. (3892900)
110 108 not 109 (10113)
Additional search February 2015 - May 2015




1 (biomarker$ or marker$).tw. (652345)
2 Laboratory Test$.tw. (31389)
3 growth factor$.tw. (287701)
4 scatter factor$.tw. (1326)
5 cytokine$.tw. (267766)
6 hepatocyte growth factor.tw. (8585)
7 (FGF or fibroblast growth factor$).tw. (33674)
8 (PDGF or platelet derived growth factor$).tw. (20842)
9 (EGF or epidermal growth factor$).tw. (61625)
10 (IGF-I or insulin-like growth factor$ or IGF1).tw. (45386)
11 (TGF-a or transforming growth factor alfa or TGFa).tw. (306)
12 (TGF-b or transforming growth factor beta or TGFb).tw. (30559)
13 (EGFR or epidermal growth factor receptor$).tw. (46446)
14 (VEGF or vascular endothelial growth factor$).tw. (58203)
15 exp Luteinizing Hormone/bl (Blood] (24870)
16 leptin$.tw. (26783)
17 exp Progesterone/bl (Blood] (18699)
18 Proteolytic enzyme$.tw. (9992)
19 expmatrixmetalloproteinase 1/ or expmatrixmetalloproteinase 2/ or expmatrixmetalloproteinase 3/ or expmatrixmetalloproteinase
9/ (24504)
20 matrix metalloproteinase$.tw. (37055)
21 MMP$.tw. (47849)
22 TIMP$.tw. (11419)
23 exp “tissue inhibitor of metalloproteinase-1”/ or exp “tissue inhibitor of metalloproteinase-2”/ (6447)
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24 exp Glycoproteins/ (662211)
25 (Ca-125 or Ca125 or cancer antigen 125).tw. (7058)
26 (Ca-19-9 or Ca19-9 or cancer antigen 19-9).tw. (4399)
27 (PP 14 or PP14).tw. (232)
28 serum placental protein$.tw. (34)
29 exp Follistatin/ (1180)
30 Osteopontin$.tw. (7267)
31 exp intercellular adhesion molecule-1/ or exp selectins/ (26225)
32 soluble intercellular adhesion.tw. (1663)
33 Soluble adhesion molecule$.tw. (795)
34 sICAM.tw. (2374)
35 sVCAM$.tw. (1360)
36 (sEcadherin or soluble E-cadherin).tw. (97)
37 (sEselectin or soluble E-selectin).tw. (713)
38 exp t-lymphocytes/ or exp natural killer t-cells/ (284378)
39 Immune cells alteration$.tw. (1)
40 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (22494)
41 Total complement level$.tw. (24)
42 Autoantibodies.tw. (35161)
43 exp Antibodies, Antiphospholipid/ (7759)
44 Anti-endometrial.tw. (22)
45 Antiphospholipid$.tw. (10351)
46 exp hla antigens/ or exp hla-a1 antigen/ or exp hla-a2 antigen/ (66724)
47 (HLA or human leucocyte antigen$).tw. (83856)
48 Anti-laminin-1.tw. (33)
49 Anti-thyroid.tw. (1478)
50 Anti-Thomsen Friedenreich antigen$.tw. (8)
51 Anti-transferrin.tw. (284)
52 Anti-LDL.tw. (183)
53 (Anti-2HSG or Heremans-Schmidt glycoprotein).tw. (3)
54 interleukin$.tw. (184697)
55 (MCP-I or monocyte chemoattractant protein-I).tw. (46)
56 (MIF or migration inhibitory factor$).tw. (4718)
57 (TNF-a or tumour necrosis factor$ alfa).tw. (1428)
58 Fas ligand$.tw. (6204)
59 Endometrial marker$.tw. (11)
60 CAMs.tw. (1823)
61 cell adhesion molecule$.tw. (22033)




66 Aromatase P450.tw. (182)
67 estrogen receptor$.tw. (41210)
68 progesterone receptor$.tw. (17437)
69 MTMMP$.tw. (7)
70 cyr61.tw. (620)
71 exp Cysteine-Rich Protein 61/ (425)
72 cysteine-rich heparin-binding protein$.tw. (9)
73 (ANXA 1 or ANXA1).tw. (355)
74 (Annexin 1 or Annexin1).tw. (358)
75 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2190)
76 serum marker$.tw. (5721)
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77 neural marker$.tw. (1026)
78 cell surface marker$.tw. (4751)





84 (endometri$ adj2 biops$).tw. (3518)
85 Follistatin$.tw. (1762)
86 Vascular Endothelial Growth Factor A/ (38477)
87 Vitamin D-Binding Protein/ (1356)
88 exp Cytokines/ (575020)
89 exp interleukins/ or exp interleukin-1/ or exp interleukin-6/ or exp interleukin-8/ or exp interleukin-12/ or exp interleukin-13/
(197567)
90 exp Epidermal Growth Factor/ (21875)
91 exp Fibroblast Growth Factors/ (26259)
92 Platelet-Derived Growth Factor/ (11355)
93 Keratin-19/ (1179)
94 exp Clinical Laboratory Techniques/ (2203416)
95 (Luteinizing Hormone$ or LH).tw. (57796)
96 cytokeratin-19.tw. (1538)
97 (VDBP or vitamin D-binding protein$).tw. (1262)
98 urinary peptide$.tw. (148)
99 VDBP-Cr.tw. (1)
100 urinary VDBP corrected for creatinine expression.tw. (1)
101 urinary marker$.tw. (679)
102 or/1-101 (4283825)
103 Endometriosis/di (Diagnosis] (3449)
104 102 or 103 (4286552)
105 exp Endometriosis/ (17833)
106 Endometrio$.tw. (22478)
107 105 or 106 (26003)
108 104 and 107 (10936)
109 (animals not (humans and animals)).sh. (4004321)
110 108 not 109 (10539)
111 (201501$ or 201502$ or 201503$ or 201504$).ed. (322721)
112 110 and 111 (215)
Appendix 3. Search strategy for CENTRAL (OVID platform)
Database: EBM Reviews - Cochrane Central Register of Controlled Trials <July 2015 (3.09.2015)>
Search Strategy:
--------------------------------------------------------------------------------
1 (biomarker$ or marker$).tw. (23692)
2 Laboratory Test$.tw. (2793)
3 growth factor$.tw. (5448)
4 scatter factor$.tw. (8)
5 cytokine$.tw. (6264)
6 hepatocyte growth factor.tw. (111)
7 (FGF or fibroblast growth factor$).tw. (433)
8 (PDGF or platelet derived growth factor$).tw. (250)
9 (EGF or epidermal growth factor$).tw. (1077)
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10 (IGF-I or insulin-like growth factor$ or IGF1).tw. (2132)
11 (TGF-a or transforming growth factor alfa or TGFa).tw. (519)
12 (TGF-b or transforming growth factor beta or TGFb).tw. (236)
13 (EGFR or epidermal growth factor receptor$).tw. (1905)
14 (VEGF or vascular endothelial growth factor$).tw. (1532)
15 exp Luteinizing Hormone/bl (Blood] (151)
16 leptin$.tw. (1399)
17 exp Progesterone/bl (Blood] (58)
18 Proteolytic enzyme$.tw. (136)
19 expmatrixmetalloproteinase 1/ or expmatrixmetalloproteinase 2/ or expmatrixmetalloproteinase 3/ or expmatrixmetalloproteinase
9/ (292)
20 matrix metalloproteinase$.tw. (676)
21 MMP$.tw. (905)
22 TIMP$.tw. (229)
23 exp “tissue inhibitor of metalloproteinase-1”/ or exp “tissue inhibitor of metalloproteinase-2”/ (101)
24 exp Glycoproteins/ (10108)
25 (Ca-125 or Ca125 or cancer antigen 125).tw. (305)
26 (Ca-19-9 or Ca19-9 or cancer antigen 19-9).tw. (71)
27 (PP 14 or PP14).tw. (23)
28 serum placental protein$.tw. (6)
29 exp Follistatin/ (13)
30 Osteopontin$.tw. (80)
31 exp intercellular adhesion molecule-1/ or exp selectins/ (929)
32 soluble intercellular adhesion.tw. (256)
33 Soluble adhesion molecule$.tw. (89)
34 sICAM.tw. (319)
35 sVCAM$.tw. (223)
36 (sEcadherin or soluble E-cadherin).tw. (4)
37 (sEselectin or soluble E-selectin).tw. (99)
38 exp t-lymphocytes/ or exp natural killer t-cells/ (2645)
39 Immune cells alteration$.tw. (1)
40 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (445)
41 Total complement level$.tw. (0)
42 Autoantibodies.tw. (428)
43 exp Antibodies, Antiphospholipid/ (85)
44 Anti-endometrial.tw. (0)
45 Antiphospholipid$.tw. (152)
46 exp hla antigens/ or exp hla-a1 antigen/ or exp hla-a2 antigen/ (563)
47 (HLA or human leucocyte antigen$).tw. (1724)
48 Anti-laminin-1.tw. (0)
49 Anti-thyroid.tw. (49)
50 Anti-Thomsen Friedenreich antigen$.tw. (0)
51 Anti-transferrin.tw. (0)
52 Anti-LDL.tw. (3)
53 (Anti-2HSG or Heremans-Schmidt glycoprotein).tw. (0)
54 interleukin$.tw. (7276)
55 (MCP-I or monocyte chemoattractant protein-I).tw. (0)
56 (MIF or migration inhibitory factor$).tw. (75)
57 (TNF-a or tumour necrosis factor$ alfa).tw. (3923)
58 Fas ligand$.tw. (47)
59 Endometrial marker$.tw. (2)
60 CAMs.tw. (53)
61 cell adhesion molecule$.tw. (568)
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66 Aromatase P450.tw. (3)
67 estrogen receptor$.tw. (1252)
68 progesterone receptor$.tw. (531)
69 MTMMP$.tw. (0)
70 cyr61.tw. (1)
71 exp Cysteine-Rich Protein 61/ (1)
72 cysteine-rich heparin-binding protein$.tw. (0)
73 (ANXA 1 or ANXA1).tw. (3)
74 (Annexin 1 or Annexin1).tw. (2)
75 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (18)
76 serum marker$.tw. (411)
77 neural marker$.tw. (9)
78 cell surface marker$.tw. (46)





84 (endometri$ adj2 biops$).tw. (464)
85 Follistatin$.tw. (26)
86 Vascular Endothelial Growth Factor A/ (560)
87 Vitamin D-Binding Protein/ (18)
88 exp Cytokines/ (13960)
89 exp interleukins/ or exp interleukin-1/ or exp interleukin-6/ or exp interleukin-8/ or exp interleukin-12/ or exp interleukin-13/
(4413)
90 exp Epidermal Growth Factor/ (91)
91 exp Fibroblast Growth Factors/ (197)
92 Platelet-Derived Growth Factor/ (99)
93 Keratin-19/ (19)
94 exp Clinical Laboratory Techniques/ (35164)
95 (Luteinizing Hormone$ or LH).tw. (2935)
96 cytokeratin-19.tw. (25)
97 (VDBP or vitamin D-binding protein$).tw. (44)
98 urinary peptide$.tw. (8)
99 VDBP-Cr.tw. (0)
100 urinary VDBP corrected for creatinine expression.tw. (0)
101 urinary marker$.tw. (67)
102 or/1-101 (90390)
103 Endometriosis/di (Diagnosis] (6)
104 102 or 103 (90394)
105 exp Endometriosis/ (469)
106 Endometrio$.tw. (1026)
107 105 or 106 (1067)
108 104 and 107 (226)
109 (animals not (humans and animals)).sh. (1)
110 108 not 109 (226)
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Appendix 4. Search strategy for EMBASE (OVID platform)
Database: EMBASE (Ovid) <1980 to 2015 Week 07 (16.02.2015)>
Search strategy:
--------------------------------------------------------------------------------
1 Laboratory Test$.tw. (41662)
2 growth factor$.tw. (318593)
3 scatter factor$.tw. (1388)
4 cytokine$.tw. (322134)
5 hepatocyte growth factor.tw. (9594)
6 (FGF or fibroblast growth factor$).tw. (37191)
7 (PDGF or platelet derived growth factor$).tw. (23530)
8 (EGF or epidermal growth factor$).tw. (69553)
9 (IGF-I or insulin-like growth factor$ or IGF1).tw. (49806)
10 (TGF-a or transforming growth factor alfa or TGFa).tw. (542)
11 (TGF-b or transforming growth factor beta or TGFb).tw. (30820)
12 (EGFR or epidermal growth factor receptor$).tw. (64664)
13 (VEGF or vascular endothelial growth factor$).tw. (73191)
14 exp luteinizing hormone/ec (Endogenous Compound] (21924)
15 leptin$.tw. (32576)
16 exp progesterone blood level/ or exp progesterone urine level/ (6285)
17 Proteolytic enzyme$.tw. (9643)
18 exp matrix metalloproteinase/ (19364)
19 matrix metalloproteinase$.tw. (41445)
20 MMP$.tw. (58466)
21 TIMP$.tw. (14174)
22 exp “tissue inhibitor of metalloproteinase 2”/ (4824)
23 exp “tissue inhibitor of metalloproteinase 1”/ (8779)
24 exp glycoprotein/ec (Endogenous Compound] (246077)
25 (Ca-125 or Ca125 or cancer antigen 125).tw. (9536)
26 (Ca-19-9 or Ca19-9 or cancer antigen 19-9).tw. (6054)
27 (PP 14 or PP14).tw. (244)
28 serum placental protein$.tw. (43)
29 exp follistatin/ (2148)
30 Osteopontin$.tw. (8475)
31 exp intercellular adhesion molecule 1/ (32066)
32 exp selectin/ (3082)
33 soluble intercellular adhesion.tw. (1788)
34 Soluble adhesion molecule$.tw. (919)
35 sICAM.tw. (2888)
36 sVCAM$.tw. (1793)
37 (sEcadherin or soluble E-cadherin).tw. (120)
38 (sEselectin or soluble E-selectin).tw. (822)
39 exp T lymphocyte/ (374675)
40 exp natural killer T cell/ (5800)
41 Immune cells alteration$.tw. (6)
42 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (24786)
43 Total complement level$.tw. (20)
44 Autoantibodies.tw. (42037)
45 exp phospholipid antibody/ (9920)
46 Anti-endometrial.tw. (23)
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47 Antiphospholipid$.tw. (13777)
48 exp HLA antigen/ (81011)
49 exp HLA A1 antigen/ (597)
50 exp HLA A2 antigen/ (3288)
51 (HLA or human leucocyte antigen$).tw. (104497)
52 Anti-laminin-1.tw. (43)
53 Anti-thyroid.tw. (1873)
54 Anti-Thomsen Friedenreich antigen$.tw. (5)
55 Anti-transferrin.tw. (290)
56 Anti-LDL.tw. (186)
57 (Anti-2HSG or Heremans-Schmidt glycoprotein).tw. (4)
58 interleukin$.tw. (199692)
59 (MCP-I or monocyte chemoattractant protein-I).tw. (112)
60 (MIF or migration inhibitory factor$).tw. (5063)
61 (TNF-a or tumour necrosis factor$ alfa).tw. (5998)
62 Fas ligand$.tw. (6708)
63 Endometrial marker$.tw. (18)
64 CAMs.tw. (2100)
65 cell adhesion molecule$.tw. (24039)




70 Aromatase P450.tw. (202)
71 estrogen receptor$.tw. (46656)
72 progesterone receptor$.tw. (19861)
73 MTMMP$.tw. (15)
74 cyr61.tw. (755)
75 exp cysteine rich protein 61/ (753)
76 cysteine-rich heparin-binding protein$.tw. (12)
77 (ANXA 1 or ANXA1).tw. (452)
78 (Annexin 1 or Annexin1).tw. (425)
79 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2620)
80 serum marker$.tw. (7720)
81 neural marker$.tw. (1119)
82 cell surface marker$.tw. (5851)





88 (endometri$ adj2 biops$).tw. (4369)
89 Follistatin$.tw. (1945)
90 exp vasculotropin/ (69810)
91 Vascular Endothelial Growth Factor A.tw. (2275)
92 exp vitamin D binding protein/ (2064)
93 exp cytokine/ (1034772)
94 exp interleukin derivative/ (2790)
95 exp interleukin 1/ (48499)
96 exp interleukin 6/ (136328)
97 exp interleukin 8/ (48884)
98 exp interleukin 12/ (31842)
99 exp interleukin 13/ (13584)
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100 exp epidermal growth factor/ (32130)
101 exp fibroblast growth factor/ (13858)
102 cytokeratin 19/ (3601)
103 platelet derived growth factor/ (18930)
104 cytokeratin-19.tw. (1918)
105 (VDBP or vitamin D-binding protein$).tw. (1413)
106 urinary peptide$.tw. (174)
107 VDBP-Cr.tw. (1)
108 urinary VDBP corrected for creatinine expression.tw. (1)
109 urinary marker$.tw. (830)
110 exp blood analysis/ (118854)
111 exp endometrium biopsy/ (4988)
112 exp urinalysis/ or exp biological marker/ (210153)
113 (biomarker or biomarkers).tw. (159748)
114 or/1-113 (2734501)
115 endometriosis/di (Diagnosis] (4979)
116 114 or 115 (2738583)
117 exp endometriosis/ (25923)
118 Endometriosis.tw. (22110)
119 117 or 118 (27911)
120 116 and 119 (10326)
121 Animal/ not Human/ (1204497)
122 120 not 121 (10279)
Additional search February 2015 - May 2015
Embase <1980 to 2015 Week 35 (3.09.2015)>
Search Strategy:
--------------------------------------------------------------------------------
1 Laboratory Test$.tw. (44290)
2 growth factor$.tw. (335543)
3 scatter factor$.tw. (1407)
4 cytokine$.tw. (343623)
5 hepatocyte growth factor.tw. (10104)
6 (FGF or fibroblast growth factor$).tw. (39159)
7 (PDGF or platelet derived growth factor$).tw. (24591)
8 (EGF or epidermal growth factor$).tw. (73599)
9 (IGF-I or insulin-like growth factor$ or IGF1).tw. (51838)
10 (TGF-a or transforming growth factor alfa or TGFa).tw. (583)
11 (TGF-b or transforming growth factor beta or TGFb).tw. (32580)
12 (EGFR or epidermal growth factor receptor$).tw. (71526)
13 (VEGF or vascular endothelial growth factor$).tw. (79087)
14 exp luteinizing hormone/ec (Endogenous Compound] (22767)
15 leptin$.tw. (34921)
16 exp progesterone blood level/ or exp progesterone urine level/ (6534)
17 Proteolytic enzyme$.tw. (9903)
18 exp matrix metalloproteinase/ (20462)
19 matrix metalloproteinase$.tw. (44380)
20 MMP$.tw. (63208)
21 TIMP$.tw. (15146)
22 exp “tissue inhibitor of metalloproteinase 2”/ (5136)
23 exp “tissue inhibitor of metalloproteinase 1”/ (9381)
24 exp glycoprotein/ec (Endogenous Compound] (260024)
25 (Ca-125 or Ca125 or cancer antigen 125).tw. (10051)
26 (Ca-19-9 or Ca19-9 or cancer antigen 19-9).tw. (6446)
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27 (PP 14 or PP14).tw. (243)
28 serum placental protein$.tw. (44)
29 exp follistatin/ (2283)
30 Osteopontin$.tw. (9173)
31 exp intercellular adhesion molecule 1/ (33492)
32 exp selectin/ (3217)
33 soluble intercellular adhesion.tw. (1865)
34 Soluble adhesion molecule$.tw. (944)
35 sICAM.tw. (3049)
36 sVCAM$.tw. (1924)
37 (sEcadherin or soluble E-cadherin).tw. (125)
38 (sEselectin or soluble E-selectin).tw. (861)
39 exp T lymphocyte/ (394405)
40 exp natural killer T cell/ (6310)
41 Immune cells alteration$.tw. (6)
42 (T helper$ or T supressor$ or T helper$ T supressor$ ratio).tw. (26082)
43 Total complement level$.tw. (20)
44 Autoantibodies.tw. (44153)
45 exp phospholipid antibody/ (10362)
46 Anti-endometrial.tw. (25)
47 Antiphospholipid$.tw. (14399)
48 exp HLA antigen/ (83748)
49 exp HLA A1 antigen/ (622)
50 exp HLA A2 antigen/ (3409)
51 (HLA or human leucocyte antigen$).tw. (109332)
52 Anti-laminin-1.tw. (43)
53 Anti-thyroid.tw. (2059)
54 Anti-Thomsen Friedenreich antigen$.tw. (7)
55 Anti-transferrin.tw. (297)
56 Anti-LDL.tw. (191)
57 (Anti-2HSG or Heremans-Schmidt glycoprotein).tw. (4)
58 interleukin$.tw. (210083)
59 (MCP-I or monocyte chemoattractant protein-I).tw. (114)
60 (MIF or migration inhibitory factor$).tw. (5342)
61 (TNF-a or tumour necrosis factor$ alfa).tw. (6488)
62 Fas ligand$.tw. (6895)
63 Endometrial marker$.tw. (18)
64 CAMs.tw. (2198)
65 cell adhesion molecule$.tw. (25207)




70 Aromatase P450.tw. (207)
71 estrogen receptor$.tw. (49530)
72 progesterone receptor$.tw. (21068)
73 MTMMP$.tw. (16)
74 cyr61.tw. (822)
75 exp cysteine rich protein 61/ (829)
76 cysteine-rich heparin-binding protein$.tw. (12)
77 (ANXA 1 or ANXA1).tw. (500)
78 (Annexin 1 or Annexin1).tw. (440)
79 (PGP 9?5 or PGP9?5 or protein gene product$).tw. (2760)
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80 serum marker$.tw. (8158)
81 neural marker$.tw. (1234)
82 cell surface marker$.tw. (6222)





88 (endometri$ adj2 biops$).tw. (4589)
89 Follistatin$.tw. (2081)
90 exp vasculotropin/ (74115)
91 Vascular Endothelial Growth Factor A.tw. (2526)
92 exp vitamin D binding protein/ (2196)
93 exp cytokine/ (1094317)
94 exp interleukin derivative/ (3281)
95 exp interleukin 1/ (50850)
96 exp interleukin 6/ (147379)
97 exp interleukin 8/ (52281)
98 exp interleukin 12/ (33479)
99 exp interleukin 13/ (14685)
100 exp epidermal growth factor/ (33057)
101 exp fibroblast growth factor/ (14499)
102 cytokeratin 19/ (3886)
103 platelet derived growth factor/ (19655)
104 cytokeratin-19.tw. (2030)
105 (VDBP or vitamin D-binding protein$).tw. (1520)
106 urinary peptide$.tw. (189)
107 VDBP-Cr.tw. (1)
108 urinary VDBP corrected for creatinine expression.tw. (1)
109 urinary marker$.tw. (883)
110 exp blood analysis/ (124468)
111 exp endometrium biopsy/ (5197)
112 exp urinalysis/ or exp biological marker/ (232619)
113 (biomarker or biomarkers).tw. (182609)
114 or/1-113 (2911073)
115 endometriosis/di (Diagnosis] (5173)
116 114 or 115 (2915302)
117 exp endometriosis/ (27433)
118 Endometriosis.tw. (23449)
119 117 or 118 (29532)
120 116 and 119 (10922)
121 Animal/ not Human/ (1261620)
122 120 not 121 (10862)
123 (201501$ or 201502$ or 201503$ or 201504$).em. (49200)
124 122 and 123 (34)
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Appendix 5. Search strategy for CINAHL database (EBSCO platform)
Database: CINAHL Plus with Full Text (EBSCOhost) <1980 to 20.04.2015>
Search strategy:
# Query Results
S97 S3 AND S96 1131
S96 S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR
S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR
S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR
S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR
S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR
S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR
S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR
S54 OR S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR
S61 OR S62 OR S63 OR S64 OR S65 OR S66 OR S67 OR
S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR
S75 OR S76 OR S77 OR S78 OR S79 OR S80 OR S81 OR
S82 OR S83 OR S84 OR S85 OR S86 OR S87 OR S88 OR
S89 OR S90 OR S91 OR S92 OR S93 OR S94 OR S95
341775
S95 TX urinary peptide* 1598
S94 TX (VDBP or vitamin D-binding protein*) 134
S93 TX cytokeratin-19 109
S92 TX (Luteinizing Hormone* or LH) 18041
S91 (MH “Diagnosis, Laboratory+”) 101773
S90 “Keratin-19” 2
S89 (MH “Platelet-Derived Growth Factor”) 394
S88 (MH “Epidermal Growth Factors”) 1264
S87 (MH “Interleukins”) 6584
S86 (MH “Cytokines”) 6860
S85 TX Vitamin D-Binding Protein 131
S84 (MH “Vascular Endothelial Growth Factor A”) 194
S83 TX (endometri* N2 biops*) 432
S82 TX (endometri* adj2 biops*) 0
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(Continued)
S81 TX genomic$ 7487
S80 TX proteomic* 2434
S79 TX microRNA 824
S78 TX microarray 3123
S77 TX (PGP 95 or PGP95 or protein gene product*) 9925
S76 TX (Annexin 1 or Annexin1) 472
S75 TX (ANXA 1 or ANXA1) 41
S74 TX cysteine-rich heparin-binding protein* 12
S73 (MH “Protein Array Analysis”) 73
S72 TX cyr61 34
S71 TX MTMMP* 0
S70 TX progesterone receptor* 1927
S69 TX estrogen receptor* 5193
S68 TX Aromatase P450 38
S67 TX Cadherin* 900
S66 TX Selectin* 28411
S65 TX Integrin* 1587
S64 TX cell adhesion molecule* 1578
S63 TX CAMs 550
S62 TX Endometrial marker* 54
S61 TX Fas ligand 338
S60 TX (TNF-a or tumour necrosis factor* alfa) 1489
S59 TX (MIF or migration inhibitory factor*) 399
S58 TX (MCP-I or monocyte chemoattractant protein-I) 13
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(Continued)
S57 TX interleukin 13809
S56 TX (Anti-2HSG or Heremans-Schmidt glycoprotein) 7
S55 TX Anti-LDL 9
S54 TX Anti-transferrin 3
S53 TX Anti-Thomsen Friedenreich antigen* 1
S52 TX Anti-thyroid 109
S51 TX Anti-laminin-1 15
S50 TX (HLA or human leucocyte antigen*) 4202
S49 (MM “HLA Antigens”) 638
S48 TX Antiphospholipid* 1249
S47 TX Anti-endometrial 34
S46 (MH “Antibodies/BL/DU”) 1294
S45 TX Autoantibodies 4385
S43 TX Total complement level 3
S42 TX (T helper* or T supressor*) 2341
S41 TX Immune cells alteration* 24
S40 TX natural killer t-cells 669
S39 (MM “T Lymphocytes”) 2404
S38 TX (sEselectin or soluble E-selectin) 91
S37 TX (sEcadherin or soluble E-cadherin) 8
S36 TX sVCAM 100
S35 TX sICAM 173
S34 TX Soluble adhesion molecule 368
S33 TX soluble intercellular adhesion 237
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(Continued)
S32 (MM “Cell Adhesion Molecules”) 52
S31 TX Osteopontin* 416
S30 TX Follistatin 74
S29 TX serum placental protein* 11
S28 TX (Ca-19-9 or Ca19-9 or cancer antigen 19-9) 262
S27 TX (Ca-125 or Ca125 or cancer antigen 125) 831
S26 (MM “Glycoproteins/BL/DU”) 224
S25 TX tissue inhibitor of metalloproteinase 423
S24 TX TIMP* 1845
S23 TX MMP* 4244
S22 TX matrix metalloproteinase* 3325
S21 TX Proteolytic enzyme* 1461
S20 (MM “Progesterone/BL/DU”) 51
S19 TX leptin* 3258
S18 (MM “Luteinizing Hormone/BL/DU”) 38
S17 TX (VEGF or vascular endothelial growth factor*) 7166
S16 TX (EGFR or epidermal growth factor receptor*) 6188
S15 TX (TGF-b or transforming growth factor beta or TGFb) 2972
S14 TX (TGF-a or transforming growth factor alfa or TGFa) 464
S13 TX (IGF-I or insulin-like growth factor* or IGF1) 3588
S12 TX (EGF or epidermal growth factor*) 6250
S11 TX (PDGF or platelet derived growth factor*) 3195
S10 TX (FGF or fibroblast growth factor*) 3395
S9 TX hepatocyte growth factor* 880
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(Continued)
S8 TX cytokine* 20821
S7 TX scatter factor* 1864
S6 TX growth factor* 76163
S5 TX Laboratory Test* 82732
S4 TX (biomarker* or marker*) 84857
S3 S1 OR S2 2841
S2 TX Endometrio* 2841
S1 (MM “Endometriosis”) 889
S4 TX (biomarker* or marker*) 61,794
S3 S1 OR S2 2,174
S2 TX Endometrio* 2,174
S1 (MM “Endometriosis”) 1,306
Appendix 6. Search strategy for other databases
Search for clinical studies
Database: Web of Science Core Collection (Thomson Reuters) <1900 to Present (20.04.2015)>
Search strategy:
1. Topic=(endometrio*) AND Topic=(diagnos* OR test* OR marker* OR biomarker*); Timespan=All Years (7425)





1. (tw:(endometriosis)) AND (tw:(diagnos*)) (420)
Database: OAIster (WorldCat.org) <20.04.2015>
Search strategy:
1. endometriosis and (marker* or biomarker*) (11)
2. endometriosis and diagnos* (446)
Database: TRIP <20.04.2015>
Search strategy:
1. (endometriosis and diagnos*) (1648)
Searches of trial registers for ongoing and registered trials
Database: ’ClinicalTrials.gov’, a service of the US national Institute of Health
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Search strategy:
1. endometriosis (220)
2. endometriosis AND diagnosis (22)
Database: WHO International Clinical Trials Registry Platform (ICTRP) <20.04.2015>
Search strategy:
1. endometriosis (523)
Searches for the reviews as potential source of references
Database: MEDION <10.01.2014>
Search strategy:
ICP Code female genital system (including breast), Signssymp medical imaging, laboratory tests, histology and cytology, endoscopy
and laparoscopy. Filter: systematic reviews of diagnostic studies (2)
Database: DARE (CRD) <20.04.2015>
Search strategy:
1. endometriosis (99)
PubMed, a ‘Systematic Review’ search under the ‘Clinical Queries’ link <20.04.2015>
Search strategy:
(endometriosis) AND systematic(sb] (418)
Category: Diagnosis; Scope: Broad
Searches for the papers recently published and not yet indexed in the major databases







Filters: Publication date from 2014/10/20 to 2015/04/20
Index test(s) set
6. Endometriosis (584)
Filters: Publication date from 2014/10/20 to 2015/04/20
Target condition set
7. 5 and 6 (267)
Filters: Publication date from 2014/10/20 to 2015/04/20
Combined sets
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Appendix 7. Summary of findings table 2: Blood biomarkers that do not distinguish between
women with and without endometriosis
Review
question
Which blood biomarkers are unlikely to serve a basis of the diagnostic test for endometriosis?
Impor-
tance
Biomarkers that do not show differential expression in women with and without endometriosis, are unlikely to be
diagnostically useful. Information regarding negative trials can focus research on better diagnostic targets.The biomarkers
that display conflicting results (distinguish women with and without endometriosis in some but not all studies) can be
identified and reported on. Studies that did not show differential expression of a biomarker in endometriosis but were
adequately designed and that met inclusion criteria for this review were included
Patients Reproductive-aged women with suspected endometriosis or persistent ovarian mass, or women undergoing infertility
work-up/gynaecological laparoscopy




Visualisation of endometriosis at surgery (laparoscopy or laparotomy) with or without histological confirmation
Study de-
sign
Cross-sectional of a single-gate design (N = 39) or two-gate design (N = 41); unable to determine if single- or two-gate
design for 2 studies; prospective enrolment; a single study could assess more than one test
Risk of
bias
Overall judgement Poor quality (no studies had ’low risk’ assessment in all 4 domains)
Patient selection bias High risk: 50 studies; unclear risk: 25 studies; low risk: 7 studies
Index test interpreta-
tion bias
High risk: 80 studies; unclear risk: 2 studies; low risk: 0 studies
Reference standard in-
terpretation bias
High risk: 0 studies; unclear risk: 29 studies; low risk: 53 studies
Flow and timing selec-
tion bias






High concern: 45 studies, unclear concern: 5 studies; low concern: 32 studies
Concerns regarding in-
dex test
High concern: 0 studies, unclear concern: 1 study; low concern: 81 studies
Concerns regarding ref-
erence standard
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77 71 mean ±
SD, ng/ml





















































































612Blood biomarkers for the non-invasive diagnosis of endometriosis (Review)









36 36 mean ±
SD, ng/ml
crude values NS I-IV luteal Philip-
poussis
200448.2 ± 8.8 46.8 ± 7.9
adjusted values (indica-
tion for surgery, BMI,
and presence of uter-
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131 146 mean ±
SD, pg/ml
crude values NS I-IV luteal Gagne
2003b
241 ± 164 221 ± 128
adjusted (indication for
surgery, infertility, BMI,
gravidity, pelvic pain and











90 89 mean ±
SEM, ng/l




















1 (0.1 - 1.
9)
































0.25 I-IV n/a Paiva 2014
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0.46 I-IV n/a Paiva 2014
2.2. apop-
totic cells
32 30 mean ±
SD, %


























0.078 0.119 NS I-IV n/a Lamp
2012
3. Cell adhesion molecules and other matrix-related proteins
3.1. bigly-
can
56 40 mean ±
SD, ng/ml




















15 15 mean ±
SD, OD












11 9 mean, ng/
ml
8.31 10.3 NS I-II luteal Goluda
1998
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1 (0.1 - 1.
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44 32 mean ±
SD, ng/ml
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28 21 mean ±
SD, IU/ml
3.5 ± 0.3 -
4.5 ±0.4





28 21 mean ±
SD, IU/ml
2.7 ± 0.3 -
3.9 ± 0.3
2.9 ± 0.3 NS I-IV luteal Lima 2006
6.4. pro-
gesterone














NS I-IV luteal Ha-
pangama
2008























18 18 n (%) 5 (27.8%) 1 ( 5.6%) NS I-IV n/a Gorai
1993
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36 35 mean ±
SD, pg/ml














NS I-IV n/a Ozhan
2014
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46 48 mean ±
SD, pg/ml














0.051 I-IV n/a Yagmur
2013
7.4. Immune cells






















22 20 mean ±
SD, x10ˆ3
cells/ml





62 57 mean ±
SD, 10ˆ9/l
























2.25 ± 0.66 0.463 III-IV n/a Yavuzcan
2013
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II); 9.8 ± 4.
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; 17.1 ± 8.
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45.98 0.67 I-IV follicular Hassa
2009
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42 40 mean ±
SD, %

























42 40 mean ±
SD, %
52.6 ± 17.9 56.2 ± 15.7 NS I-IV n/a Maeda
2002b
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62 57 mean ±
SD, %













61.8 ± 13.4 64.0 ± 11.0 NS I-IV n/a Zhang
2006a
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36.3 ± 10.5 36.3 ± 6.0 NS I-IV n/a Zhang
2006a
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22 20 mean ±
SD,
%CD4+
6.5 ± 3.2 6.5 ± 3.7 NS I-IV follicular Gogacz
2014
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5.2 (4.1 - 5.
71)













3.3 (2.1 - 4.
9)
3.7 (2.4 - 4.
5)









22 20 mean ±
SD, x10ˆ3
cells/ml









































0.902 III-IV n/a Yavuzcan
2013




















12.0 ± 1.8 0.97 III-IV n/a Yavuzcan
2013
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5.0 (5.0 - 5.
0)
5.0 (5.0 - 5.
0)
0.625 I-II luteal Kalu 2007
7.5.1.c. IL-
1β
39 19 mean ± SE,
pg/ml




















0.86 I-IV follicular Drosdzol-
Cop 2012b
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30 20 mean, ng/
L
3.6 3.6 NS I-IV n/a Li 2005
7.5.2.d.
IL-2

















7.4 (0 - 34.
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1.9 (0 - 6.
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5.0 (5.0 - 5.
0)
5.0 (5.0 - 5.
0)


















0.6 (0 - 1.
4)
1.0 (0.4 - 1.
9)
0.09 I-IV any Somigliana
2004
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41 26 mean, pg/
ml
20 10 NS III-IV n/a Suen 2014
7.5.5.a. IL-
8




9.81 ± 8.11 NS I-IV follicular Barcz 2002
7.5.5.b.
IL-8
20 10 mean ±
SD, ng/ml









2.5 (1.1 - 4.
1)













5.7 (5.0 - 8.
4)
0.074 I-II luteal Kalu 2007
7.5.5.e. IL-
8






























































3.2 (0 - 12.
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40 40 mean ±
SD, pg/ml
7.95 ± 3.14 14.39 ± 11.
20
0.203 I-II follicular Andreoli
2011
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40 40 mean ±
SD, pg/ml












I-IV n/a Paiva 2014
7.5.12.a.
IL-18


















NS I-II follicular Glitz 2009
7.5.12.c.
IL-18










39 21 mean ±
SD, pg/ml








40 40 mean ±
SD, pg/ml
6.49 ± 4.71 10.12 ± 9.
87
0.209 I-II follicular Andreoli
2011




























































0.212 III-IV n/a Jee 2008
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53 38 mean ±
SD, ng/ml
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6.47 ± 1.33 6.66 ± 1.73 0.46
• Omega-3
fatty acids















1.80 ± 0.33 1.84 ± 0.39 0.45
• Omega-3/
Omega-6









0.05 ± 0.05 0.05 ± 0.04 0.74


























0.43 I-IV n/a Paiva 2014
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45 21 mean ±
SD, U/ml















































45 21 mean ±
SD, ng/ml

















36 36 mean ±
SD, ng/ml
crude values NS I-IV luteal Philip-
poussis
20041.9 ± 0.9 1.8 ± 1.5
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(Continued)
adjusted values (indica-
tion for surgery, BMI,
and presence of uter-























13 67 mean, U/
ml

































36 36 mean ±
SD, ng/ml
crude values NS I-IV luteal Philip-
poussis
2004
2.8 ± 1.7 2.6 ± 1.3
adjusted values (indica-
tion for surgery, BMI,
and presence of uter-













43.5 41.2 NS I-IV any Hallamaa
2012
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(Continued)
Notes:
1 The biomarker was assessed within a diagnostic model of combined biomarkers in this study
2 The authors also report the negative findings for CD4+ and CD4+ CD25+ Treg cells, but these are not presented in the review as
data were not shown Olkowska-Truchanowicz 2013.
3 The authors also report the negative findings for IL-2, IL-4, IL-6, IL-8, IL-10, TNF-a, GM-CSF and IFN-γ , but these are not
presented in the review as data were not shown Oku 2004.
For a comprehensive list of all biomarkers with their biological annotation, please see Appendix 1.
Footnotes
Appendix 8. Blood biomarkers of limited diagnostic value in endometriosis
Biological group Blood biomarker1
1. Angiogenesis and growth markers Glycodelin
IGFBP-3
Leptin
2. Cell adhesion molecules sICAM-1
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(Continued)
IFN-γ





4. Tumour markers CA-19.9 (cut-off > 37 U/ml)
CA-125 (cut-off > 10-14.7 U/ml; > 16-17.6 U/ml; > 20 U/ml; > 25-26 U/ml; > 30-
33 U/ml; > 35-36 U/ml)
1 Limited diagnostic value was defined when at least 3 studies demonstrated low diagnostic estimates that do not meet or approach
the criteria for either replacement or triage test and/or negative findings; we advise against further evaluation of these biomarkers in
the diagnosis of endometriosis
For a comprehensive list of all biomarkers with their biological annotation, please see Appendix 1.
Appendix 9. Blood biomarkers that possibly have limited diagnostic value in endometriosis
Biological group Blood biomarker1









2. Apoptosis markers Annexin-V
Anti-Survivin Abs
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4. Cytoskeleton molecules CK 19
5. DNA-repair/telomere maintenance molecules Telomere length
6. Hormonal markers Prolactin
7. Immune system and inflammatory markers Anti-laminin-1 auto Abs














Immunoglobulins IgA and IgG
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(Continued)
Immune cells and cell parameters (monocytes, macrophages, neu-
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(Continued)





12. Tumour markers AFP
CA-15.3




13. Combined markers All the reported combinations, excluding the tests presented in
Table 4 as ’promising tests’
Notes:
1 Tests that appear to have limited diagnostic value, but there is insufficient data to confidently comment on their diagnostic role
(less than 3 studies with low diagnostic estimates and/or negative findings); we advise considering further investigation with a focus
of specific phases of menstrual cycle, specific types of endometriosis, by implementing different cut-off values or by utilising different
laboratory methods
For a comprehensive list of all biomarkers with their biological annotation, please see Appendix 1.
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on the statistical methods for the review and performed the analyses. Rabia Shaikh participated in literature search, study selection,
quality appraisal and data extraction for the included studies. Cindy Farquhar critically reviewed the methodological aspects and
participated in the study design.Vanessa Jordan and Carola S Scheffers were involved in quality appraisal and data extraction for the
included studies. Neil Johnson and Ben WillemMol contributed to the design of the review and critically reviewed the review content.
All the authors contributed to the revision and drafting of the review.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
General scope: this review is a part of the review series arising from the same generic protocol. The following sections were adjusted to
the main topic of the review as described below.
’Background’: the section on the index test was modified, and we removed all the information irrelevant to blood testing. We updated
the ’Rationale’ section to include a clearer definition of triage diagnostic tests.
’Objectives’:
• Substantial numbers of studies revealed biomarkers with expression levels that were not altered by the presence of endometriosis
(there was no statistically significant difference between women with and without the disease). We included these data from the
adequately designed studies, justifying our decision in the Background section under ’Rationale’, in the Methods section under
’Criteria for considering studies for this review’, ’Index tests’ and added to ’Objectives’ as a secondary objective: ’To assess the
biomarkers that were not affected by endometriosis and hence were unlikely to discriminate between women with and without the
disease’.
• We updated the list of the sources of heterogeneity.
Methods:
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• We updated ’Criteria for considering studies for this review’ as follows.
•
◦ ’Types of studies’: We removed the cohort and case-control classifications and introduced the concepts of single-gate design
and two-gate design. We defined this as the presence of a single or multiple set of inclusion criteria by clinical condition or by
reference standard. We found this classification more informative in the description of diagnostic studies, all of which are cross-
sectional in nature. We limited the inclusion criteria to the studies with a single set of inclusion criteria by reference standard (i.e. all
women who underwent abdominal surgery), but included single or multiple sets of inclusion criteria by clinical presentation (i.e.
women with suspected endometriosis or other indications for abdominal surgery), referring to these as single-gate design and two-gate
design, respectively.
•
◦ Likewise, we removed the terminology ’prospective studies’ and introduced ’studies performed on prospectively collected
samples’. This decision was guided by the fact that most diagnostic studies are retrospective in nature, as they aim to compare the
result of index test with the result of reference standard in the same group of participants, where the groups are classified by the
outcome of reference standard. Also, the analysis of the index test could have been performed retrospectively in a single batch on
stored samples after the prospective collection of samples. The timing of sample collection (before or after surgical treatment of the
disease) from a preoperatively recruited population has more impact on the test result than the timing of the laboratory assay.
Therefore, we included only studies that collected blood before the reference surgical procedure, (i.e. prospectively collected),
irrespective of the actual timing of test performance. We refrained from labelling studies as prospective or retrospective to avoid
confusion. This allowed us to include the studies from well-established high quality tissue banks using well-characterised archived
samples, as omitting these studies would have resulted in the loss of potentially valuable data.
◦ We modified the index tests to pertain only to blood biomarkers and updated the table listing the tests of interest (Table 2)
accordingly.
◦ Target conditions also included deep infiltrating pelvic endometriosis in view of the growing body of literature on this
condition as a separate entity and its diagnostic importance to optimise the surgical approach.
◦ Spectrum of disease: following an ad hoc observation, we included the studies that involved only a selected population of
women with endometriosis (i.e. specific rASRM stages) in view of the emerging evidence on the poor correlation of this classification
with infertility and pain symptoms. Exclusion of such studies could result in the loss of potentially important diagnostic information
from otherwise eligible publications. Where possible we aimed to address the impact of the inclusion of these studies in investigations
of heterogeneity.
• Search methods for identification of studies:
◦ In the protocol, we stated that we would identify the grey literature (unpublished studies including conference proceedings
and reports) and define specific search strategies. In practice, the paucity of relevant data that was available from abstracts made it
impossible to apply the selection criteria and methodological quality judgement to these studies. We anticipated that identification of
this type of study and attempts to obtain the necessary information directly from the study investigators would increase the already
labour-intensive work involved in preparation of this review. Therefore, by consensus among the key authors, we removed already
identified unpublished studies and did not complete an intended search for unpublished material.
◦ We updated the search strings for all biomarkers excluding imaging (searched separately), applying the same principles as
presented in the protocol.
• Assessment of methodological quality: We tailored the QUADAS-2 tool for the topic of the review. The differences between the
original QUADAS-2 tool and the one designed for this review are outlined in the relevant section in the Methods.
Analysis:
• The section on statistical methods was amended and tailored to the types of tests included in the review.
• We performed no sensitivity analyses and no assessment of heterogeneity due to insufficient data for most tests, except for CA-
125 at a single threshold.
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• When a test performance was judged against the predetermined diagnostic criteria, we only considered the point estimates of
sensitivity and specificity, as we believe that presenting these metrics of test performance is the most helpful and informative way to
summarise the diagnostic data. We acknowledge that the choice of the most helpful summary is subjective. There are tests where the
point estimates did not reach the predetermined criteria, but the confidence intervals (CIs) contain the values above the thresholds for
replacement tests, triage tests or both. These tests could have diagnostic value if the point values underestimated their diagnostic
potential. For the tests where the point estimates reached the criteria for a replacement or triage tests but the CIs contained values
below the thresholds, point values could have overestimated the diagnostic performance of the test. If the range of the CIs rather than
the point estimates of the data are used, the predetermined cut-off becomes meaningless. We did not consider CIs in qualifying the
test performance; however, we used the CIs in interpreting the reliability of the obtained data.
The authors list and order changed to accurately reflect their contributions to the review.
N O T E S
We split the initially planned single review on the non-invasive tests for diagnosis of endometriosis into several smaller reviews in
order to facilitate data handling and interpretation, due to abundance and diversity of the suggested tests. The review was generated
from a generic protocol, which we designed for all the reviews in this series. The other reviews from the series include: ’Endometrial
biomarkers for the non-invasive diagnosis of endometriosis’, ’Urinary biomarkers for the non-invasive diagnosis of endometriosis’,
’Imaging modalities for the non-invasive diagnosis of endometriosis’, and ’Combined biomarkers for the non-invasive diagnosis of
endometriosis’, which is also a summary review of the series.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Autoantibodies [blood]; Biomarkers [∗blood]; CA-125 Antigen [blood]; CA-19-9 Antigen [blood]; Endometriosis [∗diagnosis]; En-
dometrium [immunology]; Interleukin-6 [blood]; Ovarian Diseases [∗diagnosis]; Pelvis; Peritoneal Diseases [∗diagnosis]; Randomized
Controlled Trials as Topic
MeSH check words
Adult; Female; Humans
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